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Preface to ”Global Burden and Challenges of
Melioidosis”
Melioidosis is one of the most neglected tropical diseases (NTDs), so much so that it is not even
included in the WHO list of NTDs. Yet modeling suggests that it kills more people worldwide every
year than diseases that are much better known, such as leptospirosis and dengue. The reasons for this
under-recognition are numerous, including the fact that it mainly affects the disadvantaged rural poor
in areas that are poorly supplied with the diagnostic capability to make the diagnosis. Furthermore,
as it is strongly associated with diabetes, melioidosis is likely to become more common in the years
to come as the prevalence of diabetes increases, and rising global travel will mean that it could be
encountered anywhere in the world. Unless treated appropriately, many of those affected by this
disease will die. We are passionate about increasing the proﬁle of melioidosis in the hope that this
will save some of those lives.
The articles in this book were commissioned from authors around the world in order to provide
as complete a picture as possible of the current status (in 2018) of melioidosis in the respective
countries or regions, and the challenges faced in relation to the disease. The articles were published
online as they were completed, but are now gathered here in one book to form a deﬁnitive reference
for researchers, healthcare workers, and policy makers. We hope that this will encourage others to
study this fascinating infection, and go some way towards securing it the attention it deserves.
Direk Limmathurotsakul, David AB Dance
Special Issue Editors
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Melioidosis, an infectious disease caused by the environmental bacterium Burkholderia pseudomallei,
has remained in the shadows for far too long. Described over 100 years ago by Alfred Whitmore in
Rangoon [1], the disease is so neglected that it is not even on any of the lists of neglected tropical
diseases, despite the fact that it probably kills more people each year than diseases that are much better
known, such as leptospirosis and dengue [2]. We aim to set the record straight.
In the ﬁrst few years after its discovery, melioidosis was considered a relatively rare infection
conﬁned to areas where colonial medical services had been established, for example by the British
in Burma (now Myanmar) [1], Ceylon (now Sri Lanka) [3] and the Federated Malay States (now
Malaysia) [4], the French in Indochina (now Cambodia, Laos and Vietnam) [5–7], and the Dutch in
the Dutch East Indies (now Indonesia) [8–10]. It was the French in Indochina who proved that the
organism was a saprophyte rather than a zoonosis as had originally been suspected [11,12]. It was
discovered for the ﬁrst time in northern Australia in 1949 [13], although it appears that this is really
where it actually originated [14]. B. pseudomallei appears to have spread from there to southeast
Asia, and thence to Africa and the Americas [15,16]. The disease gained brief notoriety as a cause
of infection amongst French and American troops serving in Southeast Asia [17–19]. Its unusual
ability to remain latent after acquisition and cause a fatal disease many years later has given rise to
the nickname ‘Vietnam Time Bomb’ [20]. B. pseudomallei has more recently been categorised as a ‘Tier
1 Select Agent’ because of its biothreat potential (https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=
&SID=8a4be60456973b5ec6bef5dfeaffd49a&r=PART&n=42y1.0.1.6.61).
Undoubtedly, it was the work of the Infectious Disease Association of Thailand that led to the
recognition that melioidosis was actually a greatly-underestimated public health problem in some
parts of the world. In 1985, they organised a meeting devoted to melioidosis that highlighted 686 cases
of the disease occurring in Thailand over a relatively short time period [21]. This heralded a new
wave of interest in the disease that has culminated in this current special issue of Tropical Medicine
and Infectious Diseases. Writing in 1991, after spending 4 years observing what an important disease
melioidosis was in northeast Thailand [22], one of us reviewed existing evidence and suggested that
the disease was probably far more common worldwide than was currently appreciated [23]. This was
not a new idea, as Fournier had made similar suggestions some 3 decades earlier [24,25]. The reasons
for its under-recognition are a lack of diagnostic microbiology laboratories serving the rural poor in the
tropics, who are most likely to acquire melioidosis, and a lack of familiarity and awareness amongst
medical and laboratory staff, where such laboratories are available. More recently, the prediction
has been vindicated by growing numbers of reports of the disease in new places, and increasing
recognition within known endemic areas [26,27]. In 2016, the ﬁrst attempt was made to estimate
the global burden of human melioidosis in terms of cases and deaths, the resulting prediction being
165,000 and 89,000 per year, respectively, a mortality burden similar to that of measles [2].
Trop. Med. Infect. Dis. 2018, 3, 13 www.mdpi.com/journal/tropicalmed1
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Now, two years on from this modelling study [2], the time is right to take stock of what we
have learned since then. In this issue, we have combined articles from countries and regions around
the world that summarise the current status, including what is known locally about the burden of
melioidosis, and the key challenges facing local clinicians, laboratory staff and public health and policy
makers, in relation to this elusive but common and fatal disease. We hope that this will become a key
source of information for those who share our concern and are taking actions against this disease.
Conﬂicts of Interest: The authors declare no conﬂict of interest.
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Abstract: Melioidosis is an often fatal infectious disease with a protean clinical spectrum, caused
by the environmental bacterial pathogen Burkholderia pseudomallei. Although the disease has been
reported from some African countries in the past, the present epidemiology of melioidosis in Africa
is almost entirely unknown. Therefore, the common view that melioidosis is rare in Africa is not
evidence-based. A recent study concludes that large parts of Africa are environmentally suitable for
B. pseudomallei. Twenty-four African countries and three countries in the Middle East were predicted
to be endemic, but no cases of melioidosis have been reported yet. In this study, we summarize the
present fragmentary knowledge on human and animal melioidosis and environmental B. pseudomallei
in Africa and the Middle East. We propose that systematic serological studies in man and animals
together with environmental investigations on potential B. pseudomallei habitats are needed to identify
risk areas for melioidosis. This information can subsequently be used to target raising clinical
awareness and the implementation of simple laboratory algorithms for the isolation of B. pseudomallei
from clinical specimens. B. pseudomallei was most likely transferred from Asia to the Americas
via Africa, which is shown by phylogenetic analyses. More data on the virulence and genomic
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characteristics of African B. pseudomallei isolates will contribute to a better understanding of the global
evolution of the pathogen and will also help to assess potential differences in disease prevalence
and outcome.
Keywords: melioidosis; Africa; Middle East; Burkholderia pseudomallei; genomics; public awareness;
environment
1. Introduction
Recently, the global environmental distribution of B. pseudomallei and the world-wide incidence
and mortality of meliodosis was estimated using a modelling approach. It was predicted that
165,000 melioidosis cases occur per year worldwide, in which 89,000 people die [1]. The estimates
suggest not only a massive underreporting in countries known to be endemic but also identiﬁed
34 countries in which melioidosis is probably endemic and has never been reported. Among those
countries are 24 African countries and three countries in the Middle East. Modelling predicts that
24,000 (95% credible interval 8000–72,000) cases with 15,000 (credible interval 6000–45,000) deaths occur
annually in sub-Saharan Africa while less than 1000 annual cases and deaths were predicted for North
Africa and the Middle East [1]. Although in some African and Middle East countries sporadic cases of
human and animal melioidosis have been reported for many decades [2,3], sound epidemiological
data for the disease do not exist for any of those countries. Remarkably, melioidosis has not been
classiﬁed as a neglected tropical disease. Deﬁning the prevalence of melioidosis in these regions is
important for public health. Due to its non-speciﬁc clinical presentation, human melioidosis can mimic
many common infectious diseases such as malaria or tuberculosis. Due to its severity, misdiagnosis
will lead to inappropriate case management and the highest case fatality. Moreover, melioidosis is a
differential diagnosis of some epidemic-prone diseases like plague, which means that early diagnosis
can be important in a public health perspective. In this paper, we summarize the available information
on reported cases of melioidosis in man and animals. Furthermore, we review knowledge on the
environmental presence of B. pseudomallei in Africa and the Middle East and on the characteristics of
African B. pseudomallei strains. Lastly, we consider potential strategies to unravel the true burden of
the disease in these parts of the world.
2. Melioidosis and Environmental B. pseudomallei in Africa and the Middle East
In this section, countries were assigned to sub-regions, according to the United Nations
geoscheme. Peer-reviewed published cases of human and animal melioidosis together with reports
on environmental B. pseudomallei in the various African sub-regions and the Middle East (sub-region
Western Asia) were compiled based on journal research and by using the global occurrence database
created by Limmathurotsakul et al. [1].
2.1. Northern Africa
Environmental occurrence of B. pseudomallei is associated with high amounts of precipitation [1].
It is, therefore, not surprising that most parts of Northern Africa are not considered suitable
environments for this pathogen [1]. Neither indigenous nor imported cases of human melioidosis
have been reported from this part of Africa. There is, however, a report from Egypt in 1953 describing
melioidosis in a horse. This case was identiﬁed by a positive reaction to subcutaneous administration
of Burkholderia mallei antigen (mallein test) while testing horses for glanders. However, because
subsequent antigen tests gave inconsistent results, the authors suspected melioidosis. B. pseudomallei
was isolated from a mesenteric gland after a post-mortem examination and was shown to be
virulent in guinea pigs. Metabolic characteristics of the isolate were different from the close relative
Burkholderia mallei, indicating that the horse suffered from melioidosis but not glanders [4].
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2.2. Middle East
The environmental suitability for B. pseudomallei seems to vary signiﬁcantly within the countries
of the Middle East [1]. Turkey and parts of the Sinai Peninsula were not predicted to be suitable for
B. pseudomallei. However, there are regions in Saudi Arabia, Yemen, Iraq, and Oman that seem to be
suitable for B. pseudomallei [1].
In 1961, a case of pulmonary melioidosis was described in southern Turkey, although the
information provided on the bacteriological identiﬁcation procedure does not allow conﬁrmation
of B. pseudomallei with certainty [5]. This also applies to a report of B. pseudomallei isolation from
raw milk samples in different areas of Ankara, Turkey from 1998 [6]. A study from 1997 in Saudi
Arabia examined the bacterial ﬂora of the nasal cavity and lungs of healthy and unhealthy sheep and
calves. It was reported that B. pseudomallei was isolated from the nasal cavity of sheep [7]. Again,
the information provided on the bacterial identiﬁcation procedure does not allow ﬁrm conclusions
on the identity of the isolated bacteria. In 1997, melioidosis was reported in a camel in Dubai in the
United Arab Emirates [8]. Although the clinical signs were suggestive of melioidosis, an inadequate
amount of information on microbiological characteristics of the isolated strain was provided [8].
Although large parts of Iran have a relatively dry climate, a subtropical region along the Caspian
Sea coast and parts of the south were predicted to be environmentally suitable for B. pseudomallei [1].
A report from 1975 described the environmental presence of virulent B. pseudomallei in rice ﬁelds along
the Caspian Sea coast. Out of 157 soil samples, 19 were shown to be positive for B. pseudomallei and
the virulence of these strains was conﬁrmed in guinea pigs [9]. Furthermore, in 1979, an outbreak
of melioidosis among horses and a mule in Iran was reported [10]. The authors isolated motile
Gram-negative bacterial strains from abscesses in various organs from the horses and the mule, with
biochemical characteristics typical of B. pseudomallei but not of B. mallei [10]. In 1977, the ﬁrst case of
human pulmonary melioidosis in Iran was published [11]. To our knowledge, there have been no
further reports in the international literature of indigenous melioidosis from Iran, except for a case of
melioidosis imported from Southeast Asia into Iran [12].
2.3. Western Africa
According to the predicted environmental suitability for B. pseudomallei, western sub-Saharan
Africa is among the highest risk zones [1]. In line with this forecast, B. pseudomallei strains were already
isolated between 1967 and 1971 from lesions in pigs in a slaughterhouse in Niamey, Niger [13].
Subsequently, environmental surveys along the route of pig transport revealed the presence of
B. pseudomallei in the soil of Burkina Faso and Niger [14]. More recently, B. pseudomallei was isolated
in a blood culture of a 59-year-old man native to and living in Burkina Faso, who presented with a
mycotic aneurysm of an iliac artery [15]. Galimand and Dodin reported the isolation of B. pseudomallei
from the soil of a pig farm in Abidjan, Côte d’Ivoire in 1980. However, identiﬁcation details were not
provided [16]. In 1985, the isolation of B. pseudomallei in a 12-year-old girl from Sierra Leone presenting
with multiple abscesses was reported in The Gambia [17]. In 2009, a 29-year-old diabetic Gambian
man was diagnosed in Spain with bilateral calf abscesses due to B. pseudomallei after travelling to
The Gambia, Guinea-Bissau, and Senegal [18]. Subsequently, another case of melioidosis was reported
in a Caucasian Dutch man after traveling to The Gambia. [19].
Among all African countries, Nigeria is predicted to have by far the highest burden of
melioidosis [1]. In sharp contrast to this potential disease load, the only report of melioidosis linked
to Nigeria was documented in 2011, in which a case of a diabetic traveler was described who most
likely acquired infection during a visit to the country [20]. Taken together, the predicted high disease
burden and the low number of documented melioidosis incidences exemplify the urgent need for
detailed investigations.
In 2014, ‘The African Melioidosis Network’ (AMENET), sponsored in the context of the European
Union project ERAfrica, was established. The project aims at serological and environmental
surveillance and capacity building in the laboratory diagnosis of B. pseudomallei. In West Africa,
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Burkina Faso, Ghana, and Côte d’Ivoire are among the current target countries. In Côte d’Ivoire,
culture screening of lesions in a pig slaughterhouse and some pilot soil sampling did not conﬁrm the
presence of B. pseudomallei in this country so far [21]. However, a recent report describes cutaneous
melioidosis in a 49-year-old man presenting with leg cellulitis and an inguinal abscess after returning
from one-year travel in Côte d’Ivoire [22]. Recent environmental qPCR-based direct molecular
screening [23] and cultural screening of soil samples in Burkina Faso conﬁrmed the environmental
presence of B. pseudomallei. The phylogenetic analysis of isolated environmental strains based on whole
genome sequencing is under way [24].
2.4. Eastern Africa
The predicted environmental suitability for B. pseudomallei in Eastern Africa seems to be scattered
and possible risk zones vary in size [1]. Among the ﬁrst hints of melioidosis in this part of the continent
was a case of melioidosis in a traveler reported in 1980, who was diagnosed in Denmark but acquired
the infection in Kenya. In this case, B. pseudomallei identiﬁcation from blood, urine, and sputum
included biochemical characteristics and virulence in guinea pigs [25]. A subsequent environmental
survey testing of 81 soil and 71 water samples from three different provinces, including the possible
site of infection of the Danish tourist, failed to isolate B. pseudomallei [26]. However, recently ﬁve
indigenous cases of human melioidosis were uncovered in Kenya, even though the overall incidence in
this country seems to be low [27]. The only hint of melioidosis in Uganda is a single serological study
from 1982 describing 5.9% seropositivity (25 out of 426 individuals) in healthy adults from different
parts of the country using an indirect hemagglutination test titre of 1:40 or greater [28]. In 2011, an
indigenous case of melioidosis in a child was described in Malawi [2]. Recently, a case of melioidosis
in an Eritrean migrant worker was diagnosed in Israel, which indicated that the disease might exist in
the Horn of Africa [29].
Parts of Ethiopia were predicted to be environmentally suitable for B. pseudomallei. In the context
of AMENET, environmental studies revealed the presence of B. pseudomallei in soil samples in various
regions of the country using molecular [23] as well as cultural methods. The genomes of isolated
environmental Ethiopian B. pseudomallei strains are currently being analyzed [24]. Current efforts aim
to implement serological studies in humans and animals and capacity building in clinical laboratories.
In contrast to the situation in eastern continental Africa, Madagascar, the second largest island
state in the western Indian Ocean, was already recognized as an endemic area in the 1930s [30]. Since
there is a comprehensive summary of recent cases of melioidosis in the western Indian Ocean [31],
in particular in Madagascar, we will only brieﬂy summarize the current situation. First reports on
melioidosis in pigs were published by French scientists in 1936 and a further report on the isolation of
B. pseudomallei from soil [16] conﬁrmed the presence of this pathogen on the island. It took until 2004
for the ﬁrst human case to be reported and, in 2017, ﬁve more cases were described [32]. However,
the epidemiological situation for the indigenous population in Madagascar is unknown. Cases were
also described from La Réunion, Mauritius, and Seychelles [33–35]. In the framework of AMENET,
environmental qPCR-based molecular and cultural screening of soil samples was performed and the
environmental presence of B. pseudomallei could be demonstrated in various regions of Madagascar [36].
2.5. Central Africa
B. pseudomallei environmental suitability was predicted for all countries of Central Africa.
However, signiﬁcant regional differences seem to exist [1]. The ﬁrst indication that melioidosis
might be present in this African subregion was provided in 1956 by the isolation of B. pseudomallei
from a lymph node of a goat in Chad [37]. From 2012 to 2013, prospective screening of blood cultures
for B. pseudomallei was conducted in Gabon and led to the identiﬁcation of the ﬁrst melioidosis
case in a diabetic female patient in this country [38], and environmental B. pseudomallei could be
isolated from different sites. In the course of AMENET, the ﬁrst environmental pilot studies in the
DR Congo indicated the presence of B. pseudomallei in soil samples [24] by using direct molecular
7
Trop. Med. Infect. Dis. 2018, 3, 62
screening, as recently described [23]. Current activities focus on serological surveys and the extension
of environmental screening in various subregions. In parallel, clinical surveillance and laboratory
screening for human and animal melioidosis is being implemented.
2.6. Southern Africa
This sub-region seems to contain relatively limited areas of environmental suitability for
B. pseudomallei [1]. A report from 1956 described the isolation of B. pseudomallei from abscesses
of mammary glands and kidneys in a goat from South Africa [39].
3. Phenotype, Genomic Diversity, and Phylogenetic Relatedness of B. pseudomallei from Africa
At this point in time, the phenotypic characterization of African isolates is essentially restricted
to features needed for diagnostic and therapeutic purposes. Wiersinga and colleagues reported that
clinical and several environmental features of Gabon isolates showed the typical B. pseudomallei
diagnostic characteristics, which have also been described in other endemic parts of the world
with respect to the API 20NE biochemical proﬁle, colony morphology, antibiotic susceptibility, and
B. pseudomallei-speciﬁc latex agglutination [38]. The known B. pseudomallei susceptibility to meropenem,
amoxicillin/clavulanic acid, cotrimoxazole and ceftazidime, and characteristic biochemical patterns in
respective identiﬁcation systems, were also reported in isolates from other cases [20,38,40].
As for the phenotypic properties, information on genomic characteristics of B. pseudomallei strains
from Africa is also based on a limited number of isolates. At this point in time, most available
data have been generated using multi-locus sequence typing (MLST), which is a cost-effective
and straightforward method for investigating the epidemiology of B. pseudomallei [41,42]. The
B. pseudomallei MLST scheme developed in 2003 is based on seven housekeeping genes and strains are
classiﬁed according to their allelic proﬁle [43]. Despite the emergence of next generation sequencing
(NGS) and its advantages concerning recombination and homoplasy [44,45], MLST still provides
valuable insight into the genetic variability of an organism and the geographic distribution/prevalence
of different strains, due to its simplicity and sheer amount of deposited STs. As of March 2018, only 26
(0.47%) out of 5494 deposited isolates originate from Africa–compared to 2992 (54.46%) Australian
and 906 (16.46%) Thai strains (https://pubmlst.org/bpseudomallei/) [46]. Noteworthily, the African
B. pseudomallei strains were isolated in as few as eight different countries and do not share a single
sequence type (ST) among each other. Furthermore, only four of the 26 STs were also reported in
Southeast Asian countries, with none in Australia. While these observations might partially result
from the low number of isolates, they already hint at the great genotypic diversity of the African
isolates and indicate a segregated, geographically distinct, African subpopulation.
Since the publication of the ﬁrst closed B. pseudomallei genome of the Thai strain K96243 in
2004 [47], the phylogeny of the bacterium has been intensively studied by the emerging NGS methods.
At the same time, whole genome sequencing (WGS) offers the advantage of high coverage and,
therefore, provides better phylogenetic resolution, which makes it a more robust tool compared to other
genetic typing methods that rely on only a few loci [48]. In the ﬁrst phylogenetic study based on single
nucleotide polymorphisms (SNP) of 43 B. pseudomallei strains from Asia and Australia, the authors
presented strong evidence for an ancestral Australian origin and proposed a single transmission event
to Southeast Asia during the glacial periods [45]. Two recent genomic studies, which not only rely on
larger datasets but also on more geographically diverse ones, support these ﬁndings and further extend
them in a global context [49,50]. Phylogenetic analyses show that the South American strains form
a sub-cluster within an otherwise African-dominated B. pseudomallei clade, which in turn branches
from the Asian one [50,51]. Therefore, Sarovich and colleagues hypothesized that B. pseudomallei
was transmitted from Asia to Africa ~2000 years ago when people from Southeast Asia migrated to
Madagascar. Nevertheless, the introduction of B. pseudomallei to Africa by birds via the Asia-East
Africa ﬂyway is another possibility, which is noted by the authors [49]. Moreover, Chewapreecha et al.
estimated the most recent common ancestor for the American strains to be from 1759 or 1806 using
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the BEAST (Bayesian Evolutionary Analysis by Sampling Trees) method. A time span that coincides
with the height of the slave trade (1650–1850) therefore offers a plausible explanation for the onward
transmission to the Americas by diseased people or contaminated cargo [50].
It has been argued that the observed difference between predicted and reported meliodosis cases
in Africa might not only be due to underreporting and the lack of diagnostic facilities, but it might
also be attributed to variations in B. pseudomallei virulence [52]. WGS is a well-established technique to
address this question on a genetic basis and can further be used to identify geographically-segregated
gene variants [50]. For example, a few virulence-associated genes (e.g. bimABm, fhaB3) have
been described in the literature to correlate with speciﬁc clinical presentations and the severity of
melioidosis [53]. Therefore, this might account for geographical differences. Additionally, there are reports
of African isolates that lack the ﬁmbrial and adhesion virulence protein [52], the type II O-antigenic
polysaccharide, or the ﬁlamentous hemagglutinin [49]. Even though host and environmental factors
are also crucial determinants, it will be most interesting to see how diverse the African B. pseudomallei
population is and whether bacterial diversity contributes to geographical differences in disease
prevalence and outcome. There is no doubt that an extended analysis of more African isolates
will not only help to get more detailed insights of B. pseudomallei epidemiology and virulence within
Africa, but also substantially contributes to our comprehensive understanding of the global evolution
and dissemination.
4. Current and Future Challenges
In light of the history of melioidosis in other parts of the world, which shows the degree to which
highly-endemic regions may go undetected, and the high case fatality rate of undiagnosed melioidosis,
there is an urgent need to deﬁne risk areas throughout Africa and the Middle East. The ﬁrst step
should be to conduct serological surveys of humans and animals to estimate the degree of exposure
to B. pseudomallei in various regions. Based on these results, one can then geographically target
raising clinical awareness among infectious disease specialists together with microbiological capacity
building, which are both needed to detect cases of melioidosis. For the latter, one can learn from other
resource-limited settings in which simple laboratory algorithms for the identiﬁcation of B. pseudomallei
from clinical specimens have been successfully applied [54]. Known groups at risk such as diabetics
will be targeted ﬁrst.
Serological surveys should be complemented by environmental studies. It will be necessary to
systematically determine the environmental distribution and load of B. pseudomallei in the different
African regions and habitats. When screening soil samples from Thailand and Vietnam, a recent study
demonstrated a higher detection rate using a quantitative multi-target PCR approach compared to
culture. Moreover, samples with high PCR signals were more likely to be culture-positive compared to
samples with low signals [23]. In the environmental studies conducted in Burkina Faso and Madagascar
in the context of AMENET, we can conﬁrm that speciﬁc molecular signals are obtained at a signiﬁcantly
higher rate when compared to positive cultures.
In endemic regions, prospective studies are then required to determine the incidence and
prevalence of melioidosis in humans and animals. Although the limited available information suggests
similar clinical presentations and risk factors in African melioidosis cases as compared to other
endemic regions, this has to be veriﬁed. In this context, it will be important to assess the virulence
traits of African B. pseudomallei strains compared to Australian and Asian isolates through WGS and
experimental infection models.
The identiﬁcation of environmental factors determining the presence of B. pseudomallei and,
thereby, the risk of acquiring infection will be important for any prevention and preparedness
strategies. Such factors might be identiﬁed by e.g., regressing land use patterns, soil types, and
vegetation on results from molecular soil screening and seroprevalence data. Studies on B. pseudomallei
population structure and phylogenetic relatedness offer the chance to analyze past and contemporary
environmental dissemination of this pathogen.
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The true magnitude of the melioidosis burden in Africa is still to be determined. However, we can
expect it to rise in the coming years on this continent like on the others, due to socio-anthropological
changes and the increase of the groups at risk for this disease.
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Abstract: Burkholderia pseudomallei is endemic in northern Australia, with cases of melioidosis most
commonly occurring during the wet season in individuals with diabetes, hazardous alcohol use,
and chronic kidney disease. Pneumonia is the most common presentation and the majority of
patients are bacteraemic—however, infection may involve almost any organ, with the skin and soft
tissues, genitourinary system, visceral organs, and bone and joints affected most commonly. Central
nervous system involvement is rarer, but has a high attributable mortality. Increased awareness
of the disease amongst healthcare providers, ready access to appropriate antibiotic therapy and
high-quality intensive care services has resulted in a sharp decline in the case fatality rate over the
last 20 years. Further improvement in clinical outcomes will require a greater understanding of the
disease′s pathophysiology, its optimal management, and more effective strategies for its prevention.
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1. History
Melioidosis was initially described in Australia in 1949, following an outbreak in sheep in central
west Queensland [1]. The ﬁrst human case of melioidosis in Australia was described in Townsville,
North Queensland from 1950 [2] and cases were subsequently reported in the Northern Territory (NT)
from 1960 [3].
Melioidosis is endemic across northern, tropical Australia north of latitude 20◦ S [4–7], with
focal areas of endemicity described in much more southern, temperate regions (latitude 31◦ S) [8–10].
Outbreaks, related to contaminated water, have been described in pigs in south-east Queensland
(latitude 25.5◦ S) [11] and human and bovine cases have also been identiﬁed in the same region [12–14].
Even in dry, arid desert regions of Central Australia, cases of melioidosis have occurred following
intense rainfall, highlighting the organism’s ability to survive in harsh environments [15].
The incidence of melioidosis differs across northern Australia. In the Top End of the NT, yearly
incidence rates range between 5.4 and 50.2/100,000 population [6,16]. Indigenous Australians are
disproportionately affected and bear the greatest burden of the disease. During the monsoonal rains of
2009–2010, a wet season with above average rainfall, incidence increased to 102.4/100,000 population
in the Top End Indigenous population [16]. In the Torres Strait Islands, the mean incidence is
33.1/100,000 population [17].
Despite the high incidence of disease in northern Australia, background seropositivity rates are
relatively low compared to those seen in Southeast Asia, even if a lower indirect haemagglutination
assay titre cut-off of 1:40 is used. Rates range from 5 to 12.8%, with the highest identiﬁed in Indigenous
Australians and people living in rural locations [18,19].
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It was previously believed that Burkholderia pseudomallei colonised Australia from Southeast Asia,
but phylogeographic reconstruction suggests an Australian origin for B. pseudomallei, with dispersal
into Southeast Asia occurring after one or more introduction events during the last glacial period [20].
B. pseudomallei in northern Australia is genetically diverse; there is signiﬁcant differentiation
between the genotypes present in isolates from Queensland and the Northern Territory [21].
The organism rarely moves across major biogeographic boundaries; however, in Darwin, an Asian
B. pseudomallei strain, sequence type (ST)-562, has become a common ST affecting patients with
melioidosis in this area [22].
2. Melioidosis Cases and the Presence of B. pseudomallei
B. pseudomallei has been identiﬁed from a number of Australian animals, including goats [23],
sheep [1], camels [24], and alpacas [25], all of which are considered to be highly susceptible to
melioidosis [26]. Melioidosis commonly presents as mastitis in goats, but zoonotic transmission
remains exceedingly rare [26]. Outbreaks have occurred in pigs [11] and cases have been identiﬁed
in a wide variety of domestic and native Australia animals and birds [27–34]. B. pseudomallei has
been detected in faecal samples from wallabies and chickens, suggesting that faecal shedding may
contribute to the geographical expansion of the disease [35].
Melioidosis in humans is considered an opportunistic infection in Australia, with the vast
majority of people having at least one identiﬁable risk factor. The most common risk factors identiﬁed
are diabetes mellitus, hazardous alcohol use, chronic lung disease, and chronic kidney disease [6].
In healthy people, death from melioidosis is considered extremely rare if appropriate antibiotics and
intensive care support are available [6,17].
In Australia, melioidosis is usually acquired percutaneously or by inhalation. Infection by
ingestion is considered unusual, although outbreaks caused by contaminated drinking water supplies
have occurred [36,37]. In northern Australia, cases of melioidosis follow a seasonal pattern and
are strongly associated with monsoonal rains [17,38,39]. An increase in the dew point, cloud
cover, temperature, rainfall, and groundwater have all been associated with an increased risk of
the disease [40]. An increase in the number of people with melioidosis pneumonia has been attributed
to cyclones and tropical storms in the NT [41] and cyclones coincide with increased melioidosis cases in
Western Australia [42]; however, no correlation is seen between melioidosis cases and severe weather
events in Far North Queensland (FNQ) [43]. Melioidosis cases associated with severe weather events
have been shown to be caused by different B. pseudomallei MLST genotypes, suggesting that airborne
dissemination may not come from a common source [44].
Pneumonia is the most common presentation of melioidosis in Australia [45]. Bacteraemic
presentations vary between 55% and 74% with particularly high rates observed in FNQ [6,17]. While
this may partly be explained by differences in case ﬁndings, it is yet to be determined if strains in FNQ
are intrinsically more virulent.
Genitourinary involvement is common in Australia, with prostate abscesses occurring in up to
21% of males [46]. Imaging is required to conﬁrm the diagnosis; however, the absence of symptoms
and normal urinalysis may be sufﬁcient to exclude prostatic involvement [47]. Drainage of prostatic
abscesses is usually required to hasten cure and prevent relapse.
Osteomyelitis and septic arthritis occurs in up to 16% of Australian presentations [17]. Operative
intervention is often required, with the majority of patients requiring multiple procedures [48].
Paediatric melioidosis is uncommon in Australia and, in Darwin, has traditionally been associated
with skin and soft tissue infection [49,50]. In contrast to Southeast Asia, acute suppurative parotitis
is extremely rare in Australia [5], which is likely related to ingestion being an uncommon mode of
transmission. Case-fatality rates in Darwin children are comparable to that of adults but, in FNQ,
the rates of bacteraemia and mortality are much higher—60% and 50%, respectively—with fatal
cases occurring despite optimal treatment [51,52]. The explanation for this observation is uncertain,
although it may be partly explained by less active case ﬁnding in FNQ. Children in Darwin who
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present with only skin lesions have been shown to sometimes be infected with minority strains that
lack the virulence factor ﬁlamentous hemagglutinin gene—fhaB3—which may be more common in
FNQ strains [53].
Neurological melioidosis (meningoencephalitis and involvement of the brainstem, cerebellum,
and spinal cord) occurs in up to 5% of Australian melioidosis cases [54]. B. pseudomallei isolates
possessing a B. mallei—like bimA allele (bimBm) have been shown to have increased persistence in
phagocytic cells, increased virulence, and to be neurotropic and, hence, strongly associated with
neurological disease [55,56].
Environmental sampling has identiﬁed B. pseudomallei from soil and water across northern
Australia [57,58]. B. pseudomallei has been isolated from groundwater seeps in endemic areas [59]
and melioidosis cases have been linked to contaminated drinking well water [60], as well as two
documented outbreaks in remote indigenous communities being linked to contaminated water
supplies [36,37]. B. pseudomallei is seen in undisturbed, heavily grassed areas, but is also associated
with the presence of livestock animals [61]. Soil texture and lower pH levels promote growth of
the organism [61]. In Australia, soil exposure often occurs in domestic gardens, [6] where, due to
the addition of speciﬁc fertilisers and imported grasses, more B. pseudomallei is seen compared to
other environments [61,62]. B. pseudomallei has also been isolated from air samples from outside the
home of a patient with suspected inhalational melioidosis [63]. Outbreaks have been associated with
contaminated wound irrigation ﬂuid, although this is exceptionally rare [64]. Geographical locations
of conﬁrmed cases are shown in Figure 1.
Figure 1. The geographic distribution of confirmed human cases (A), animal cases (B), and environmental
isolates (C) of culture-conﬁrmed B. pseudomallei.
Mapping shows geographical locations of culture-conﬁrmed B. pseudomallei isolates only and
does not reﬂect incidence.
3. Surveillance Systems and Reporting
Human melioidosis is a notiﬁable disease in the NT, Western Australia and Queensland.
Notiﬁcation usually occurs directly from the microbiology laboratory and public health departments
gather information about each case, including occupational or recreational exposure, risk factors, and
clinical presentation [7]. In the NT, detailed clinical information has been collected prospectively for
over 28 years and a similar database has recently been established in Far North Queensland. Guidelines
for the management of animal melioidosis are available, including recommendations for safe disposal
of dead affected animals [65].
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4. Diagnosis
Clinicians in northern Australia have a high index of suspicion of melioidosis, particularly during
the wet season and in people with predisposing risk factors. Culture, the mainstay of diagnosis of
melioidosis, is accessible throughout endemic areas of Australia. Vitek 2 (bioMérieux, France)—the
automated biochemical system—is routinely used to conﬁrm the isolation of B. pseudomallei from
cultured specimens [66].
Matrix-assisted laser desorption/ionization time-of-ﬂight (MALDI-TOF) mass spectrometry is
available in many Australian laboratories and can be utilised to rapidly identify B. pseudomallei from
cultured specimens [67]; however, there is a requirement to expand existing databases with pathogens
endemic to different localities to help prevent incorrect identiﬁcation of other Burkholderia species.
A lateral ﬂow antigen detection assay has been developed as a rapid diagnostic tool, which is
proving to be useful as an adjunct to the diagnosis of melioidosis, however, it is not yet routinely
available [68]. Polymerase chain reaction is available in some areas to conﬁrm bacterial isolates
from clinical specimens, but is not sensitive or speciﬁc enough for routine use directly on clinical
samples [69–71].
Serological testing using an indirect haemagglutination assay is available in Australia, but its use
is limited in the diagnosis of acute disease in those from endemic locations because of background
seropositivity. It is used for identifying people previously exposed to B. pseudomallei prior to
commencing immunosuppressive treatment or for seroprevalence surveys [72,73].
In northern Queensland, the microbroth dilution method has been used to provide
epidemiological cut-off values of clinical isolates of B. pseudomallei to meropenem, ceftazidime,
trimethoprim-sulfamethoxazole (TMP-SMX) and doxycycline [74]. Meropenem and ceftazidime
provide reliable ﬁrst-line agents against melioidosis, with primary resistance being extremely
rare [75,76]. Primary resistance to TMP-SMX in Australian isolates is also extremely rare [77].
Secondary resistance is also uncommon; however, whole-genome sequencing of B. pseudomallei
isolates from patients receiving intravenous meropenem for melioidosis treatment have exhibited
decreased meropenem susceptibility [78]. Additionally, in cystic ﬁbrosis patients, multidrug-resistant
B. pseudomallei has been identiﬁed after prolonged antibiotic therapy [79].
A chest X-ray is performed on all patients with melioidosis. A computed tomography (CT) scan of
the abdomen and pelvis is also routinely performed in all adult patients with conﬁrmed or suspected
melioidosis to identify abscesses in the prostate, liver, spleen, and kidneys. For pregnant women
and children, an abdominal ultrasound is considered a reasonable alternative. In patients with CNS
involvement, CT images may be normal and magnetic resonance imaging (MRI) is preferred. MRI
often shows extensive hyperintense changes on T2-weighted images; microabscesses, leptomeningeal
enhancement, and trigeminal nerve involvement are also common [54,80,81].
5. Treatment
Treatment of melioidosis in Australia consists of an intensive phase with intravenous antibiotics
followed by a prolonged eradication phase with oral antibiotics. Meropenem or ceftazidime is used in
the intensive phase and both are readily available in Australia, even in remote areas. Additionally, sick
patients from rural or remote areas are quickly transferred to referral hospitals or tertiary care centres.
Antibiotic regimens are presented in Table 1.
In people with neurological infection, bone or joint infection, genitourinary infection, and skin
and soft tissue infections, TMP-SMX is added to the intensive regimen during the intensive phase.
Folic acid 5 mg (child: 0.1 mg/kg up to 5 mg) orally, daily, is given to all people receiving TMP-SMX.
Due to concerns regarding adherence to prolonged oral antibiotics, in the NT a longer intensive
phase has been developed [10] (Table 2). Using this strategy, the rates of relapse in the NT are very low,
even when there is poor adherence to oral eradication therapy [6,53]. A prolonged intensive phase is
also used in FNQ, although in this region relapse is more commonly explained by poor initial source
control rather than non-adherence to oral eradication therapy [17].
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To facilitate adherence to prolonged intravenous antibiotic therapy, ceftazidime administered to
outpatients via a peripherally-inserted central catheter using 12-h elastomeric infusers has been widely
adopted in Australia and is safe and effective [82].
Table 1. Antibiotic dosing for treatment of melioidosis in Australia.
Phase Antibiotic Adult Dose Child Dose
Intensive Meropenem
1 g intravenously 8-hourly
2 g intravenously 8-hourly 1
25 mg/kg up to 1 g intravenously
8-hourly
50 mg/kg up to 2 g intravenously
8-hourly 1
Intensive Ceftazidime 2 g intravenously 6-hourly 50 mg/kg up to 2 g intravenously6-hourly
Intensive and
eradication
Trimethoprim-
sulfamethoxazole
≥60 kg: 320 + 1600 mg orally
12-hourly
40–60 kg: 240 + 1200 mg orally
12-hourly
6 + 30 mg/kg up to 240 + 1200 mg
orally 12-hourly
Eradication Amoxicillin-clavulanate 20/5 mg/kg orally 8-hourly 20/5 mg/kg orally 8-hourly
Eradication Doxycycline 100 mg orally 12-hourly Not recommended
1 For cases with neurological involvement.
Table 2. Recommended antibiotic duration for the treatment of melioidosis in Australia.
Site of Infection Minimum IntensivePhase Duration (Weeks)
Eradication Phase
Duration (Months)
Cutaneous infection only 2 3
Bacteraemia without focus 2 3
Pneumonia without lymphadenopathy or ICU admission 2 3
Pneumonia with lymphadenopathy 1 or ICU admission 4 3
Deep seated collection 2 4 3 3
Septic arthritis 4 3 3
Osteomyelitis 6 6
Central nervous system infection 8 6
Mycotic aneurysm or other arterial infection 8 6
1 Deﬁned as any hilar or mediastinal lymph node greater than 10 mm. 2 Involving the liver, spleen, kidneys, or
prostate. 3 Start of intensive phase begins after the last drainage or tissue specimen grows B. pseudomallei.
Oral eradication therapy is routinely prescribed and TMP-SMX remains the treatment of choice.
Oral doxycycline is considered as an alternative for people who cannot tolerate TMP-SMX, while oral
amoxicillin-clavulanate may be used as an alternative in pregnant women or young children [83].
Case-fatality rates have decreased dramatically over the last 20 years, and is felt to be due to earlier
recognition and diagnosis, ready access to therapy, and improving intensive care unit support [6,17].
Between 1989–1997, up to 92% of critically unwell patients with melioidosis died; however, with the
introduction of an intensivist-led model of care and the empirical use of meropenem, case-fatality
rates in this patient group dropped to 26% [84]. The reduced case-fatality rate coincided with the
introduction of adjunctive treatment with granulocyte colony-stimulating factor (G-CSF); however,
the attributable mortality beneﬁt of G-CSF is uncertain [85,86]. In FNQ, G-CSF is not used and mortality
rates are comparable to those seen in the NT [17].
6. Awareness and Prevention of Melioidosis
People who are at risk of acquiring melioidosis are advised to wear gardening gloves and footwear
when coming into contact with soil [73]. Australian Government authorities provide easily-accessible
recommendations on how to prevent melioidosis. This includes advice to remain indoors during wet
and windy weather conditions, to wear a mask when using a pressure hose outside and to limit alcohol
consumption [87]. A melioidosis awareness campaign in the NT, promulgating the aforementioned
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recommendations, provided factsheets, posters, and radio announcements to people at risk of acquiring
melioidosis, as well as enclosed shoes to particularly vulnerable populations [88].
People receiving long-term haemodialysis are at particular risk of developing melioidosis [89].
In Darwin, prophylaxis using oral TMP-SMX three times per week post-dialysis is a safe and effective
way to reduce this risk and is recommended in other areas where melioidosis is prevalent [90].
Melioidosis serology is recommended in all people prior to starting immunosuppressive treatment
in the Top End of the NT. If positive, a urine specimen, sputum sample, and throat, rectum and
wound swabs should be collected for melioidosis culture to exclude active disease [73]. High-risk
immunosuppressed patients are given prophylaxis with daily dosing of oral TMP-SMX for the duration
of the wet season.
In animals, strategies to reduce the risk of acquiring disease include limiting their access to
high-risk areas and providing sufﬁcient drainage to help avoid surface water accumulation. It is
recommended that penned animals are kept on dry solid ground or concrete [91], while unpenned
animals should be removed from the area of contamination source and have their water supplies
chlorinated [26]. Ultraviolet light sterilisation may also be used to reduce B. pseudomallei levels in
contaminated well water [60].
7. Major Achievements
The Darwin Prospective Melioidosis Study started on 1 October 1989. Since this time,
the programme has documented the many and varied presentations of melioidosis. The program has,
in close collaboration with colleagues in Thailand, also undertaken long-term studies, and developed
the current treatment guidelines that are used globally, which have helped halve the case fatality rate
of melioidosis in northern Australia from 30% to under 15%. Discoveries include the documentation
of the spread of melioidosis by introduced grasses and birds. The storage of all isolates with linked
patient data will serve as a resource for future research into diagnostics, therapeutics, and vaccines.
Over 1000 B. pseudomallei isolates from humans, animals, and the environment across Australia
have been submitted to the B. pseudomallei MLST database (http://bpseudomallei.mlst.net/). This
has permitted the comparison between clinical and environmental isolates, as well as studies of the
diversity of B. pseudomallei in Australia [92].
8. Current and Future Challenges
Changes in the world′s climate is likely to have an effect on the range and transmission of
B. pseudomallei; a rise in the sea surface and ambient temperature may lead to an increase in melioidosis
cases in Australia [40]. The genetic diversity of B. pseudomallei populations has been characterised by
using multilocus sequence typing (MLST); however, due to its high recombination rate, B. pseudomallei
isolates may share the same MLST despite being genetically and geographically distinct [93].
Therefore, whole-genome sequencing—which may not always be readily available—is required
to identify strain origin in cases where the same ST is identiﬁed between geographically-different
locations. Geographically-distinct virulence-associated genes have been found to be over-represented
in Australian B. pseudomallei isolates [94]. The pathogenic nature of most of these virulence factors is
not well established and requires further elucidation.
In addition to environmental factors, host factors, including increasing rates of diabetes mellitus
and ongoing hazardous alcohol use are expected to increase the population at risk of melioidosis.
Further education targeting risk factors and strategies to prevent B. pseudomallei exposure are required.
In the absence of a suitable vaccine candidate, the use of prophylactic antibiotics to target at-risk
populations requires further research.
Extending the intensive phase of intravenous antibiotics in melioidosis has been associated with
favourable outcomes and a minimal risk of relapse; therefore, the beneﬁts of, and ongoing need for,
prolonged oral antibiotics during the eradication phase for every patient with melioidosis requires
further work. The effect of adequate source control on the duration of therapy also requires exploration.
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The above challenges will be made possible with continued collaboration both across endemic
areas of Australia, as well as with colleagues internationally.
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Abstract: Melioidosis is known to occur in Bangladesh, but there are few reports about the condition
in the published international literature. We set out to review all known cases of melioidosis in the
country to date, using both retrospective and prospective data. A web-based literature search was
conducted to identify all published case reports, original articles and conference abstracts. Cases
were also included from a prospective study conducted in 2017. Fifty-one cases were identiﬁed
between 1961 and 2017. Cases have been reported from sixteen out of the 64 districts of Bangladesh.
The median age of the patients at presentation was 45 years (IQR 37–52), with a signiﬁcant male (77%)
predominance. Many patients (14/39; 36%) were farmers and 83% had diabetes mellitus. A skin/soft
tissue abscess was the most common primary clinical presentation (13/49; 27%), followed by septic
arthritis (10/49; 20%), pneumonia, and a deep-seated abscess/organ abscess (7/49; 14%). The major
challenges to the diagnosis and treatment of melioidosis in Bangladesh are the lack of resources and
the lack of awareness of melioidosis. Capacity development programs are urgently required to deﬁne
the burden of disease and to tackle the mortality rates.
Keywords: melioidosis; Burkholderia; Bangladesh
1. Introduction and History of Melioidosis in Bangladesh
Melioidosis is an important cause of infectious disease across Southeast Asia, and it is believed to
be a problem in Bangladesh, based on anecdotes and a few case reports [1–3]. The disease is caused by
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a highly pathogenic, soil-borne, Gram-negative bacterium, Burkholderia pseudomallei [4]. Bangladesh
is an example of a highly populous, agricultural country where melioidosis may be a signiﬁcantly
underdiagnosed cause of infection and death. A lack of awareness among microbiologists and
clinicians and a lack of diagnostic microbiology infrastructure are factors that are likely to lead to the
underreporting of melioidosis. The ﬁrst reported, conﬁrmed case of melioidosis that was acquired
from Bangladesh (at that time known as East Pakistan) was a British sailor, who was travelling east
of Suez [5]. In October 1960, his ship was carried half a mile inland near Chittagong by a cyclone,
and was deposited in a paddy ﬁeld [5]. The crew stayed there for three months and were repatriated
in January 1961. The patient developed symptoms in May in the UK of that year and eventually
received a diagnosis of melioidosis based on pus cultures in Liverpool [5]. Several individual case
reports/series of melioidosis have been published from Bangladesh since that time. Cases have also
been reported among Bangladeshi immigrants presenting in other countries [5–16].
The clinical presentation of melioidosis is widely varied, and a deﬁnitive diagnosis requires
a skilled microbiology laboratory, making it more difﬁcult to diagnose in low-resource settings such as
Bangladesh. Agriculture is the most productive sector of the country’s economy, contributing about
30% of the nation’s GDP and providing over 90% of Bangladesh’s rural employment [17]. A recent
modelling study predicted a melioidosis burden of nearly 17,000 cases and 9500 deaths a year in
Bangladesh [3,18]. This review identiﬁes 51 cases covering all the published case reports, series,
and unpublished cases during the period from 1964 (the case report of the 1961 British sailor) to 2017,
with the aim of generating further evidence to increase the awareness of the disease in the national
and international healthcare community.
2. Review of Melioidosis Cases and Presence of B. pseudomallei in Bangladesh
This was a descriptive study involving both retrospective and prospective data analysis.
A web-based literature search was conducted using PubMed, Google Scholar, Medline, ResearchGate,
and the Bangladesh Journals Online (BanglaJol) database to identify all published, culture-conﬁrmed
case reports of melioidosis in Bangladesh. The key search terms were ‘melioidosis’, ‘Burkholderia’,
and ‘Bangladesh’. Additional published cases were also identiﬁed from the personal EndNote database
of one of the authors (D.A.B.D.). We also conducted a prospective study during 2017 in Dhaka to
identify cases among patients admitted with an acute febrile illness and included patients conﬁrmed
as having culture-positive melioidosis, in this review.
2.1. Published and Unpublished Cases
Overall, we identiﬁed 25 case reports/case series, one original article, and three conference
abstracts describing cases of culture-conﬁrmed melioidosis in Bangladesh. Of these, one case report,
one original article, and two conference abstracts were excluded due to the duplication of data.
Additional cases were diagnosed through our research project in 2017. The cases were reported
between 1964 and 2017. Of the 24 case reports, twelve described Bangladeshi immigrants diagnosed
overseas (UK, Belgium, USA, Cuba, and Kuwait), all of whom had a history of travelling to Bangladesh
before their illness [5–16], whereas the rest were diagnosed and reported within Bangladesh [19–31].
2.2. Deﬁnitions of Clinical Manifestations:
In this review, major organ involvement and clinical features were classiﬁed as follows.
(a) Pulmonary: pneumonia, including complications such as a lung abscess or a pleural effusion.
(b) Musculoskeletal (MSK): septic arthritis, osteomyelitis, and others.
(c) Genitourinary (GU): infection of the urinary and genital tract, including the kidneys.
(d) Neurological: involvement of the brain and spinal cord, including the meninges.
(e) Organ abscess/deep-seated abscess: Abscess involving any solid organ or in any deep-seated site
such as the muscles.
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(f) Cutaneous: infection and abscess of the skin and subcutaneous tissue.
(g) Bacteraemia without focus: acute sepsis without any speciﬁc focus.
2.3. Climate Data
The monthly average mean temperature in degrees Celsius and the monthly average rainfall in
millimetres for the years 1961 to 2015 were collected from the climate change knowledge portal of the
World Bank [32].
2.4. Statistical Analysis
The results were expressed as median ± interquartile range (IQR) for continuous variables.
A choropleth map was drawn using geographic information system (GIS) data to illustrate the
distribution of the cases [33]. A choropleth map typically uses either differences in colour value
(sometimes in combination with hue) or differences in spacing (e.g., the intensity of a hatched pattern)
to represent the differences. The one sample t-test was applied to determine the level of signiﬁcance.
Statistical analysis was performed using IBM SPSS Statistics 22 for Windows, and GraphPad Prism
7 was used to display the results. Informed patient consent was obtained from the prospectively
studied cases, with ethical permission being granted by the institutional committees of Dhaka Medical
College (DMC) and the Bangladesh Institute of Research and Rehabilitation for Diabetes, Endocrine,
and Metabolic Disorders (BIRDEM).
2.5. Important Findings
Between 1964 and 2017, 51 cases of culture-positive melioidosis were diagnosed from Bangladesh,
with all the published cases listed in Table 1. The median age of the patients at presentation was
45 years (IQR 37–52), with a signiﬁcant male (79.6%) predominance (Table 2). The oldest patient
was 90 years old and the youngest was 8 years old. The median age of the patients in Bangladesh
was slightly lower compared to India, Thailand, Taiwan, and Australia [34–37]. However, the male
preponderance was higher than the ﬁndings from the same countries. A similar male predominance
was found in Malaysia [38]. This is probably because in countries such as Bangladesh, males are more
involved with outdoor activities. Moreover, the access to healthcare for women is still restricted due to
many reasons, including cultural and socioeconomic factors in Bangladesh [39,40].
The majority of the patients for whom data was available (14/39; 36%) were farmers by profession,
which is compatible with another hospital-based serosurveillance carried out in Bangladesh in 2010,
where farmers had an increased risk of seropositivity (risk ratio = 1.4, 95% CI 1.0–1.8; p = 0.03) [41].
The survey recorded 28.9% positivity for B. pseudomallei through an indirect haemagglutination assay
among 1244 adult febrile patients [41]. However, another study reported 22.6% to 30.8% seropositivity
in three districts (Gazipur, Mymensingh, and Sylhet) where melioidosis cases were detected earlier,
compared to 9.8% in a district (Kishoreganj) where no melioidosis cases were either detected or
reported (p < 0.01) [42]. The same study found no signiﬁcant difference among different occupational
groups (χ2 = 3.835, p = 0.280) [42]. Over 88% (23/26) of cases in Bangladesh had a deﬁnitive history of
soil exposure (Table 2). This is related to the occupational activities of the patients.
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Table 1. Reports of all culture-conﬁrmed melioidosis cases from Bangladesh.
Year of Report Presumed Location of Infection in Bangladesh Location of Diagnosis No. of Case/Cases Reference
1964 Chittagong UK 1 5
1969 Unknown UK 1 16
1970 Unknown UK 1 15
1988 Unknown Bangladesh 1 30
1991 Sylhet UK 1 13
1999 Sylhet UK 3 10
1999 Sylhet UK 1 14
2000 Unknown UK 1 12
2001 Sherpur Bangladesh 1 31
2007 Unknown Belgium 1 8
2007 Rangpur Belgium 1 9
2012 Unknown USA 1 7
2013 Unknown Bangladesh 1 27
2014 Gazipur, Mymensingh, Tangail, Dhaka,Narayanganj, Khagrachari, Comilla Bangladesh 15 23
2014 Gazipur Bangladesh 1 26
2014 Unknown Kuwait 1 6
2015 Gazipur Bangladesh 1 19
2015 Gazipur Bangladesh 1 21
2015 Mymensingh Bangladesh 1 25
2015 Unknown Bangladesh 1 24
2015 Gazipur Bangladesh 1 28
2016 Brahmanbaria Bangladesh 1 22
2016 Khagrachari Bangladesh 1 29
2017 Unknown. Cuba 1 11
2017 Narayanganj, Tangail, Feni, Comilla,Mymensingh, Dhaka, Noakhali, Jamalpur Bangladesh 11 20
Table 2. Baseline demographic characteristics of the culture-conﬁrmed cases.
Variables Number (%) p Value
Age (years; median, (IQR)) 45 (37–52)
Sex (n = 51)
Men 41 (80)
0.0001Women 10 (20)
Occupation (n = 39) ψ
Farmer 14 (36)
Housewife 8 (21)
Worker/day labourer 4 (10)
Unemployed 4 (10)
Carpenter 2 (5)
Others 7 (18)
History of soil/environmental exposure (n = 26) ψ
Yes 23 (88)
0.0001No 3 (12)
ψ Variables have missing data. By one sample t-test.
Cases have been reported from sixteen out of 64 districts of Bangladesh, all of which were in the
eastern and northern parts of the country (Figure 1). In five patients, the geographic location could not be
identified. The highest number of cases (9/46; 18%) were recorded from Gazipur, followed by Tangail
(6/46; 12%), Sylhet (5/46; 10%), Mymensingh (4/46; 8%), Feni (4/46; 8%), and others. This study confirms
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that the Gazipur, Tangail, Sylhet, and Mymensingh districts are hotspots for melioidosis in Bangladesh.
Our findings are in consensus with the soil surveillance carried out in these districts in 2011 and confirmed
its presence. The isolates were phenotypically identical, arabinose negative and showed a specific 550 bp
band in PCR [42]. The reason behind the dearth of cases to the west may be multiple. The agricultural
pattern is regionally variable in Bangladesh, especially for rice, which is mainly grown in the north, south,
and northeast districts [43]. Moreover, rice is cultivated in two seasons in the north, northeast, and south,
but it is cultivated only once a year in the western districts [43]. There is also a clear variation in the
pattern of rainfall. High rainfall occurs twice in the northeastern part of the country compared to the
west [44]. However, the lack of cases in western Bangladesh could also be due to a lack of diagnosis
and/or the underreporting of cases. The communication to the capital from the western and northwestern
parts of the country is also more difficult compared to other regions. The infrastructure development
index (IDI) is also very poor for those districts [45], so many patients may not travel to Dhaka and other
major centres for diagnosis and treatment.
Figure 1. ChoroplethmapbasedonGISdata. Themap illustrates the frequencybydistrict of culture-confirmed
cases of melioidosis (n = 46).
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In thirty-eight cases, the period between the onset of symptoms and the diagnosis of melioidosis was
calculated (Table 3). Themedian durationwas 36 days (IQR 18.75–79.5). Specific risk factors/co-morbidities
were identified in forty-eight cases. A high proportion (40/48; 83%) of the cases had diabetes mellitus
(Table 3). Among these, 11 were already known to have diabetes at presentation and the rest (29; 76%)
were diagnosed after hospital admission. The other comorbidities were smoking (3/48; 6%), chronic
kidney disease (CKD; 2/48; 4%), and hypertension (2/48; 4%). We also found alcoholism, ischaemic
cardiomyopathy (ICM), and haemoglobin E (HbE) trait in single cases. The presence of B. pseudomallei
was confirmed in various culture samples. Twenty-three patients (45%) were positive on pus culture.
The second most common positive sample was blood (22/51; 43%). Other sources of the bacterium were
joint fluid (10/51; 20%), other swabs (6/51; 12%) such as skin, nasotracheal, and tracheal; urine (5/51; 10%)
and sputum (3/51; 6%). In total, fourteen patients (27%) died and thirty-seven (73%) survived.
Table 3. Prehospital and laboratory characteristics and clinical outcome of culture-conﬁrmed cases.
Variables Number (%)
Time between symptom onset and diagnosis (days; median, (IQR)) 36 (18.75–79.5)
Risk factors (n = 48) ψ
Diabetes mellitus 40 (83)
Chronic kidney disease 2 (4)
Hypertension 2 (4)
Smoking 3 (6)
Others (alcoholism, ICM, Hb ET) € 3 (6)
Culture-positive samples (n = 51) ψ
Blood 22 (43)
Pus 23 (45)
Joint ﬂuid 10 (20)
Urine 5 (10)
Sputum 3 (6)
Other samples (skin/nasotracheal/tracheal aspirate) 6 (12)
Mortality (n = 51) ψ
Survived 37 (73)
Died 14 (27)
Variables have missing data. ψ includes multiple positive sites. € ICM—ischaemic cardiomyopathy, Hb
ET—haemoglobin E trait.
The majority of cases were diagnosed during the rainy season from June to September (Figure 2).
The primary clinical presentation and major system involvement of 49 cases are shown in Table 4.
In two patients, there was insufﬁcient information in the reports to enable their classiﬁcation.
A skin/soft tissue abscess was the most common primary clinical presentation (13/49; 27%), and none
of the patients with localised cutaneous lesions died. The second most common presentation was septic
arthritis (10/49; 20%), with one death occurring within this group of patients (a known diabetic woman
with CKD who was admitted to hospital with shock and subsequently developed acute-on-chronic
renal failure and died). The next most common presentations were pneumonia (7/49; 14%) and
a deep-seated abscess/organ abscess (7/49; 14%). Two patients died of pneumonia and one with
an organ abscess. Five patients (10%) presented with a urinary tract infection and/or acute kidney
injury (AKI), and three of these patients died. All of these cases were admitted with shock and multiple
organ involvement. Four (8.1%) patients presented with sepsis without any focus, and three (6%)
presented with symptoms and signs suggesting a possible diagnosis of meningitis, although no lumbar
punctures were done. All seven of these patients (median age 50 (IQR, 40–59)) were diabetic and
developed multiple organ failure during admission and died.
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Table 4. Clinical description of culture-conﬁrmed melioidosis cases (n = 49).
Clinical Variables Number (%) Number of Deaths (%)
Primary Clinical Presentation
Skin and subcutaneous abscess 13 (27) 0 (0)
Septic arthritis 10 (20) 1 (10)
Pneumonia 7 (14) 2 (29)
Organ abscess/deep-seated abscess 7 (14) 1 (14)
Urinary tract Infection/Acute kidney injury 5 (10) 3 (60)
Sepsis without focus 4 (8) 4 (100)
Meningitis 3 (6) 3 (100)
Major System Involvement ψ
Musculoskeletal 21 (43) 1 (5)
Organ abscess/deep-seated abscess 13 (27) 1 (8)
Cutaneous 13 (27) 0 (0)
Pulmonary 10 (20) 2 (20)
Genitourinary 9 (18) 3 (33)
Bacteraemia without focus 4 (8) 4 (100)
Neurological 3 (6) 3 (100)
Total 14 (27)
ψ Includes multisystem involvement.
Figure 2. The monthly cases of culture-conﬁrmed melioidosis, the average rainfall in mm, and the
average temperature in degrees Celsius. Data represented from 1961 to 2015 [32].
In terms of treatment, 46.3% (19/41) patients were treated with ceftazidime and 41.4%
(17/41) received meropenem. Among the cases diagnosed overseas and before 1999, four (9.7%)
received cotrimoxazole plus chloramphenicol, and one patient (2.4%) received doxycycline plus
amoxicillin/clavulanic acid as intensive phase therapy in this series.
3. Current Recommendations and Availability of Measures against Melioidosis
3.1. Surveillance Systems and Reporting
3.1.1. Human
Melioidosis is not a statutorily notiﬁable disease in Bangladesh, and there is no formal surveillance
system in place for human melioidosis. Reported cases therefore tend to arise from individual
researchers who have a speciﬁc interest. At present, the health directorate (Ministry of Health and
Family Welfare, Bangladesh) has no speciﬁc program or operational plan on melioidosis in Bangladesh.
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3.1.2. Animal
The infrastructure and facilities for veterinary services and research in Bangladesh are very weak.
There is no surveillance system for animal melioidosis currently in place. No veterinary reports have
ever been issued from Bangladesh.
3.2. Guidelines
Currently, Bangladesh does not have any national management or treatment guideline for
melioidosis. The majority of indigenous cases were diagnosed and treated at BIRDEM General
Hospital. The Microbiology Department of BIRDEM hospital follows the Clinical and Laboratory
Standard Institute (CLSI) guidelines wherever possible. BIRDEM doctors follow current published
treatment guidelines [46].
3.3. Treatment
The antimicrobial susceptibility pattern of clinical isolates showed 100% sensitivity to ceftazidime,
imipenem, piperacillin–tazobactam, amoxicillin–clavulanic acid, and tetracycline by both disk diffusion
and MIC methods in Bangladesh [47]. Intravenous antibiotics (ceftazidime and meropenem/imipenem)
for the acute phase and oral antibiotics for the eradication phase are available in the local market
(district and divisional level). Patients usually need to purchase their own drugs for the ﬁrst two
to three days of treatment, and thereafter, they are supplied by the hospital free of cost. It takes
some time to order the drug, gain approval from the relevant authority, and obtain a supply from the
hospital pharmacy. It is worth mentioning that a free supply of these drugs is only possible in tertiary
level hospitals (medical college hospitals), and not in primary (subdistrict) or secondary (district)
hospitals. In private clinics, patients need to bear the whole treatment cost. In a developing country
such as Bangladesh, it is difﬁcult for many to bear the treatment cost of melioidosis. There is also
a dearth of intensive care unit (ICU) beds in tertiary level hospitals in Bangladesh. The moderately
high mortality is probably due to late diagnoses, a delayed door-to-needle time for the delivery of
appropriate antibiotics, and a lack of ICU care.
4. Awareness of Melioidosis
Awareness of melioidosis among clinicians, microbiologists, and health policymakers is
inadequate. Although several case reports have been published in local and international journals,
the probability of clinicians considering melioidosis as a diagnosis and requesting the laboratory
to look speciﬁcally for the bacterium remains low. Public awareness of this organism, particularly
among farmers and other high-risk populations, is very low. Recently, the Bangladesh Association
for Advancement of Tropical Medicine (BAATM) and the Bangladesh Society of Medicine (BSM) took
some special initiatives to raise awareness among clinicians by organising seminars and lectures.
David A. B. Dance and Susanna J. Dunachie recently visited Bangladesh on their invitations and
conducted seminars in Dhaka. The third South Asian Melioidosis Congress is planned to take place in
Bangladesh in 2019, which will further contribute to raising awareness.
5. Major Achievements
So far, the scientists of Ibrahim Medical College and BIRDEM have conducted research on
melioidosis in Bangladesh despite the relatively low numbers of cases reported. Doctors at BIRDEM
have diagnosed the majority of cases so far in Bangladesh. However, apart from IMC and BIRDEM,
microbiologists elsewhere in Bangladesh are unfortunately not currently diagnosing melioidosis.
Therefore, we plan to organise capacity development workshops with the support of Mahidol Oxford
Research Unit (MORU) and LaoOxford-Mahosot Hospital–Wellcome Trust Research Unit (LOMWRU)
for the microbiologists and the clinicians working at tertiary level hospitals in Bangladesh, though
funding is currently pending. We also recently completed a prospective study to see if melioidosis
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is a signiﬁcant cause of febrile illness in Bangladesh at DMC and BIRDEM in collaboration with the
University of Oxford, which will form the basis for a long-term study of melioidosis in Bangladesh.
6. Current and Future Challenges
The major challenges to the diagnosis and the treatment of melioidosis in Bangladesh are a lack
of resources and a lack of awareness. Clinicians do not think about this disease in the ﬁrst instance,
and subsequently, microbiologists are not alerted to look speciﬁcally for the bacterium. In addition,
microbiologists unfamiliar with B. pseudomallei are likely to discard the bacterium as a clinically
insigniﬁcant environmental Pseudomonas species. Microbiologists other than those at the BIRDEM
laboratory probably do not have the skills, training, and capacity to identify the organism. Therefore,
diagnostic capacity development is the key area where immediate attention and funding is required.
Awareness-building programs among clinicians are also necessary. Diabetes was found to be the
most common risk factor for melioidosis in this series, and this was a similar observation elsewhere.
The incidence of diabetes is rapidly increasing in Bangladesh, with 8.4 million people currently living
with diabetes [48]. Therefore, we predict that melioidosis could become an enormous clinical challenge
in Bangladesh. CKD, hypertension, and smoking were also identiﬁed as comorbidities in this series,
which are also quite prevalent among Bangladeshi populations. Melioidosis infects both animals and
humans. Surveillance among animal populations in the hotspot areas is also required to measure the
burden. A One Health approach is needed for the successful mitigation and control of the problem.
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Abstract: Melioidosis continues to be a major health care problem in Brunei Darussalam. The age
of patients, gender distribution, risk factors, and clinical presentations are similar to those reported
from other countries in the region. The incidence of melioidosis was high during the wet months and
in the Temburong district, which has the highest annual rainfall. In spite of adequate facilities for
diagnosis and treatment, the mortality remains high (27%). Women and those presenting with septic
shock had higher mortality. There is a case for making melioidosis a notiﬁable disease in Brunei
Darussalam. Coordinated efforts between policy-makers and various stakeholders are required to
effectively combat the disease.
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1. Introduction
Melioidosis is endemic in many countries of Southeast Asia, including Brunei Darussalam and in
northern Australia. It is estimated that 40% of all cases occur in the East Asia Paciﬁc region [1].
Brunei Darussalam is a country in Southeast Asia, located in the northeastern part of Borneo
island, with geographical coordinates of 4◦30′ N 114◦40′ E. The country is divided into four districts:
Brunei Muara, Tutong, Kuala Belait, and Temburong. The climate in Brunei Darussalam is tropical
equatorial and humid subtropical at higher altitudes with heavy rainfall [2]. The annual average
rainfall is more than 2300 mm for the whole of Brunei Darussalam and increases inland, with altitude,
to more than 4000 mm with maximum rainfall in the Temburong district [3]. The mean monthly rainfall
follows seasonal patterns with two maxima and two minima. The ﬁrst maximum is from October to
January, with December being the wettest month, while the second minor maximum is from May to
July, with May being relatively wetter [4].
In line with the aims of this special issue on melioidosis, this article addresses various aspects of the
disease in Brunei Darussalam. It is divided into the following parts: (i) a review of available literature
on melioidosis from Brunei Darussalam; (ii) the current approaches to diagnosis, management,
and prevention; (iii) epidemiological study of melioidosis with data obtained from 2015–2016;
(iv) melioidosis in animals; and (v) future challenges.
2. Review of Literature from Brunei Darussalam
The ﬁrst published report on melioidosis (24 cases) in Brunei Darussalam was by Luqman et al. [5].
It was more prevalent in the agricultural districts and in the period (1993, 1994) the rate increased from
2.9 to 5.6/100,000. The majority (79.2%) had risk factors, mostly diabetes mellitus. Septicaemia was the
presenting feature in 75% of cases, with 62.6% having multi-organ involvement. The mortality rate
was 20.8% and on follow-up, 60% of patients presented with relapse of the disease.
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The many and varied radiological manifestations of melioidosis in Brunei Darussalam were
reviewed by Lim and Chong [6]. Multiple organ involvement, especially the lungs, liver, and spleen,
were common. The ‘honeycomb’ appearance of abscesses, especially large abscesses and those seen in
the liver, was characteristic of melioidosis.
Chong et al. reported the characteristics of pancreatic melioidosis (4/65 cases who had undergone
CT imaging, median age 29.5 years (range 25–48 years)). Pancreatic involvement ranged from
multi-focal micro-abscesses to focal large abscesses, and associated ﬁndings included splenic vein
thrombosis, peri-pancreatic inﬂammation, and peri-pancreatic fat streaking. Pancreatic involvement
was typically part of multi-organ involvement [7].
Pande and Hj Abdul Kadir reported their experience with melioidosis affecting the extremities
(n = 14/48 (29.1%); median age 45 years (range 14–55)). The majority (n = 13, 92.8%) were men,
with 35.7% (n = 5) being expatriates working as labourers. Septic arthritis was the most common
presentation (n = 5), followed by cellulitis, abscess, and osteomyelitis (n = 3 each) [8].
The antibiograms of Burkholderia pseudomallei from Brunei Darussalam over a period of ten
years (679 isolates from 623 patients) showed that carbapenems, third-generation cephalosporins
(ceftazidime), piperacillin, and chloramphenicol had the highest susceptibility rates of between 98%
and 100%. Amoxicillin-clavulanic acid had a moderate susceptibility rate (76–100%) and quinolones
(ciproﬂoxacin, 32–68%) and co-trimoxazole (6–54%) had the lowest susceptibility rates. It is, however,
recognized that the disk diffusion method overestimates the resistance rate for co-trimoxazole [9].
The gentamicin susceptibility of the isolates was not reported.
A case of right frontal lobe brain abscess due to co-infection with B. pseudomallei and
Cryptococcus neoformans in a patient with underlying systemic lupus erythematosus was reported
by Samad et al. [10]. The patient was non-diabetic but was on steroid therapy and the diagnosis was
conﬁrmed only after surgical drainage.
Chong et al. reported their experience with urogenital melioidosis (n = 13, nine new cases, four
relapses; median age 38 (range 29–63 years)). The kidneys were involved in 72.3% followed by the
prostate (60%). Testicular and seminal vesicle involvement was noted in one case each. There was no
involvement of the gynaecological system [11].
In the clinical case series mentioned above, a male preponderance was noted, with diabetes
mellitus being the most common risk factor [7,8,11].
3. Current Approach to Diagnosis, Management, and Prevention
3.1. Microbiological Diagnosis
In Brunei Darussalam, the diagnosis of melioidosis is conﬁrmed by the isolation of B. pseudomallei
from clinical specimens, such as blood, sputum, abscess aspirates, pericardial ﬂuid, skin lesions,
or other clinical specimens. The clinical specimens are collected during the initial admission to the
hospital. Positive blood culture bottles are subcultured onto blood agar and MacConkey agar; urine
specimens are inoculated onto cystine lactose electrolyte-deﬁcient (CLED) agar; respiratory specimens,
onto blood agar, MacConkey agar, and chocolate agar; and pus specimens into cooked meat broth.
These are incubated at 37 ◦C for at least 24 h before being examined. For pus specimens, subsequent
subcultures are made from the broth onto blood agar and MacConkey agar and reincubated at 37 ◦C for
at least another 24 h before re-examination. Selective agars, such as those studied by Peacock et al. [12],
are not used in Brunei Darussalam, which means that in some cases growth of B. pseudomallei may be
missed. In a patient with high clinical suspicion of melioidosis, but with negative cultures, reactivity
in a B. pseudomallei serological test (sent abroad) is taken as a strong evidence of the disease.
The cultures are then examined for colony morphology and Gram-staining. Morphologically,
B. pseudomallei is identiﬁed as large, wrinkled colonies that have a metallic appearance with an earthy
odour. On Gram staining, the organism appears as Gram-negative bacilli with bipolar staining, which
gives a characteristic ‘safety pin’ appearance. The cultured colonies are further identiﬁed using the
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VITEK system, a commercial bacterial identiﬁcation system. However, it is noted that with the use
of the VITEK system there is potential for misidentiﬁcation of B. pseudomallei as Burkholderia cepacia,
which is regionally dependent [13]. This is of particular signiﬁcance as the study reporting this was
from Malaysian Borneo, on the same island as Brunei Darussalam.
All of the isolated organisms are tested for antibiotic susceptibility using Etest and, at present,
the results of susceptibility testing are not validated by an external reference laboratory.
3.2. Management
Patients who are clinically suspected to have melioidosis, particularly those with a background
history of uncontrolled diabetes mellitus, are empirically treated with an antibiotic that has activity
against B. pseudomallei, i.e., either with intravenous (IV) ceftazidime (up to 2 g every 8 h) or,
for clinically-severe cases, with IV imipenem (up to 1 g every 8 h) or IV meropenem (up to 1 g
every 8 h) while waiting for culture results to become available.
In patients with conﬁrmed B. pseudomallei bacteraemia, and in those patients who were empirically
treated with either IV imipenem or meropenem and who have been stable for 48 h, the IV antibiotic
is de-escalated to IV ceftazidime. Further investigations, like chest radiographs, ultrasound of the
abdomen and pelvis, or computed tomography (CT) scan of the thorax, abdomen, and pelvis (CT-TAP),
are usually performed to exclude deep-seated infection with organ abscesses that may be drainable.
The antibiotic treatment for melioidosis comprises two phases, i.e., the intensive phase and the
eradication phase. In the intensive phase, IV antimicrobial therapy with either IV ceftazidime or IV
meropenem or imipenem is recommended for at least 10–14 days for pulmonary disease or if there are
no other obvious deep-seated sources. The intensive phase may be extended to at least 4–6 weeks with
drainage of deep-seated abscesses. The patient is then continued on to the eradication phase with oral
co-trimoxazole (5 mg/kg of the trimethoprim component every 12 h) as the ﬁrst line antimicrobial
therapy for at least 12 weeks in total. If co-trimoxazole is contraindicated or the patient develops
adverse reactions to the medication, then the second-line treatment would be with oral co-amoxiclav
(625 mg every 8 h) and oral doxycycline (2 mg/kg every 12 h) to complete a total minimum of 12 weeks.
However, clinicians need to be aware of the risk of treatment failure with this second-line eradication
phase regimen [14,15]. Currently no post-exposure prophylaxis is offered in Brunei Darussalam.
3.3. Preventive Measures
Patients who are admitted with suspected or conﬁrmed pulmonary melioidosis are nursed in
droplet isolation for at least 24 h after appropriate antibiotics are commenced.
In the laboratory setting, biosafety level 3 practices are adopted while handling and processing
specimens [16].
4. Epidemiological Study of Melioidosis with Data Obtained from 2015–2016
4.1. Material and Methods
All culture-positive cases of melioidosis recorded between January 2015 and December 2016
were retrieved from the electronic database of the Clinical Microbiology Laboratory, Department of
Laboratory Services, RIPAS Hospital. All patients were investigated and managed as per the protocol
mentioned in the previous section.
Demographic, clinical and diagnostic information (laboratory and imaging) was collected through
the Hospital Information Management System (BruHIMS). The study was approved by the Medical
and Health Research and Ethics Committee (MHREC).
Data are presented as descriptive statistics. Wherever possible, differences between groups were
analysed using the chi-square test. A p-value of <0.05 was considered signiﬁcant.
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4.2. Results
4.2.1. Demographics
A total of 115 cases were detected in 2015 (n = 46) and 2016 (n = 69). There were 84 (73%) male
and 31 (27%) female patients with an age range from 2 to 86 years (median 48 years).
There were four (3.5%) patients under the age of 15 years, all with no risk factors, who presented
with abscesses in soft tissue (n = 3) and neck (n = 1). They were admitted in the months of January,
April, August, and December.
Excluding a two-year-old expatriate patient, the median age of expatriate patients was 41.5 years
(n = 25). The age range for Bruneian patients (n = 89) was 14 to 86 years with a median age of 52 years.
The ethnic distribution of the cases is given in Table 1.
Table 1. Ethnic distribution of cases of melioidosis.
Country No. %
Malay 88 76.5
Chinese: Bruneian 1 0.9
Expatriates 26 22.6
Bangladesh 10 8.7
Indonesia 8 7
India 4 3.5
Philippines 1 0.9
Thailand 1 0.9
Nepal 1 0.9
Malaysia 1 0.9
During 2015–2016, the ethnic distribution of the population of Brunei Darussalam was Malay
(65.7%), Chinese (10.3%), and expatriates (23.9%) [17].
The overall incidence rates per 100,000 population in 2015 and 2016 were 11 and 16.3, respectively.
The number of cases and incidence rate per 100,000 population from each of the four districts is
presented in Table 2.
Table 2. District-wise incidence of melioidosis/100,000 population for 2015–2016.
District Pop. 2015 Cases Inc/100,000 Pop. 2016 Cases Inc/100,000
Muara 288,400 33 11.44 292,705 51 17.42
Tutong 48,700 9 18.48 49,438 8 16.18
Kuala Belait 69,000 2 2.89 69,992 6 8.57
Temburong 10,400 2 19.23 10,543 4 37.93
Population ﬁgures obtained from http://www.depd.gov.bn/sitePages/Population.aspx [17].
The incidence was highest in the Temburong district in both years (Figure 1). Except in the Tutong
district, there was an increase in incidence for the remaining districts from 2015 to 2016.
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Figure 1. Map showing incidence/100,000 population for 2015 and 2016 by district, Brunei Darussalam.
4.2.2. Month-Wise Number of New Cases
The number of cases (2015 and 2016 combined) according to the month of admission is presented
in Figure 2.
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Figure 2. Meliodosis cases by month (2015–2016).
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The maximum number of admissions were recorded in the months of January and May with
smaller peaks in June, July, and December.
4.2.3. Risk Factors
A number of risk factors were identiﬁed and are presented in Table 3.
Table 3. Risk Factors for melioidosis.
Risk Factor Cases %
Diabetes mellitus 86 74.8
Chronic renal disease 23 20
Cardiac disease 17 14.8
Lung diseases (COPD/TB) 16 13.9
Excessive alcohol intake 6 5.2
Thalassemia 5 4.3
Malignancy 2 1.7
None 9 7.8
Note: Most of the chronic renal disease patients were those with end-stage renal failure on dialysis and thalassemia
patients who were transfusion-dependent and had iron overload.
Diabetes mellitus was the most common risk factor, recorded in 74.8% of cases. More than one
risk factor was present in 37.4% of cases, and there was no obvious risk factor seen in 7.8% (n = 9).
4.2.4. Clinical Presentations and Diagnosis
Various clinical presentations were recorded (Table 4), pneumonia being the most common (47%).
In seven cases (6%) no focus of infection could be found.
Table 4. Clinical presentation of melioidosis.
Presentation Cases %
Septic shock 25 21.7
Pneumonia 54 47
Soft tissue abscess 21 18.3
Musculo-skeletal 10 8.7
Neurological 1 0.9
No evidence of primary focus 7 6
Thirteen of 25 cases of septic shock had pneumonia as the primary source of infection, including
in the 54 cases of pneumonia.
Internal organ abscesses were most commonly noted in spleen and liver (Table 5).
Table 5. Internal organ abscess in melioidosis.
Organ Cases %
Spleen 27 23.5
Liver 20 17.4
Prostate 5 6
Lymph node 4 3.5
Kidney 2 1.7
Parotid 1 0.9
Brain 1 0.9
In most cases (67%), the diagnosis was conﬁrmed by blood culture (Table 6).
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Table 6. Source of culture for diagnosis of melioidosis.
Modality No. of Isolates %
Blood culture 77 67
Fluid culture 11 9.6
Pus culture 37 32.2
CT-TAP was performed in 50.5% (n = 58) of cases. The reasons for a patient not undergoing
CT-TAP were septic shock and serious illness, presentation as cellulitis or soft tissue abscess, and issues
with payment for expatriate workers.
4.2.5. Outcome of Treatment
In the years 2015 and 2016, there was an overall mortality of 27% (Table 7). Mortality in patients
presenting with septic shock was 64%. The mortality in women was 41.9% (13/31) compared to 21.4%
(18/84) in men (p < 0.005).
Table 7. Outcome of treatment of cases.
Outcome Cases %
Recovery 79 68.7
Death 31 27
Relapse 5 4.3
Of the ﬁve cases with relapse, one patient died during readmission with septic shock (not included
in the 31 fatalities).
In 2015, 11 patients (23.9%) were admitted with septic shock and the mortality was 26.1% (n = 12)
compared to 14 patients (20%) and 27.5% (n = 19), respectively, in 2016. Five of the nine patients
without any risk factors succumbed to the disease.
4.3. Discussion
This is the ﬁrst detailed epidemiological study of melioidosis from Brunei Darussalam. The data
have revealed a slight increase in incidence from 11 to 16 per 100,000 population between 2015 and
2016. It also showed a high number of expatriate workers being affected. Diabetes mellitus and chronic
renal disease were the most common risk factors, whilst pneumonia and soft tissue abscess were the
most common clinical presentations. The data suggested a possible link with seasonal variation in
rainfall with more cases diagnosed in the wet months. Interestingly the highest incidence rate was
from the Temburong district, which has the highest annual rainfall. The mortality was 27%, being
higher in women and patients presenting with septic shock.
For the purpose of discussion, we have compared our results with other large epidemiological
studies from Asia-Paciﬁc published after 2010 [18–25]. Our ﬁndings of male preponderance, the median
age of patients, diabetes mellitus and chronic renal disease as the most common risk factors,
and pneumonia and soft tissue abscesses as the most common presentations, are similar to the
studies reviewed.
Though occupational history was not consistently recorded in the hospital notes, similar to
a previous study [8], 25 expatriate patients with varied nationalities (median age 41.5 years) were
noted. Generally the majority of these were labourers working in the agriculture or construction
industries, with a high chance of exposure to contaminated soil and water.
The overall incidences of 11 and 16.3 per 100,000 population in 2015 and 2016, respectively, are
considerably higher than those reported from Thailand and Singapore [22,25]. It is important to
note that, in Singapore, a recent decrease in incidence was reported [25], while the incidence has
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remained constant or increased in Australia and Thailand [18,22]. Our rates are comparable to the
rate of 16.45/100,000 reported from the state of Kedah, Malaysia by Hassan et al. [21]. In contrast,
another study based on the melioidosis registry from the Pahang state of Malaysia reported a much
lower rate of 4.3/100,000 (adult 6.0/100,000 and paediatric 1.6/100,000) [26]. This reﬂects geographical
differences, as seen in our study, with different rates between districts, even for a small country.
The current rates reported showed marked increase compared to the incidence rates (2.9 to
5.6/100,000 for 1993 and 1994, respectively) reported by Luqman et al. [5]. The upsurge may well be
contributed to by better awareness and improvement in diagnostic facilities. Melioidosis was possibly
under-diagnosed and under-reported in the past [27]. Another plausible reason for the upward trend
is the rise in the overall population along with an increase in the number of people with risk factors,
such as diabetes and chronic kidney disease.
There were four patients (3.5%) under the age of 15 years, comparable to the rate reported by
Hassan et al., (5.5%), and higher than the rate reported by How et al., (1.6/100,000) [21,26]. Consistent
with reports in the literature, our paediatric patients had no risk factors, presented with soft tissue
abscesses, two of them during the wet months of December and January, and recovered completely
with treatment [28]. Unlike Kingsley et al., we did not observe any cases of neonatal melioidosis [29].
In the present study, a higher number of cases was observed in the wet months of May to July
and December to February, with 64.3% being admitted during these months. The incidence was also
higher in the Temburong district, which records the highest rainfall amongst the four districts. A high
level of moisture in the soil during months of high rainfall has been reported to correlate with an
increased incidence of melioidosis [30,31]. This association has been reported from Australia [18,20],
Singapore [25], Malaysia [21], and India [23]. In contrast, Limmathurotsakul et al. reported a negative
association between the total annual rainfall and the number of cases in each year of their study from
Thailand [22]. However, in this study monthly rainfall data and the number of cases per month were
not available. Consistent with an incubation period of a few weeks, the incidence may also be higher
in the corresponding period after high rainfall [32].
Diabetes mellitus was recorded as a risk factor in 74.8% of cases, similar to the proportion in
India [23] and Malaysia [24]. Other studies have reported it in 39–57% of their cases [18,20–22,25].
In two studies from Australia [18,20], excessive alcohol use was the second most common risk factor.
In the present study it was noted in 5.2% of cases but could be underreported due to a reluctance to
volunteer such a history. However, the sale of alcohol is banned in Brunei Darussalam and, therefore,
our ﬁnding is likely to be a true reﬂection of the real situation.
The number of patients with melioidosis without any risk factors was lower (7.8%, n = 9) in
the present study compared to other studies (13–22%) [18,20,23,24] but similar to that reported by
Kingsley et al. [29]. It has been suggested that individuals with no risk factors have less severe
symptoms and mortality is rare [29]. However, in the present study 5/9 patients succumbed to the
disease, three of whom presented with septic shock, and two with large soft tissue abscesses suggesting
fulminant infection.
Consistent with the studies reviewed, pneumonia was the most common clinical presentation
followed by soft tissue abscesses [18,20–25]. Septic shock was the mode of presentation in 21.7% (n = 25)
cases. In a review of case reports published from Malaysia, a high frequency of primary neurological
presentation was noted (7.5%) [29]. The rates reported by other authors [18,21,23,24] and one case in
the present study is much lower. This may be due to selection bias in the case reports reviewed.
Internal organ abscesses were most common in the spleen and liver, as noted in the
literature [18,21,23,24]; however, the proportion was much higher in the present study. We had
only one case of subdural empyema and no cases with mycotic aneurysms or pericardial involvement.
The proportion of prostatic abscesses in the present study was 4.3%; there is a wide variation reported
in the literature, from 0.3% in Thailand [33], to a high of 20% in Australia [18]. Our ﬁnding of the
frequency of parotid involvement (n = 1, 0.9%) is comparable to other studies [23,24,29], but much
lower than that reported in Thai children (20–30%) [34]. We did not ﬁnd any case with pancreatic
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involvement in the present study. The four cases previously reported were seen over a period of six
years, compared to two years of the present study [7]. Moreover, only about 50% of patients in the
present study underwent CT-TAP for various reasons, which could have resulted in under-reporting
of internal organ abscesses.
The overall mortality in the present study was 27%, with a higher mortality in women (41.9%)
compared to men (21.4%; p < 0.05). This association has also been reported by Kingsley et al. [29].
Mortality was also signiﬁcantly higher in patients who presented with septic shock.
There is a wide variation in the reported mortality in the literature, from 9.5% in India [23],
42.6% in Thailand [22], and between 32–63% in Malaysia [19,21,24]. Decreasing mortality rates have
been reported from Australia [18] and Singapore [25]. The reasons put forward for this are access to
standardized health care and the institution of prompt treatment according to recommendations [35].
In Singapore, in particular, it is thought to be due to efforts to optimise diabetes care and
enhanced environmental and water management [25]. Our current rate is slightly higher than that
reported in the earlier study by Luqman et al., (20.3%) [5], possibly due to late presentations and
multiple comorbidities.
Five cases (4.3%) had recurrence of the disease, which is a similar rate to that reported by
Currie et al. [18]. One of the 31 cases that did not survive also presented with a recurrence. They
had underlying risk factors of diabetes mellitus (4/6), malignancy (2/6), and chronic renal disease
(1/6). Non-compliance with previous treatment was recorded in two cases. The institution of prompt
treatment along international guidelines explains the lower current rate compared to relapses seen in
60% of cases in the past [5].
The strength of the present study is that, owing to the method of data collection, it can be taken as
a true reﬂection of the disease state in the country. A limitation of the study was its retrospective nature.
Data, particularly on occupation and alcohol abuse as risk factors, were not adequately recorded.
5. Melioidosis in Animals
All livestock farms in Brunei Darussalam are advised through the Department of Agriculture and
Agrifood about good animal husbandry practices as a method of prevention of diseases.
According to the Animal Health and Disease Control Unit under the Livestock and Veterinary
Services Division, 93 and 128 goats were treated for presumedmelioidosis in 2015 and 2016, respectively.
This was based on farmers’ complaints and clinical ﬁndings, but no bacteriological evidence was
obtained. A positive response to treatment was noted in 80% of cases. The high susceptibility of goats
to melioidosis has been reported in the literature [36,37].
It has been suggested that goats and humans are exposed to similar levels of B. pseudomallei in
the environment and, hence, the incidence is likely to be similar [37]. However, data on melioidosis
incidence in animals are not available in Brunei Darussalam to conﬁrm this.
In Brunei Darussalam, the goat farms are mostly small, with herds less than 500 head. The goat
houses use raised ﬂooring and practice ‘cut and carry’ grass for feeding to avoid direct contact of
animals with the soil. Cattle livestock are imported from Australia, and Sabah and Sarawak in
Malaysia, and kept in holding yards for seasonal sales and are then slaughtered shortly afterwards
(short-term rearing), so that goats make up the longest-standing ruminant population. Buffaloes are
less susceptible to melioidosis, as noted in a review [38].
In late 2016, a few goat and sheep carcasses were submitted for autopsy with lesions suspicious of
melioidosis. The farm had recently carried out excavation work, followed by heavy rain. The animals
were 2–6 months of age and, hence, thought to be immunocompromised. The bacteriological tests were
negative for B. pseudomallei. The sick animals from the farm were treated and water was disinfected as
a precautionary measure. Workers in the farm and fodder plantation with respiratory symptoms were
advised to attend the nearest health centre.
43
Trop. Med. Infect. Dis. 2018, 3, 20
6. Future Direction
It is clear from the Health Information Booklet 2016, published by the Ministry of Health, Brunei
Darussalam, that diabetes, pneumonia, and septicaemia are amongst the top 10 causes of death in
the country [39]. The number of cases of melioidosis in 2016 (n = 69) was listed after the number of
cases of gastroenteritis and food poisoning in the list of waterborne diseases. However, melioidosis
does not feature in the list of notiﬁable diseases in Brunei Darussalam, unlike in Australia [20] and
Singapore [25].
Evidence-based guidelines are now available for prevention of melioidosis in endemic areas [40].
Suntornsut et al. explored the barriers in implementing preventive measures for melioidosis and have
suggested a number of interventions. Based on these, the authors have recommended a multifaceted
intervention involving community and government agencies [41].
Kingsley et al. have stressed the importance of making melioidosis notiﬁable and starting
registries in endemic countries to improve the efforts to effectively control the disease [29]. Through
such registries, it will be possible to obtain reliable clinical and epidemiological information, note
trends in the incidence, and determine effective treatment and mortality.
Involvement of the various stakeholders that encounter melioidosis in their practice and the
formation of a national registry would help to ensure that data collected is complete and standardized.
This will allow comparisons and the analysis of trends. Thus, the formation of a regional or
international registry would allow the condition to be better studied. If Brunei Darussalam were
to follow Australia and Singapore in making the condition a notiﬁable disease, this would further
enhance awareness and this may have an impact on the clinical course of the disease in the future.
Acknowledgments: We are grateful to Diana Dennis and Raihan Zurhairah Bte Hj Zulkipli, Division of Livestock
and Veterinary Services, Department of Agriculture and Agrifood, for their input on melioidosis in animals in
Brunei Darussalam. We are also grateful to Woo Boon Chu, Clinical Microbiology Laboratory, Department of
Laboratory Services, for help with retrieving a list of cases of melioidosis.
Author Contributions: K.P. conducted the data collection and analysis, and the writing and revision of the
manuscript; K.A.A.K. conducted the data collection and revision of the manuscript; R.A. wrote and revised the
manuscript; and V.H.C. wrote and revised the manuscript.
Conﬂicts of Interest: The authors declare no conﬂict of interest.
References
1. Limmathurotsakul, D.; Golding, N.; Dance, D.A.B.; Messina, J.P.; Pigott, D.M.; Moyes, C.L.; Rolim, D.B.;
Bertherat, E.; Day, N.P.J.; Peacock, S.J.; et al. Predicted global distribution of Burkholderia pseudomallei and
burden of melioidosis. Nat. Microbiol. 2016, 1. [CrossRef] [PubMed]
2. Geography of Brunei. Available online: https://en.wikipedia.org/wiki/Geography_of_Brunei (accessed on
3 January 2018).
3. Rainfall. Available online: https://www.bsp.com.bn/panagaclub/pnhs_old/geology/HTM/OVERVIEW/
CLIMATE/RAIN/rain1_1.HTM (accessed on 3 January 2018).
4. Climate. Available online: http://bruneiweather.com.bn/climate (accessed on 3 January 2018).
5. Luqman, N.; On, S.C.; Satyawany, N.; Da, P. Melioidosis in Brunei—epidemiological and clinical proﬁle.
Brunei Int. Med. J. 1999, 1, 291–297.
6. Lim, K.S.; Chong, V.H. Radiological manifestations of melioidosis. Clin. Radiol. 2010, 65, 66–72. [CrossRef]
[PubMed]
7. Chong, V.H.; Lim, K.S.; Sharif, F. Pancreatic Involvement in melioidosis. JOP 2010, 11, 365–368. [PubMed]
8. Pande, K.C.; Hj Abdul Kadir, K.A. Melioidosis of the extremities in Brunei Darussalam. Singap. Med. J. 2011,
52, 346–350.
9. Khairul Azmi, A.K.; Sattayavani, M.; Pande, K. Melioidosis: Antibiogram of cases in Brunei Darussalam.
Brunei Int. Med. J. 2014, 10, 19–24.
44
Trop. Med. Infect. Dis. 2018, 3, 20
10. Samad, I.; Wang, M.C.; Chong, V.H. Intracerebral coinfection with Burkholderia pseudomallei and Cryptococcus
neoformans in a patient with systemic lupus erythematosus. Southeast Asian J. Trop. Med. Public Health 2014,
45, 352–356. [PubMed]
11. Chong, V.H.; Sharif, F.; Bickle, I. Urogenital melioidosis: A review of clinical presentations, characteristic and
outcomes. Med. J. Malays. 2014, 69, 257–260.
12. Peacock, S.J.; Chieng, G.; Cheng, A.C.; Dance, D.A.B.; Amornchai, P.; Wongsuvan, G.; Teerawattanasook, N.;
Chierakul, W.; Day, N.P.J.; Wuthiekanun, V. Comparison of Ashdown’s medium, Burkholderia cepacia medium,
and Burkholderia pseudomallei selective agar for clinic isolation of Burkholderia pseudomallei. J. Clin. Microbiol.
2005, 43, 5359–5361. [CrossRef] [PubMed]
13. Podin, Y.; Kaestil, M.; McMahon, N.; Hennessy, J.; Ngian, H.U.; Wong, J.S.; Mohana, A.; Wong, S.C.;
William, T.; Mayo, M.; et al. Reliability of automated biochemical identiﬁcation of Burkholderia pseudomallei is
regionally dependent. J. Clin. Microbiol. 2013, 51, 3076–3078. [CrossRef] [PubMed]
14. Chetchotisakd, P.; Chierakul, W.; Chaowagul, W.; Anunnatsiri, S.; Phimda, K.; Mootsikapun, P.;
Chaisuksant, S.; Pilaikul, J.; Thinkhamrop, B.; Phiphitaporn, S.; et al. Trimethoprim-sulfamethoxazole
versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis
(MERTH): A multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet 2014, 383,
807–814. [CrossRef]
15. Dance, D. Treatment and prophylaxis of melioidosis. Int. J. Antimicrob. Agents 2014, 43, 310–318. [CrossRef]
[PubMed]
16. Centers for Diseases Control and Prevention. Biosafety in microbiological and biomedical laboratories.
Section IV. Laboratory biosafety level criteria. Available online: https://www.cdc.gov/biosafety/
publications/bmbl5/bmbl5_sect_iv.pdf (accessed on 9 February 2018).
17. Population. Available online: http://www.depd.gov.bn/sitePages/Population.aspx (accessed on 3 January 2018).
18. Currie, B.J.; Ward, L.; Cheng, A.C. The epidemiology and clinical spectrum of Melioidosis: 540 cases from
the 20 year Darwin prospective study. PLoS Negl. Trop. Dis. 2010, 4, e900. [CrossRef] [PubMed]
19. Deris, Z.Z.; Hasan, H.; Siti Suraiya, M.N. Clinical characteristics and outcomes of bacteraemic melioidosis in
a teaching hospital in a northeastern state of Malaysia. J. Infect. Dev. Ctries. 2010, 4, 430–435. [PubMed]
20. Hanna, J.N.; Humphreys, J.L.; Brookes, D.L.; Messina, T.; Raulli, A. Melioidosis in North Queensland,
2000–2009. Commun. Dis. Intell. 2010, 34, 444–447.
21. Hassan, M.R.A.; Pani, S.P.; Peng, N.P.; Voralu, K.; Vijayalakshmi, N.; Mehandrakar, R.; Aziz, N.A.; Michael, E.
Incidence, risk factors and clinical epidemiology of melioidosis: A complex socio-ecological emerging
infectious disease in the Alor Setar region of Kedah, Malaysia. BMC Infect. Dis. 2010, 10, 302. [CrossRef]
[PubMed]
22. Limmathurotsakul, D.; Wongratanacheewin, S.; Teerawattanasook, N.; Wongsuvan, G.; Chaisuksant, S.;
Chetchotisakd, P.; Chaowagul, W.; Day, N.P.J.; Peacock, S.J. Increasing incidence of human melioidosis in
northeast Thailand. Am. J. Trop. Med. Hyg. 2010, 82, 1113–1117. [CrossRef] [PubMed]
23. Vidyalakshmi, K.; Lipika, S.; Vishal, S.; Damodar, S.; Chakrapani, M. Emerging clinico-epidemiological
trends in melioidosis: Analysis of 95 cases from western coastal India. Int. J. Infect. Dis. 2012, 16, e491–e497.
[CrossRef] [PubMed]
24. Zueter, A.; Yean, C.Y.; Abumarzouq, M.; Rahman, Z.A.; Deris, Z.Z.; Harun, A. The epidemiology and clinical
spectrum of melioidosis in a teaching hospital in North-Eastern state of Malaysia: A ﬁfteen-year review.
BMC Infect. Dis. 2016, 16, 333. [CrossRef] [PubMed]
25. Pang, L.; Harris, P.N.A.; Seiler, R.L.; Ooi, P.L.; Cutter, J.; Goh, K.T.; Cook, A.R.; Fisher, D.; Chai, L.Y.A.
Melioidosis, Singapore, 2003–2014. Emerg. Infect. Dis. 2018, 24, 140–143. [CrossRef] [PubMed]
26. How, S.H.; Ng, T.H.; Jamalludin, A.R.; Tee, H.P.; Kuan, Y.C.; Alex, F.; Sc, M.; Aminudin, C.A.; Sapari, S.;
Quazi, M.H. Pahang melioidosis registry. Med. J. Malays. 2009, 64, 27–30.
27. Foong, Y.C.; Tan, M.; Bradbury, R.S. Melioidosis: A review. Rural Remote Health 2014, 14, 2763. [PubMed]
28. McLeod, C.; Morris, P.S.; Bauert, P.A.; Kilburn, C.J.; Ward, L.M.; Baird, R.W.; Currie, B.J. Clinical presentation
and medical management of melioidosis in children: A 24-year prospective study in the Northern Territory
of Australia and review of the literature. Clin. Infect. Dis. 2015, 60, 21–26. [CrossRef] [PubMed]
29. Kingsley, P.V.; Leader, M.; Nagodawithana, N.S.; Tipre, M.; Sathaikumar, N. Melioidosis in Malaysia:
A review of case reports. PLoS Negl. Trop. Dis. 2016, 10, e0005182. [CrossRef] [PubMed]
45
Trop. Med. Infect. Dis. 2018, 3, 20
30. Liu, X.; Pang, L.; Sim, S.H.; Goh, K.T.; Ravikumar, S.; Win, M.S.; Tan, G.; Cook, A.R.; Fisher, D.; Chai, L.Y.
Association of melioidosis incidence with rainfall and humidity, Singapore, 2003–2012. Emerg. Infect. Dis.
2015, 21, 159–162. [CrossRef] [PubMed]
31. Merritt, A.J.; Inglis, T.J.J. The role of climate in the epidemiology of melioidosis. Curr. Trop. Med. Rep. 2017, 4,
185–191. [CrossRef] [PubMed]
32. Currie, B.J.; Fischer, D.A.; Anstey, N.M.; Jacups, S.P. Melioidosis: Acute and chronic disease, relapse and
re-activation. Trans. R. Soc. Trop. Med. Hyg. 2000, 94, 301–304. [CrossRef]
33. Suputtamongkol, Y.; Hall, A.J.; Dance, D.A.; Chaowagul, W.; Rajchanuvong, A.; Smith, M.D.; White, N.J.
The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int. J. Epidemiol. 1994, 23,
1082–1090. [CrossRef] [PubMed]
34. Cheng, A.C.; Currie, B.J. Melioidosis: Epidemiology, pathophysiology and management. Clin. Microbiol. Rev.
2005, 18, 383–416. [CrossRef] [PubMed]
35. Wiersinga, W.J.; Currie, B.J.; Peacock, S.J. Melioidosis. N. Engl. J. Med. 2012, 367, 1035–1044. [CrossRef]
[PubMed]
36. Choy, J.L.; Mayo, M.; Janmaat, A.; Currie, B.J. Animal melioidosis in Australia. Acta Trop. 2000, 74, 153–158.
[CrossRef]
37. Limmathurotsakul, D.; Thammasart, S.; Warrasuth, N.; Thapanagulsak, P.; Jatapai, A.; Pengreungrojanachai, V.;
Anun, S.; Joraka, W.; Thongkam koon, P.; Saiyen, P.; et al. Melioidosis in animals, Thailand, 2006–2010.
Emerg. Infect. Dis. 2012, 18, 325–327. [CrossRef] [PubMed]
38. Sprague, L.D.; Neubauer, H. Melioidosis in animals: A review of epizootiology, diagnosis and clinical
presentation. J. Vet. Med. 2004, 51, 305–320. [CrossRef] [PubMed]
39. Health Information Booklet 2016. Available online: www.moh.gov.bn/.../Health%20Indicator%20Booklet/
HIB_2016.pdf (accessed on 3 January 2018).
40. Limmathurotsakul, D.; Kanoksil, M.; Wuthiekanun, V.; Kitphati, R.; de Stavola, B.; Day, N.P.J.; Peacock, S.J.
Activities of daily living associated with acquisition of melioidosis in northeast Thailand: A matched
case-control study. PLoS Negl. Trop. Dis. 2013, 7, e2072. [CrossRef] [PubMed]
41. Suntornsut, P.; Wongsuwan, N.; Malasit, M.; Kitphati, R.; Michie, S.; Peacock, S.J.; Limmathruotsakul, D.
Barriers and recommended interventions to prevent melioidosis in northeast Thailand: A focus group study
using the behaviour change wheel. PLoS Negl. Trop. Dis. 2016, 10, e0004823. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
46
Tropical Medicine and 
Infectious Disease
Meeting Report
A Report from the Cambodia Training Event for
Awareness of Melioidosis (C-TEAM), October 2017
Sotharith Bory 1 ID , Frances Daily 2,*, Gaetan Khim 2, Joanne Letchford 2, Srun Sok 3, Hero Kol 4,
Muy Seang Lak 4, Luciano Tuseo 5, Chan Vibol 5, Sopheap Oeng 2 and Paul Turner 6,7 ID
1 Infectious Diseases Unit, Calmette Hospital, Phnom Penh 12201, Cambodia; sotharith_bory@yahoo.com
2 Diagnostic Microbiology Development Program, Phnom Penh 12302, Cambodia;
gaetan.khim@dmdp.org (G.K.); joanne.letchford@dmdp.org (J.L.); oeng.sopheap@dmdp.org (S.O.)
3 Hospital Services Department, Ministry of Health, Phnom Penh 12152, Cambodia; soksrun@gmail.com
4 Preventive Medicine Department, Ministry of Health, Phnom Penh 12152, Cambodia;
herokol@yahoo.com (H.K.); sreanglak@yahoo.com (M.S.L.)
5 World Health Organization, Phnom Penh 12302, Cambodia; tuseol@who.int (L.T.); chanv@who.int (C.V.)
6 Cambodia Oxford Medical Research Unit, Angkor Hospital for Children, Siem Reap 17252, Cambodia;
pault@tropmedres.ac
7 Centre for Tropical Medicine and Global Health, Nufﬁeld Department of Medicine, University of Oxford,
Oxford OX3 7FZ, UK
* Correspondence: fdaily@dmdp.org; Tel: +855-12-626-33
Received: 31 January 2018; Accepted: 17 February 2018; Published: 23 February 2018
Abstract: Melioidosis is an endemic infection in Cambodia, a lower middle income SE Asian
country. Despite more laboratories isolating and identifying Burkholderia pseudomallei in recent years,
the infection remains under-recognised and under-diagnosed, particularly in the adult population.
Lack of knowledge about the disease and lack of utilization of microbiology laboratories contributes
to this, along with laboratory capacity issues. Treatment costs often hamper optimal management.
In response to these issues, a national one-health training event was held in October 2017 to raise
awareness of the disease amongst clinical, laboratory, and public health professionals. The meeting
format, ﬁndings, and outcomes are described here.
Keywords: melioidosis; Cambodia; epidemiology
1. Introduction
Melioidosis, infection by the environmental Gram-negative bacterium Burkholderia pseudomallei,
is an endemic but signiﬁcantly unrecognized disease in Cambodia, a lower middle income SE
Asian country with a population of ~16 million. It was ﬁrst diagnosed in Phnom Penh in 1928 in
a Russian national, although he was almost certainly infected in Thailand [1]. Subsequently, pulmonary
melioidosis was described in a resettled refugee who had lived in Thailand for several years before
diagnosis [2], and also a porcine outbreak was identiﬁed in the 1960s [3]. However, it was not until
2005, that human melioidosis cases began to be regularly identiﬁed in-country, initially in children
following the establishment of a diagnostic microbiology laboratory at Angkor Hospital for Children,
Siem Reap [4]. Since then, signiﬁcant laboratory capacity building has occurred nationally and several
hundred cases in both children and adults have been described [5–9]. Not unexpectedly, mortality is
higher in adults (more than 50%) than in children [4,6–8]; however, as with adults, children who are
bacteraemic have higher mortality (72%) [8]. Serologic screening using the indirect haemagglutination
assay (IHA) revealed that 16% of tested children from Siem Reap province had evidence of exposure
to B. pseudomallei and the organism was conﬁrmed to be present in rice paddy soil [10].
A recent global mathematical modelling study predicted that in 2015, Cambodia would have
had 2083 (95% credible interval 850–5451) melioidosis cases resulting in 1149 (464–3042) deaths [11].
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Lack of clinician awareness and limited diagnostic microbiology capacity may explain the discrepancy
between the model predictions and the low number of cases conﬁrmed in Cambodia each year.
With aim of improving clinical, laboratory, and public health professional awareness of
melioidosis, a national one-health training event was held in Phnom Penh, 17–19 October 2017.
2. The C-TEAM Meeting
There were more than 180 meeting attendees, representing national, provincial and
non-governmental hospitals, universities and research institutes, as well as government ministries
(Health, Agriculture, Fisheries and Forestry, Environment, Rural Development), international and
non-governmental organizations and partners. Hospitals were asked to prepare a summary of
melioidosis cases and B. pseudomallei isolate numbers prior to the meeting. Where possible, it was
requested that data be stratiﬁed by date (year), specimen type, and geo-location (home province). Prior
to presentation every effort was made to verify the accuracy of the data.
The ﬁrst day featured plenary talks from international clinical and laboratory melioidosis experts,
followed by situation updates from several national, provincial and non-governmental hospitals.
Representatives from six major participating hospitals presented data on their clinical and laboratory
capacity. In particular, melioidosis case numbers, diagnostic procedures, and treatment regimens were
shared. The day concluded with presentations on melioidosis in animals, environmental reservoirs of
B. pseudomallei, prevention and public engagement activities.
The second and third days featured parallel workshop sessions for clinicians and laboratorians.
Cambodian clinicians presented cases to demonstrate the breadth of melioidosis infection, including
pneumonia, sepsis, head and neck abscesses, hepatic, splenic, prostatic abscesses, and bone and
joint infections. Expert speakers provided commentary on the cases and led discussions around
diagnosis and treatment. Particular attention was paid to deﬁning the optimal diagnostic approach
and appropriate treatment choices [12,13]. Sessions on the radiologic features and surgical management
of melioidosis were included. The recently updated national treatment guidelines were presented
and discussed and encouragement was given to participants to collect case data prospectively in the
hope of gaining more knowledge about the local epidemiology. Laboratorians gave local situation
updates and participated in dry and wet laboratory sessions to gain experience of best practices for
safe handling and identiﬁcation of B. pseudomallei from clinical specimens, as well as determination
and reporting of appropriate antimicrobial susceptibilities. Identiﬁcation test demonstrations and
hands-on practical sessions included the three-disk test (co-amoxiclav, colistin/polymixin B, and
gentamicin) [14], InBios Active Melioidosis Detect lateral ﬂow assay [15], and Mahidol University
latex agglutination test [16,17]. There was a demonstration of the advantages of Ashdown’s agar
and broth, B. pseudomallei selective media, for culture of non-sterile site specimens such as throat
swabs [18]. Diagnostic Microbiology Development Program (DMDP)-developed standard operating
procedures and job aids were shared with meeting participants. Two training videos were prepared
for the meeting, providing overviews of specimen processing and identiﬁcation of B. pseudomallei
(the Khmer language version can be found at: https://vimeo.com/237880199).
The meeting concluded with an interactive session for clinicians and laboratorians aimed at
promoting communication and identiﬁcation of areas where co-operative efforts between clinical and
laboratory teams could be used to improve diagnosis and management patients with melioidosis.
3. Summary of the Current Situation
Since the ﬁrst national melioidosis conference, held in August 2010, there has been a steady
increase in the number of culture conﬁrmed cases from 173 (isolated and identiﬁed from ﬁve
microbiology laboratories since October 2005) to 2592 up to September 2017 (from 17 microbiology
laboratories) (Figure 1). Partner organizations, including the DMDP, have worked with the Ministry
of Health Bureau of Medical Laboratory Services to improve laboratory diagnostic capacity over
48
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this time. Despite the increase, the annual cases remain well below the levels predicted by the
mathematical model.
 
Figure 1. Annual numbers of conﬁrmed melioidosis cases in Cambodia, October 2005–September 2017
(* incomplete years).
To date, the majority of cases have been children (at least 60% (1565/2592), but age data not
available for all cases), which is in contrast to other countries where children account for 5–15% of
all cases. This is likely due to overrepresentation of cases from three children’s hospitals that have
well-established microbiology laboratories and clinical diagnostic algorithms. In many hospitals, both
public and private, there is as yet no systematic sampling for patients with presumed infections, hence
very few microbiology investigations are requested by doctors. In addition, in many hospitals in
Cambodia, some patients are required to pay for services including microbiology testing and treatment,
which is often cited as a barrier to increasing the number of specimens requested and treating the
patient with recommended treatment.
Data on culture-conﬁrmed B. pseudomallei cases are not yet routinely collated at a national level.
Of data obtainable and presented at the meeting, home province information was only available in
one third of patients (34%, 889/2592). Despite this, the data conﬁrm that 23 of 25 provinces have had
culture-conﬁrmed cases, suggesting the infection is endemic throughout the country (Figure 2). As soil
testing has been limited to one province and no water studies have yet been carried out, it is unknown
whether there are areas in the country where the infection is more likely to be acquired.
The month of culture conﬁrmation was available for only one ﬁfth of all cases, but where recorded,
the majority of cases (71%, 377/528) occurred during the wet season months of May to October,
which is consistent with other endemic areas. Where documented (19% of all cases; 481/2592), adults
were more likely to have risk factors than children, with the most common being diabetes mellitus,
hazardous alcohol use and corticosteroids. The majority of adults had presented with pneumonia
and/or sepsis, whereas children were more likely to have head and neck infections. Both of these
ﬁndings are consistent with other endemic countries; however, one province had a high number of
head and neck presentations in adults (30% of all presentations), which is unusual in this age group.
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Figure 2. Geographic distribution of melioidosis cases in Cambodia, October 2005–September 2017.
Province of residence was available in 889 conﬁrmed cases. Shading represents the total number of
culture-conﬁrmed melioidosis cases per province. The numbers represent the count of participating
microbiology laboratories per province; however, one was unable to contribute its culture conﬁrmed
cases prior to the meeting.
The most common B. pseudomallei culture-positive specimen type reported was pus
(55%, 1530/2765 specimens) followed by blood culture (34%, 941/765). Only 73 sputum cultures
were documented, despite pneumonia being a common clinical presentation. Bronchoalveolar
lavage/aspirates were positive in 17 specimens and there were 26 pleural fluid specimens positive
for the bacterium. Commonest diagnostic methods in routine use were the three-disc test
(82%, 14/17 laboratories) and the bioMerieux API 20NE test strip (59%, 10/17 laboratories). One third
(35%, 6/17) of the laboratories reported use of Ashdown selective media, although it is not yet routinely
used or readily available in all of these laboratories. Several laboratories reported routinely releasing
antibiotic susceptibility data on drugs that are not recommended for melioidosis treatment, such as
ceftriaxone, cefuroxime, colistin and fosfomycin. Prior to the meeting, some laboratories were unaware
of the limitations of disc diffusion testing for co-trimoxazole [19].
Treatment choice and length of treatment varied between hospitals, with some using ceftriaxone
during the initial phase, rather than the recommended ceftazidime. Many hospitals reported
they often lack sufﬁcient supplies of ceftazidime and therefore treat patients with inferior drugs
(e.g., co-trimoxazole or ceftriaxone) or with shortened courses of ceftazidime. Carbapenems are not
readily available in almost all hospitals, so rarely prescribed. Eradication phase options sometimes
included co-amoxiclav as ﬁrst-line treatment, rather than the recommended co-trimoxazole, mostly
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without consideration of amoxicillin:clavulanate ratio. The length of treatment and follow up during
this phase was inconsistent. Outcome data was very incomplete with hospitals often having no
information as patients were lost to follow up, or outcome had not been collated.
4. Outcomes and Future Plans
The major outcome of the meeting was the successful drawing together of a broad range of
Cambodian health professionals to share knowledge and experience of the epidemiology, clinical and
laboratory diagnosis, treatment and prevention of melioidosis. Many of the animal and environmental
sector participants heard for the ﬁrst time about the importance of this disease and were eager
to learn more. Local data were collated and presented alongside state-of-the-art lectures from
global melioidosis experts. Current challenges in clinical case detection, awareness of risk factors
(e.g., diabetes), laboratory diagnosis, treatment and limited collation of epidemiological data were
highlighted. Updated national diagnosis and treatment guidelines were showcased. Laboratory staff
were made aware of current best practices for safe culture and identiﬁcation of B. pseudomallei, and
were provided with key standard operating procedures and job aids. The need for reliable surveillance
data was recognised as a priority. It is hoped that the enthusiasm shown by all participants at the
meeting will be translated into a sustained effort to improve clinical diagnosis, laboratory conﬁrmation,
treatment, outcomes and surveillance of melioidosis in Cambodia moving forwards. Further training
workshops, plus development and provision of an information package summarizing the current
situation and outstanding challenges to policy makers, clinicians, laboratory technicians and other
stakeholders, will consolidate the considerable momentum generated at the C-TEAM meeting.
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Abstract: The ﬁrst cases of human melioidosis were described in Vietnam in the 1920s, almost
a century ago. It was in Vietnam in the thirties that the saprophytic nature of B. pseudomallei was ﬁrst
recognized. Although a signiﬁcant number of French and U.S. soldiers acquired the disease during
the Vietnam wars, indigenous cases in the Vietnamese population were only sporadically reported
over many decades. After reuniﬁcation in 1975, only two retrospective studies reported relatively
small numbers of indigenous cases from single tertiary care hospitals located in the biggest cities in
the South and the North, respectively. Studies from provincial hospitals throughout the country were
missing until the Research Network on Melioidosis and Burkholderia pseudomallei (RENOMAB) project
started in 2014. From then on seminars, workshops, and national scientiﬁc conferences on melioidosis
have been conducted to raise awareness among physicians and clinical laboratory staff. This led
to the recognition of a signiﬁcant number of cases in at least 36 hospitals in 26 provinces and cities
throughout Vietnam. Although a widespread distribution of melioidosis has now been documented,
there are still challenges to understand the true epidemiology of the disease. Establishment of
national guidelines for diagnosis, management, and reporting of the disease together with more
investigations on animal melioidosis, genomic diversity of B. pseudomallei and its environmental
distribution are required.
Keywords: melioidosis; Burkholderia pseudomallei; Vietnam; public awareness; animal; environment
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1. Introduction
Although sporadic cases of melioidosis have been reported from Vietnam since the year
1927, the disease has only recently attracted the deserved attention among Vietnamese health care
professionals. This neglect is particularly remarkable, given the fact that a fundamental characteristic
of B. pseudomallei—namely, the environmental reservoir of this pathogen—was demonstrated for the
ﬁrst time in Vietnam [1,2]. Although many melioidosis cases among French and American soldiers
were reported during the long-lasting armed conﬂicts, this had no sustainable effect on the recognition
of melioidosis in the indigenous Vietnamese population. In this report, we summarize the history
of melioidosis in Vietnam in humans and animals starting almost a century ago and ﬁnally describe
more recent activities trying to unravel the burden of disease and to increase awareness. We also
discuss current knowledge on environmental B. pseudomallei in Vietnam, the population structure of
Vietnamese B. pseudomallei and its phylogenetic relatedness. Finally, we address current and future
challenges in prevention and diagnosis of the disease.
2. Review of Melioidosis in Vietnam
2.1. Human Melioidosis
2.1.1. 1920s to 1950s
The ﬁrst case of human melioidosis in Vietnam was detected in 1925 in an ill-nourished female
patient, pregnant in the ﬁfth month, living at Thu Duc, close to Saigon (now Ho Chi Minh City).
Six days after onset of symptoms, the patient had a miscarriage and, after 14 days of illness, the patient
died [3]. B. pseudomallei was isolated from the blood at the Pasteur Institute of Ho Chi Minh City and
the identiﬁcation was conﬁrmed at the Institute for Medical Research, Malaysia [4].
Subsequently cases were reported by Menard in 1928 from Ho Chi Minh City and Tonkin (now
Hanoi in the North), as cited by Pons (1930) [5]. Further culture-conﬁrmed cases of melioidosis,
including cases related to trafﬁc accidents (see below Section 3) were then reported at Hue city (Central
Vietnam) and from the North [1]. In 1947, 28 cases of acute, sub-acute, and chronic melioidosis were
described from various hospitals in the South [6]. Of those, only nine cases were Vietnamese patients.
The others were 15 Caucasians, 2 black patients, and 1 patient of Chinese and 1 of south Asian descent.
Fatal outcomes were reported in 19 out of those 28 cases, although the outcome was not documented
for all patients. From 1951 to 1953, ﬁve pulmonary cases of melioidosis were diagnosed at hospitals in
both southern Vietnam and France. All of the cases were French citizens with a history of residence or
station in the region of Vietnam, Laos, and Cambodia [7]. A case of chronic pulmonary melioidosis was
also described in a soldier suffering from a chest wound caused by a bullet in Vietnam [8]. Between 1948
and 1954, approximately 100 cases were reported among 400,000 French forces stationed in Vietnam,
Laos, and Cambodia, as cited by Sanford (1978) [9]. In 1956, a fatal case of septicemic melioidosis was
diagnosed in a 40-year-old south Vietnamese soldier admitted to Cong Hoa Hospital [10].
2.1.2. 1960s to 1980s
It is interesting to note that already in 1967, Mo and Duong stated that the disease was most
likely underdiagnosed in hospitals of southern Vietnam and that cases of melioidosis were probably
misdiagnosed as tuberculosis or disseminated fungus infections. The authors also mentioned
several cases detected annually in different hospitals of the South and described the development of
melioidosis in a young soldier after a military operation in a swampy area of the South [11]. With the
deployment of the U.S. Armed Forces in Vietnam, melioidosis started to be detected in the U.S. military
personnel. As cited by Diamond and Pastore (1967), through February 1967, 35 cases were diagnosed
in U.S. troops stationed in Southeast Asia, with 8 fatal cases reported [12]. Those patients were
diagnosed because diseased or wounded soldiers were referred to modern hospitals of either Republic
of South Vietnam or United States, where microbiological laboratories were available for diagnosis
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of melioidosis as well as for other infectious diseases. Within the year of 1966, a series of 9 cases
of pulmonary melioidosis in U.S. soldiers was described [13]. Another nine cases of melioidosis in
U.S. soldiers, including four fatal cases, were diagnosed in Vietnam in Long Binh (now Dong Nai
province in the South) [14]. Since more cases of melioidosis were subsequently reported in U.S. soldiers,
melioidosis became one of six major tropical infectious diseases for which U.S. physicians needed to
maintain a high index of suspicion in febrile soldiers returning from Vietnam [15]. From April 1965
to December 1969, 187 cases with 13 deaths were reported in the U.S. Army personnel stationed in
Vietnam. Until the U.S. withdrawal in 1972, approximately two to three culture-conﬁrmed cases were
detected among the U.S. soldiers every month [9,16,17]. Serology using indirect hemagglutination
(IHA) showed that 8.9% of the sera from the Vietnam veterans had titers of 1:40 or greater [18]. Based on
such titers it was estimated by Clayton et al. that approximately 250,000 among three million U.S.
Army personnel got infected with B. pseudomallei when serving in Vietnam [18,19]. Although these
estimates might be interpreted with some cautions considering the limited speciﬁcity and sensitivity
of the non-standardized IHA test, this study indicated a potential reservoir of latent B. pseudomallei
infection among personnel returning from Vietnam. Indeed, it became obvious that latent infection
and reactivation, sometimes after many years, does occur [20]. This phenomenon led to the melioidosis
nickname ‘Vietnam Time Bomb’ [21]. A possible human-to-human transmission via sexual contact
was suggested in the wife of a returning Vietnam veteran with prostatitis due to B. pseudomallei
infection [22]. Melioidosis was also diagnosed in a newborn whose father had served in Vietnam,
although the source of a possible transmission remained unclear [23]. Despite this large number of
melioidosis cases related to Vietnam during this period of time, very little information on the disease
was reported for the indigenous population (Table 1).
Table 1. Number of indigenous Vietnamese patients with melioidosis and the respective outcome
reported over time in medical journals.
Year of Reporting No. of Patient No. of Recoveries a No. of Deaths No. of Unknown Outcome Reference
1926 1 0 1 0 [3]
1949 9 5 0 4 [6]
1958 1 0 1 0 [10]
1967 1 1 0 0 [11]
1995 7 1 6 0 [24]
1990 1 1 0 0 [25]
1999 9 0 0 9 [26]
2008 55 32 17 6 [27]
2018 70 30 18 22 [28]
a Recovery during the study.
2.1.3. 1990s until Present
In 1991, a medical thesis defended at Hanoi Medical University described 16 cases detected in
hospitals of Hanoi over a 10-year period from 1980 to 1990, with seven fatal outcomes [29]. A study
by Phung et al. (1993) using an IHA test revealed seropositivity in populations living in suburban
communities of Hanoi ranging from 6.4% to 31.8%. This study also observed an association of
seropositivity with rice farming [30]. In a study on cellular lipid and fatty acid composition of
B. pseudomallei, seven patients with melioidosis were listed from whom strains were isolated in
Vietnam between 1981 and 1991 [24]. In 1999, a retrospective study in the South reported only nine
culture-conﬁrmed cases with melioidosis from 3653 blood cultures of febrile patients admitted to the
largest hospital for tropical diseases in Ho Chi Minh City from 1992 to 1998 [26]. Antibiotic treatment
and patient outcomes were not reported in this study. In 2008, another retrospective study in the
largest general hospital in the North reported 55 culture-conﬁrmed cases observed in a period of
time from 1997 to 2005. Analysis of clinical data showed that septicemia with pneumonia was the
most common clinical presentation and diabetes was the most common risk factor. Seventeen out of
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40 septicemic patients died, with nine deaths occurring within 48 h after admission. Based on the
residential addresses of the patients, it was concluded that melioidosis is widely distributed and occurs
in at least 18 of 25 northern provinces [27]. In the context of the Research Network on Melioidosis
and Burkholderia pseudomallei (RENOMAB; see below Section 5) that started in 2014, a recent study
reported 70 cases detected within seven months at ﬁve hospitals in North Central Vietnam. During
the study period, the detection rate of B. pseudomallei ranged from 3.4% to 10.2% among positive
blood cultures in those hospitals. Fifty-eight patients had septicemia. Of the 36 patients with known
outcome, 18 patients died, with 6 deaths occurring within 48 h after admission [28]. However, as for
other regions, the true burden of melioidosis in North Central Vietnam still needs to be determined
(see below Section 7). The few epidemiological data available for Vietnam imply that rice farmers are
at particular risk to acquire a B. pseudomallei infection [26–28].
2.2. Animal Melioidosis
2.2.1. 1930s to 1960s
At the time when the first human case of melioidosis was detected in Vietnam, the disease was
considered to be a zoonosis and animals a reservoir for B. pseudomallei. This assumption was based on
the observation that B. pseudomallei could infect laboratory rodents and its virulence was comparable
to Yesinia pestis, the causative agent of plague. However, a large microbiological study of more than
20,500 rats collected in southern Vietnam found only one rat to be culture-positive for B. pseudomallei as
cited by Luong (1956) [31]. None of the 560 wild rats caught in Hanoi were positive for B. pseudomallei
by culture [1]. Serological studies showed that serum collected from pigs contained antibodies against
B. pseudomallei, as cited by Luong (1956) [31]. In 1954, melioidosis was detected in rabbits and guinea
pigs at the Pasteur Institute of Ho Chi Minh City, as cited by Luong (1961) [32]. In 1955, Luong described
culture-confirmed melioidosis cases in pigs at a pig farm near a rubber plantation in Thu Dau Mot (now
Ho Chi Minh City), with the isolation of B. pseudomallei from creamy pus in lung and spleen abscesses [31].
Using serology and culture methods, several deaths of pigs were confirmed to be caused by melioidosis
in the farms at Tan Son Nhat and Gia Dinh (now both are Ho Chi Minh City) [32].
2.2.2. 1970s until Present
In 1971, cases of melioidosis were reported in the U.S. Army dogs in the Republic of South
Vietnam. During a six-month period, 31 working dogs died, with four conﬁrmed melioidosis cases.
B. pseudomallei was cultured from the dogs’ lungs and various organs. The dogs came from different
units in diverse locations in Vietnam. All of the dogs showed lesions in the lungs, epididymides,
and testes [33]. The author stated that melioidosis remained underdiagnosed because bacteriologic
cultures were not routinely performed at necropsy of the U.S. Army working dogs and that the disease
does not seem to be uncommon in dogs. A serologic surveillance on 64 healthy U.S. military scout and
tracker dogs after service in the Republic of South Vietnam showed that 12 (19%) dogs had developed
antibodies against B. pseudomallei, with IHA titers higher than 1:80 [34]. After reuniﬁcation in 1975,
no further information about melioidosis in pigs or other livestock, as well as dogs, has been reported
in Vietnam. Only recently, in the context of RENOMAB, a study carried out by a group at the National
Institute of Veterinary Research reported a culture-conﬁrmed melioidosis case of a pig in a farm at
Nghe An province in North Central Vietnam [35].
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3. B. pseudomallei in the Environment
The ﬁrst experimental indication of the saprophytic nature of B. pseudomallei and its environmental
reservoir was provided in Vietnam by Vaucel in 1937 [1]. His studies were triggered by the observation
that individuals who developed melioidosis after trafﬁc accidents were either immersed for a prolonged
time in water of a pond or had a skull wound contaminated with mud. To test the hypothesis that
B. pseudomallei exists in the environment, Vaucel submerged the scratched abdomen of guinea pigs
into water of a pond collected in the North. Five days later, a moribund animal was sacriﬁced and
B. pseudomallei was isolated from pus of the liver and spleen and other sites on solid media in pure
culture [1]. About 20 years later in 1955, Chambon provided ﬁnal evidence by directly isolating
seven B. pseudomallei strains from ﬁve environmental samples including pond muds, rice ﬁeld water,
and a sample of pond water collected in the South [2]. In 1961, Luong provided further evidence for
environmental B. pseudomallei, when two strains were cultured from water samples of a water spinach
plantation from southern Vietnam [32].
Apart from this early environmental work, there are only a few more recent studies sampling
rice ﬁelds for B. pseudomallei. In 1991, a study reported the isolation of B. pseudomallei from 4 out of
240 soil samples, and 1 out of 190 surface water samples collected in rice ﬁelds at four communities
surrounding Hanoi was positive for B. pseudomallei [30]. Between 1992 and 1998 soil samples were
collected from 137 rice ﬁelds around Ho Chi Minh City in southern Vietnam and nine ﬁelds were found
to be positive [26]. The low B. pseudomallei detection rate from soil in those sampling studies is likely
to be the result of the current culture protocols for environmental B. pseudomallei which have a limited
sensitivity. It has been shown recently, that a multitarget quantitative PCR approach improves the
detection rate and can predict cultivability of B. pseudomallei [36]. By using this multitarget qPCR,
B. pseudomallei was detected in 35 (83.3%) out of 42 soil samples collected at 28 rice ﬁelds in southern
Vietnam. From those samples, B. pseudomallei strains could be isolated from six (14.3%) samples by
using conventional culture methods [36].
A recent prediction of the global environmental presence of B. pseudomallei at 5 × 5 km2 spatial
resolution suggested that predominant parts of Vietnam are highly suitable for the environmental
occurrence of B. pseudomallei [37]. However, mountainous areas near the border with Laos and China,
especially in the Northwest region, some regions in the Central Highlands, and a zone involving
the lower South Central Coast were found to be less suitable. It will be most important to test
these predictions in future environmental studies and also to investigate the environmental factors
involved in creating a habitat for B. pseudomallei at a high spatial resolution. The country harbors
an enormous diversity of habitats ranging from tropical rain forest to dry forest, natural grassland,
and agricultural land such as rice paddies to wetland habitats including rivers and lakes and coastal
wetlands. Apart from the limited studies on rice ﬁelds, there is no information on the potential role of
such different habitats as environmental reservoirs for B. pseudomallei. Since Vietnam has an enormous
north–south expansion, including humid subtropical climate in the north, tropical monsoon climate in
the center, and tropical wet and dry climate in the south, the potential inﬂuence of climate factors on
the environmental presence of B. pseudomallei needs to be investigated. For the development of any
preventive strategies or environmental countermeasures it will be important to deﬁne risk areas for
infection and the role of different habitats and climate factors more precisely.
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4. Phenotype, Genomic Diversity, and Phylogenetic Relatedness of B. pseudomallei
When the ﬁrst B. pseudomallei strain was isolated from clinical specimens in 1925, the occurrence
of different morphotypes, in this case rugose and ultra-rugose colonies on agar, were described [4].
As we now know various morphotypes represent a frequent characteristic of this species. Subsequent
work demonstrated virulence of clinical and environmental B. pseudomallei strains in experimental
infections and described antibiotic susceptibility to drugs available at that time [4,8,11,38]. A more
recent study with 25 strains from northern Vietnam reported an antibiotic resistance proﬁle that
is also found in other endemic areas, with susceptibility to currently-recommended antibiotics for
treatment of melioidosis such as ceftazidime, imipenem, meropenem, and co-trimoxazole. Resistance
and intermediate resistance to tetracycline were noted for one strain and three strains, respectively [27].
In a study describing physiological and biochemical characteristics of 15 environmental and
clinical B. pseudomallei strains from northern Vietnam, all strains shared typical B. pseudomallei
characteristics with respect to motility, salt tolerance, growth temperature, sugar assimilation,
cytochrome c oxidase and acid production, and colony morphology on different routine agar
media [24]. The composition of cellular lipids and fatty acids were similar among the tested
strains [24]. Biochemical and antigenic characteristics typical for B. pseudomallei were also described
by Phuong et al. (2008) using the API 20 NE system and through agglutination of those strains with
a B. pseudomallei-speciﬁc monoclonal antibody [27].
The Burkholderia pseudomallei ‘Multi-Locus Sequence Typing’ (MLST) database is a rich resource
to assess the genomic population structure based on seven housekeeping genes (https://pubmlst.org/
bpseudomallei/ [39]. Since the development of the B. pseudomallei MLST scheme in 2003 [40], 104 isolates
from Vietnam have been deposited in the database (5309 isolates overall) as of 14 February 2018 [27,41].
A total of 61 sequence types (STs) were identified, emphasizing the great genotypic diversity of the
sampled population in this region. Of those, 31 STs were uniquely reported in Vietnam so far and most of
the remaining STs are shared with neighboring countries like Thailand or Cambodia. The co-occurrence
of the latter and the concomitant lack of regional specificity have already been noticed for other STs [41].
As already implied by Phuong et al. (2008), analysis of current B. pseudomallei MLST data showed the
Vietnamese strains to mainly cluster with other Asian isolates as opposed to the Australian STs.
However, special care must be taken when analyzing B. pseudomallei MLST data. Its high
recombination rate complicates the inferences of phylogenetic relationships of sequence types (STs) [42,43].
Nevertheless, the unprecedented amount of deposited data and the comparatively cheap prices render it
a valuable tool, despite the emergence of next generation sequencing. With the advent of next generation
sequencing (NGS), whole genome sequencing (WGS) has proven a powerful tool to study population
genetics at a much higher resolution. This was recently shown by De Smet et al. (2015), reporting two
strains, which shared one ST due to homoplasy, but could be distinguished by WGS [44].
Phylogentic studies based on single nucleotide polymorphisms (SNP) present strong evidence for
an Australian B. pseudomallei origin [43,45] and a single transmission event to Southeast Asia [43,46].
In a recent study by Chewapreecha et al. (2017) on the global evolution and prevalence of B. pseudomallei,
19 strains from Vietnam (spanning a time period from 1947 to 2011) were subjected to whole genome
sequencing and placed in a global context (469 isolates) [46]. A SNP-based phylogenetic analysis of
these genomes clearly resolved Australian, Asian, and African/American clusters.
Strains from Vietnam appeared in 7 of 17 Asian subgroups, with most of the other members of the
subgroup being from Thailand and Cambodia and belonging to the ‘Mekong sub-region’. The other
Asian subgroups contained mainly isolates from Malaysia and Singapore (‘Malay cluster’). It could be
shown that the transitions of B. pseudomallei between these two sub-regions was less than within the
sub-region. As noted by the authors, this observation might be linked to trading networks and cultural
links. Furthermore, the results indicate that the Mekong sub-region might have been a hotspot for the
evolution of B. pseudomallei in Southeast Asia. Unfortunately, in contrast to other Asian clusters, no time
could be estimated for the emergence of the most recent common ancestor of the Vietnam-containing
subgroups. Besides, the study also demonstrates the potential of WGS to account for geographical
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differences in disease outcome, by screening for region-speciﬁc (virulence) loci [46]. The insights,
based on just 19 Vietnamese isolates, already imply the wealth of information that can presumably be
gained from such a high level of resolution. Should more rigorous clinical and environmental sampling
schemes be applied and a higher number of strains analyzed, this will likely increase our knowledge
of B. pseudomallei phylogeny and virulence tremendously. There is no doubt that these are interesting
times for studying the genomic diversity of B. pseudomallei in Vietnam.
5. Activities to Raise Awareness of Melioidosis in Vietnam and Major Achievements
As in many parts of the world, neither melioidosis nor characteristics of B. pseudomallei are
mandatory components of curricula at medical universities in Vietnam. This leads to a lack of
knowledge among many doctors and other health care professionals about how to diagnose and
manage the disease. As outlined above, this limited clinical awareness together with limited laboratory
resources result in signiﬁcant underdiagnosis. This has been very obvious in the central part of Vietnam.
Although it is located in the same geographical belt and is close to highly endemic areas of Laos and
northeast Thailand, cases of melioidosis were not reported from there until recently.
In 2014, a bilateral project called Research Network on Melioidosis and Burkholderia pseudomallei
(RENOMAB), sponsored by the German Ministry for Education and Research and the Vietnamese
Ministry of Science and Technology, was started. The project involved 40 national and regional
hospitals in 27 provinces and cities throughout the country. By organizing a series of workshops on
diagnosis of melioidosis for laboratory staff, hundreds of culture-conﬁrmed cases have recently been
detected [28]. Two national scientiﬁc conferences on melioidosis were organized in order to raise
awareness of the disease among infectious disease physicians, microbiological laboratory staff, medical
teachers, researchers, and health-care managers.
Active melioidosis case-ﬁnding reports were presented at national scientiﬁc conferences for
infectious and respiratory diseases [47,48]. Scientiﬁc papers on melioidosis have started to appear in
national journals [49]. The existence of the disease was also broadcasted in a wide range of public
media such as hospital web portals, newspapers and television programs. A private Facebook group
named Research Network on Melioidosis in Vietnam (Hoi Nghien cuu Melioidosis tai Vietnam)
was created and consists of approximately 600 members from the healthcare system interested in
melioidosis diagnostics. At the time of writing, 36 hospitals in 26 provinces and cities reported
culture-conﬁrmed melioidosis cases (Figure 1). Of these, 28 hospitals detected the ﬁrst cases of the
disease after joining case-ﬁnding activities within RENOMAB. This project has shown that melioidosis
is widely distributed throughout the country with a potential area of high endemicity in North Central
Vietnam [28]. The organization of the 9th World Melioidosis Congress in 2019 in Hanoi will be a golden
opportunity to further raise awareness for melioidosis and to promote research on different aspects of
epidemiology, diagnosis, and treatment in Vietnam.
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Figure 1. Location of hospitals taking part in the RENOMAB project and reporting culture-conﬁrmed
melioidosis cases. All of the B. pseudomallei strains were sent to the reference laboratory at the Institute
of Microbiology and Biotechnology, Vietnam National University, Hanoi. B. pseudomallei identiﬁcation
of bacterial strains was conﬁrmed by using either recA sequence analysis or B. pseudomallei-speciﬁc
TTSS1 real-time PCR assay [28]. Border lines of provinces or cities are shown. The color indicates the
number of hospitals within the province or city that reported cases of melioidosis. Geographic map
was constructed by the MapInfo 7.8 (MapInfo, Troy, NY, USA).
6. Current Recommendations for Diagnosis and Treatment and for Reporting and Prevention
6.1. Diagnosis and Treatment
Currently, there are no ofﬁcial guidelines for diagnosis and treatment of melioidosis issued by
the Vietnamese Ministry of Health, and B. pseudomallei has not been yet on the list of any national
surveillance programs for infectious agents. The current recommendations that have been distributed
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via seminars, workshops, and national conferences, are based on studies and guidelines from the
international literature.
In well-equipped laboratories commercially-available biochemical tests and automated
identiﬁcation systems are routinely used. However, even under such circumstances, a lack of
awareness and of additional diagnostic tools can lead to unreliable diagnoses, since misidentiﬁcation
of B. pseudomallei has been well documented for such systems [50]. In remote areas where laboratory
facilities and resources for consumables are still limited, the identiﬁcation of bacterial pathogens mostly
relies on some basic microbiological tests, and the identiﬁcation of Gram-negative non-fermenting
bacterial species is even more challenging. We therefore recently introduced a simple laboratory
algorithm for identiﬁcation of B. pseudomallei from clinical specimens under such resource-constrained
conditions. The algorithm makes use of the inherent resistance of B. pseudomallei to gentamicin and
colistin and the susceptibility to amoxicillin-clavulanic acid [28].
Although the sensitivity and speciﬁcity of this algorithm have not been validated yet, compared
to more sophisticated identiﬁcation procedures including selective media such as Ashdown’s agar for
non-sterile sites, it proved to be an effective and inexpensive procedure leading to the diagnosis of
a signiﬁcant number of melioidosis patients at provincial general hospitals in North Central Vietnam in
a short period of time after introduction [28]. We therefore currently recommend the implementation
of this simple algorithm in clinical laboratories for a presumptive diagnosis of B. pseudomallei from
clinical materials. Conﬁrmation of the identiﬁcation can be obtained in reference laboratories using
speciﬁc type three secretion system 1 (TTSS1) real-time PCR assays and sequencing of the recA gene as
reliable target [28].
6.2. Surveillance and Prevention
Melioidosis is not a notiﬁable disease in Vietnam. There is neither a formal surveillance system
for human nor for animal melioidosis in Vietnam. There are also no ofﬁcial recommendations on
prevention. The limited epidemiological data available in Vietnam indicate that rice farmers are at
a particular risk, similar to other parts of Southeast Asia. At present, it seems plausible to primarily
target the rice farming population in terms of better diagnostics and evaluation of possible preventive
measures. The majority of them are living in remote areas where the primary healthcare system of
the country does not cover microbiological investigations. It is therefore most likely that fatal cases of
melioidosis in remote areas are still grossly under recognized.
7. Current and Future Challenges
Although some progress has recently been made in Vietnam to increase awareness of melioidosis
and to enhance laboratory skills for identiﬁcation of B. pseudomallei from clinical specimens, there are
still signiﬁcant efforts needed to further improve capacity building in different regions of Vietnam.
Apart from further improving the identification capacity in the laboratories via diagnostic workshops
and scientific conferences it will be crucial to generally increase the number of clinical specimens—such as
urine, throat swabs, sputum, pus, etc.—to be sent to the laboratory for microbiological investigations.
Since bacteremic melioidosis is a common clinical presentation and also associated with a high case
fatality rate, increasing the number of blood cultures in patients with prolonged fever has a high priority.
There are financial barriers and insurance issues that hinder an appropriate use of blood cultures in the
diagnosis not only for melioidosis, but also for other systemic infections, which need to be addressed.
Epidemiological studies are needed to determine the true incidence and prevalence of melioidosis in
the various regions. The same is true for the veterinary field, where information on melioidosis is still
very scarce.
In parallel to capacity building in the clinical laboratory, studies on the environmental distribution
of B. pseudomallei in Vietnam will be important to deﬁne risk areas for the indigenous population more
precisely. This information can be used to further target clinical microbiology activities. In addition,
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serological screening of the indigenous population using newly-developed devices might help to
detect exposure to B. pseudomallei and to identify possible endemic hot spots.
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Abstract: Melioidosis, although endemic in many parts of Southeast Asia, has not been systematically
studied in Hong Kong, which is a predominantly urban area located in the subtropics. This review
describes the early outbreaks of melioidosis in captive animals in Hong Kong in the 1970s, as well as
the early reports of human clinical cases in the 1980s. A review of all hospitalized human cases of
culture-conﬁrmed melioidosis in the last twenty years showed an increasing trend in the incidence of
the disease, with signiﬁcant mortality observed. The lack of awareness of this disease among local
physicians, the delay in laboratory diagnosis and the lack of epidemiological surveillance are among
the greatest challenges of managing melioidosis in the territory.
Keywords: melioidosis; Burkholderia pseudomallei; Hong Kong
1. Introduction
Melioidosis is an emerging infectious disease caused by Burkholderia pseudomallei that causes
signiﬁcant morbidity and mortality [1]. Melioidosis was ﬁrst described in Southeast Asia in the early
1910s [2]. Since then, melioidosis has been well recognized to be highly endemic in northern Australia
and many parts of Asia, with the highest prevalence observed in Southeast and South Asia [3,4].
It is being increasingly reported in previously non-endemic regions [4].
Melioidosis is endemic in regions located at tropical latitudes between 20◦ N and 20◦ S [1].
However, there is an increasing bulk of evidence of this disease in territories with no previous
documentation of melioidosis, as well as an expansion of the geographical areas with a signiﬁcant
burden of the disease outside the tropics, including Southern China [5,6] and Taiwan [7]. Hong Kong
is also considered to be situated in an endemic region with high environmental suitability for
B. pseudomallei [3,4].
Despite its high fatality rate, melioidosis is often a neglected disease. It has been estimated that
the disease was regularly under-reported in many countries [4]. B. pseudomallei is a natural saprophyte,
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thus human cases of melioidosis were frequently associated with exposure to soil and contaminated
waters in rural areas [8]. Epidemiological studies from urbanized cities like Hong Kong were therefore
rarely performed. Melioidosis is currently not a statutorily notiﬁable disease in Hong Kong, and this
disease has never been systematically studied in Hong Kong. Therefore, the local burden of illness is
currently largely unknown.
This review aims to provide an overview of melioidosis in Hong Kong. In the ﬁrst part,
the history of melioidosis in humans and animals and evidence of B. pseudomallei in the environment,
as reported in the literature, is reviewed. In the second part, a review of all clinical cases of
culture-conﬁrmed melioidosis managed in public hospitals in Hong Kong in the past 20 years
is presented. This is followed by results of a survey performed among local infectious diseases
physicians and microbiologists on the local practice of diagnosis and management of melioidosis.
Lastly, challenges in the control and clinical management of this disease are discussed.
2. History of Melioidosis in Hong Kong: Presence in Animals, Humans and the Environment
The earliest record of B. pseudomallei in Hong Kong came from isolates obtained from bottlenose
dolphins and a harbor seal kept in an oceanarium in 1975 and 1976 [9]. This outbreak at the oceanarium
caused 24 dolphins to succumb to this illness [10]. Subsequently, B. pseudomallei was isolated from
other dolphins and numerous other captive sea mammals, including sea lions and pilot whales, as well
as birds in a nearby aviary, including zebra doves and scarlet macaws, from 1978 to 2000 [9,11].
A clinical review was performed to evaluate all the melioidosis cases in animals kept at the
oceanarium in the period from 1974 to 2003. A total of 49, 31, 16 and 5 cases of melioidosis were
recorded in cetaceans, pinnipeds, birds and terrestrial mammals during this period, respectively.
All but four succumbed to the disease. Melioidosis caused 55% and 50% of all known causes of deaths
in cetaceans and pinnipeds, respectively, during this period [12].
An experimental acellular B. pseudomallei vaccine that was tested to be safe and effective in
hamsters was given to false killer whales and bottlenose dolphins in the oceanarium from 1986 to 1987.
The vaccine produced a high level of speciﬁc antibodies in these cetaceans, and was able to reduce
mortality in the cetaceans from 45% in 1983 to less than 1% in 1988 [13].
The ﬁrst human case of melioidosis in Hong Kong was reported in 1983 [14], followed shortly by
another ﬁve cases reported in 1984 [10]. All these patients were immunocompromised, with either
diabetes or had been receiving immunosuppressive therapy for autoimmune diseases. All patients
had bacteremia with or without pulmonary involvement. None of them had reported travelling
to other endemic areas. Mortality was high, and the majority of them did not receive adequate
anti-microbial therapy.
The ﬁrst serological study was published in 1984, in which 22 elderly patients admitted to a
general medical unit of a teaching hospital were screened for hemagglutinating antibodies against
lipopolysaccharide antigens of B. pseudomallei. 23% of patients in this small cohort had evidence of
possible subclinical infection [10,15]. This was followed by another serological survey published in
1987 involving 275 patients with underlying tuberculosis or chronic pulmonary diseases. This study
showed that 14% of subjects had serological evidence of exposure to B. pseudomallei. Among those with
positive antibodies against B. pseudomallei, 77% of subjects had not traveled to other endemic areas [15].
This ﬁnding, together with the ﬁrst few human cases described above, produced the earliest evidence
that melioidosis was also endemic in Hong Kong, and that human exposure to the bacterium was not
at all rare.
Subsequent to those early case reports, eight more human cases of culture-conﬁrmed
melioidosis were published from 1987 to 2015 (Table 1). Most of these patients had underlying
immunocompromised conditions, including diabetes and hematological malignancies with prolonged
neutropenia. One 40-year-old man, with concomitant miliary tuberculosis, was found to have X-linked
chronic granulomatous disease. Most patients had bacteremia, pulmonary infection or deep organ
abscess. One 82-year-old man developed a mycotic aneurysm in the aortic arch. Such clinical
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presentation had been reported rarely elsewhere [16]. All of these subsequently reported cases received
either intravenous ceftazidime or carbapenem as induction therapy. Three out of these eight patients
died due to melioidosis.
There was also a case series published in 2010, describing ﬁve patients with autoantibodies
against interferon-γ with positive IgG or IgM antibodies against B. pseudomallei. All these patients
had concomitant non-tuberculous mycobacteriosis, penicilliosis and/or non-typhoidal salmonellosis.
None of these patients had a positive culture of B. pseudomallei [17].
As in neighboring regions located at similar latitudes, where B. pseudomallei had been isolated
from the soil [7,18], the bacterium was also isolated from the environment in soil samples in Hong
Kong as early as the 1970s [9]. These early reports showed that B. pseudomallei was isolated in soil
samples taken from sea sludge, farms and a children’s playground [10]. In 2000, multiple soil and
water samples from an aviary were also found to harbor the bacterium [9]. More recently, among
1400 soil samples collected from the oceanarium in Hong Kong, over a 15-month period, 6.8% of the
samples were positive for B. pseudomallei by PCR [19].
An epidemiological study, using multilocus sequence typing, on isolates obtained from captive
animals and the environment from 1975 to 2000 in Hong Kong, showed that there were two major
clusters involving three serotypes. All of these serotypes had been identiﬁed in human cases of
melioidosis from Hong Kong [9]. The seasonality of melioidosis cases among the captive animals also
correlated with the timing of detection of B. pseudomallei in soil samples [14]. Such epidemiological
data suggested that humans, as in the case of animals, acquired the same strains of B. pseudomallei from
direct exposure to soil and water [9].
3. Review of Culture-Conﬁrmed Melioidosis Cases in Humans in the Past 20 Years
To determine the burden of illness caused by melioidosis in Hong Kong, a retrospective review
of all patients admitted to all public hospitals in Hong Kong with B. pseudomallei isolated from one
or more clinical specimens during the period from 1998 to 2017, was conducted. In Hong Kong,
public hospitals under the Hospital Authority of Hong Kong provide more than 80% of in-patient
services to the population in the territory [20]. All patients with one or more clinical specimens with
B. pseudomallei isolated were identiﬁed from the Clinical Data Analysis and Reporting System (CDARS),
which is a central computerized database of the Hospital Authority, including patients’ demographic
characteristics, diagnoses, laboratory data and drug treatment.
A total of 61 culture-conﬁrmed cases of melioidosis was identiﬁed during this 20-year period.
A progressive increase in the number of cases was observed over this period (Figure 1). 72.1% of the
subjects were male, and the median age was 67 (range 8–100, interquartile range 58–83). Only three
pediatric cases, with an age between 8 and 17 years, were identiﬁed. 60.7% of them had bacteremia,
42.6% had a pulmonary infection, 23.0% had deep organ abscesses (most common being prostate,
kidneys, spleen and liver), 11.5% had skin and soft tissue infection and 6.5% had bone and joint
infection. A relapse of melioidosis was observed in two patients within 12 months of the initial episode.
The overall case fatality rate was 31.1%. Mortality was associated with the presence of bacteremia only
(odds ratio 5.14, 95% conﬁdence interval 1.26–21.07, p = 0.023).
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Figure 1. The number of culture-conﬁrmed human cases of melioidosis over a 20-year period.
This series of human cases together with earlier case reports published in the 1980s strongly
suggested that melioidosis is endemic in Hong Kong. The saprophytic nature of B. pseudomallei has
been well recognized since the 1950s [1]. As such, occupational and recreational exposure to soil and
contaminated water surfaces, e.g., those working in farms and rice paddies, and those with ingestion
or inhalation of food and water contaminated with soil, were consistently described as risk factors for
acquiring melioidosis [1,28]. Therefore, not surprisingly, large cohorts of human cases of melioidosis
were most commonly reported from rural parts of countries and regions, where primary industry is
common [29,30]. Lower incidence of melioidosis was observed in higher-income countries possibly
due to lower exposure rates [4]. However, our review and other studies of melioidosis performed
in urban cities [31] serve as a good reminder that melioidosis, though less prevalent, should not be
neglected in these cities, due to the high mortality and rising incidence. In urbanized areas, working in
construction sites, military forces and recreational exposure to soil and contaminated waters have been
described as risk factors for acquiring the infection [1,32,33].
We observed a rising trend of culture-conﬁrmed cases over the last 20 years in Hong Kong.
An increase in the incidence of human cases of melioidosis has also been reported in Asia in
the past decade [4]. For example, Hainan witnessed an increasing trend of annual incidence of
melioidosis, with most cases residing in Sanya and Haikou cities [6]. There are several postulations
accounting for the rising trend observed in Hong Kong. Improved case detection with better
microbiological diagnostic tools is a possibility. Weather changes, through their impacts on
environmental contamination, have been shown to cause clustering of human cases of melioidosis [34].
In Hong Kong, the detection rate of B. pseudomallei from soil was shown to have signiﬁcant positive
correlation with ambient temperature and relative humidity [19]. Therefore, the signiﬁcant warming
trend and more frequent extreme precipitation events since the 20th century, as reported by the Hong
Kong Observatory, could possibly increase human exposure to the bacterium from the environment.
The expanding scope of international traveling was proposed to be a source of the importation of cases
and the emergence of melioidosis in developed countries as well [4]. Human cases of melioidosis
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from Hong Kong and other Southeast Asian countries have been shown to share the same serotype [9],
supporting the possibility that the disease could be acquired during travel. Lastly, our patients were
older than those in other cohorts [29,30], and melioidosis is well recognized to recrudesce after a
prolonged period of time [35]. Most of the patients described in the published case reports from Hong
Kong had a wide spectrum of underlying immunocompromised conditions (Table 1). Therefore, aging
and the increase in immunocompromised diseases and therapies could have contributed to the increase
in the incidence of melioidosis by reactivation of the disease after acquisition earlier in life [21,24].
Distinct from the experience in some other Asian countries [36,37], pediatric infections were rare
in our cohort. On the other hand, the spectrum of disease involvement observed in our cohort was
similar to those described in other studies [35], with bacteremia, pulmonary infection, deep organ
abscesses and genitourinary infection being the most common. Bacteremia was present in 61% of
cases, and was the major predictor for mortality. The recurrence rate in our cohort was similar to
that described previously [35]. Although standard antimicrobial therapy was given to the majority of
patients, case fatality rate was still high at 31%. The case fatality rates observed in other developed
countries were 14–18% [30,31]. The higher case fatality rate in our cohort could partly be due to the
older age of our patients, as compared to most other studies [6,31,38].
4. Current Practice of Management of Melioidosis in Hong Kong
An online survey was performed among local infectious disease physicians and microbiologists
from May to July 2018 to evaluate the contemporary local practice in diagnosis and management of
melioidosis. The survey was sent to 44 infectious disease physicians and microbiologists, of whom 28
(64%) responded to the survey. They had a median of eight years (interquartile range 3–13) of experience
as a specialist. The majority of the respondents (57.1%) had managed 1–2 culture-confirmed cases of
melioidosis in the past, while 32.2% had seen three or more cases, and 10.7% had never seen a case.
For laboratory diagnosis, 67.9% of the respondents had access to matrix-assisted laser
desorption/ionization time-of-ﬂight mass spectrometry (MALDI-TOF MS) as one of the usual methods
of identiﬁcation of B. pseudomallei, while 46.4% and 42.9% regarded biochemical and phenotypic testing
and Vitek as the usual methods of identiﬁcation respectively. 25.0% regarded 16S rRNA sequencing
as one of the usual methods of identiﬁcation. The majority (71.4%) did not ﬁnd serology to be useful
in diagnosing melioidosis, mainly due to the perceived low speciﬁcity of the assay. 19.2% of the
respondents, however, did believe serology would increase case detection, especially in patients who
had negative cultures after antibiotics treatment, and those with compatible epidemiological exposure.
All respondents would prescribe either ceftazidime or meropenem for at least two weeks for the
initial treatment of melioidosis. 82.1% of them would choose trimethoprim-sulfamethoxazole, and the
remainder amoxicillin-clavulanate, for at least three to six months, as an eradication therapy.
The majority of respondents regarded the lack of awareness among clinicians as the greatest
challenge in the management of melioidosis in Hong Kong. The relatively small number of cases
in Hong Kong limited the experience and expertise for this disease entity. The low level of clinical
suspicion would cause a delay in diagnosis. Respondents were also concerned with the currently
available diagnostic tools, and problems of misidentiﬁcation of B. pseudomallei as other Burkholderia or
Pseudomonas species. In terms of treatment, the greatest challenge was ensuring adherence and the
management of adverse reactions secondary to prolonged courses of antibiotics.
5. Challenges in the Control and Management of Melioidosis
It is uncertain whether melioidosis is being under-diagnosed in Hong Kong. A recent study
estimated that Hong Kong would expect to see 67 new cases of melioidosis annually [4]. This estimation
was much higher than the number of cases observed in our review for the last two decades. As reﬂected
in our local survey, under-diagnosis could be due to the low level of clinical suspicion among clinicians.
The diagnosis of melioidosis can be difﬁcult in clinical cases, as B. pseudomallei might not be readily
isolated from clinical specimens [39], or misidentiﬁed as other Burkholderia species by certain automated
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systems [40]. Cases diagnosed to be pulmonary tuberculosis or other bacterial cases of pneumonia in
Hong Kong have also been suspected to be melioidosis [6,10,15]. Moreover, we have only included
culture-conﬁrmed cases in our review; culture-negative cases conﬁrmed only by serological evidence
of infection were not included in the analysis. Since we have observed an increasing number of cases
over the last 20 years, continual surveillance of this disease in the territory should be implemented.
Improvements in the laboratory diagnosis of melioidosis are urgently needed. Molecular
techniques, involving 16S rRNA or groEL gene sequencing, would be useful for identiﬁcation,
in particular, to differentiate B. pseudomallei from other closely related Burkholderia species, including
B. thailandensis [24,41]. As observed in our survey, MALDI-TOF MS is being increasingly used in
Hong Kong microbiology laboratories. This technique has recently been shown to be an accurate
method for the identiﬁcation of B. pseudomallei [42]. Preliminary data also showed that proﬁling
metabolites from various lipid classes is a potential biomarker for the diagnosis of melioidosis [39].
The case fatality rate observed in Hong Kong was higher than that observed in other high-income
countries. As indicated by the results of our survey, the relatively low number of cases detected in Hong
Kong led to a low level of clinical suspicion and possibly a delay in diagnosis. Empirical treatment of
melioidosis, for example, is seldom initiated for patients with community-acquired pneumonia in Hong
Kong. Awareness of this disease should be raised, and the diagnosis should be particularly considered
in patients with compatible clinical manifestations and associated epidemiological risk factors.
The growing number of cases of melioidosis could partially be explained by the aging population
and the increase in immunocompromising diseases and therapies. Currently, there is no local guideline
in the prevention and management of the disease in patients at high risk of complications and mortality
from melioidosis. Recommendations have been issued for the workup of melioidosis in seropositive
patients initiating immunosuppressive therapy and symptomatic seropositive immunocompromised
patients [36]. Routine serological testing of antibodies against B. pseudomallei is currently not performed
in immunocompromised patients in Hong Kong. The only published local seroprevalence surveys
were done in the 1980s. A study should, therefore, be considered to evaluate the current seroprevalence
rate of melioidosis in Hong Kong, and to determine whether routine screening is necessary for
immunocompromised patients in Hong Kong.
6. Conclusions
Melioidosis is endemic in the urban city of Hong Kong. Although the observed incidence was
lower than in other neighboring countries and regions, there was an increasing number of cases in the
last 20 years. Surveillance of the disease should be considered, and more effort should be in place to
raise clinicians’ awareness of the disease.
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Abstract: Melioidosis, caused by the bacterium Burkholderia pseudomallei, is an infectious disease of
humans or animals, and the speciﬁc environmental conditions that are present in western Indian
Ocean islands are particularly suitable for the establishment/survival of B. pseudomallei. Indeed,
an increasing number of new cases have been reported in this region (Madagascar, Mauritius, Réunion
(France), and Seychelles, except Comoros and Mayotte (France)), and are described in this review.
Our review clearly points out that further studies are needed in order to investigate the real incidence
and burden of melioidosis in the western Indian Ocean and especially Madagascar, since it is likely
to be higher than currently reported. Thus, research and surveillance priorities were recommended
(i) to improve awareness of melioidosis in the population and among clinicians; (ii) to improve
diagnostics, in order to provide rapid and effective treatment; (iii) to implement a surveillance and
reporting system in the western Indian Ocean; and (iv) to investigate the presence of B. pseudomallei
in environmental samples, since we have demonstrated its presence in soil samples originating from
the yard of a Madagascan case.
Keywords: Melioidosis; Burkholderia pseudomallei; western Indian Ocean; diagnosis; MLST; Madagascar;
Mauritius; Réunion; Seychelles
1. Introduction and History of Melioidosis in the Western Indian Ocean
Melioidosis (also known as Whitmore’s disease or Nightcliff gardener’s disease) is an
infectious disease that can infect humans or animals. This disease is caused by the bacterium
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Burkholderia pseudomallei. A recent study mapped documented human and animal cases and the
presence of environmental B. pseudomallei in the world, in order to estimate the global burden
of melioidosis by a formal modeling framework and assess the environmental suitability for
B. pseudomallei [1]. Human cases are mainly reported in hyperendemic areas of Southeast Asia and
northern Australia, with sporadic reports in parts of the Americas, Africa, Paciﬁc Ocean islands,
southern China, Hong Kong and Taiwan, and South Asia. It has been predicted that the speciﬁc
environmental conditions which are present in western Indian Ocean islands are particularly suitable
for the establishment/survival of B. pseudomallei [1], and an increasing number of new cases have
been reported in this region [2]. A map of the western Indian Ocean with its different islands can be
accessed at the website [3]. It was long ago hypothesized that the trade of (healthy or sick) animal
carriers could contribute to the spread of the disease to non-endemic areas.
In Thailand, melioidosis is considered a disease predominantly of rice farmers, which is brought
about by their frequent exposure to environments containing B. pseudomallei. The organism is a
saprophyte found in soil and water, and people become infected, particularly after heavy rains,
by contact with contaminated soil or water through percutaneous inoculation, by inhalation, or even
through ingestion of contaminated water (e.g., aspiration in near-drowning events during ﬂooding or
tsunamis, or consumption of unchlorinated water). Person-to-person transmission can occur, albeit very
rarely, through contact with blood and body ﬂuids of an infected person. Infected people generally have
underlying predisposing conditions, such as diabetes mellitus, renal disease, cirrhosis, thalassemia,
cystic ﬁbrosis, chronic obstructive lung disease, or immunosuppressive therapy. Clinical presentations
vary widely, and include skin and soft tissue abscesses, pneumonia, and disseminated infection with
septic shock, the latter having mortality rates above 80% [4]. The diverse clinical manifestations and
the inadequacy of conventional bacterial identiﬁcation methods render B. pseudomallei identiﬁcation
difﬁcult, particularly in regions where this organism is not well-recognized, and could result in a
serious underestimation of the disease in low-income countries, where capacity building is needed in
the health services, as recently discussed by Limmathurotsakul et al. [1].
In Madagascar, the ﬁrst isolation of B. pseudomallei occurred in Antananarivo in 1932 when Girard,
a former Director of the Pasteur Institute of Madagascar, examined a dead guineapig inoculated with a
submaxillary node of a slaughtered pig [5].
The presence of this bacterium in Madagascar was also reported later (1977) by Galimand and
Dodin working in the ‘Whitmore bacillus laboratory’ in the Pasteur Institute in Paris. They isolated and
identiﬁed the bacterium from soil samples originating from the zoo of Antananarivo and from a pig
farm in the same city [6]. There are two isolates (770429-id6- and Soil1977-id7-) in the B. pseudomallei
multilocus sequencing typing (MLST) database (https://pubmlst.org/bpseudomallei/) originating
from soil collected from the Antananarivo region in 1977. These isolates correspond to ST-6 (alleles: 1, 1,
7, 2, 4, 5, 1) and ST-27 (alleles: 1, 3, 19, 4, 5, 1, 1), respectively [7]. ST-6 has not been reported in any other
isolate to date; however, ST-27 was also found in a 1978 soil sample from Chantilly, France, during a
devastating and highly unusual melioidosis outbreak (the so-called ‘Affaire du Jardin des Plantes’) that
lasted several years and that resulted in the death or slaughter of dozens of animals across several zoos
and equestrian clubs, probably by the transport of infected animals and/or contaminated manure [8].
A case of animal melioidosis, also related to the French outbreak, occurred in 1979 in a horse that
had recently been imported from France into Réunion Island [6]. This epizootic of melioidosis across
France and beyond was extraordinary, and greatly extended the known boundaries of this disease,
being the ﬁrst report of this disease in a temperate region [6].
Subsequently, between 2004 and 2017, there were six human cases of melioidosis that were
detected and probably acquired in the city of Mahajanga (Madagascar), of which three were diagnosed
and treated in Réunion Island in 2004, 2005, and 2016. Considering other islands of the western Indian
Ocean, there were two cases in Mauritius in 2004 and 2006, one autochthonous case in 2012, and four
imported cases in Réunion Island (three from Madagascar, in 2004, 2005, and 2016 respectively, and one
from South Asia in 2017), and ﬁnally, two cases in cooks from the same facility in Seychelles in 2013.
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These cases are described in more detail in the next section. Since the cases were all investigated
separately, some methodologies used for culturing and identifying B. pseudomallei were slightly
different between the different laboratories concerned. We also describe the isolation of B. pseudomallei
in the yard of case #9 from Madagascar.
2. Review of the Human Cases
N.B. Cases are numbered chronologically, independently of the country of origin.
2.1. Madagascar
Case #1. The ﬁrst human case of melioidosis in the region was detected in May 2004 in a
60-year-old Frenchman living in Mahajanga, a city on the northwestern coast of Madagascar, along the
Mozambique Channel, who had been transferred to a hospital in Réunion Island. He was admitted
to an intensive care unit for management of respiratory distress and septic shock. About 20 or
30 years before the onset of the disease, he had lived for an unknown period of time in Vietnam,
where melioidosis is endemic. He was a heavy drinker and smoker with cachexia. Four blood
cultures and one bronchoalveolar lavage specimen, taken the ﬁrst day after admission, were positive
for B. pseudomallei [9]. The initial treatment was a combination of piperacillin and ciproﬂoxacin
(the initial identiﬁcation was ‘Pseudomonas sp.’), followed by ceftazidime when B. pseudomallei was
recognized. Interestingly, two secondary cases (cases #2 and #3), acquired 150 and 180 days after the
initial case and transmitted by a ﬁberoptic bronchoscope, were detected. A manufacturing defect
rendered the decontamination processes of the bronchoscope insufﬁciently effective, and culture
with subsequent DNA restriction analysis conﬁrmed the secondary transmissions. These nosocomial
transmissions concerned an 81-year-old man suffering from a chronic pulmonary disease, and a woman
undergoing glucocorticoid therapy for lupus. Both secondary cases were also treated with ceftazidime
(120 mg/kg/day) until recovery, followed by trimethoprim/sulfamethoxazole for 20 weeks.
Case #5. The second case in Madagascar was a 58-year-old Frenchman with an unremarkable
medical history who had lived for the previous ﬁve years in Antananarivo [10]. The patient, a retired
manager, had spent most of his life in France, and he had traveled for short periods in Tunisia, Turkey,
and Mauritius (six years previously). His ﬁrst symptoms (high fever with cough) appeared during
a two-week holiday trip to Mahajanga in March 2005. He was initially admitted to a hospital in
Antananarivo, where he was treated for ten days with amoxicillin/clavulanic acid and levoﬂoxacin
after a chest X-ray showed a patchy inﬁltrate of the right upper and middle lobes. His sputum acid-fast
stain was negative. After clinical improvement, the patient was discharged, but ﬁve days later he
became feverish again, and was referred to a hospital in Réunion Island for further management.
Although four blood cultures were negative, B. pseudomallei was isolated from his bronchoalveolar
lavage. He responded to treatment, which ﬁrstly comprised imipenem for two weeks, followed by
oral trimethoprim/sulfamethoxazole and doxycycline. He was discharged at day 20 on eradication
treatment with trimethoprim/sulfamethoxazole for a further ﬁve months.
Cases #8 and #9. The third and fourth cases in Madagascar were rural farmers aged 52 and
45 years, respectively [11]. They were both admitted to the University hospital in Mahajanga with
sepsis in July 2012 and in May 2013, respectively. One of them had an opacity in the lower left
lung and a pleural effusion, whilst the other developed hepatic failure after one week of admission.
They were both suffering from diabetes mellitus, and hepatomegaly and splenomegaly were detected
by abdominal ultrasound examination during their hospitalization. The diagnosis of B. pseudomallei
was possible thanks to a speciﬁc research study on melioidosis that was being conducted in this
hospital during the period 2012–2013, which supported the purchase of consumables, such as blood
culture bottles and culture media (chocolate, blood and Ashdown agars). However, both patients died
despite antibiotic treatment.
Case #10. The ﬁfth case in Madagascar was a 44-year-old Frenchman admitted with acute anuria
and fever to the emergency service of a Belgian hospital near the French border in March 2013 [12].
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He had a severe inﬂammatory syndrome, spondylodiscitis at L1, lung inﬁltrates, pyelonephritis, and a
prostatic abscess. He was treated with a ﬂuoroquinolone after the isolation of an organism initially
identiﬁed as B. cepacia on a VITEK II instrument (bioMérieux, La Balme-Les-Grottes, France) from
his blood cultures. The patient’s clinical condition remained stable, with decreasing inﬂammatory
syndrome and fever, and he was discharged for few days until the real causative agent was identiﬁed.
When B. pseudomallei was correctly identiﬁed by MALDI-TOF MS using the security-relevant reference
library, and subsequently conﬁrmed by a highly-speciﬁc PCR assay, the patient was readmitted to
the hospital, the antimicrobial treatment was immediately changed (to meropenem 1 g iv t.i.d. and
trimethoprim/sulfamethoxazole 2 × 160/800 mg t.i.d.) and his condition improved. Interestingly,
the patient, a gardener by profession, reported frequent travels to his secondary residence in Mahajanga,
usually for 3 weeks, every 3 or 4 months.
Case #13. The last case from Madagascar was recently described by Allou et al. [2], and concerned
a 63-year-old Frenchman, with no signiﬁcant past medical history, who lived in Madagascar and made
frequent trips to Mayotte, an island between Madagascar and Mozambique. After his admission
to Mahajanga Hospital, where he was treated with oﬂoxacin for cough and fever lasting one week,
his condition worsened (vomiting, dehydration, deterioration of consciousness) and he was transferred
to an ICU at Saint Denis Hospital, Réunion Island, with septic shock and coma on admission. Brieﬂy,
a total body-computed tomography (TB-CT) scan showed multiple bilateral lung abscesses, a liver
abscess, splenomegaly, and hepatomegaly. Despite immediate antimicrobial treatment (meropenem,
colistin, amikacin), the evolution was marked by multiple organ failure and the patient died on
day one. Blood cultures and respiratory samples were positive for a Burkholderia identiﬁed as
B. thailandensis by a MALDI-TOF mass spectrometer (Bruker Biotyper, Bruker Daltonics, Bremen,
Germany) but conﬁrmed later as B. pseudomallei by qPCR targeting three genetic markers of the type
III secretion system (orf1, orf13, and BsSCU2). It is noteworthy that B. pseudomallei was not at that time
included in the IVD MALDI Biotyper database but in a separate database (SR: security-relevant) which
was not available at the hospital. The strain was susceptible in vitro to ticarcillin/clavulanic acid,
trimethoprim/sulfamethoxazole, and ceftazidime, and was resistant to meropenem and levoﬂoxacin.
The meropenem resistance (MIC = 12 mL/L) was unusual, and the presence of a possible metallo
β-lactamase (MBL) was investigated with the RUO Etest MBL MP/MPI US 8/2 (bioMérieux,
La Balme-Les-Grottes, France), but failed. The higher MIC values to different antibiotics suggested
that this resistance could be due to a non-speciﬁc mechanism, such as efﬂux or impermeability.
The six cases are summarized in Table 1. After investigations, all cases were likely to
have been acquired in Mahajanga, a favorite tourist destination in Madagascar located on the
country’s northwestern coast on the Mozambique Channel (15◦43′ S, 46◦18′ E), 550 km from
Antananarivo. Typing of strains isolated from ﬁve human cases by multilocus sequencing typing
(MLST; Godoy et al. [7]) showed new sequence types (STs), all of which were possibly related to each
other (varying by 1, 2, or 3 alleles, depending on the combinations).
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2.2. Soil Investigation in Mahajanga, Madagascar, in the Yard of Case #10
A soil investigation was carried out in the yard of the ﬁfth case from Madagascar (#10). His house
in Mahajanga was located on the seashore (separated by an asphalted road). Mahajanga (sometimes
spelled Majunga) has a tropical wet and dry/savanna climate (Köppen-Geiger classiﬁcation [13],
with a pronounced dry season in the low-sun months, no cold season, and a wet season in the high-sun
months (from November to April) (http://www.mahajanga.climatemps.com/). Sampling and culture
of B. pseudomallei isolates from soil was done according to Appendix B. In brief, a total of 11 soil and
water samples (Figure A1) were collected, among which was A12, a dark, dry, turf-like soil sold as
fertilizer/manure by a local supplier. Sandy soil samples A4, A5, and A7-9 had been augmented with
the dark soil A12.
The soil samples were processed as described in Appendix B, and subsequent cultures were
spread on Ashdown’s agar plates (supplemented with colistin 50 mg/L) which were incubated at
37 ◦C. The plates were examined on a daily basis. Colonies with morphology typical for B. pseudomallei
(pink/purple, flat, slightly dry, wrinkled-smooth but with surface roughness in the outer half of the
colonies) were subcultured onto chocolate agar plates. Only samples A4, A8, and A12 gave rise to
B. pseudomallei-like colonies on Ashdown medium. Identification of those isolates was confirmed by
MALDI-TOFmass spectrometry (Bruker Biotyper, Bruker Daltonics, Germany) using the security-relevant
database (B. pseudomallei with scores >2) and by PCR amplification targeting a genetic marker of the type
III secretion system1 (TTS-1; 115-base-pair region within orf2) [14]. The three isolates were tested by disk
diffusion on agar, and were found to be susceptible in vitro to amoxicillin/clavulanic acid, ceftazidime,
imipenem, trimethoprim/sulfamethoxazole, levofloxacin, chloramphenicol, minocycline, but resistant to
meropenem, according to the recommendations of the Antibiogram Committee of the French Society of
Microbiology (CA-SFM guidelines 2015 for Burkholderia cepacia).
Total DNA was also extracted from 20 g of soil as described in Appendix B. As with the culture
results, only soil samples A4, A8, and A12 were positive by PCR amplification for B. pseudomallei. MLST
of soil isolates identified two novel STs: ST-1430 (4, 2, 3, 1, 5, 2, 1) and ST-1431 (1, 2, 3, 1, 5, 1, 1) from
A12 and A4, respectively (Table 2). The isolate from sample A8 is still under investigation. The isolate
from case #10 (the owner of the yard where the B. pseudomallei isolates were found) was also novel, being
ST-1043 (4, 1, 3, 2, 5, 2, 1), which shares five alleles with soil isolate A12, but only two with soil isolate A4.
A consecutive investigation to trace back the origin of the fertilizer identiﬁed its origins as the
surrounds of the Amborovy airport (15◦40′56.59′ ′ S, 46◦22′20.50′ ′ E); however, none of four soil samples
taken from this location were positive for B. pseudomallei, either by culture or PCR.
Further genotyping (or WGS) of B. pseudomallei strains from the western Indian Ocean island
region will play an important role in unraveling historical and contemporary epidemiological
investigations in this region. Of historical importance are the postulated links between animal
cases in Paris and Réunion Island and the presence of B. pseudomallei in the Antananarivo zoo in
the 1970s [6,8], which are thought to illustrate the potential for B. pseudomallei to be disseminated
across large geographic distances via infected animals or manure. It was previously reported that B.
pseudomallei was transported from France to Réunion Island in the 1970s via an infected horse, which
became ill with melioidosis after its arrival [6]. Although it has long been assumed that this horse
contracted melioidosis in France, molecular characterization of this isolate would help to establish
whether the horse in fact acquired B. pseudomallei from the environment in the Indian Ocean. In another
instance, MLST characterization of B. pseudomallei isolates has enabled us to identify ST-27 isolates
from both the Paris zoo outbreak and a 1977 soil isolate obtained from a zoo in Antananarivo. This
previously unreported ST overlap suggests the possibility of transmission of B. pseudomallei between
these two regions. However, it is not known whether ST-27 was introduced into France via Madagascar,
or vice versa. Another possibility that should be considered is that of laboratory cross-contamination.
On a contemporary level, molecular ﬁngerprinting of B. pseudomallei from the western Indian Ocean
island region will enhance surveillance measures, public health, and veterinary awareness of the
disease, and epidemiological investigation to identify B. pseudomallei ‘hotspots’.
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2.3. Mauritius
Case #4. The ﬁrst recorded case of melioidosis in Mauritius occurred in January 2004 [15] when a
40-year-old woman on immunosuppressive treatment for systemic lupus erythematosus (SLE) was
admitted to hospital with fever, nausea, and vomiting. She was initially started on ciproﬂoxacin,
and was changed to cefotaxime and metronidazole after 48 h because of persistent fever. However,
she developed cellulitis of her leg, became increasingly drowsy and confused, and passed away
a week later. Her blood cultures became positive after 5 days of incubation, and by the time the
organism was identiﬁed as B. pseudomallei by API 20NE and consistent with phenotypic characteristics,
the patient had died. She lived in a low-socioeconomic suburb of Port Louis, and had never travelled
abroad. According to her mother, her residence became very muddy at times of heavy rainfall and,
although January is generally a wet month in Mauritius, January 2004 was wetter than average.
The clinical isolate was subsequently referred to US Centers for Disease Control and Prevention for
MLST genotyping, where it was found to be a novel ST, ST-1549 (alleles: 4, 12, 34, 2, 5, 2, 1).
Case #6. In 2006, B. pseudomallei was isolated from a swab from the leg wound of a Bangladeshi
worker, who had been in Mauritius for less than one year and was admitted for a non-healing wound.
The laboratory was prompted into speciating the organism by API 20E because of its positive oxidase
test, colistin and aminoglycoside resistance, and the appearance of wrinkled colonies after 48 h.
The patient was not diabetic and not generally unwell. He was treated with intravenous meropenem
and oral trimethoprim/sulfamethoxazole. He was lost for follow-up, possibly because he returned to
Bangladesh. It was difﬁcult to obtain a clear history from the patient because of language difﬁculties,
and although he stated that he had sustained the wound when he had fallen off his bed in Mauritius,
it is possible that he acquired the infection in Bangladesh, with reactivation of infection from a latent
focus occurring several months later. Since then, there have been no further documented cases of
melioidosis in Mauritius.
2.4. Réunion Island
Case #7. In addition to the three imported cases from Madagascar described hereinabove (cases
#1, #5 and #13), an autochthonous case was hospitalized in Réunion Island in 2012 [16]. A 57-year-old
patient presenting with type 2 diabetes mellitus and hypertension was admitted to Saint-Pierre
Hospital with fever (39 ◦C), an elevated C-reactive protein (248 mg/L), and acute urinary retention
requiring the placement of a urinary catheter. Empirical ceftriaxone treatment was initiated, based
on an early diagnosis of acute bacterial prostatitis (tender and enlarged prostate without any other
physical abnormalities). The urine and three blood cultures were positive for B. pseudomallei using
the Vitek Compact (bioMérieux, La Balme-Les-Grottes, France). The bacterium was reported as being
sensitive to ceftazidime, imipenem, doxycycline, and resistant to all aminoglycosides and colistin
according to EUCAST criteria [18]. The therapy was switched to iv ceftazidime and doxycycline.
When he recovered he was discharged, but used a peripheral catheter to complete a 4-week course
of ceftazidime, and oral doxycycline and trimethoprim/sulfamethoxazole were given to complete
5 months of eradication treatment. The identiﬁcation of B. pseudomallei was conﬁrmed by MALDI-TOF
mass spectrometer (MS) (Bruker Biotyper, Bruker Daltonics, Bremen, Germany), PCR targeting type III
secretion system genes, and 16S rDNA sequencing. This patient had always lived in Réunion Island,
except for three trips of one week to Mauritius ﬁve years before becoming ill. No risk factors for
exposure were identiﬁed.
Case #14. The last reported case (2017) was an imported case in a 40-year-old man who lived
in Indonesia, and was working as a ﬁtter’s mate on a cruise ship, which stopped in southeast China
and Singapore before cruising to Réunion Island [2]. He had no signiﬁcant past medical history but
developed a fever 15 days after departure from Singapore, and was treated with amoxicillin/clavulanic
acid. Five days later, when his condition worsened, he was transported by helicopter from the
ship to Saint Denis hospital, Réunion Island. He was admitted with fever (40.6 ◦C), extensive skin
pustules on the face, hepatomegaly, septic shock, and multiple organ failure, requiring intubation.
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TB-CT scan revealed cerebral venous thrombosis, multiple bilateral lung abscesses, a liver abscess,
splenomegaly, and hepatomegaly. Despite immediate antimicrobial therapy with high doses of
meropenem (continuous treatment 6 g/day) and amikacin, blood cultures remained positive until day
10. A second TB-CT scan and magnetic resonance imaging of the brain were performed, which showed
two subdural empyemas (of 9.5 mm). Antibiotic treatment was changed to ceftazidime (12 g/day
by continuous infusion) and the patient’s condition improved on day 15, and he was discharged
from the ICU on day 70. The last imaging (day 63) showed a reduction in the size of the bilateral
lung abscesses, an almost complete regression of the splenic and hepatic abscesses, and a signiﬁcant
reduction of the cerebral abscesses. Blood cultures, respiratory samples and skin abscesses were
positive for a Burkholderia species identiﬁed as B. thailandensis by MALDI-TOF MS but conﬁrmed as
B. pseudomallei by qPCR targeting three genetic markers of the type III secretion system (orf1, orf13,
and BsSCU2), as previously reported (see case #13 from Madagascar). The strain was susceptible
in vitro to amoxicillin/clavulanic acid (2/1) (MIC of 2 mg/L), ceftazidime (MIC of 1 mg/L),
meropenem (MIC of 0.75 mg/L), imipenem (MIC of 0.38 mg/L), trimethoprim/sulfamethoxazole
(1/19) (MIC of 0.064 mg/L), and doxycycline (MIC of 0.25 mg/L).
2.5. Seychelles
In January 2013, two patients were hospitalized at Seychelles Hospital with a history of fever,
cough, shortness of breath, and chest pain. Their condition deteriorated after admission and they were
transferred to the ICU [17]. They were both cooks from the same facility and both had a history of
illicit substance abuse. The Seychellois, who had no history of travel, passed away, whereas the other
cook, who survived, was from Mauritius, but had been in the Seychelles for the previous ten years.
The initial diagnosis was MERS-CoV, legionellosis, or possible tuberculosis. Lung and blood samples
were sent to the Health Protection Agency in England and to the National Institute for Communicable
Diseases in South Africa for investigation. Samples from both patients grew B. pseudomallei, conﬁrmed
by qPCR and serology (high IgG titers consistent with a recent infection). The bacterial isolates were
sensitive to a wide range of antibiotics, and one of the isolates had a novel ST, ST-1432 (4, 2, 3, 2, 5, 2, 1).
A third possible case, who worked at the same premises but not in the kitchen, was identiﬁed through
active case ﬁnding. This third patient originally came from Madagascar. He had equivocal antibody
results (1:4000) suggestive of possible exposure to B. pseudomallei. The possibility of a point source of
contamination was investigated, but no common source of infection was identiﬁed.
2.6. Genetic and Genomic Relatedness between Strains Isolated in the Western Indian Ocean
In recent years, whole-genome sequencing (WGS) has become a cost-effective method for
strain genotyping, including for MLST. Using WGS data for phylogenomic analyses has also been
instrumental in unravelling the early origins of B. pseudomallei in Australia, and its subsequent
dissemination to tropical regions across the globe, including the western Indian Ocean region.
Three studies to date have used WGS to investigate B. pseudomallei strains from western Indian
Ocean islands [19–21]. Sarovich and colleagues [19] were the ﬁrst to identify an Asian origin for
the Madagascan B. pseudomallei strains included in the phylogenetic analysis. Their study showed
that the introduction of this bacterium into Madagascar was likely associated with the migration of
Austronesian peoples (or their animals) from Indonesian Borneo approximately 2000 years ago [19].
B. pseudomallei was subsequently transmitted from the western Indian Ocean region to mainland Africa,
and then the Americas, during the Atlantic slave trade [19,20]. The mechanism/s of B. pseudomallei
dissemination to other western Indian Ocean islands is not yet well understood, but it is likely that it
has also been anthropogenically driven. It is also unknown how many of the Indian Ocean islands
harbor B. pseudomallei, with conﬁrmed cases found only in the most populous islands (Madagascar,
Mauritius, Réunion Island, and Seychelles).
Table 2 presents the ST and alleles for 8/13 cases identiﬁed in the western Indian Ocean, as well
as for the two soil isolates from the garden of case#10 from Mahajanga, Madagascar. MLST analyses
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have shown that there is no ST overlap between islands, and the STs identiﬁed on these islands are
not found elsewhere, with the exception of ST-1053, which has been located in both Madagascar [19]
and in an imported American case thought to have originated in Ghana [21], although the possibility
that this patient had travelled to Madagascar cannot be ruled out. It is also important to stress that the
ST of case #13 (hospitalized in Saint Denis, La Réunion, but originally from Mahajanga, Madagascar)
and E1 (soil from Mahajanga, Madagascar) are identical (ST-1430), indicating the possibility that the
Mahajanga environment was the source of infection in case #13.
3. Current Recommendations and Availability of Measures against Melioidosis
So far, only sporadic melioidosis has been reported in this region, but the increasing number of
reported cases ([2], this study) should raise awareness among all those working in the healthcare sector
and public health policy makers of the possibility of melioidosis, especially during the rainy season.
Doctors and laboratory staff should know how to conﬁrm the diagnosis and treat the disease. Indeed,
the association between rainfall and melioidosis has been well demonstrated in hyperendemic regions,
with 75% and 85% of cases occurring during the wet season in northeastern Thailand and northern
Australia [22,23]. The contaminated soil in the garden of case #10 highlights the risk of occupational or
recreational exposure to B. pseudomallei, and predisposing risk factors, such as diabetes mellitus, chronic
lung or renal diseases, hazardous alcohol use, or thalassaemia, should be considered when gardening
or cultivating in endemic zones. Additionally, B. pseudomallei has been reported to infect a wide range
of animals, such as horses, sheep, goats, cattle, pigs or cats, with anecdotal reports of transmission from
animals to humans [22]. Contaminated secretions and excreta represent a possible source of exposure
or environmental contamination. As the bacterium typically enters the body through pre-existing
cutaneous lesions, including minor trauma such as insect bites, and develops in the wound, contact
with contaminated waste may represent an underestimated source of infection.
As with many other tropical regions, melioidosis is probably considerably underreported in the
western Indian Ocean islands, and fostering its reporting within national surveillance systems would
help to improve monitoring of the incidence of this disease in the western Indian Ocean. Soil (including
domestic yards and gardens [24]), surface water and animal waste sampling to test for the presence
of B. pseudomallei could also be proposed, especially in and around the city of Mahajanga, which has
been associated with all the cases from Madagascar. In addition, a seroprevalence survey could be
undertaken among all farmers and gardeners in this area.
4. Awareness of Melioidosis
To improve prevention and control of melioidosis, we recommend that physicians consider
melioidosis in the differential diagnosis of patients with (1) acute febrile illnesses; (2) risk factors for
melioidosis [22] (impaired neutrophil function, diabetes mellitus, pre-existing renal or lung diseases,
malignancy, thalassemia and/or excessive alcohol consumption); and (3) compatible occupational or
recreational exposure history (soil and water exposure: i.e., farmers, gardeners). However, healthy
people can also get the disease if they are infected with a high bacterial load, such as contact with
muddy soil without good hand and foot protection. Clinical manifestations are broad, and range from
subclinical infection to localized abscess formation, pneumonia, and systemic sepsis. Pneumonia is
the most commonly recognized presentation of melioidosis associated with high fever, signiﬁcant
muscle aches, and chest pain [25]. Melioidosis could easily be confused with tuberculosis or even
plague, particularly in Madagascar, where this disease is prevalent, or with pneumonia caused by other
pathogens. Acute melioidosis septicemia is the most severe form of the infection. It presents as a typical
sepsis syndrome with hypotension, high cardiac output, and low systemic vascular resistance. In many
cases, a primary focus in the soft tissues or lungs can be found. The syndrome, usually in patients with
underlying risk factors, is characteristically associated with multiple abscesses involving soft tissues,
the lung, the liver, and spleen. Blood culture is an effective way to diagnose many melioidosis cases,
as 50% or more of infections have bacteremia [26].
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With the exception of a localized hospital-based study of patients with hyperthermia (≥39 ◦C),
with or without shivering and septic shock, in Mahajanga in 2012, which led to the recognition of
cases #8 and #9, no systematic case ﬁnding of B. pseudomallei infection has been conducted in the
western Indian Ocean islands. Generally, there is no awareness of melioidosis in the population and
among clinicians, because its diagnosis has been rare, despite the very high prevalence of diabetes
in Mauritius. Some laboratory technicians and the clinical microbiologists who diagnosed the cases
described above are aware that B. pseudomallei is a possibility when they isolate an oxidase-positive
Gram-negative bacillus that is resistant to colistin and aminoglycosides, and which produces wrinkled
colonies and/or has an earthy smell. However, this knowledge is not universal.
5. Current and Future Challenges
Further studies are needed in order to investigate the true burden of melioidosis in the western
Indian Ocean, and especially Madagascar, since it is likely to be higher than currently reported.
This could be done by enhancing diagnostic microbiology provision and surveillance systems, training
and education of healthcare staff, serological studies and environmental investigations.
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Appendix A
Figure A1. Schematic representation of the estate and yard of the ﬁfth case from Mahajanga,
Madagascar (#10). The estate is located along the seashore (separated by an asphalted road).
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Appendix B. Materials and Methods
Appendix B.1. Soil Sampling and Culture of B. pseudomallei from Soil and Water
Eleven soil samples and one artesian well water sample were taken from the yard of case
#10—(Mahajanga, Madagascar) in 2014 (see Figure A1, Appendix A), one year after the owner fell sick.
Soils: Twenty grams of each soil sample, identiﬁed as A1 to A10 and A12, were shaken at 220 rpm
at 37 ◦C for 24 h in 20 mL of distilled water. Ten ml of supernatant were removed and were placed into
30 mL of modiﬁed Ashdown’s broth (+colistin 50 mg/L). After 48 h, 10 μL of supernatant were spread
on modiﬁed Ashdown’s medium (+gentamicin at 8 mg/L). The plates were examined on a daily basis.
Colonies with morphology typical for B. pseudomallei were subcultured onto chocolate agar.
B. pseudomallei colonies were identiﬁed by basic screening tests (Gram stain, oxidase test),
rapid detection of the capsular polysaccharide (CPS) produced by B. pseudomallei (Active Melioidosis
DetectTM (AMD) rapid test (InBios)) [27], MALDI-TOF mass spectrometry, and molecular identiﬁcation
based on the ampliﬁcation of the B. pseudomallei speciﬁc target TTS1 (see below).
Water: Sample A10 comprised 1 liter of water from the artesian well. The water was ﬁltered
through a membrane (pore size 0.45 μm, diameter 47 mm) on a ﬁltration ramp (Combisart Multi-Branch
Systems Manifolds, Sartorius, Göttingen, Germany). The membrane was subsequently placed in
Ashdown broth (supplemented with colistin 50 mg/L). After incubation for 48 h, the membrane was
transferred onto an Ashdown agar plate (containing gentamicin at 8 mg/L) and incubated for 48 h.
No suspicious colonies of B. pseudomallei were detected.
Appendix B.2. Molecular Detection of B. pseudomallei from Soil
DNA was extracted from 20 g of soil as previously described [28]: In brief, 20 g of soil was
incubated for 48 h with shaking at 37 ◦C in 20 mL of selective modiﬁed Ashdown’s broth [29] containing
colistin; the sample was then centrifuged twice, and the pellet processed for DNA extraction using
a modiﬁed protocol of the PowerSoil DNA isolation kit (MoBio Laboratories, Carlsbad, NM, USA).
Modiﬁcations included the addition of 0.8 mg of aurintricarboxylic acid (ATA) and 20 μL of proteinase
K (20 mg/mL). DNA was eluted in 100 μL of 10mM Tris HCl. B. pseudomallei DNA was detected by
conventional PCR targeting a 115 bp stretch of the B. pseudomallei speciﬁc orf2 of type III secretion
system (TTS1) as described below. Brieﬂy, 4 μL of DNA were ampliﬁed in duplicates in 25 μL volumes.
Appendix B.3. Identiﬁcation of B. pseudomallei Isolates by PCR
The PCR was conducted in a ﬁnal reaction volume of 25 μL containing 2 μL of DNA, 0.5 U of
FIREPol DNA polymerase, 1× FIREPol Master Mix Ready to Load (2.5 mM MgCl2), 100 μM of dNTP
(Solis Biodine, Tartu, Estonia), and 200 nM of each primer. Primers used to amplify a 548 bp of the
B. pseudomallei TTS1 gene were BPTT4176F (CGTCTCTATACTGTCGAGCAATCG) and BPTT4290R
(CGTGCACACCGGTCAGTATC) [14]. The PCR was performed on a thermocycler (Multigene, Labnet,
Woodbridge, NJ, USA) with an initial denaturing step at 95 ◦C for 1 min, an extension step at 95 ◦C
for 60 s, 54 ◦C for 60 s, and 72 ◦C for 2 min for 30 cycles; and a ﬁnal extension step at 72 ◦C for 10
min. Samples were separated by agarose gel electrophoresis, stained with ethidium bromide, and
visualized with the gelscan (Inﬁnity, VX2-1126MX, Montreal Biotech, Dorval, QC, Canada).
Appendix B.4. MLSTF
The molecular typing tool multilocus sequence typing (MLST), based on sequence polymorphisms
in seven genetically stable housekeeping genes, was developed by Brian Spratt at Imperial College
London as the initial phylogenetic tool for population analysis of B. pseudomallei [7].
PCR conditions were as follows: for each locus, the PCR mixture contained 0.5 U FIREPol DNA
polymerase (Solis Biodine, Tartu, Estonia), 200 nM of primers, 1× buffer master mix FIREPol Master
Mix Ready to Load (2.5 mM MgCl2), 100 μM of dNTP, and 2 μL of extracted DNA in reaction volumes
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25 μL. These were carried out in a 96-well plate format, with initial denaturation at 95 ◦C for 4 min,
followed by 30 cycles of 95 ◦C for 30s, 62 ◦C for 30 s, and 72 ◦C for 60 s. The samples were maintained
at 72 ◦C for a further 10 min, cooled to 4 ◦C, and stored at −20 ◦C. The DNA fragments were sent for
sequencing (each strand; forward and reverse) to Beckman Coulter with the primers used in the initial
PCR ampliﬁcation.
For each locus, sequences obtained were analyzed using the MLST database containing the
sequences of alleles, allelic proﬁles, and information about the Burkholderia isolates, with analysis
tools. This tool is stored on a publicly-available web-based database, allowing comparisons to be
made between isolates from different laboratories (https://pubmlst.org/bpseudomallei/). MLST is
the gold standard for comparison of isolates from different geographical locations due to high
inter-laboratory reproducibility.
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Abstract: A recent modeling study estimated that there could be as many as 20,000 human melioidosis
cases per year in Indonesia, with around 10,000 potential deaths annually. Nonetheless, the true
burden of melioidosis in Indonesia is still unknown. The Indonesia Melioidosis Network was formed
during the ﬁrst melioidosis workshop in 2017. Here, we reviewed 101 melioidosis cases (99 human
and two animal cases) previously reported and described an additional 45 human melioidosis cases.
All 146 culture-conﬁrmed cases were found in Sumatra (n = 15), Java (n = 104), Kalimantan (n = 15),
Sulawesi (n = 11) and Nusa Tenggara (n = 1). Misidentiﬁcation of Burkholderia pseudomallei was not
uncommon, and most cases were only recently identiﬁed. We also evaluated clinical manifestations
and outcome of recent culture-conﬁrmed cases between 2012 and 2017 (n = 42). Overall, 15 (36%) cases
were children (age <15 years) and 27 (64%) were adults (age ≥15 years). The overall mortality was
43% (18/42). We conducted a survey and found that 57% (327/548) of healthcare workers had never
heard of melioidosis. In conclusion, melioidosis is endemic throughout Indonesia and associated
with high mortality. We propose that top priorities are increasing awareness of melioidosis amongst
all healthcare workers, increasing the use of bacterial culture, and ensuring accurate identiﬁcation of
B. pseudomalleiand diagnosis of melioidosis.
Keywords: Burkholderia pseudomallei; melioidosis; Indonesia
1. Introduction
Melioidosis in Indonesia was ﬁrst diagnosed in Cikande, on Java island, in 1929 [1]. From then
to 1960, a few additional cases were reported in Jakarta, Bogor and Surabaya, on Java island [2–5].
More recent reports concerned four culture-conﬁrmed melioidosis cases among tsunami survivors in
Banda Aceh, Sumatra, in 2005 [6], 51 culture-conﬁrmed melioidosis patients in Malang, Java from 2011
to 2013 [7], and three culture-conﬁrmed melioidosis patients in Makassar and Luwu Timur, Sulawesi,
in 2013 [8]. Nonetheless, the reported cases are likely to be the tip of the iceberg and the true burden of
melioidosis in Indonesia is still unclear.
A recent modeling study estimated the annual number of human melioidosis cases in Indonesia
at 20,038, with 10,224 deaths annually if mortality was 51% [9]. This alarming estimate is possible,
considering that, in Indonesia with a total population of about 260 million, about 1.6 million die every
year, and about 350,000 and 150,000 of those who die are estimated to have communicable diseases
and diabetes, respectively, deﬁned as the primary causes of death using International Classiﬁcation
of Diseases (ICD) principles and Global Burden of Disease (GBD) analysis [10]. If melioidosis was
an undiagnosed contributory cause in only 2% of these, this would account for 10,000 deaths [9].
The under-diagnosis and under-reporting of melioidosis worldwide are considered to be due to a
lack of diagnostic microbiology laboratories serving the poor rural populations that are at greatest
risk of infection, and a lack of awareness of the disease amongst physicians and laboratory staff [9,11].
Even good microbiological laboratories may initially miss the diagnosis and discard B. pseudomallei as
a contaminant, especially in non-endemic areas [9,12]. Recent evidence suggests that, in Indonesia,
where melioidosis is possibly highly endemic countrywide [9], capacity and utilization of bacterial
cultures is limited [13], that misidentiﬁcation of B. pseudomallei as another species or a contaminant is
common, and that awareness of the disease among physicians and laboratory staff is very low [6–8].
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Under a collaboration between Primate Research Center, Bogor Agricultural University and
Health Security Partners (HSP), a workshop on ‘Melioidosis: Detection, Diagnosis, Treatment and
Prevention Using a One-Health Approach’ was held in Bogor, Indonesia, from 14 to 16 August
2017. A total of four doctors, 12 veterinarians, seven microbiologists, one clinical pathologist and 16
other healthcare providers from 33 institutions attended, and the potential burden and challenges
of melioidosis were discussed among participants. The Indonesia Melioidosis Network was formed
during the meeting. In addition, the Indonesian Association of Clinical Microbiologists (PAMKI) held
a session on ‘Epidemiology and Clinical Aspect of Melioidosis’ during their Annual Scientiﬁc Meeting
in Padang, from 12 to 14 October 2017, and more evidence of melioidosis in Indonesia was additionally
reported at this meeting.
Here, we review the known and additional evidence of melioidosis in Indonesia, present the
results of a surveillance study showing awareness and knowledge of the disease and the organism
among healthcare providers in Indonesia, and discuss the needs and future challenges to save lives
from melioidosis in Indonesia.
2. Melioidosis Cases and Presence of B. pseudomallei in Indonesia
We performed (1) a retrospective review of published or reported melioidosis cases in Indonesia,
(2) a retrospective study to identify unpublished culture-conﬁrmed melioidosis cases in hospitals in
which the microbiology laboratories had isolated B. pseudomallei from clinical specimens, and (3) a
retrospective study to evaluate clinical manifestations of recent culture-conﬁrmed patients from 2012
to 2017.
Firstly, we searched PubMed and SCOPUS for indigenous cases of melioidosis reported in
Indonesia between 1 January 1921 and 30 November 2017, using the MeSH terms ‘melioidosis’
or ‘pseudomallei’. We also searched bibliographies from selected studies for secondary references.
Our search included literature in English, Dutch, German and Indonesian.
In addition to the 64 melioidosis cases previously reviewed [8], we found an additional 35
culture-conﬁrmed human melioidosis cases and two animal cases (Table 1 and Figure 1). Prior to
1960, two additional cases were reported in Cimahi [14] and Salatiga [15] on Java island. We found
that an additional report by Verbunt et al. in 1937 [16] was the same case described by Sudibyo [4].
All other cases were recently reported. The ﬁrst animal case was reported in 2014, being a 3-year-old
cynomolgus monkey (Macaca fascicularis) raised at Primate Research Center, Bogor [17]. At the
15th Asia-Paciﬁc Congress on Clinical Microbiology and Infection in 2014, a human melioidosis
case was reported from Medan, Sumatra [18]. At the ﬁrst National Melioidosis Workshop in 2017,
a human melioidosis case from Yogyakarta, Java [19], 13 cases from Abdul Wahab Sjahranie Hospital,
Samarinda, East Kalimantan, eight cases from Dr. Wahidin Sudirohusodo Hospital, Makassar,
South Sulawesi, and one case from Prof. Dr. WZ Johannes Hospital, Kupang, East Nusa Tenggara,
were reported [20]. At the PAMKI meeting 2017, nine melioidosis cases presenting at Eka Hospital,
Pekanbaru, Sumatra [21], and the second animal case from Samboja, Kalimantan [22] were reported.
The animal was a Bornean orangutan (Pongo pygmaeus) of unknown age from the Borneo Orangutan
Survival Foundation in Samboja, East Kalimantan. Both animal cases died shortly after clinical
presentation, and the diagnosis was made post-mortem [17,22].
Secondly, to evaluate whether melioidosis had been diagnosed by routine microbiological
laboratories in Indonesia but had not been reported, at the ﬁrst National Melioidosis Workshop
and at the PAMKI meeting, we requested participants to review the microbiology laboratory results
in their hospitals to determine whether B. pseudomallei had been identiﬁed. To avoid duplication,
cases that had already been reported (Table 1) were not included.
We received information of an additional 45 melioidosis cases (Table 2). A total of 18 and ﬁve
culture-conﬁrmed melioidosis cases were observed at Sardjito Hospital, Yogyakarta, and at Tarakan
Hospital, Jakarta, respectively, from 2012 to 2017. In addition, B. pseudomallei was isolated from clinical
specimens at Dr. Zainoel Abidin Hospital, Banda Aceh (n = 1), Cipto Mangunkusumo Hospital, Jakarta
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(n = 4), a private laboratory (Granostic), Surabaya (n = 8), Ulin Hospital, Banjarmasin (n = 1) and Hasan
Sadikin Hospital, Bandung (n = 8).
Figure 1 shows the locations of all 146 cases (144 human cases and two animal cases) noted in this
article (Tables 1 and 2). Locations were towns where the cases were living or likely to have acquired
melioidosis, where such information was available. In the event that the patients’ home addresses
were not available, the address of the hospitals where the patients presented were used.
Thirdly, we also requested permission to analyze anonymous information of patients diagnosed
from 2012 to 2017 to describe clinical manifestations and outcome of recent cases of melioidosis in
Indonesia (Table 3). The retrospective study was approved by the education and research departments
of ﬁve participating hospitals. Overall, we obtained anonymous data of 45 human cases available
from Yogyakarta (n = 18), Samarinda (n = 13), Makassar (n = 8), Jakarta (n = 5) and Kupang (n = 1).
We excluded three cases with incomplete data.
Of 42 patients included in the analysis, ﬁve (12%) were neonates (age <1 month). One and four
neonatal cases were observed in Jakarta and Yogyakarta, respectively. All ﬁve neonatal cases were
blood culture-positive for B. pseudomallei, and three of them died. Another seven cases were found in
infants (age 1 month to <2 years) and three cases in children (age 2 to <15 years). Thus, of the total,
15 (36%) cases were children (age <15 years) and 27 (64%) were adults (age ≥15 years). Diabetes was
the most commonly identiﬁed risk factor amongst adults (Table 3), 60% of the cases (25/42) were blood
culture-positive for B. pseudomallei, and the overall mortality was 43% (18/42).
Specimens, diagnostic methods, and antibiotic susceptibility results of those 42 cases with
complete clinical data are described in Table 4. Of the 42 cases, only 15 (36%) had antibiotic susceptibility
test (AST) results available. We were informed that AST was often not routinely performed for
B. pseudomallei because the laboratory staff did not know the correct standard operating procedures,
quality control and guidelines on how to handle and perform AST on B. pseudomallei. As some AST
results were not typical for B. pseudomallei, including those previously reported from Malang [7],
we note that the AST results may be inaccurate or some isolates might not actually be B. pseudomallei.
As isolates are not routinely kept in Indonesia, a retrospective study for further evaluation is
not possible.
Nonetheless, a total of 10 isolates (ﬁve from Samarinda and ﬁve from Makassar) reported as
B. pseudomallei were sent to the Indonesia Research Partnership on Infectious Disease (INA-RESPOND)
reference laboratory at Tangerang Regional General Hospital for further characterisation. In addition,
16S rRNA gene sequencing [23] and a PCR assay targeting the type III secretion system of
B. pseudomallei [24] were performed. Nine of ten isolates were conﬁrmed as B. pseudomallei by PCR.
One isolate from Makassar was later identiﬁed as Burkholderia stabilis using 16s sequence analysis.
The patient was a 77 year-old male presenting with an acute ischaemic stroke. The positive blood
culture was obtained 19 days after hospital admission due to a lack of clinical improvement of alteration
of consciousness, and the patient had no other signs and symptoms of sepsis, suggesting that B. stabilis
was probably a contaminant. This case was not included in the list of melioidosis cases described
above. This also supports our hypothesis that some isolates reported as B. pseudomallei might be other
bacteria, and that training for B. pseudomallei identiﬁcation is critically needed, country-wide.
Details of these nine conﬁrmed isolates and associated clinical manifestations are described in
Table 5. Further studies on the nine isolates, including AST, multilocus-sequence typing and whole
genome sequence typing, are in progress.
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Table 4. Specimens, diagnostic method and reported but unveriﬁed antibiotic susceptibility test results
in 42 culture-conﬁrmed melioidosis cases with available clinical data from 2012 to 2017.
Characteristics Total (n = 42)
Specimens *
Blood 25 (60%)
Pus 8 (19%)
Urine 7 (17%)
Tissue ** 2 (5%)
Sputum 1 (2%)
Diagnostic method
Vitek 2 identiﬁcation system 37 (88%)
Microgen 5 (12%)
Antibiotic susceptibility test
Not done 27 (64%)
Done ***
Gentamicin (S) 0/13 (0%)
Amoxicillin-clavulanic acid (S) 2/5 (40%)
Ceftazidime (S) 12/14 (86%)
Doxycycline (S) 7/9 (78%)
Meropenem (S) 14/15 (93%)
Imipenem (S) 2/2 (100%)
Trimethoprim-sulfamethoxazole (S) 6/7 (86%)
* One adult patient had two culture-positive specimens. ** Tibial tissue (1), scrotal tissue (1). *** Data are number of
isolates demonstrating susceptibility to the antimicrobial over the total number of isolates tested (%). Data are from
the microbiology laboratories that had isolated B. pseudomallei from clinical specimens. Some AST results were not
typical for B. pseudomallei, including resistance to amoxicillin-clavulanic acid, ceftazidime, doxycycline, meropenem
and trimethoprim-sulfamethoxazole. We note that the AST results may be inaccurate or some isolates might not
actually be B. pseudomallei.
 
Figure 1. Location of 146 melioidosis cases. Black dots represent locations of 99 previously-reported
human cases, red stars represent locations of two previously-reported animal cases and red
dots represent locations of 45 newly-reported human cases. An interactive map is available at
melioidosis.info website [25].
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Table 5. Demographics of nine patients with B. pseudomallei conﬁrmed with PCR assays *.
Bacterial Strain Year of Isolation/Location of Isolation Strain Source/Clinical Manifestations Outcome
HBPMS00001 2015/Konawe,Southeast Sulawesi
Tibial tissue of 55-year old male patient presenting
with open wounds with purulent discharge from
legs, cough and fatigue
Fully recovered
HBPSK00002 2016/Samarinda,East Kalimantan
Pus of 55-year-old female patient with unknown
clinical characteristics Unknown
HBPMS00003 2016/Kolaka,Southeast Sulawesi
Blood of 56-year-old female patient presenting
with decreased consciousness, generalized seizure,
focal seizure of hand, headache, fever,
swollen knee.
Died
HBPMS00004 2016/Luwu Utara,South Sulawesi
Pus of 39-year-old female patient presenting with
lump on neck and weight loss. Fully recovered
HBPMS00005 2016/Pinrang,South Sulawesi
Blood of 53-year-old male patient presenting with
decreased consciuousness, fever, productive cough,
shortness of breath, nausea, vomiting, abdominal
pain and bloating. Icteric sclera and skin. Left leg
swollen, pain and tenderness.
Died
HBPSK00001 2016/Kutai Timur,East Kalimantan
Blood of 4-year-old female patient presenting with
fever, petechiae, poor appetite, anaemia Died
HBPSK00003 2016/Kutai Timur,East Kalimantan
Pus of 37-year-old female patient presenting with
skin ulcer on neck, fever Fully recovered
HBPSK00004 2017/Kutai Kartanegara,East Kalimantan
Blood of 61-year-old male patient presenting with
right hemiplegia, fever, decreased consciousness. Died
HBPSK00005 2016/Samarinda,East Kalimantan
Urine of 44-year-old male patient presenting with
fever, abscess on knee Fully recovered
* 16S rRNA gene sequencing [23] and a PCR assay targeting the type III secretion system of B. pseudomallei [24].
3. Current Recommendations and Availability of Measures against Melioidosis
Currently, there are no national guidelines for diagnosis, treatment and prevention of melioidosis
in Indonesia. In response to the evidence of the emergence of melioidosis in Indonesia, the international
consensus guidelines for diagnosis [11] and treatment [26] of melioidosis have been recommended by
the Indonesian Melioidosis Network.
At the ﬁrst melioidosis workshop, it was recommended that the top priority was to provide
education about melioidosis to all clinicians including general practitioners, internists, paediatricians,
surgeons, and neurologists, at the hospitals where melioidosis cases have been found (Tables 1 and 2).
This could be done by clinical pathologists or microbiologists at case reviews or local meetings in each
hospital. Clinicians should be advised to consider melioidosis in any patients presenting with a fever,
and communication between clinicians and laboratory staff is recommended if melioidosis is highly
suspected; for example, diabetic patients presenting with community-acquired sepsis. Abdul Wahab
Sjahranie Hospital, Samarinda has already introduced these steps since September 2016, and the
clinicians’ response has been positive, with communication between clinicians and laboratory staff
occurring for suspected cases and for specimens collected. Two melioidosis cases were diagnosed
in 2017 after the implementation of the measures described above. It is important for melioidosis to
be included in the curriculum of all medical schools in Indonesia in the future as meliodosis is not
currently included in the curricula of any of the medical schools in the country.
Secondly, a simple and easy-to-perform laboratory algorithm for the identiﬁcation of
B. pseudomallei from clinical samples, such as that described by Trinh et al. [27], should be implemented
in all microbiological laboratories in Indonesia. Future plans include the delivery of a workshop on how
to prepare Ashdown agar, identiﬁcation of B. pseudomallei, antibiotic susceptibility testing, and biosafety
issues at a national meeting for laboratory staff. Again, in the longer term, these should be included
routinely in training programmes for laboratory technicians. Although Vitek 2 is the most common
method used for identiﬁcation of Gram-negative bacilli in Indonesia, there have been some problems
with its use for the identiﬁcation of B. pseudomallei, which may have led to under-reporting [28–30].
The BD Phoenix is also used for identiﬁcation of isolates in some large hospitals in Indonesia. However,
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B. pseudomallei is not in the Phoenix database [31], and misidentiﬁcation of all B. pseudomallei isolates
as B. cepacia is probably occurring in those institutions [31]. These issues will need to be urgently
addressed. Microbiology laboratories in Indonesia that need conﬁrmatory tests for isolates suspected
as B. pseudomallei, can send them to the INA-RESPOND reference laboratory for conﬁrmation by PCR.
4. Surveillance Systems and Reporting of Melioidosis in Indonesia
Melioidosis is not currently a notiﬁable disease in Indonesia. We are initially considering the
establishment of an online system to enable reporting of melioidosis cases from all microbiology
hospital laboratories in Indonesia, particularly from those in the Indonesia Melioidosis Network.
The system could be similar to ProMED-mail [32] or that of the International Melioidosis Society [25]
but speciﬁc to Indonesia. The other option would be to use either of these currently running systems.
The appropriate surveillance system will be discussed further at the next meeting of the Indonesia
Melioidosis Network.
The aim of reporting is to understand the distribution, morbidity and mortality of culture-confirmed
melioidosis cases in Indonesia. We are certain that the 146 culture-conﬁrmed melioidosis cases observed
to date are just the tip of the iceberg, and continuing and enhancing the reporting system will provide a
better understanding of the true burden and distribution of the disease. The results of this surveillance
system should be used to encourage health policy makers and the infectious diseases network in
Indonesia to give melioidosis the priority it deserves.
5. Awareness of Melioidosis in Indonesia
A questionnaire was developed to evaluate medical practitioners’ knowledge and awareness
of melioidosis. From 21 August to 4 October 2017, an online questionnaire using Google forms
was distributed by the WhatsApp application to multiple formal and informal networks of medical
researchers in Indonesia. To reduce response bias, we embedded questions about awareness of
melioidosis amongst those on other infectious diseases, including dengue and typhoid. Approval
for the study was obtained from the Faculty Medicine Hasanuddin University Ethics Committee,
Makassar, Indonesia.
A total of 568 participants completed the questionnaire. The median age of participants was
33 years (IQR 29–36; range 20–65 years), and 196 (34%) were male. Their occupations were general
practitioner (n = 373, 66%), clinical pathologist (n = 75, 13%), internist (n = 45, 8%), pulmonologist
(n = 14, 2%), paediatrician (n = 9, 2%), obstetrician (n = 9, 2%), neurologist (n = 8, 1%), ophthalmologist
(n = 8, 1%), anaesthesiologist (n = 5, 1%), surgeon (n = 5, 1%), cardiologist, (n = 4, 1%) and others
(n = 13, 2%). Participants were from Sulawesi (n = 231, 41%), Java (n = 213, 38%), Kalimantan (n = 50,
9%), Sumatra (n = 28, 5%), Maluku (n = 16, 3%), Papua (n = 16, 3%), Nusa Tenggara (n = 7, 1%) and
Bali (n = 6, 1%).
A total of 323 (57%) participants reported that they had never heard of melioidosis, while all
participants reported that they had heard of dengue and typhoid. Only 44% of participants (n = 249)
accurately answered that melioidosis was caused by a bacterium, while 184, 21 and 114 answered
that melioidosis was caused by a parasite, a virus and ‘I don’t know’, respectively. 98% (n = 555)
and 95% (n = 539) accurately answered that dengue and typhoid were caused by a virus and a
bacterium, respectively. Only 153 participants (27%) accurately answered that the recommended
diagnostic tests for melioidosis included blood or urine culture (n = 151 and 60, respectively), 285 (50%)
answered ‘I don’t know’ how to diagnose melioidosis, and the remaining participants answered
inaccurately that the recommended diagnostic tests for melioidosis were stool exam (n = 19, 3%) or
did not include bacterial culture (n = 111, 20%). Only 101 participants (18%) accurately answered
that the recommended treatment for melioidosis included ceftazidime (n = 101), 231 (41%) answered
‘I don’t know’ how to treat melioidosis, and the remaining participants answered inaccurately that
the recommended treatments for melioidosis were chloramphenicol (n = 56, 10%), ﬂuoroquinolones
(n = 14, 2%), antivirals (n = 24, 4%), supportive treatment without appropriate antibiotics (n = 137,
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24%), or ﬂuid management without appropriate antibiotics (n = 5, 1%). Eighty-seven percent of the
participants stated that MoH should promote education about melioidosis to healthcare workers
(n = 492) and that MoH should promote awareness of melioidosis to lay people (n = 495).
The results of this online questionnaire shows that knowledge about melioidosis is limited among
healthcare workers in Indonesia. Education about melioidosis for medical students should be initiated
immediately countrywide, and melioidosis should be included in continuing medical education
in Indonesia.
Limitations of this online questionnaire include the uneven distribution of participants, and that
awareness and knowledge might be underestimated by the biased sampling or overestimated because
the study was conducted after the ﬁrst melioidosis workshop.
6. Current and Future Challenges
We consider that increasing awareness of melioidosis amongst all healthcare workers is the
top priority; however, support from all stakeholders is needed. Awareness amongst veterinary
professionals also needs to be improved as infections with B. pseudomallei have been identiﬁed in
domestic animals and also certain wildlife including non-human primates (NHP) [33–37].
The second challenge is to increase the use of bacterial culture in Indonesia. In this respect,
the under-diagnosis of melioidosis is just a reﬂection of a generalized limited capacity and
under-utilization of diagnostic microbiology in the country. Diagnostic microbiology services in
Indonesia face multiple challenges, including: (1) the size and conﬁguration of the Indonesian
archipelago, which makes the provision of equitable microbiology services to all parts of the country
difﬁcult; (2) the limited number of trained laboratory staff relative to the total population of Indonesia;
and (3) historical limitations in the ﬁnancial and regulatory support from government to develop
microbiology services. To overcome these problems, the Indonesian government has established a new
national regulation, which includes the provision of microbiology services as one of the requirements
for hospital accreditation. This new national regulation has been being implemented gradually in
all government hospitals since 2018. We hope that, over the next few years, Indonesia will be able to
increase its microbiological capacity considerably.
To improve diagnosis of melioidosis, not only does the capacity of clinical microbiology
laboratories need to be expanded [13], but all healthcare workers should also be informed about
the importance of bacterial culture in patients presenting with sepsis [38]. Recent evidence suggests
that bacterial culture is under-utilized in Indonesia compared to the country’s health expenditure,
and this could be related to the reimbursement system for bacterial culture, local customs and practice
of clinicians, and a lack of support from related stakeholders and organizations [13].
The third challenge is biosafety and biosecurity, as B. pseudomallei is classiﬁed as a Tier 1 (top
tier) Select Agent in the United States that can affect both humans and animals and possibly cause
occupational infections [39]. Biosafety guidance for laboratories is needed. All laboratories where
melioidosis cases have been found should be evaluated for their facilities, safe practices, and biosecurity
with additional training and resources provided if necessary.
Drug availability is not a challenge in Indonesia. Ceftazidime and carbapenems are widely
available throughout the country, and may be used and reimbursed within Indonesia’s universal
health system if the diagnosis can be made.
Future challenges, after diagnosis of melioidosis is improved and if the burden of melioidosis
is shown to be as high as expected [9], are to prevent melioidosis by reducing exposure, for example
by wearing protective gear such as rubber boots and gloves during exposure to soil. Preventive
measures are most important for people with the following conditions: diabetes, heavy alcohol
consumption, kidney disease, lung disease, cancer, receiving immunosuppressive therapy and cuts
or sores on the skin. Indonesia is an agricultural country, in which the majority of the population
are rice farmers, and more than 10 million people are diabetics. It is known that changing behaviour
is complex, and a multifaceted intervention is required. In Thailand, there are numerous barriers
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to adoption of behaviours recommended for melioidosis prevention [40]. Developing an effective
prevention programme to reduce people’s exposure to B. pseudomallei in the environment and to
educate them to seek medical attention if melioidosis is suspected, will be a formidable challenge in an
Indonesian context.
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Abstract: Melioidosis is clearly highly endemic in Laos, although the disease has only been diagnosed
regularly in humans (1359 cases) since 1999, and only a single animal case has been microbiologically
conﬁrmed. Burkholderia pseudomallei is extensively and abundantly present in soil and surface water
in central and southern Laos, but the true distribution of the disease across the country remains to be
determined. Surveillance is almost non-existent and diagnostic microbiology services are not yet well
established, whilst awareness of melioidosis is low amongst policy-makers, healthcare providers,
and the public. It is hoped that this situation will improve over the next decade as the country rapidly
develops, especially as this is likely to be accompanied by a further increase in the prevalence of
diabetes, meaning that more people in this predominantly agricultural population will be at risk of
contracting melioidosis.
Keywords: melioidosis; Burkholderia pseudomallei; Laos; Lao PDR
1. History
The Lao People’s Democratic Republic (Laos) is a land-locked country in Southeast Asia with
a population of approximately 6.5 million people, the majority of whom are subsistence farmers,
although the country is developing rapidly. Melioidosis was not recognized in Laos until 1999 [1].
Given that Laos is adjacent to highly endemic parts of Thailand, it is likely that the bacterium that causes
it has long been present in the environment but that it was not recognized due to a lack of laboratory
facilities and awareness amongst healthcare staff. In fact, the detection of Burkholderia pseudomallei in
the Lao environment preceded the detection of cases of human melioidosis, although this was not
reported until later [2]. An even earlier case was almost certainly acquired in Laos during military
action in 1954, although the diagnosis was made in a hospital in Vietnam [3].
2. Review of Melioidosis Cases and Presence of B. pseudomallei
2.1. Human
Diagnostic microbiology services for human infectious disease have been relatively
underdeveloped in Laos compared withmost neighbouring countries such as Thailand, China,
and Vietnam. The conﬁrmation of melioidosis as an important public health problem in Laos
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followed the establishment of a research collaboration between the Microbiology Laboratory of
Mahosot Hospital, one of the main central referral hospitals in the capital, Vientiane, and the
Mahidol-Oxford-Research Unit in Thailand, which had been working on melioidosis in Ubon
Ratchathani since 1986. This led to the creation of the Lao-Oxford-Mahosot Hospital-Wellcome
Trust Research Unit (LOMWRU), which has supported the provision of diagnostic services for
melioidosis, including the use of selective culture media and reagents (Ashdown’s agar and broth,
latex agglutination and API 20NE) and collated data on culture-positive cases since 1999. Between 2000
and 2004, LOMWRU found B. pseudomallei in 14 patients with bacteraemia, representing 3% of positive
blood cultures [4]. Since then, the number of cases diagnosed has increased each year, reﬂecting greater
awareness of the disease amongst healthcare workers as well as the growing numbers of Lao people
with underlying diseases that predispose to melioidosis such as diabetes, which was estimated to have
a prevalence of 5.6% of the Lao population in 2016 [5].
In addition to receiving clinical samples from Mahosot Hospital itself, samples are sent to Mahosot
Microbiology Laboratory from other hospitals in and around Vientiane and from other provinces,
particularly associated with studies of the aetiology of fever in Luangnamtha, Salavan, and latterly
Xiangkhouang provinces. In total, the LOMWRU/Mahosot Microbiology Laboratory has diagnosed
1232 cases of culture-positive melioidosis between 1999 and 2017. The majority came from Vientiane
Capital and Vientiane Province, which represent the main catchment areas for Mahosot Hospital;
however, since Mahosot Hospital acts as a central referral hospital for parts of Laos and accepts samples
from other hospitals for the investigation of possible melioidosis, cases have been seen originating
from every province in Laos except Luangnamtha. Details of these cases will be reported elsewhere.
In addition, support was provided by the Centre d’Infectiologie Christophe Mérieux du Laos
(CICML) to establish a diagnostic microbiology laboratory in Khammouan Provincial Hospital in
Thakhek in 2009, and staff were trained in the recognition of B. pseudomallei and invited to refer
any isolates whose identity was uncertain to LOMWRU. Between 2010 and 2017, 79 patients were
conﬁrmed with melioidosis, all of whom came from Khammouan Province.
Between 2011 and 2016, the European Union provided €3,000,000 to support the further
development of diagnostic capacity in Laos (https://ec.europa.eu/europeaid/case-studies/
eu-support-epidemiology-and-laboratory-capacity-laos_en). Laboratory staff in Champasak,
Savannakhet, Luangphrabang, Oudomxai, and Luangnamtha were trained in the identiﬁcation
of B. pseudomallei and asked to refer suspect isolates to the National Centre for Laboratory and
Epidemiology (NCLE) in Vientiane for conﬁrmation. Between 2012 and 2017, this resulted in the
identiﬁcation of a further 48 cases of culture-positive melioidosis.
The data from these three sources have been combined in Table 1, and Figure 1 presents a map
showing the distribution of cases and laboratories capable of conﬁrming the diagnosis. An additional
19 Lao patients diagnosed in Thailand [6] and two additional travel-associated cases [7,8] have not
been included in the table. Undoubtedly, these ﬁgures only represent the ‘tip of the iceberg’ in Laos,
and the distribution of cases across the country is subject to considerable sampling bias. There are
still large areas of the country that do not have access to good diagnostic laboratories. Awareness of
melioidosis amongst both physicians and laboratory staff remains low, and, even where laboratories
do exist, the use of diagnostic microbiology has not yet been fully assimilated into routine clinical
practice. The fact that patients usually have to pay for diagnostic tests acts as a further disincentive to
investigating the aetiology of infection.
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Figure 1. Location of homes of 1310 cases of melioidosis and hospital laboratories capable of making a
diagnosis of melioidosis in Laos (data only available for 1310 of 1359 cases).
2.2. Animal
Animal meliodosis is undoubtedly present in Laos, although to date only a single case, in a
goat, has been conﬁrmed by the LOMWRU laboratory (Newton, P.N.; Vongsouvath, M. (LOMWRU,
Vientiane, Lao PDR). Unpublished observations, 2003). Animal surveillance in Laos is limited.
Furtherstudies of melioidosis in animals are just beginning to be initiated.
2.3. Environment
Several studies have demonstrated that B. pseudomallei is widespread in the environment, at least
in central and southern Laos, although the country has not been extensively and systematically
sampled to determine the true nationwide distribution of the organism. B. pseudomallei was ﬁrst
isolated in 36% of 110 soil samples collected in and around Vientiane in 1998 [2]. A subsequent study
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found the organism to be abundantly present in soil in Salavan, but not in a transect from eastern
Vientiane to Xiangkhouang [9]. A single isolate from soil in Luangnamtha was reported in this study,
although subsequent studies of this isolate have shown that it was actually Burkholderia cepacia that
cross-reacted in a B. pseudomallei-speciﬁc latex agglutination test (Dance, D.A.B. (LOMWRU, Vientiane,
Lao PDR). Unpublished observations, 2011). B. pseudomallei was later conﬁrmed to be present in both
soil and surface water in Salavan, including the Sedone river [10]. However, these earlier studies were
undertaken using culture alone, which may have underestimated the presence of B. pseudomallei [11].
B. pseudomallei was also found to be readily isolated from a rice paddy in Vientiane about 56 km
from Vientiane’s capital [12]. More recently, a nationwide study of the presence of B. pseudomallei
in the Mekong and its tributaries in Laos demonstrated its presence in 9% of the rivers in the dry
season and in 57% of the rivers in the rainy season, mainly in turbid river water with associated
B. pseudomallei-positive sediments, and exclusively in the south and centre of the country, suggesting
that rivers may be useful in assessing the distribution and aquatic dispersal of B. pseudomallei [13].
3. Current Recommendations and Availability of Measures against Melioidosis
3.1. Surveillance Systems and Reporting
3.1.1. Human
Melioidosis is not statutorily notiﬁable in Laos and there is no formal surveillance system for
human melioidosis. Data are currently only collated by researchers with an interest in the disease as
above. Informally, both LOMWRU and the Thakhek laboratories send monthly anonymized reports of
episodes of bacteraemia (and other B. pseudomallei isolates in the case of the Thakhek laboratory) to the
Ministry of Health and other relevant organisations.
3.1.2. Animal
There is no surveillance system for animal melioidosis in Laos.
3.2. Guidelines
Melioidosis was included in a manual on diagnosis and treatment of infectious diseases produced
(in Lao/English and Lao/French editions) by the Institut de la Francophonie pour la Médecine
Tropicale du Laos in 2002 (updated in 2004) that was approved by the Minister of Health. Melioidosis
was also included in the ‘National Treatment Guideline’ (fourth edition) in Lao that was issued in
2012. Both of these were distributed to district and provincial hospitals with the aim of improving
the quality of management of infections, including melioidosis, but it is not known how widely
available they are and whether they are followed. Neither is available online or outside Laos.
The recommendations are also not entirely consistent with current international consensus guidelines
on melioidosis treatment [14]. In addition, advice about clinical and epidemiological clues to the
diagnosis, which samples to submit, and how to treat patients, have been distributed to users of the
Mahosot Microbiology Laboratory through the Mahosot Microbiology Review, an internally distributed
newsletter which is available both in English and Lao languages. Diagnostic guidance is contained
in a laboratory user manual for the Mahosot laboratory, which is to be issued shortly, and plans are
in place to include revised treatment guidelines in updated national antibiotic guidelines that are
under development.
4. Awareness of Melioidosis
Awareness of the disease amongst health professionals has gradually increased in the area in
and around Vientiane since the establishment of LOMWRU but is otherwise patchy, although some
clinicians in provinces of relatively high incidence (e.g., Salavan and Savannakhet) regularly consider
the diagnosis and manage patients accordingly.The disease is not yet considered a priority by the
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Ministry of Public Health. Although no formal surveys have been conducted, awareness amongst the
public is likely to be even lower than that in Thailand [15].
5. Major Achievements
Activities relating to melioidosis in Laos are at a very early stage. A case series of the ﬁrst
1088 patients with melioidosis is in preparation and it is planned that a national workshop, analogous
to those that have taken place in neighbouring countries such as Cambodia, will be held in the near
future. It is hoped that this will lead to the establishment of a national network of clinicians and
researchers with an interest in the disease.
6. Current and Future Challenges
Based on the experience at Mahosot Hospital, it is likely that there are still hundreds of people
dying of undiagnosed melioidosis in Laos each year, and this is likely to increase as diabetes becomes
more common, as it has in neighbouring countries [16]. The biggest challenges facing those who wish
to reduce this burden are the relative under-development of diagnostic microbiology services across
the country, the lack of a ‘culture of culture’ amongst clinicians, and a lack of awareness of the disease
amongst policy-makers, healthcare providers, and the public. It is hoped that signiﬁcant progress can
be made in these areas over the next decade.
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Abstract: Malaysia is an endemic hot spot for melioidosis; however, a comprehensive picture of
the burden of disease, clinical presentations, and challenges faced in diagnosis and treatment of
melioidosis is not available. This review provides a nonexhaustive overview of epidemiological
data, clinical studies, risk factors, and mortality rates from available literature and case reports.
Clinical patterns of melioidosis are generally consistent with those from South and Southeast Asia in
terms of common primary presentations with diabetes as a major risk factor. Early diagnosis and
appropriate management of Malaysian patients is a key limiting factor, which needs to be addressed
to reduce serious complications and high mortality and recurrence rates. Promoting awareness
among the local healthcare personnel is crucial to improving diagnostics and early treatment, as
well as educating the Malaysian public on disease symptoms and risk factors. A further matter of
urgency is the need to make this a notiﬁable disease and the establishment of a national melioidosis
registry. We also highlight local studies on the causative agent, Burkholderia pseudomallei, with regards
to bacteriology and identiﬁcation of virulence factors as well as ﬁndings from host–pathogen
interaction studies. Collectively, these studies have uncovered new correlations and insights for
further understanding of the disease.
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1. Introduction
1.1. Historical Background
Melioidosis was ﬁrst documented in what was then known as Malaya in an outbreak in 1913
involving laboratory guinea pigs and rabbits at the Institute for Medical Research, Kuala Lumpur [1].
Since then, melioidosis has been recognized as an endemic disease in Malaysia. Stanton et al. also
described two of the earliest human cases in Kuala Lumpur who presented with symptoms consistent
with melioidosis and whose autopsy swabs grew Bacillus whitmori [2]. In 1932, Stanton and Fletcher
described a total of 39 cases of melioidosis in Kuala Lumpur [3]. There was a long hiatus in documented
melioidosis cases in the Malayan Peninsula, possibly due to World War II and post-World War II
insurgencies that plagued the Indo-China region through the 1950s and 1960s. In 1957, Malaya gained
independence from the United Kingdom and the Malaysian Federation was subsequently formed with
the union of Malaya, Singapore, Sabah, and Sarawak in 1963. With the stabilized geopolitical climate,
interest in melioidosis was reignited with environmental surveillance and serosurveillance conducted
in several states by the United States of America Medical Research Unit (USAMRU) in the 1960s [4–7].
In the nationwide serosurveillance study, participants from Kedah and Sabah (Figure 1) recorded the
highest seroprevalence against B. pseudomallei [5], while B. pseudomallei was isolated from soil and
water from several states in Peninsular Malaysia and Sabah [4,6,7]. In 1970, Thin et al. described ten
cases of melioidosis involving military personnel presenting at military hospitals in Malacca (Melaka)
and Singapore over a three-year period [3].
Figure 1. A map of Malaysia indicating the major states with reported cases of melioidosis (black boxes)
presented in this review. The majority of case reports are from hospitals and medical centers in
Pahang and Sabah due to the diligence of the state health authorities in initiating state-level registries
for melioidosis.
Cases of animal melioidosis are not rare, nor are they unfamiliar to veterinarians in Malaysia.
Recorded reports of animal melioidosis date back to almost 100 years ago, beginning with the 1921
seminal work of Stanton and Fletcher [8]. Since then, melioidosis has been reported in local goats,
sheep, cattle, pigs, deer, monkeys, horses, cats, dogs, and rabbits [9–13]. In addition, a number
of State Veterinary Services Departments in Malaysia keep records of animal melioidosis cases
for surveillance and control purposes, mainly as a means to mitigate loss of animals of economic
importance, especially ruminant livestock. Fatal melioidosis was also reported among orangutans
at the Sepilok Rehabilitation Centre in Sandakan, Sabah in 1965 and 1968, where B. pseudomallei was
successfully isolated from the Centre [14]. Primates are indeed susceptible to B. pseudomallei infection,
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as reported in Johor and Kuala Lumpur in the 1960s, involving pig-tailed macaques, a spider monkey,
and a gibbon [10]. The variety of animals reported to be affected by melioidosis and the many locations
from which the animal cases came, suggest a wide distribution of B. pseudomallei in the environment in
Malaysia. Although direct zoonotic transmission of melioidosis appears rare in the country, with only
one published report available thus far of a case of transmission from sheep to human [15], the risk may
be underestimated. Furthermore, the risk of indirect zoonotic transmission, which could potentially
occur via environment contaminated with B. pseudomallei shed from infected animals, has not been
properly assessed. For the better management and control of human melioidosis in the country, cases of
animal melioidosis should not be taken lightly.
Research led by Malaysian clinicians and microbiologists on melioidosis started to gain
momentum in the late 1980s and early 1990s with numerous publications—in particular, clinical reports
and reviews [16–19]. The research interest subsequently expanded to include molecular microbiology,
genomics, and pathogenesis [20–28], with the availability of better facilities, funding, and trained
local experts.
1.2. Modes of Transmission
The B. pseudomallei natural environmental habitat in endemic areas is soil and water. Most cases
of melioidosis occur in persons with regular contact with contaminated soil or water, via penetrating
wounds or pre-existing skin abrasions [29]. Inhalation via contaminated dust or water as in severe wet
weather conditions is the next most common route of entry and is characterized by pneumonia and
more severe infection [30]. Heavy rains precipitate ﬂooding, which facilitates churning of B. pseudomallei
to the surface soil, aerosolizing the bacteria and increasing exposure potential. Zueter et al. [31] in their
case series from Kelantan observed that the highest frequency of admissions occurred during the rainy
season from November to February. Hassan et al. [32] found that cases and deaths from melioidosis
in the Alor Setar region of Kedah increased linearly with mean monthly rainfall. Pagalavan [33]
reported a case after a near-drowning episode, where the patient most probably acquired the infection
through aspiration.
2. Burden of Disease and Epidemiology
Melioidosis is not a notiﬁable disease in Malaysia; therefore, the true incidence of melioidosis
in Malaysia is unknown, although more than a thousand cases have been reported throughout
Malaysia [34]. Incidence may vary between states, and even within the same state, there may be
various hotspots [35]. States that are active in agriculture generally report a higher incidence of
melioidosis. Pahang, the largest state in Peninsular Malaysia, where agriculture is the main economic
activity, recorded incidences of culture-conﬁrmed adult melioidosis of 6.1 per 100,000 population per
year from 2000–2003 [36]. The state of Kedah, which is situated at the Malaysia–Thailand border and is
the largest rice producer in Malaysia, reported an incidence of 16.35 per 100,000 population a year [32].
Table 1, Table 2 and Table 4 present selected results from six studies pertaining to Malaysia. Four of
these studies used data from systematic compilation of cases from hospital laboratories [18,31,33,36],
the ﬁfth used data from a registry [32], and the sixth is a synthesis of published case reports from
Malaysia providing more detailed information on individual cases [37]. Table 3 presents results from
four studies on paediatric melioidosis in Malaysia.
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2.1. Demography and Risk Factors
Melioidosis may occur at any age, including newborns. The peak incidence in the Malaysian
case series is between 40 and 60 years of age (median, 44–51 years) (Table 1), the age range during
which most co-morbid conditions develop. A preponderance of the disease among males was noted;
the gender difference may be due to a higher potential for males to be involved in soil-related
occupations and activities facilitating exposure. In four of ﬁve case series, most cases were reported
in persons of Malay ethnicity, possibly reﬂecting the higher proportion of Malay rice paddy farmers
and agriculture employees with potential for exposure to contaminated water and/or soil [36] or the
predominant Malay ethnic composition of certain states [31–33].
Most cases (58–85%) had at least one risk factor reiterating B. pseudomallei’s classiﬁcation as an
opportunistic pathogen and that susceptibility of the host is a vital factor in the acquisition of infection.
More than one risk factor was reported in 8.1–36% of cases. No risk factor was reported in 15–42%
of cases, possibly reﬂecting under-reporting, unknown residual factors, and high bacterial load or
inhalation route in some cases (Table 1). Data on environmental risk factors was sparse in all of
the Malaysian case series, underscoring the need to acquire this important information to assist in
the education and prevention of melioidosis. Workers in the agricultural and construction sectors,
military personnel, eco-tourists, and persons involved in rescue operations are groups known to
be at high risk because of their contact with contaminated soil or water [38–40]. Employment in
the farming/ﬁshing/forestry industry was reported in 2–25% of cases followed by 3–18% for the
construction/trucking industry. Four cases were involved in rescue operations in the recreational
forests of Pahang; all of the four cases had co-infection with leptospirosis and three of the four had a
fatal outcome [37,40].
Several underlying medical conditions or drug therapy that may impair host defense predispose
individuals to melioidosis [41,42]. As reported in other endemic areas of the world, type 2
diabetes mellitus is the most common co-morbid condition associated with melioidosis in Malaysia;
38–75% of melioidosis patients were either newly diagnosed or had pre-existing type 2 diabetes
mellitus (Table 1). Other co-morbid conditions associated with melioidosis include chronic renal
disease (6–19%), tuberculosis (9–16%), immune disorders/steroid therapy (2.9–9.5%), solid tumors
(0.7–10%), haematological malignancies (0.7–8%), chronic lung disease (2.8–3.0%), chronic heart
disease (7.0%), smoking (10%), chronic alcoholism (0.7–2.0%), hemolytic anaemia (0.7–2.0%),
and malnutrition/anaemia (8%).
2.2. Clinical Presentation
Melioidosis presents as a febrile illness with protean clinical manifestations, ranging from acute
fulminant pneumonia and/or septicemia mimicking other community-acquired infections, to a chronic
infection that may mimic tuberculosis or malignancy. The disease is characterized by abscess formation
in multiple organs and is referred to as ‘the great mimicker’ because of its similarity to other infections
that obscure its correct diagnosis [38]. The pitfalls and optimal approaches to diagnosis have been
previously reviewed by Kingsley et al. [43] and are highlighted in a latter section.
In the Malaysian case series, more than 90% of cases were of acute onset [31,37], presenting as
acute respiratory infection, acute bacteraemia, or soft tissue infection with fever almost always present.
Soft tissue infections include infections of nonskeletal tissue surrounding or supporting organs and
other structures including subcutaneous tissue, muscle, lymph nodes, blood vessels, and soft tissue
organs (namely, the liver or spleen). Less than 10% of cases were chronic in onset (symptoms more
than two months), presenting as chronic pneumonia, chronic skin ulcers/abscesses, and disseminated
infection progressing to sepsis, while subclinical infections have also been documented. The major
reasons for emergency hospital admissions were acute pulmonary infection progressing to acute
respiratory failure, acute bacteraemia progressing to septic shock, severe soft tissue infection, or pyrexia
of unknown origin [31,37,43].
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The clinical spectrum of melioidosis may be classiﬁed into four non-mutually exclusive categories
(Table 2): (1) Acute pulmonary infection presenting as pneumonia is the most common clinical
presentation, reported in 33–63% of the Malaysian case series. The infection may be primarily acquired
via inhalation or alternatively via hematogenous spread following inoculation. (2) Acute blood stream
infection was reported in 19–61% of Malaysian case series; patients with co-morbid disease such as
diabetes are more likely to present with this form of the disease. Patients may present with a history
of fever (median, 6 days; range, 3 days–several months), respiratory distress, abdominal discomfort,
muscle tenderness, and disorientation. The clinical picture may vary from a simple bacteraemia with
no evident focus of infection, to fulminant septic shock and multiorgan abscesses with 16–34% of
cases presenting with septic shock. (3) Disseminated infection, occurring in 16–37% of cases, presents
with symptoms of fever, weight loss, abdominal pain, muscle and joint pain, headache, and seizures,
and with clinical signs of abscess formation in multiple organs with or without bacteraemia. (4) Acute
localized infection, occurring in about 10% of cases, may present as skin ulcers, subcutaneous tissue
abscesses, parotid abscess, or ocular infection. The infection may remain localized or may rapidly
progress through the blood stream to more widespread infection.
The lungs were the most common site of primary infection followed by soft tissue and bone/joint
infection (Table 2). Genitourinary and neurological infections were less frequent. Mortality occurring
within 24–48 h of admission precluded a complete workup to identify the site of infection.
Pulmonary melioidosis (41–58%) has been observed for both acute and chronic forms of lung
involvement. The chronic form of lung involvement mimics tuberculosis where patients present
with symptoms of fever and cough with purulent sputum and about one-third of patients possibly
having haemoptysis. Pleural involvement occurred in 9–33% of cases and thoracic empyema was
occasionally seen. Soft tissue and skin infection (17–36%) is the second most common primary site
of presentation. Soft tissue involvement manifests as subcutaneous, intramuscular, and deep-seated
abscesses with no particular preference for speciﬁc anatomical sites. B. pseudomallei could occasionally
be isolated from aspiration of abscesses/skin pustules or skin biopsies. Bone and joint infections
(6.0–13%) present mainly as septic arthritis, most commonly affecting the knee, followed by the
ankle, wrist, and elbow joints, whilst osteomyelitis was less common. Genitourinary infections
(3.2–10%) presented as prostatic abscesses, pyelonephritis, perinephric abscesses, or scrotal abscesses.
Meanwhile, neurologic melioidosis (4.8–7.5%) presented mainly as pyemic such as brain abscesses,
subdural empyema, epidural abscesses, etc. [37]. Hassan et al. [32] and Puthucheary et al. [18] also
reported only brain abscesses in their case series whilst meningoencephalitis was uncommon. A similar
pattern of pyemic lesions of neurological melioidosis was noted among three cases reported from a
registry in Sarawak [44]. The clinical scenario of no identiﬁed focus of infection (7.5–24%) was more
likely to occur in bacteraemic than nonbacteraemic patients [37].
Besides the primary infection, it was not uncommon for secondary foci of infection to
occur. Overall, 49% of cases had secondary foci of infection. Secondary subcutaneous tissue
abscesses (21%) were most common in all primary diagnostic groups followed by secondary
pneumonia [37]. Liver (4.0–18%) and splenic (2.0–12%) abscesses were commonly found in bacteraemic
cases (Table 2) with the ‘honeycomb’ or ‘Swiss cheese’ appearance of liver and spleen which is
characteristic of melioidosis. Case reports noted a frequency of 13% of prostate abscesses in male
patients [37], whereas the case series reported a lower proportion (0.9–2.6%) although this could
be attributed to the more complete investigational workup available for case reports than case
series. Other rare presentations of melioidosis reported in Malaysia include mycotic pseudoaneurysm
(7.5%), pericardial effusion (1.0–2.0%), and heart valve vegetation (3.0%). In mycotic pseudoaneurysm,
a pulsatile abdominal mass was the predominant clinical sign and fever was a consistent clinical feature.
Diagnosis was made on the basis of CT ﬁndings; aneurysms were located in the major abdominal
arteries and most had surgical intervention [37].
In summary, the clinical patterns of cases reported from Malaysia are consistent for the
most part with previous case reports from South and Southeast Asia where pneumonia is the
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most common primary presentation followed by soft tissue abscesses with diabetes a major risk
factor [37]. Concomitantly, symptoms more frequently observed in Malaysian patients included
primary neurological infection and internal foci of infection such as abscess of the liver, spleen,
and prostate, and mycotic pseudoaneurysms were higher than previously reported in the region [37].
Neurological melioidosis is primarily pyemic in Malaysia; the distinct syndrome of brain stem
encephalitis with ﬂaccid paralysis noted in 4% of melioidosis cases in northern Australia [30] was
uncommon in Malaysia and was reported in less than 1% of cases [37].
2.3. Paediatric Melioidosis in Malaysia
B. pseudomallei infections are reported less commonly in children than in adults [45]. In Malaysia,
paediatric melioidosis has been described in detail in only four studies, reporting between 13 and
42 culture-conﬁrmed cases each (Table 3). These studies, describing children with melioidosis from
both Peninsular Malaysia (Pahang [46], Kuala Lumpur [47]) and Malaysian Borneo (Sabah [44],
Sarawak [35]), have shown varying incidences and host risk factors for disease. However, all report
high rates of disseminated disease and septicaemia with high case fatality rates. The incidence of
paediatric melioidosis has been estimated to be 0.6, 0.7, and 4.1 per 100,000 children in Sabah, Pahang,
and Sarawak, respectively. Marked regional variations in incidences are known, although the reasons
for these variations remain unclear. For example, incidences as high as 20.2 per 100,000 children were
reported in some districts in Sarawak, while no cases were documented in other districts [35].
The importance of an underlying medical condition in the predisposition to childhood melioidosis
varied between the different studies in Malaysia. In the study from Kuala Lumpur, 69% of children had
an underlying medical condition, mainly haematological malignancy [47]. In Sabah, where high rates
of β-globin gene deletions are found in the local ethnic population, 41% of children had thalassemia
major. Interestingly, this higher incidence of melioidosis among children with transfusion-dependent
thalassemia reduced signiﬁcantly with the institution of iron chelation therapy, indicating that it
was the iron overload that was important in the pathogenesis [44]. Other conditions documented in
these studies included primary immunodeﬁciency, renal failure, diabetes mellitus, hypoaldosteronism,
albinism, congenital heart disease, and malnutrition. In contrast, no underlying medical conditions
were noted in children with melioidosis in Pahang and Sarawak. However, 32% of those in Sarawak
were noted to have poor nutritional status and this may also be an important host risk factor.
In contrast to the paediatric melioidosis literature from most endemic regions [48,49], a large
proportion of children with melioidosis in Malaysia presented with disseminated or septicaemic
disease. This proportion ranged between 44% and 93% in the various studies. Pneumonia was the
predominant manifestation in those with disseminated disease, occurring in as many as 76–83% of cases
in Sabah [44] and Sarawak [35]. Undifferentiated fever, with no overt focus of infection, was another
important manifestation, occurring in over 28% of children with disseminated melioidosis in two of
the studies. Septic arthritis and osteomyelitis occurred in almost 10–15% of children in the Bornean
studies. Splenic (and, less frequently, liver) abscesses were also common ﬁndings; splenic abscesses
were noted in >50% of children in Sabah and Sarawak who had abdominal ultrasound imaging.
Neurological involvement was less common, documented in a total of nine children overall. As has
been reported in other melioidosis endemic regions, neonatal infections also occurred [50].
Localized melioidosis infection in Malaysian children typically involved either lymph nodes
(mainly cervical), skin and soft tissue, or the lacrimal glands. Parotid infectionswere rare, documented in
only 3% of children, in stark contrast to the >25% of children who present with this manifestation
in Cambodia and Thailand [49,51]. Children with melioidosis in Malaysia had extremely high
fatality rates. Overall, between 24–59% of culture-confirmed melioidosis cases had a fatal outcome.
Bacteraemia, disseminated disease, and involvement or dysfunction of a high number of organs were
associated with poorer outcomes. Case fatality rates invariably exceeded 75% when septicaemic shock
was present. In addition, those with underlying medical conditions had higher fatality rates. In contrast,
children with localized disease had significantly better outcomes with only one death recorded.
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A delay in diagnosis and in initiation of appropriate antimicrobial treatment was observed in
most paediatric melioidosis studies in Malaysia. In Sarawak, the diagnosis was initially missed by
nearly 90% of primary healthcare providers and the median duration of symptoms was 14 days before
these children were ﬁnally admitted to hospital. In Sabah, an appropriate antimicrobial was initiated at
admission in <50% of children. These delays likely contributed to the high fatality rates observed and
highlight the lack of awareness both in the community and in healthcare professionals in Malaysia.
3. Laboratory Diagnosis of Melioidosis in the Malaysian Healthcare System
Melioidosis is a challenging infectious disease to diagnose even for an endemic country like
Malaysia. The absence of pathognomonic clinical presentations, coupled with the lack of familiarity
with the disease among attending physicians and laboratory personnel, are the main factors
contributing to misdiagnoses especially in rural settings. In Malaysian public tertiary hospitals
equipped with modern-day microbiology facilities, laboratory diagnosis of melioidosis is typically
included in the routine blood culture test that is done as part of the sepsis workup for patients with
fever. Although Ashdown’s agar is widely used in other melioidosis-endemic countries [52,53], it is not
widely used in diagnostic laboratories in Malaysia. Instead, Francis media agar [21], MacConkey agar,
blood agar, and chocolate agar are the common media used in public healthcare, where use of different
combinations of agar media varies from one hospital to another.
Once isolated from clinical samples, conﬁrmation of B. pseudomallei is either by manual
(API 20NE biochemical kit, bioMérieux, Marcy-l’Étoile, France) or automated biochemical systems
(Vitek 2, bioMérieux, France; BD Phoenix, Becton Dickinson, Franklin Lakes, NJ, USA; MALDI-TOF
MS, Bruker, Bremen, Germany) for any bacterial isolates initially conﬁrmed to be nonmotile,
Gram-negative, and oxidase-positive bacilli. Nonetheless, there are also pitfalls in biochemical
tests where B. pseudomallei isolates were misidentiﬁed as other Burkholderia species, as previously
observed by Podin et al. [54]. Two tests recommended in the guidelines of the Melioidosis Diagnostic
Workshop 2013 [55] are not currently included in the routine clinical microbiology laboratory
identiﬁcation workﬂow, due to various reasons such as budgetary constraints and regional variations
of B. pseudomallei phenotypes: antibiotic susceptibility tests for amoxicillin-clavulanate, colistin,
and gentamicin, and the B. pseudomallei-speciﬁc latex agglutination assay. While highly sensitive,
rapid, and speciﬁc, the use of B. pseudomallei-speciﬁc latex agglutination assay is too costly for public
hospitals. Although antibiotic susceptibility tests for amoxicillin-clavulanate, colistin, and gentamicin
are not done routinely, this diagnostic algorithm is certainly worth adopting in Malaysia as
it has been shown to be useful in resource-limited laboratories in north-central Vietnam [56].
However, gentamicin-susceptible isolates need to be assessed with extra care due to the discovery
of gentamicin-susceptible strains that are predominantly found in Central Sarawak [26]. On average,
about 3–5 days are still needed for most hospital laboratories in Malaysia to diagnose melioidosis:
20–48 h of blood and agar plate culture, followed by 48–72 h of biochemical identiﬁcation processes.
Serological tests to detect the presence of anti-B. pseudomallei antibody titers using either the
indirect hemagglutination assay (IHA) or enzyme-linked immunosorbent assay (ELISA) are widely
accepted as unreliable for the diagnosis of melioidosis in Malaysia. The current use of IHA and ELISA
in the country is limited to contact investigations and interim monitoring of persons found associated
with melioidosis-conﬁrmed cases of either humans or animals. Mohd Noor et al. [57] reported the
potential application of their optimized in-house IgM ELISA method for diagnosis of acute melioidosis.
The robustness of this assay in diagnosing acute melioidosis in public hospital settings remains to be
seen and is pending validation. At the institutional level, the Institute for Medical Research, which is
the biomedical research arm of the Malaysian Ministry of Health, has since replaced IHA with the
optimized in-house IgM ELISA as the method of choice to test for recent exposure to B. pseudomallei.
Although not standardized at the national level, molecular methods for conﬁrmation of B. pseudomallei
are also available and doable in Malaysia using either conventional polymerase chain reaction (PCR)
or real-time PCR on the type three secretion system (TTSS)-1 and other gene targets with high levels of
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speciﬁcity and sensitivity [58]. If carefully adapted into the existing melioidosis diagnostic workup,
these molecular methods may have a shorter diagnostic turnaround time. Nonetheless, bacterial culture
cannot be totally abandoned as direct detection of B. pseudomallei remains complicated due to presence
of inhibitors [59].
4. Mortality and Recurrence
Based on incidence and mortality of melioidosis in Malaysia, it is estimated that more than
2000 patients die of melioidosis per year, which is much higher than death resulting from dengue
or tuberculosis infection. Despite advances in treatment, the case fatality ranged from one-third to
about half of patients (33–54%) in four of the ﬁve Malaysian case series and in the review of case
reports that included all cases, irrespective of bacteraemic status (Table 3). However, when stratiﬁed by
bacteraemic status, the mortality was about threefold higher among bacteraemic cases compared with
nonbacteraemic cases (48–65% vs. 19%). This was previously observed by Puthucheary et al. [18] when
they reported 65% mortality, selected on the basis of positive bacteraemic status. A study evaluating
patients with bacteraemic melioidosis in Kelantan also reported up to 63% mortality [60]. The normal
pathological consequence of bacteraemia is septic shock. Septic shock was the strongest predictor for
mortality; in most cases, signs of septic shock occurred within 24 h of admission, presenting as acute
respiratory distress syndrome. The mortality among cases with septic shock was 100% compared
to 30% among cases without septic shock [37]. Zueter et al. [31] also concluded that septic shock
[odds ratio (OR) = 16.5, 95% conﬁdence interval (CI = 6.1–44.9)] was the strongest predicting factor for
mortality adjusted for other factors.
With regards to other factors contributing to mortality, Zueter et al. [31] found that age >40 years
(OR = 6.47, 95% CI = 1.7–23.8) and the presence of at least one co-morbid condition (OR = 3.0,
95% CI = 1.1–8.4) were independent predicting factors. Among co-morbid conditions, diabetes mellitus
was the major underlying risk factor for mortality; 69% of patients had diabetes mellitus in the
case series by Hassan et al. [32]. With regards to organ involvement, pneumonia and bacteraemia
accounted for most deaths. How et al. [36] found that patients with pneumonia, multiple organ
involvement, and bacteraemia had a statistically-signiﬁcant higher mortality than patients with
subcutaneous, musculoskeletal, or internal organ involvement without pneumonia; mortality from
acute pneumonia was about 65–73% [18,32,36,37]. Hassan et al. [32] reported that patients with soft
tissue abscesses were also at risk for mortality and that osteomyelitis/septic arthritis and liver and
splenic abscesses were good predictors of mortality among bacteraemic cases. Patients with pneumonia
had approximately threefold higher mortality than those with soft tissue abscesses (63% vs. 18%,
p = 0.003) [37]. Zueter et al. [31] found that 23% of fatal melioidosis cases were directly attributable to
lack of prompt acute-phase treatment.
Patients who survive an initial episode of acute melioidosis have a high potential to develop
clinical recurrence, possibly due to failure of the host to eliminate the organism during the initial
episode of infection (relapse) or due to reinfection. In Malaysia, the reported rate of culture-conﬁrmed
clinical recurrence varied from 2.6% to 19% (Table 4). Chaowagul et al. [61] reported a twofold higher
recurrence rate of 15–30% per year in northeast Thailand. The lower recurrent infection rate in Malaysia
is perhaps an underestimate, reﬂecting the high proportion of cases lost to follow-up and shorter
duration of follow-up. Published data on the recurrence rate in Malaysia did not speciﬁcally note the
proportion of relapse and reinfection because serotyping is not routinely performed for clinical isolates.
Similar to tuberculosis, melioidosis infection may be dormant with prolonged latency [11].
Factors contributing to dormancy include survival of B. pseudomallei in protected environments,
such as phagocytic cells or enclosed abscesses, or the ability of the organism to form a protective
covering in infected tissues where antimicrobials cannot penetrate [11]. Reactivation from a latent
focus and recurrence into a fulminating form may occur when host defense is compromised
as in diabetes mellitus [62]. Risk factors for recurrence amongst Malaysian patients included
severity of disease (positive blood culture, multifocal disease), incomplete or inadequate treatment
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with amoxicillin-clavulanate during the intensive phase of treatment, and improper eradication
therapy—amoxicillin-clavulanate, oral quinolones, or doxycycline monotherapy—and nonadherence
or duration less than 12 weeks [11]. The most important factor predisposing to relapse is nonadherence
to eradication therapy (oral antimicrobial therapy) or inadequate antibiotic therapy. Recurrence was
noted to occur in immunocompromised patients despite the full course of microbial therapy.
Zueter et al. [31] reported that incomplete treatment, or missed or delayed diagnosis, contributed to
the occurrence of recurrent infection among four patients in their case series, all of whom died during
the recurring episodes. How et al. [36] reported that patients who did not receive speciﬁc therapy
and those who received speciﬁc therapy for less than two weeks had a 40% and 25% higher risk of
relapse, respectively.
5. Molecular Pathogenesis of B. pseudomallei
5.1. B. Pseudomallei Bacteriology
B. pseudomallei is intrinsically resistant to a diverse group of antibiotics including
penicillins, rifamycins, aminoglycosides, and many third-generation cephalosporins. It is also
relatively resistant to quinolones and macrolides, limiting options for therapeutic treatment of
melioidosis [11]. Among 81 B. pseudomallei isolates from Malaysia tested against nine different
antimicrobial agents, susceptibility to ceftazidime, amoxicillin-clavulanic acid, meropenem, imipenem,
and trimethroprim-sulfamethoxazole was noted [63]. Despite the high percentage of susceptibility
reported, it was interesting to note that the overall results highlighted the emergence of
multidrug-resistant isolates. Of the 81 isolates, six were found to carry bpeB, amrB, penA, and BPSS1119
genes, believed to be associated with multidrug resistance. Although the majority of B. pseudomallei
in Malaysia is gentamicin resistant, more than 80% of B. pseudomallei from Central Sarawak of
Malaysian Borneo were found to be susceptible to aminoglycosides and macrolides, attributed to
a novel nonsynonymous mutation within the amrB gene of the AmrAB-OprA efflux pump [26].
Unaltered virulence was observed for these gentamicin-sensitive isolates, suggesting that the loss of
aminoglycoside and macrolide resistance has little consequence for virulence and might even enhance
environmental survival of these isolates. Thus far, this intriguing phenomenon has not been observed in
other parts of Malaysia. A recent study by Zueter et al. [64] on genotyping of 83 clinical B. pseudomallei
isolates from Peninsular Malaysia revealed 32 different sequence types (STs), of which 13 were novel.
All non-novel STs were previously identified in other Asian countries [65,66], suggesting that Malaysian
isolates may not be distinct from those of Southeast Asian countries. A lack of relationship between
B. pseudomallei STs and clinical melioidosis presentation agrees with previous studies indicating an
absence of association between any ST and disease outcome, but host and environmental factors are
possible reasons for the diverse nature of the clinical presentation of melioidosis [67,68].
5.2. Host–B. pseudomallei Interaction and Identiﬁcation of Potential Virulence Factors
Host–pathogen interaction studies on B. pseudomallei have been actively undertaken in Malaysia,
facilitated by the availability of various established host model systems, such as in vitro cell-based
models and in vivo models (vertebrate and invertebrate). Findings from these studies have contributed
new knowledge to the ﬁeld of melioidosis pathogenesis and the identiﬁcation of new potential
virulence factors as well as mechanisms of immune response subversion.
Chin et al. [69] investigated the host transcriptional response in a murine acute-phase melioidosis
model through microarray-based expression proﬁling, and highlighted the vital link between innate
and adaptive immunity during B. pseudomallei infection. They demonstrated that TLR2 was induced
to initiate an inﬂammatory response, followed by an increase in transcripts associated with cell
death, caspase activation, and peptidoglysis that ultimately promote tissue injury in the host [69].
In addition, suboptimal activation and function of the downstream complement system correlated
with uncontrolled spread of bacteria, eventually leading to death of the infected host. In a parallel
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study on a diabetic model of acute melioidosis, Chin et al. [70] suggested that the presence of elevated
glucose levels impaired the host innate immune system by delaying the identiﬁcation and recognition
of B. pseudomallei surface structures. Subsequently, this resulted in delayed activation of various
inﬂammatory and immune responses, as well as the general ‘alarm signal’ of infection, which may
contribute to the increased susceptibility of individuals with pre-existing diabetes to melioidosis [70].
Utilizing the invertebrate model Caenorhabditis elegans, the team at Universiti Kebangsaan
Malaysia demonstrated that direct prolonged interaction between C. elegans and B. pseudomallei
is required for a complete lethal effect, suggesting that live or proliferating bacteria continuously
produce toxins in order to mediate the full killing effect [71,72]. To explore the possibility of
toxin-mediated killing, Ooi et al. [72] demonstrated over-expression of the C. elegans ABC transporter
gene, pgp-5, upon B. pseudomallei infection, suggesting that the host actively thwarted the pathogenic
assaults during infection. A genome-wide transcriptome analysis of infected C. elegans revealed
a previously-undescribed mechanism by which B. pseudomallei suppressed host immunity by
speciﬁcally targeting an intestinal transcription factor, GATA/ELT-2, thus reducing its availability and
consequently inhibiting the expression of GATA transcriptional targets, which include host defense
effectors [73].
Chieng et al. [74] conducted a study to understand B. pseudomallei adaptation to the intracellular
environment of macrophage cells and demonstrated that the bacterium adapted rapidly within
macrophages through regulation of its metabolism and growth rates. Of note, the type VI secretion
system was induced throughout the infection, highlighting its major role in ensuring pathogen
survival and replication in the cell cytosol. However, expression of many known virulence factors was
suppressed, suggesting possible host immune system avoidance by intracellular B. pseudomallei [74].
In a separate study by the group from University Malaya, Vellasamy et al. [27] investigated the
host immune response to B. pseudomallei infection in lung epithelial cells. They demonstrated the
over-expression of several host carbohydrate metabolic pathways and suppression of the alternate
complement, coagulation, lysosome, and phagosome pathways, suggesting bacterial adaptation
and evasion of the host innate immune response. Overall, new knowledge from host–pathogen
interaction studies of B. pseudomallei has revealed mechanisms by which the host responds and some
of the mechanisms by which the pathogens avoid host defenses, thereby surviving and growing in
host cells. This information should contribute to the identiﬁcation of new therapeutic targets and
vaccine candidates.
The ability of B. pseudomallei to adhere, invade, survive, and replicate within mammalian host
cells is among the key factors in its pathogenesis [28]. A cohort of Malaysian human, animal,
and environmental B. pseudomallei isolates was characterized by various biochemical assays to
determine the secretion of selected virulence determinants [75,76]. A proteome analysis of B.
pseudomallei culture supernatant identiﬁed metabolic enzymes, transcription/translation regulators,
potential virulence factors, chaperones, transport regulators, and hypothetical proteins, several of
which were immunoreactive [77]. This study was extended to further evaluate the role of the cell
invasion protein, BipC, in pathogenesis of B. pseudomallei. BipC, an immunoreactive protein, is involved
in actin binding to facilitate internalization of B. pseudomallei into host cells, as a bipC mutant was
impaired in adherence, invasion, and intracellular survival in epithelial cells, and BipC protein is
required for full virulence in a murine model of melioidosis [78,79]. Recently, Vadivelu et al. [80]
showed that B. pseudomallei localized within the nuclear compartment of host cells, suggesting that
the nucleus may play a role as an occult or transient niche for persistence of intracellular pathogens,
potentially leading to recurrent episodes or recrudescence of infection.
B. pseudomallei is also known to form bioﬁlm, an important aspect in bacterial pathogenesis due to
its ability to promote bacterial survival or spread within the host and protection from antibiotics [81].
Small colony variants (SCVs) of B. pseudomallei, which displayed signiﬁcantly greater capacity to
form bioﬁlms, were shown to be less lethal in a C. elegans infection model compared to the K96243
isolate, reﬂecting theSCV ability to persist in the infected host. Recently, Chin et al. [82] noted that
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genes involved in surface-associated motility, surface composition, and cell wall biogenesis were
over-expressed in a high bioﬁlm producer and are probably required for the initial attachment of
bioﬁlms. Up-regulation of genes related to the two component signal transduction systems and a
denitriﬁcation enzyme pathway suggest that the B. pseudomallei high bioﬁlm producer is able to sense
the surrounding environmental conditions and regulate the production of extracellular polymeric
substance matrix, a hallmark of microbial bioﬁlm formation [82].
Overall, in vivo and in vitro studies using experimental melioidosis animal and cell culture
models have aided in revealing a variety of bacterial factors that may contribute to survival,
pathogenicity and long-term persistence of B. pseudomallei within the host.
6. Challenges and Future Perspectives
A major challenge in the war against melioidosis in Malaysia is the lack of awareness among
healthcare personnel and the general public as well as difﬁculties and limitations of fast and
effective diagnosis. Melioidosis molecular diagnostic methods are conﬁned to only a small number
of laboratories in research and academic institutions in Malaysia, and are more often employed for
research purposes. Two factors have probably prevented the widespread application of molecular
methods for routine clinical diagnosis of melioidosis: (1) the seemingly lower demand for these
methods compared to those for other infectious diseases such as dengue and tuberculosis, and (2) the
unanalyzed cost effectiveness of these molecular methods on melioidosis treatment and management
in the country.
Until an effective, portable, and simple diagnostic device is developed for melioidosis,
the diagnosis challenge for Malaysia is at least twofold. Awareness about melioidosis among physicians,
healthcare personnel, and the general public should be enhanced with periodic and continuous health
promotion, education, and/or training. In addition, a diagnostic workﬂow that is more rapid than the
existing one and preferably more robust needs to be developed, validated, and adopted in as many of
the public hospitals as possible. In the currently available healthcare services and infrastructure, it is
probably more feasible and pragmatic if more people are sufﬁciently trained to suspect melioidosis,
such that patients insist on seeking early medical treatment, while physicians and healthcare personnel
are able to initiate empirical treatment and concurrently submit patient samples to the nearest available
laboratory for deﬁnitive diagnosis in a timely manner. The successful diagnosis of melioidosis, and for
many other diseases, requires—at the minimum—the tripartite interaction and cooperation among
patients, physicians, and laboratory personnel in Malaysia.
Prevention of infection in areas where the disease is endemic can be difﬁcult since contact with
contaminated soil is common. In endemic areas, persons with open skin wounds and those with
diabetes or other comorbid conditions should be educated to avoid contact with soil and standing
water, as they are at increased risk for acquiring melioidosis. Wearing boots during agricultural work
can prevent infection through the feet and lower legs. Post-exposure antimicrobial prophylaxis (PEP)
is suggested for at-risk rescue operations workers [83]. In healthcare settings, using standard contact
precautions (mask, gloves, gown, and hand washing) is considered sufﬁcient protection.
In some states of Malaysia, the incidence of melioidosis is more frequent, with a large number
of people being diagnosed each year. In the state of Pahang, the incidence and mortality rates are
relatively high. To tackle this, the Medical Department of the International Islamic University Malaysia
(IIUM) with the assistance of the State Health Department, started the Pahang Melioidosis Registry.
The aim of this registry is to create awareness among doctors in Pahang on diagnosis and treatment of
melioidosis and to reduce patient mortality [84]. In 2014, the Sabah Health Department published a
guideline for clinical and public health management of melioidosis in Sabah. The Sabah Melioidosis
Registry keeps an account of all cases and local authorities are making efforts to spread awareness
about early symptoms and disease management [85].
Melioidosis continues to pose a potential threat, especially in Southeast Asian countries.
The relatively low case fatality rate in Malaysia’s neighbor, Singapore, is likely to be related to increased
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awareness amongst healthcare personnel, resulting in early diagnosis and treatment, optimal antibiotic
therapy, and improved supportive management. In Malaysia, there remain many problems in the
clinical management of this disease, particularly for patients from rural areas of the country as well as
young children. How these issues negatively impact the productivity and socio-economy of the country
remains uninvestigated. Low-cost, practical, accurate, and fast detection kits are not available in the
market yet. The emergence of intrinsically antibiotic-resistant strains of B. pseudomallei and co-infection
with leptospirosis are also challenges that have to be addressed quickly. Recently, a network of
microbiologists, molecular biologists, and clinicians has been established and is referred to as the
Malaysian Melioidosis Network. The aims of the network are primarily (1) to foster cooperation
between the bench-scientists and healthcare personnel; (2) to work closely with the Ministry of Health
Malaysia and provide informed advice on public awareness, improved diagnostics, and emergence
of antimicrobial resistance; and (3) to campaign for melioidosis to be classiﬁed as a notiﬁable disease
with well-curated incidence data made available. These efforts are currently ongoing.
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Abstract: Burkholderia pseudomallei is the causative agent of melioidosis, an endemic disease in tropical
areas around the world. Cumulative human cases have demonstrated that melioidosis is prevalent
and increasingly recognized in the American continent. Even though the ﬁrst reports of melioidosis
in Mexico, Central America, and the Caribbean Islands date back to the late 1940s, the potential of
the disease as a public health concern in the region has not been fully appreciated. Unfortunately,
recent studies predicting the global distribution of the disease and the demonstration of melioidosis
endemicity in Puerto Rico have not increased recognition of the disease by health professionals
in this region. Furthermore, a lack of both diagnostic capacity and awareness of the disease has
resulted in a limited number of studies that have attempted to accurately determine its prevalence
and geographical distribution. In this review, a summary of reported cases in the countries of this
region are presented, as well as recommendations to increase the diagnosis and awareness of the
disease as an important public health problem in Mexico, Central America, and the Caribbean islands.
Keywords: Burkholderia pseudomallei; melioidosis; Mexico; Central America; Caribbean; epidemiology;
awareness
1. Introduction
Melioidosis is an emerging, potentially fatal disease caused by Burkholderia pseudomallei, which
can be acquired through inoculation, inhalation, or ingestion. Inhalation of the bacterium results in
the most rapid and fulminant disease, whereas percutaneous inoculation is slower to progress and
is often limited to a cutaneous lesion [1,2]. B. pseudomallei can also cause asymptomatic infections in
healthy individuals, or can induce an acute, chronic, or latent disease. Melioidosis can be confused
with pneumonia or tuberculosis, and the bacterium is resistant to a wide variety of antibiotics, while
its pathogenic mechanismsare not completely understood. Further, the disease most commonly affects
individuals with underlying conditions, including type 2 diabetes, excessive alcohol consumption,
and chronic lung disease [1,3,4]. Target organs commonly include the lung, spleen, and prostate, but
B. pseudomallei has also been shown to establish infections in the bone marrow, central nervous system,
kidneys, and the gastrointestinal tract [5].
The magnitude of melioidosis in the Western Hemisphere is not fully understood. However,
cases occur sporadically in the Americas, with an increasing number of them observed among people
with no travel history to known endemic countries [6]. New endemic foci have been reported in
countries such as Mexico, Costa Rica, Guadeloupe, and Puerto Rico. A prior review of melioidosis
cases in the Americas described 120 identiﬁed human cases that occurred between 1947 and 2015,
95 of which (79%) were likely acquired in the Americas; the mortality rate was 39% [6], indicating
that B. pseudomallei is widespread in the American continent. Additionally, Limmathurotsakul et al.
Trop. Med. Infect. Dis. 2018, 3, 24 www.mdpi.com/journal/tropicalmed128
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predicted that B. pseudomallei is present in tropical latitudes, and that the highest risk zones included
South and Central America [7]. Mexico had the highest predicted incidence of melioidosis in North
America, with 550 cases per 100,000 population each year; while in Central America, El Salvador was
predicted to have 114 cases, and, in the Caribbean, 24 cases were predicted for Haiti [7]. In addition to
the high prevalence of diabetes (13.1% Mexico, 10.1% Central America, and 11.2% in The Caribbean) [8]
and limited access to health care, this study suggested that melioidosis might be endemic in many
countries of this region, but be signiﬁcantly underreported. Given the diagnostic limitations and little
or no surveillance, it is likely that B. pseudomallei is present in many more tropical countries where it
has not yet been identiﬁed [9].
Melioidosis requires speciﬁc antibiotic treatment, since B. pseudomallei has natural resistance
to several commonly used antibiotics such as penicillin, ampicillin, ﬁrst and second generation
cephalosporins, gentamicin, tobramycin, and streptomycin [10]. However, it is still important
to determine the antimicrobial sensitivity proﬁle to newer antibiotics [11]. Current therapy
recommendations are based on the outcome of a number of clinical trials in endemic regions and other
clinical observations [12]; however, in non-melioidosis endemic areas, empiric antimicrobial therapy
for pneumonia may not include drugs that are active against B. pseudomallei. Therefore, melioidosis
represents a challenge for clinical and microbiology laboratory staff in regard to diagnosing it accurately,
ensuring appropriate therapy, and alerting public health ofﬁcials to its potential endemicity.
Deﬁning the global distribution and updating the epidemiology of B. pseudomallei is important
for developing an accurate melioidosis risk map, and expanding the list of countries with sporadic
occurrence that may be upgraded to endemic status as a result of the recognition of increasing numbers
of indigenous cases and the detection of B. pseudomallei in the environment. Further, an accurate disease
distribution analysis will help raise awareness among healthcare workers in affected areas. Here, we
present an updated review of B. pseudomallei cases in this region that were published from 1945 to 2017.
We deliberately did not include Canada and the United States of America (USA) as, although there
have been two apparent cases of indigenous melioidosis in the continental USA in recent years [13,14],
they occurred in a part of the USA that is predicted to not be suitable for the environmental survival of
B. pseudomallei, and there was no evidence of a local environmental source. We also excluded Canada,
since although (similar to the USA) there have been a number of cases imported from other endemic
areas [15–18], there is no concrete evidence of indigenous melioidosis in either country.
2. Review of Melioidosis Cases and Presence of B. pseudomallei in Each Country
We conducted a search of the literature (PubMed, MEDLINE, and Google Scholar) in order
to identify published reports of melioidosis cases originating from Mexico, Central America, and
the Caribbean islands. Some keywords used included combinations of ‘Burkholderia pseudomallei’,
‘melioidosis’, ‘Mexico’, ‘Central America’, ‘Caribbean’, ‘Pseudomonas pseudomallei’, and ‘Malleomyces
pseudomallei’. Thus, we reviewed 37 papers (from 1945 to 2017) and, when available, the following
information was collected from each article: year of diagnosis, number of cases, gender, age, travel
history, country of diagnosis, diagnostic laboratory results, signs, symptoms, and patient outcomes.
ArcGIS online (ESRI, Redlands, CA, USA) was used to generate the map in Figure 1. Reported cases
are summarized in Table 1, and are discussed in more detail below.
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Figure 1. Melioidosis cases reported (1945–2017). Adapted from: Esri, HERE, DeLorme, increment P
corp., NPS, NRcan, Ordnance Survey, © OpenStreetMap contributors, USGS, NGA, NASA, CGIAR, N
Robinson, NCEAS, NLS, OS, NMA, Geodatastyrelsen, Rijkswaterstaat, GSA, Geoland, FEMA, Intermap,
and the GIS user community.
2.1. Mexico
Fourteen cases of melioidosis have been reported that were likely acquired in Mexico (see Table 1).
The ﬁrst case reported dated from 1958, and was of a 22-year-old white man from Oklahoma, USA,
with a travel history to border towns in Mexico [22]. He was diagnosed with melioidosis in the USA
by complement ﬁxation studies for ‘Malleomyces pseudomallei’. However, no bacteriologic conﬁrmation
was obtained on material from the abscesses cavity [22]. The second case, which was diagnosed in
the USA, was reported in 1985 [25]. The patient was a 72-year-old Hispanic male, who had lived in
the city of Manzanillo all of his life, and who was working as a clerk. He had never traveled outside
of Mexico. He died 72 h after admission to the hospital. At autopsy, the lungs showed patchy areas
of consolidation, and histological sections revealed suppurative acute bronchopneumonia [25]. The
third case was presented in 1989 at a cystic ﬁbrosis conference. Three of 19 sputum samples from
patients with cystic ﬁbrosis were positive for ‘Pseudomonas pseudomallei’, of which two patients died
from pulmonary illness [26]. Years later, in 2009 [40], 2010 [6], and 2013 [40], other cases of melioidosis
were reported in Mexico that were diagnosed in USA; however, the documented information regarding
signs, symptoms, and travel history is very limited. The only information available from the case
reported in 2010 is that it resulted in death [6]. Subsequently, in 2011, two more Mexican patients
were diagnosed in the USA, one of whom was a 10-year-old child, and the second was a 22-year-old
alcoholic female [6]. In both cases, the patients survived the disease. There is another report of
melioidosis diagnosed in Mexico in 2012 in a 29-year-old medical resident with an acute illness
(fever, malaise, and dyspnea) with 72 h of disease progression, with a history of recent travel to a
tropical Mexican region (Acapulco) one week previously [47]. Computed tomography (CT) showed
irregular hyperdense images with ground glass opacities in the lung, and he received treatment with
trimethoprim/sulfamethoxazole with adequate progress and cure. Microbiological identiﬁcation was
performed using the VITEK®2 (bioMérieux, Marcy-l'Étoile, France) system that has been reported
sometimes to have problems differentiating between B. pseudomallei and B. cepacia [53]. In this case,
the isolate was not conﬁrmed by a reference laboratory, such as the Centers for Disease Control and
Prevention (CDC).
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Further cases of melioidosis in Mexico have been reported more recently. In 2014, a 59-year-old
female with a four-day history of right-sided upper back and anterior chest pain, fever, and shortness
of breath was diagnosed in the USA with melioidosis, which was believed to have been contracted
in Mexico [50]. She had traveled to Los Cabos, Mexico, one week before hospital admission. A CT
scan of the chest showed an irregular mass in the apical segment of the right upper lobe with ground
glass opacities, and an enlarged right paratracheal lymph node. The isolate was later conﬁrmed and
identiﬁed as B. pseudomallei by the CDC. It is important to note that the patient had diabetes mellitus
and a well-controlled HIV infection, as well as having received a renal transplant. Additionally,
she was present when a hurricane hit the zone, and so had multiple risk factors for acquiring
the disease. Another important associated risk factor was reported in a 70-year-old smoker from
Mexico with no history of travel to any other melioidosis-endemic area [51]. The patient presented
with fever, chills, and an enlarging left neck mass. CT revealed a supraclavicular mass that was
drained, and the organism grown was conﬁrmed by the CDC as B. pseudomallei. The patient reported
symptom resolution with a decrease in the size of the supraclavicular mass after antibiotic therapy.
In 2015, the ﬁrst case of melioidosis was reported in a northern state of Mexico (Sonora) in a
48-year-old male who presented with fever and a history of abscess in the right subscapular region
with hepatomegaly and splenomegaly, but without pulmonary symptoms [52]. Microbiological
identiﬁcation using the VITEK®2 (bioMérieux) system identiﬁed the pathogen as B. pseudomallei, and
the use of trimethoprim/sulfamethoxazole resolved his symptoms. The recent increasing occurrence of
melioidosis in patients with no travel history outside Mexico indicates that B. pseudomallei is endemic,
mainly in tropical regions of the country. It is likely that, due to the lack of advanced diagnostic
methods, melioidosis remains an underdiagnosed disease in this country.
2.2. Central America
Cases have been reported in Central America from Guatemala to Panama, except in Nicaragua
and Belize (Figure 1).
2.2.1. Guatemala
Only two cases of melioidosis have been reported in Guatemala between 2012–2013 (Table 1).
The ﬁrst report was from a 71-year-old male with diabetes [6], and the second was from a 22-year-old
healthy female. In the former case, the potential risk of exposure was the use of a thermal sulfur hot
spring in that country [6]. Both cases survived, and were diagnosed in the United States; however, no
more detailed information was available.
2.2.2. El Salvador
Thirteen cases of melioidosis were reported in 1981 by Bloch et al. in residents of El Salvador who
had never traveled outside of the country [6,23] (Table 1). However, limited information is available
from those cases. A subsequent case of melioidosis was reported in 2000 in a 37-year-old female
resident of El Salvador who survived the disease, despite having diabetes mellitus [6]. Additionally,
Salvadorian refugees have been diagnosed with melioidosis during immigration health screening. One
refugee was diagnosed with melioidosis in the USA in 2001 [33]. In this case, the patient presented
with a cerebral abscess, but survived. However, the identity of the bacterium was not conﬁrmed by
a reference laboratory. The last documented case was diagnosed in 2003 in a 47-year-old male with
diabetes mellitus, who had traveled to El Salvador three weeks earlier [35]. A CT scan indicated the
presence of pulmonary abscesses, and the patient died from sepsis and multiorgan system failure [35].
Bacterial isolates were conﬁrmed as B. pseudomallei. This case is of importance, because the laboratory
workers manipulating the samples were exposed to B. pseudomallei cultures without utilizing proper
laboratory practices; however, no workers were infected. In response to this incident, laboratory safety
recommendations for B. pseudomallei were revised [35].
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2.2.3. Honduras
Two cases of melioidosis were reported in 2005 in patients who traveled to Honduras a few days
before hospital admission (Table 1). A 48-year-old male with diabetes and Guillain–Barré syndrome,
with a history of recent travel to Honduras, was diagnosed with pneumonia and perirectal abscess.
B. pseudomallei was isolated from cultures of blood and abscess ﬂuid. Fortunately, the patient survived
the infection [36]. In the same year, an 80-year-old female resident of Honduras was admitted to
hospital with a diagnosis of pneumonia after four days of headache, fever, and muscle pain [36]. She
died after two days in hospital, and B. pseudomallei was identiﬁed in a blood culture drawn when she
was admitted. Both cases were diagnosed in the USA, and the identiﬁcation of B. pseudomallei was
conﬁrmed by real-time PCR [36].
2.2.4. Costa Rica
Melioidosis in Costa Rica was reported in 1998 in a 56-year-old male with diabetes mellitus,
presenting with fever and lung infection; he died a few days after hospital admission [30] (Table 1).
The isolate from blood and bronchial aspirate was later conﬁrmed and identiﬁed as B. pseudomallei by
VITEK®2 (bioMérieux) [30]. The second case diagnosed was reported in 2000 in a 63-year-old male
smoker with diabetes mellitus and a history of working with cattle, [6,32]. The patient developed fever
and a cough with yellowish expectoration. A chest roentgenogram revealed an inﬂammatory inﬁltrate
in the right lung. He died 72 h post-admission. B. pseudomallei was identiﬁed from a blood sample
and bronchial secretions by the National Reference Laboratory (Hospital Nacional de Niños, Costa
Rica). Another case was reported in 2009, but no detailed information was provided [41]. In 2010, a
42-year-old female was diagnosed with melioidosis, which was probably acquired while vacationing in
Costa Rica [6]. The latter two patients both survived. In 2014, the ﬁrst case of B. pseudomallei infection
of the central nervous system was reported in this country [49]. A 45-year-old male with diabetes
mellitus presented with headache, fever, photophobia and convulsive crisis. Cerebrospinal ﬂuid and
empyema cultures were positive for B. pseudomallei, as identiﬁed by the VITEK®2 (bioMérieux) system
and conﬁrmed by a local reference laboratory (INCIENSA) [49]. The patient survived after 20 weeks of
ceftazidime and trimethoprim/sulfamethoxazole treatment.
2.2.5. Panama
The ﬁrst reports of melioidosis in the Americas, dating from 1945–1957, were acquired in Panama
(Table 1). The ﬁrst of these possible cases of melioidosis was diagnosed in the USA in 1945 in a
31-year-old male who was employed in the Panama Canal Zone from 1927–1928 [19]. The patient was
admitted to hospital for the diagnosis and treatment of sinuses and ulcers of the right buttock and
thigh that had been present for eight years [19]. The organism was isolated from pus and tissue debris,
and was reported as ‘Malleomyces pseudomallei’. It was reported that before the chronic phase of the
disease, the patient had suffered from an acute pneumonic phase. A second case of melioidosis, which
was probably acquired in Panama, was reported in 1957 [20,21]. The patient was a 20-year-old male
who was treated for ‘ﬂu-like syndrome’. After three days, he developed genitourinary symptoms, and
later became systemically ill. He had pyuria, and a chest roentgenogram showed a small inﬁltrate
in the upper lobe of the left lung. After one month, he developed an acute septic arthritis of the
shoulder joint; pus was removed, and Pseudomonas pseudomallei was isolated in culture [20]. However,
in the two aforementioned cases, the cultures were not available for further studies, and could not
be considered as veriﬁed cases of melioidosis. Another case of melioidosis in Panama has been
reported more recently. In 2011, a 31-year-old male with diabetes mellitus, who developed liver and
skin abscesses, was diagnosed with B. pseudomallei infection [46]. The patient had no travel history
outside the country [46]. Unfortunately, limited information about the methodology that was used for
B. pseudomallei identiﬁcation was included.
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2.3. Caribbean Islands
2.3.1. Puerto Rico
As of October 2017, there have been seven cases of melioidosis reported or associated with Puerto
Rico, based on case reports or submissions to the USA CDC reference laboratory. The earliest case was
reported in 1982 in a 62-year-old Puerto Rican woman with systemic lupus erythematosus [24] (Table 1).
The patient had a one-week history of fever, chills, generalized weakness, and malaise. She had a
history of chronic non-productive cough; additionally, she had never traveled outside the country.
The patient died 48 h after admission, and the CDC later conﬁrmed the organism as Pseudomonas
pseudomallei [24]. The second case reported in Puerto Rico was in 1998 in an 11-year-old male with
chronic granulomatous disease [28]. At the time of admission, he presented with fever, right neck pain,
and two weeks of productive cough. A chest CT revealed a right hilar mass and right paraesophageal
lymphadenopathy, as well as a right supraclavicular mass. The API rapid NFT (non-fermentative)
system identiﬁed B. pseudomallei, and this identiﬁcation was subsequently conﬁrmed by the CDC.
The patient died after a few days of antibiotic therapy [28]. In 2003, a B. pseudomallei infection was
reported in a 55-year-old female with diabetes mellitus, who had been exposed to ﬂood waters during
the rainy season in this country [34]. This report highlighted the role played by ﬂood waters as a risk
factor in the epidemiology of melioidosis. In 2009, an 88-year-old male Puerto Rican veteran who
had served in Korea and Panama was diagnosed in USA with melioidosis [6,40]. The potential risk
of exposure was environmental (digging a ditch), and he survived the disease [6,40]. No additional
information was provided. In 2010, a 38-year-old male presented with symptoms of chest pain and
shortness of breath; his only relevant medical history was obesity [42]. He died 1 h after arriving at the
hospital. A histological analysis demonstrated acute necrotizing pneumonia with pyogranulomatous
splenitis, hepatitis, and focal myocarditis. B. pseudomallei was identiﬁed by the CDC [42]. Doker et al.
also reported another conﬁrmed case of melioidosis in 2012 [42]. A 60-year-old male with a three-day
history of nausea, anorexia, and abdominal and chest pain, was admitteded to an emergency room [42].
He had diabetes mellitus, obesity, alcohol use, and was a smoker.In addition, the patient reported
intermittent intravenous use of heroin and cocaine. B. pseudomallei was identiﬁed and conﬁrmed at the
CDC; the patient survived [42]. Thus, the earliest case in Puerto Rico was reported in 1982, followed
by one in each of the following years: 1998, 2003, 2009, 2010, 2012, and 2017. Six of the seven clinical
cases came from the eastern portion of the island. No information is currently available on the origins
of the seventh case, which occurred in the summer of 2017.
Due to the sporadic nature of these reports, surveillance was not considered a priority until the
2012 case, which prompted a closer look at the potential local endemicity of the disease [42]. The
study included a serological survey, which found that 6% of the contacts of the 2010 patient and 25%
of the contacts of the 2012 patient were seropositive; the study also found an association between
seropositivity and a history of skin wounds and/or a history of drug use. Environmental sampling of
soil near the 2012 patient’s residence yielded two B. pseudomallei isolates that were closely related to the
isolate from the patient, strongly indicating that this area was the source of his infection [42,54]. The
results of this study prompted an extensive environmental survey of soil and water based on potential
habitats around the island. Isolates of B. pseudomallei were recovered from soil samples in the northern
part, indicating that the organism is not geographically restricted to the eastern portion of the island
(C.M. Hall, personal communication). This suggests that surveillance around the island may yield
more cases. However, the effects of Hurricane Maria in 2017 were still being dealt with at the time of
writing this manuscript. It is unknown how long it will take to rebuild the public health infrastructure
of the island.
In addition to the presence of B. pseudomallei in humans and the environment in Puerto Rico,
Hemme et al. found the presence of antibodies against B. pseudomallei in one of 24 non-human primates
(Erythrocebus patas) that were tested [55]. This study suggested probable transmission through contact
with contaminated soil and water.
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2.3.2. Other Caribbean Islands
Sporadic cases of melioidosis have been associated with other Caribbean islands, and are
typically diagnosed in tourists who return to their home countries or residents who seek medical
treatment or consultation in countries with laboratory capability to diagnose the disease. Islands
that are associated with cases of melioidosis include Aruba [39,45], the British Virgin Islands [37],
Guadeloupe [29,43,56], the Dominican Republic [38], Martinique [27,31,44], Trinidad, and Tobago [18].
A case of melioidosis was reported in a child with cystic ﬁbrosis who had travelled to Aruba some
three months previously [39]. Interestingly, the occurrence of melioidosis in animals, particularly
sheep, goats, and pigs, had previously been reported in the 1950s [57]. Unfortunately, no isolates
from the animal melioidosis outbreak were available for conﬁrmation; however, this remains the only
reported instance of animal meliodosis in this region.Two cases of melioidosis have been reported
from Guadeloupe [29,43] and a report of three further cases from Guadeloupe in 2017 is also in
submission [56]. The CDC is also currently investigating two cases of melioidosis in the US Virgin
Islands [56]. Based on predicted environmental suitability, it is likely that other Caribbean islands may
be endemic for this bacterium [7]. Discussions with various stakeholders in the Caribbean indicate
that surveillance for melioidosis is typically not a priority for them [56].
3. Current Challenges in the Diagnosis and Treatment ofMelioidosis in the Region
Melioidosis has generated further interest in view of the detection of B. pseudomallei infection
in countries that were previously considered non-endemic (Figure 1). These sporadic occurrences
over a prolonged period are unlikely to have resulted from repeated importation, and along with
a high predicted incidence of the disease in this region [7], suggest that the pathogen is likely to
be endemic but underdiagnosed across this region. The high proportion of melioidosis cases in
this review that were diagnosed and conﬁrmed outside of the region, mainly in the USA (26 of
63 cases, representing 41.27%), strongly suggests a lack of reliable diagnostic testing within the
region. Signiﬁcant confusion exists regarding the identiﬁcation and diagnosis of melioidosis in this
part of the world. Puerto Rico was the ﬁrst country in the region where B. pseudomallei endemicity
was clearly demonstrated [42].However, in Mexico, Central America, and other Caribbean islands,
the diagnosis is being made with increasing frequency based on identiﬁcation with commercial
systems such as API 20E, API 20NE, VITEK®1 and 2 (bioMérieux). However, a limitation of these
commercially-available systems is that the misidentiﬁcation of B. pseudomallei for B. cepacia may
occur with VITEK®2 [53]. However, API 20NE and 20E have correctly identiﬁed 98% and 99% of
B. pseudomallei cases, respectively [58].
There is a variety of serological assays (ELISAs, indirect hemagglutination assay, and indirect
immunoﬂuorescence assay) available for the identiﬁcation of B. pseudomallei in endemic regions,
although their usefulness is limited by high rates of background antibody [59,60]. However,
seroprevalence studies would be very valuable to assess the endemicity in this region, because
only Puerto Rico has been clearly demonstrated as endemic, using a combined approach of
seroepidemiology and environmental detection [42]. Ashdown’s selective agar is still considered
the gold standard for optimal diagnosis, and is recommended for the isolation of B. pseudomallei from
clinical specimens from sites with a normal ﬂora. However, it is not always available and is not
routinely used in non-endemic areas [61]. B. pseudomallei grows on many commercially available
culture media (MacConkey, sheep blood and chocolate agar), but it is likely that many laboratories
in the region may misidentify the bacterium as Pseudomonas species or other Burkholderia species,
particularly with some commercial systems with poorly ability to identify B. pseudomallei [62–64].
Likewise, clinical manifestations of melioidosis do not make the diagnosis any simpler, because the
disease is frequently clinically indistinguishable from many infections caused by other bacteria. This
indicates that a limited experience and lack of familiarity with B. pseudomallei amongst clinicians and
laboratory staff, in combination with unreliable diagnostic tests in non-endemic regions, may result in
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continued misidentiﬁcation of the pathogen, and therefore underestimation of melioidosis cases in
the region.
Pneumonia was the most common clinical presentation associated with the melioidosis cases
described here. Chronic melioidosis with cavitary lung lesions and subcutaneous and visceral abscesses
were also found in many cases, and the protean nature of melioidosis was evidenced by one case
affecting the central nervous system. Therefore, the diagnosis of melioidosis should be considered
by physicians in any patients presenting with those signs and symptoms who are returning from or
residing in potentially endemic tropical regions. In addition, medical personnel should be aware of
the conditions that predispose to melioidosis, including diabetes mellitus, alcoholism, chronic lung
disease, cancer, and other immunosuppressive disorders [62], which should increase the chances of
making the diagnosis.
The accurate diagnosis of melioidosis is important in order to guide antibiotic treatment and
prevent relapse. The recent recommendations for therapy of melioidosis have been comprehensively
summarized elsewhere [12,65]. One other issue requiring attention to reduce the risk of melioidosis
acquisition in the healthcare setting is the possible accidental exposure of laboratory workers to
infection. Snifﬁng culture plates is an unsafe laboratory procedure that is still performed in some
countries of this region, and should be forbidden. Based on anecdotal experience, several clinical
laboratorians in Mexico routinely sniff culture plates in order to identify the characteristic smell
(referred to as a corn ‘tortilla’-like) of Pseudomonas aeruginosa colonies (with which Burkholderia spp.
may be confused), which is a potentially high-risk activity in a laboratory setting. Consequently,
physicians should notify laboratory staff when samples are submitted from patients with symptoms,
risk factors, or history that is suggestive of melioidosis.
4. Awareness of Melioidosis
Disease awareness and education are important for melioidosis prevention and diagnosis.
Consequently, physicians and health care personnel must be made aware of the increasing number of
cases of apparently indigenous melioidosis reported in Mexico, Central America, and the Caribbean
islands. For example, health departments should raise awareness of melioidosis by distributing printed
information, in addition to running training seminars and workshops for healthcare professionals.
The future development of practical tools to detect, assess, and notify cases should be evaluated
and implemented by health organizations such as PAHO (Pan American Health Organization) and
CARPHA (The Caribbean Public Health Agency); it is worth noting that the websites for these
agencies do not currently mention melioidosis. Modeling of the predicted distribution and burden of
melioidosis showed that the population at risk in this region is about 246 million, in which 2000 could
have melioidosis, and 1000 might die each year [7]. If the prediction is correct, melioidosis is more
than a sporadic disease in this region.
Unfortunately, public awareness of melioidosis is very low, even in endemic countries such as
Thailand [66]. It is evident that people from Mexico, Central America, and the Caribbean Islands are
not aware of the disease, and therefore, they do not know anything about how to prevent it. Raising
awareness and knowledge about melioidosis among researchers and representatives of the public
health sectors will allow the development and implementation of guidelines for prevention, diagnosis,
and therapy. Furthermore, health departments should consider making melioidosis a reportable
disease, which would help improve surveillance and encourage the redeﬁnition of endemic areas.
5. Future Challenges
Current melioidosis morbidity and mortality in well-known endemic regions have decreased
due to better clinical management and advances in diagnostic techniques. However, in Mexico,
Central America, and the Caribbean islands, the inadequate diagnosis and treatment of patients with
melioidosis is a public health problem that is almost certainly leading to unnecessary deaths. In
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this context, national reporting systems should be improved in order to inform strategies to prevent,
prepare for, detect, and respond to melioidosis cases.
Therefore, (1) timely and accurate diagnosis is needed to ensure effective antibiotic therapy;
(2) there is a need to introduce selective media, such as Ashdown agar, in order to improve the yield
of B. pseudomallei from patients who are suspected to have melioidosis; (3) it is necessary to instruct
healthcare professionals about diagnosis, treatment, and preventive measures to combat melioidosis;
(4) reporting cases that occur in areas where melioidosis is not currently recognized as endemic will
help technicians and clinicians become familiar with this pathogen, and alert public health ofﬁcials.
Finally, recognizing melioidosis as an endemic disease affecting this region will allow the establishment
of educational campaigns for professionals and the general public, especially those with risk factors,
and the development of guidelines for the prevention and treatment of the disease.
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Abstract: Sporadic cases of melioidosis have been diagnosed in Myanmar since the disease was
ﬁrst described in Yangon in 1911. Published and unpublished cases are summarized here, along
with results from environmental and serosurveys. A total of 298 cases have been reported from
seven states or regions between 1911 and 2018, with the majority of these occurring before 1949.
Findings from soil surveys conﬁrm the presence of Burkholderia pseudomallei in the environment in all
three regions examined. The true epidemiology of the disease in Myanmar is unknown. Important
factors contributing to the current gaps in knowledge are lack of awareness among clinicians and
insufﬁcient laboratory diagnostic capacity in many parts of the country. This is likely to have led to
substantial under-reporting.
Keywords: melioidosis; Burkholderia pseudomallei; Myanmar
1. Introduction and History of Melioidosis in Myanmar
All historical accounts of melioidosis start with Myanmar (formerly Burma), since the disease
was ﬁrst recognized in 1911 in Rangoon (now Yangon) General Hospital by Alfred Whitmore, a
British pathologist who worked in Burma between 1906 and 1924 [1]. In 1913, Whitmore reported 38
post-mortem cases of a ‘glanders-like disease’, the majority of whom were male and bore stigmata of
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morphine injection. Krishnaswamy, Whitmore’s assistant, reported in 1917 that he had personally seen
more than 200 cases in Rangoon over six years, during which the disease accounted for approximately
one in every 20 autopsies he had conducted [2]. In the ensuing years, reported case numbers in the
country dwindled, and after the end of World War II, the disease disappeared from sight for more than
50 years. This hiatus corresponded ﬁrstly with the transition from colonial rule to independence (in
1948) and later with a prolonged period of military rule in Myanmar (1962–2011), during which the
country became closed off from the rest of the world, investment in healthcare slowed, and research
stagnated. Microbiologists working in larger centres inside Myanmar have reported sporadic cases
over the last 20 years, but the true epidemiology of the disease is unknown. Most health facilities in
Myanmar do not have the capacity to identify B. pseudomallei, and most health staff are not aware of
this disease. It is therefore likely that melioidosis is signiﬁcantly underdiagnosed in Myanmar, and
the projected annual number of cases (more than 6000) and deaths (more than 3000) from a recent
modelling study could well be an accurate reﬂection of the true situation [3].
2. Review of Melioidosis Cases and Presence of B. pseudomallei in the Country
We searched the PubMed database for cases of melioidosis or evidence of B. pseudomallei using the
following search terms: ((Myanmar) OR Burma)) AND ((melioid*) OR pseudomallei) OR glanders*)).
A separate search was performed for ‘Parotid abscess AND Myanmar’ (no hits). We also consulted
the Myanmar medical literature and the melioidosis global database [4], and contacted consultant
microbiologists in the biggest centres in the country (public sector).
2.1. Results
Evidence for the presence of B. pseudomallei in Myanmar comes from reports of clinical cases,
environmental sampling and serosurveys. Melioidosis has never been diagnosed in animals in
Myanmar although, by analogy with neighbouring countries, infections in animals are almost certainly
occurring undiagnosed.
2.1.1. Clinical Cases
We found a total of 298 published and unpublished cases of melioidosis in Myanmar since 1913
(Table 1). The vast majority (257) were published before the end of 1948. The next report of a case
diagnosed inside the country came about half a century later in 2000 in Mandalay [5]. Of the remaining
cases, several were diagnosed outside Myanmar, and the remainder came from a very small number
of centres. Eighty-ﬁve were known to have been culture-conﬁrmed. The report by Krishnaswamy in
which he mentions 200 cases does not state explicitly that these were culture-conﬁrmed; however, given
his position as Whitmore’s assistant and the descriptions of the ﬁrst 38 cases in which the diagnosis
was conﬁrmed by culture, it is likely that these too were conﬁrmed cases. Of note, only ﬁve cases (~2%)
were in females and three in children. A total of 276/298 (93%) cases were diagnosed in patients from
the Yangon area with six from Kayin state, two from Rakhine state, one from Bago region, two from
Ayeyarwady, two from Magway, two from Pyay and four not speciﬁed (Table 1 and Figure 1).
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Figure 1. Map of Myanmar showing distribution of reported cases (1912–present) by state or region,
categorized by predominant climate type. Each black dot represents a case.
In 2014, the results of all the blood cultures processed by the laboratory of Yangon General
Hospital between 2005 and 2013 were published [26]. B. pseudomallei was not isolated from any of
the 3865 cultures; however, the authors note that bacterial isolation and sub-optimal identiﬁcation
techniques may have been one explanation. In addition, the number of cultures requested was low
relative to the number of admissions in this busy hospital, which exceeds 50,000 per year.
2.1.2. Serological Evidence for B. pseudomallei in Myanmar
The gold standard for the diagnosis of melioidosis is bacterial isolation. Serology is difﬁcult
to interpret in endemic countries due to background positivity rates, but gives some indication of
population exposure. A cross-sectional sero-survey of 968 migrant workers from Myanmar was
undertaken in Thailand, close to the western border, in 2005 using a haemagglutination assay [27].
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The majority of participants (99%) came from Kayin or Mon States and Bago or Yangon Regions.
The median [IQR] population IHA titre was 1:20 [1:10 to 1:40], with no regional variation observed.
Sixty-nine (7%) participants had a titre ≥1:160, which is a recommended cut-off in Thailand used
to support a clinical diagnosis of melioidosis. Only 8% of surveyed adults were agricultural
workers. Between 2016 and 2017, blood samples were taken for serological testing using a hemolysin
co-regulated protein 1 (Hcp1)-based ELISA from 265 febrile patients presenting to a three outpatient
clinics in a large suburb of Yangon as part of a research study [28]. All patients tested negative (optical
density cut-off 1.16); median [interquartile range] of 0.02 [0.01–0.04] [29].
2.1.3. Evidence from Environmental Surveys
Myanmar has a variable landscape, ranging from the delta region in the south and west, to
the drier central plains, and ending at the Himalayan foothills in the north. Using a mathematical
modelling approach and taking into account known cases, climate and soil type, Myanmar has been
predicted to provide a very suitable environment for the causative bacterium [3]. Results of a farm
survey performed in two townships in Yangon (Thanlyin and Hmawbi) were reported in 2016. From
120 soil samples and 12 water samples collected and processed according to standard microbiological
guidelines for the detection of B. pseudomallei, there were seven positive results (conﬁrmed by molecular
methods) [30]. A national survey is underway by the authors, and preliminary testing has detected the
bacterium by culture of soil samples from townships in Yangon, Kayin and Mon Regions, which is in
agreement with the provenance of some of the reported clinical cases (Table 2). Full results should be
available by the end of 2018.
Table 2. Preliminary results of a soil survey being conducted in Myanmar.
Site Number State or Region Township Total Number ofSamples
Number of
Positive Samples
1 Yangon Hmawbi 1 40 0
2 Yangon Tontay 10 5
3 Yangon Thanlyin 20 0
4 Yangon Kyauktan 20 3
5 Yangon Thone Gwa 20 0
6 Yangon Kha Yan 20 0
7 Yangon Dala 20 0
8 Kayin Kyain Seikgyi 60 0
9 Kayin Myawaddy 140 9
10 Kayin Kawkareik 50 1
11 Kayin Hpa-an 50 1
12 Mon Kyaikhto 40 0
13 Mon Bilin 30 0
14 Mon Thaton 30 0
15 Mon Yae 30 0
16 Mon Thanbyuzayat 40 5
17 Mon Kyaikmaraw 30 2
18 Mon Mawlamyaing 20 0
19 Mon Chaung Sone 20 0
20 Mon Paung 20 0
1 Note: an earlier survey found B. pseudomallei in Hmawbi (see text).
3. Current Recommendations and Availability of Measures Against Melioidosis
Currently, there is no requirement to notify cases of melioidosis in the country. The Ministry of
Health and Sports has set up a national system for communicable disease surveillance and response.
This targets epidemic-prone diseases, speciﬁc diseases under national surveillance (DUNS), emerging
infectious diseases, climate-related communicable diseases, and vaccine-preventable diseases, but not
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melioidosis [31]. Under-recognition of the disease is very likely due to a lack of awareness among
health staff, under-utilisation of microbiology services by clinicians and inability of many laboratories
to identify the organism due to poor availability of necessary reagents, as well as a shortage of
microbiologists, particularly in rural areas. There are no standard treatment guidelines for melioidosis,
and the few patients identiﬁed are managed on a case by case basis.
4. Awareness of Melioidosis
With the exception of a few ‘enthusiasts’, melioidosis is almost entirely unknown among
healthcare providers. Raising awareness among health staff, clinicians and laboratory staff is therefore
the essential prerequisite to identifying melioidosis patients. When diagnostic and treatment services
for suspected melioidosis cases are established, raising awareness among the population working in
agriculture should follow in high-risk areas. Microbiology in Myanmar is perceived as a diagnostic
rather than a clinical service, and there is limited interaction between microbiologists and clinicians,
which means opportunities to raise awareness are missed. This was highlighted in the report by Hlaing
et al. in 2004 of melioidosis co-infection in a patient with tetanus. A report that B. pseudomallei had
been isolated was duly sent to the ward, but went unnoticed for several days and was acted upon only
when the patient deteriorated.
5. Current and Future Challenges
The burden of melioidosis in Myanmar needs to be deﬁned. The evidence suggests that the
disease is under-recognised and under-reported. While the majority of cases have been reported from
Yangon, evidence from a multicentre abscess survey, routine blood culture surveillance data at a large
centre and a recent serosurvey suggests it may not be a leading cause of sepsis in the greater Yangon
region, despite the fact that it was clearly an important cause of death in the early 20th century [2,21,26].
Reasons for a possible decline in incidence in areas of Yangon where it was common previously are
unclear, although the strong link with injection drug use in the early fatal cases raises the possibility
of contamination of the morphine, which is likely to have originated from Upper Burma [32]. An
alternative explanation is that this group was relatively immunocompromised and more susceptible
to infection following exposure in Yangon itself, and that with increasing urbanization, the risk of
exposure has fallen. It is probable that there are unrecognised melioidosis ‘hot-spots’ elsewhere,
so accurate data across the whole country are needed. Diabetes mellitus, a well-known risk factor
for melioidosis, has moved into the top ten causes of death in the country in the last three years
(http://www.healthdata.org/myanmar), which may drive up case numbers in the future. Important
contributing factors to the current lack of knowledge are a lack of microbiology laboratory diagnostic
capacity, particularly in smaller townships and rural areas, low rates of blood culture requesting, and
lack of awareness of the disease among clinicians. Many laboratories at township level have been
upgraded as part of the National Health Plan, but are not functional due a shortage of microbiologists.
Myanmar has a national reference laboratory (National Health Laboratory), established in 1963, and
a system for disease reporting. Addition of B. pseudomallei to the list of notiﬁable pathogens might
yield more information on the distribution of cases in the country, but is unlikely to uncover large
numbers until the capacity and usage of diagnostic microbiology increase. Environmental surveys may
be useful to help target scarce resources to augment case-based surveillance in areas where it is likely
to have the highest yield. This should be accompanied by advocacy meetings with state/regional and
township health authorities to raise awareness among clinicians and health providers.
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Abstract: Melioidosis has only been sporadically reported throughout Melanesia and the Paciﬁc
region since the ﬁrst report from Guam in 1946; therefore, its contribution to the disease burden in this
region is largely unknown. However, the outcome of a small number of active surveillance programs,
serological surveys, and presumptive imported cases identiﬁed elsewhere provide an insight into its
epidemiology and potential signiﬁcance throughout the region. Both clinical cases and environmental
reservoirs have been described from the rural district of Balimo in the Western Province of Papua
New Guinea and from the Northern Province of New Caledonia. In both these locations the incidence
of disease is similar to that described in tropical Australia and Burkholderia pseudomallei isolates are
also phylogenetically linked to Australian isolates. Serological evidence and presumptive imported
cases identiﬁed elsewhere suggest that melioidosis exists in other countries throughout the Paciﬁc.
However, the lack of laboratory facilities and clinical awareness, and the burden of other infections of
public health importance such as tuberculosis, contribute to the under-recognition of melioidosis in
this region.
Keywords: Papua New Guinea; Oceania; melioidosis
1. History
The Western Paciﬁc is home to the island communities of Oceania, including 15 countries within
Melanesia, Micronesia, Polynesia, and Australasia (Figure 1). Each of these countries has diverse
geography, demography, and socio-economic status. Melioidosis within Australasia will not be
discussed in this review.
The ﬁrst reported cases of melioidosis in Oceania outside Australasia were from two military
personal stationed on Guam during World War II [1]. In Papua New Guinea (PNG), melioidosis seems
sporadic. The ﬁrst reports were from animals kept in a zoo in the urban capital of Port Moresby
in 1963 [2–4]. The ﬁrst human case from PNG was recorded in 1965 from a patient referred to Port
Moresby General Hospital from Gemo Island, the then-leprosarium [5]. A case of melioidosis reported
from Sydney was reported in a man with a history of World War II service in PNG [6]. Similarly,
Kingston, a year later, reported from the same repatriation hospital a case of presumptive reactivation
illness from an individual 24 years after World War II military service in Milne Bay, PNG [7]. In New
Caledonia, Burkholderia pseudomallei was ﬁrst isolated from soil as part of an animal health program in
1984 [8] and the ﬁrst human case was reported in 1999 [9].
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Figure 1. Map of Oceania based on the United Nations geoscheme M49 coding classiﬁcation, devised
by the United Nations Statistics Division.
2. Review of Conﬁrmed Human Melioidosis Cases
2.1. Melioidosis Is Rare in PNG’s Urban Capital
Since PNG independence in 1975, seven cases of culture-conﬁrmed melioidosis have been
reported from the PNG capital Port Moresby as a result of active case detection [10–13]. De Buse and
colleagues reported a ﬁve-year-old boy presenting with pyrexia of unknown origin (PUO), who failed
to respond to malaria treatment. Two from three blood cultures taken revealed Staphylococcus aureus.
During exhaustive clinical work-up, B. pseudomallei along with S. aureus was recovered from a pus-ﬁlled
nodule excised from the abdominal wall. Subcutaneous abscesses appeared which, upon culture,
grew B. pseudomallei. Lee and Naraqi undertook a retrospective study in a review of Gram-negative
pneumonia presenting in adults at Port Moresby General Hospital between February 1977 and May
1979. Of the 3500 adult in-patients during this time, 550 had been admitted with acute pneumonia.
Of the 80 patients with Gram-negative bacteraemia, four were found to have primary pneumonia
caused by B. pseudomallei. One of the cases was melioidosis pneumonia with left side consolidation and
cavitation resembling pulmonary tuberculosis. The patient was a 36-year-old female who presented
acutely ill with fever, cough, and pleuritic chest pain. She had a past history of tuberculosis but no
other traditional co-morbidity factors were described.
Melioidosis was included in a prospective study of adult atypical pneumonia at Port Moresby
General Hospital over a ten-month period, reported in 1991 [14]. Of the 175 adults admitted to
the study, none revealed evidence of melioidosis using culture or indirect haemagglutination (IHA)
serology. Currie described a report of melioidosis in PNG presenting in a 28-year-old highland man
residing in Port Moresby with fulminating pneumonia [12]. The patient had a history of excessive
alcohol consumption, smoking, and glucose intolerance; he died a day after admission.
Between 2000 and 2002, laboratory surveillance for B. pseudomallei at the Port Moresby General
Hospital Pathology Department and at the Central Public Health Laboratory, Port Moresby, was
undertaken. From 2285 blood cultures tested from patients at Port Moresby General Hospital, two
(0.09%; 95% CI 0.01–0.32%) were positive for B. pseudomallei. In an attempt to determine the prevalence
of melioidosis in the tuberculosis (TB) patient cohort in Port Moresby, 1309 sputum samples from
529 patients were selectively cultured for B. pseudomallei; only 1/1309 was positive for B. pseudomallei [13].
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These studies confirm that melioidosis does exist in the urban capital but it is rare, despite the large and
increasing population and increasing numbers with risk factors such as diabetes and hazardous alcohol
use [15].
2.2. Melioidosis Hotspot: The Balimo Region of the Western Province, PNG
In contrast to the rare reports of melioidosis in Port Moresby, a focus of endemicity has been
reported and studied in the remote Balimo region of the Western Province. Following an unpublished
clinical report of melioidosis in this community in 1983 [16], two periods of active case detection
were conducted as part of a broader development of microbiology facilities in the 1990s. Over an
18-month period this resulted in the diagnosis of eight culture-conﬁrmed cases [17]. A feature of
the disease in this region is childhood predilection with chronic presentation, which can mimic TB.
Sero-epidemiology revealed a seroprevalence in some village communities as high as those in regions
in northern Australia. In the environment, particularly sites that children frequent, B. pseudomallei
was isolated (in 2.6% of 274 soil samples overall) [18]. Of 13 clinical and 26 environmental isolates
analysed, only three multi-locus sequence type (MLST)-derived genotypes have been described—the
most common being ST267, with the others (ST667 and ST668) differing from ST267 by only one SNP
in the ace gene [19]. Further phylogenetic analysis shows the origins of these isolates to be in the
Australian clade, yet some characteristics of the Asian isolates are also evident. It has therefore been
proposed that the ancient land mass that joined Australia and New Guinea 20,000 years ago during
the last ice age provided a land bridge, which may have facilitated movement of ancestral stains of B.
pseudomallei from Australia to Asia via PNG [19].
Since the late 1990s, further cases of suspected melioidosis from Balimo District Hospital have
been noted and some have been conﬁrmed with culture of B. pseudomallei. However, the majority go
unreported due to a downgrading of laboratory and clinical facilities over recent decades in Balimo as
in many other rural locations in PNG. This includes no resident medical staff being present in Balimo
and only sporadically-available bacteriological culture facilities. In this community the emergence of
multidrug-resistant tuberculosis has also complicated the clinical diagnosis of melioidosis. Only when
the diagnostic capacity for infectious diseases is improved will the true burden of melioidosis be
realised and managed in this community.
2.3. Elsewhere in Oceania
Since the ﬁrst description in Guam, melioidosis elsewhere in Oceania has been equally sporadic
and reports are opportunistic. Several cases in Australia have been attributed to infection acquired in
Fiji [20,21]. There is seroprevalence evidence from East Timor [22], but to date, no conﬁrmed culture of
B. pseudomallei. Only in New Caledonia has melioidosis been more thoroughly studied and reported.
Similar to in PNG, the ﬁrst melioidosis studies in New Caledonia were conducted and reported
by animal health workers [8]. The ﬁrst human case was reported in 1999 [9]; since then, 19 melioidosis
cases have been reported and studied [23–25]. As seems the case in PNG, melioidosis in New Caledonia
is mostly restricted to one regional province, although whether there are biogeographic, demographic,
or simply healthcare access factors at play can be only determined through a thorough and structured
epidemiological and environmental study across the dispersed islands of that nation. As in Australia
and other endemic regions, the most common presentation is community-acquired pneumonia, which
may mimic TB, yet 32% presented with chronic disease including skin lesions.
As is the case in the Balimo region of PNG, there is evidence in New Caledonia of a persistent,
dominant clonal strain as deﬁned by MLST, with ST292 being the most common in the highly-endemic
east coast region. All isolates analysed with MLST were shown to cluster—along with the other isolates
from Melanesia—within the Australian clade rather than the Asian clade [25].
In recent years there has been a cluster of fatal melioidosis cases on the island of Yap, located in
the Federated States of Micronesia (Figure 1) [26,27]. This is currently being investigated by the US
Centers for Disease Control.
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3. Current Recommendations and Availability of Measures against Melioidosis
The studies of melioidosis from isolated communities within this region highlight the difficulties in
diagnosing and treating melioidosis without appropriate laboratory and clinical facilities. It is likely—as
it almost certainly remains the case today in Balimo—that the disease carries very high mortality in such
circumstances. In many of these communities, the gold-standard parenteral antibiotics meropenem and
ceftazidime are not available. In these communities, cotrimoxazole or even chloramphenicol may be
the only available antibiotics for therapy of suspected or confirmed melioidosis.
4. Awareness of Melioidosis, and Current and Future Challenges
Melioidosis is not a notiﬁable disease in any country in Oceania outside Australasia; as a result,
the general awareness of the disease in this region is poor. With such limited data and such poor ability
to obtain quality data, it is therefore unwise to generalise regarding the signiﬁcance of melioidosis
in Oceania. However, the evidence so far gathered and reported suggests that melioidosis is rare in
urban centres, where microbiology facilities are able to detect the organism, but is likely to remain
undiagnosed in some rural communities that lack the healthcare systems needed to identify it. With the
development of an enhanced rural medical workforce plus laboratory facilities, perhaps including
the introduction of non-culture-based detection methods that do not rely on extensive laboratory
expertise, this may change. However, the burden of other diseases of public health importance such as
multidrug-resistant TB, may yet overwhelm these developing health systems.
The spatial clustering of clinical melioidosis linked to parameters of the environmental reservoir,
the diversity of the geography, and the limited ability to diagnose infection in this region, support the
need for the establishment of a systematic remote sensing study to predict, identify, and locate regions
that may harbour unrevealed melioidosis. Until these studies are conducted, melioidosis will remain
an under-recognised, enigmatic condition, with high mortality rates.
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Abstract: The ﬁrst documented case of melioidosis in the Philippines occurred in 1948. Since then,
there have been sporadic reports in the literature about travelers diagnosed with melioidosis
after returning from the Philippines. Indigenous cases, however, have been documented rarely,
and under-reporting is highly likely. This review collated all Philippine cases of melioidosis published
internationally and locally, as well as unpublished case series and reports from different tertiary
hospitals in the Philippines. In total, 25 papers and 41 cases were identiﬁed. Among these, 23 were
indigenous cases (of which 20 have not been previously reported in the literature). The most common
co-morbidity present was diabetes mellitus, and the most common presentations were pulmonary
and soft tissue infections. Most of the cases received ceftazidime during the intensive phase, while
trimethoprim-sulfamethoxazole was given during the eradication phase. The known mortality
rate was 14.6%, while 4.9% of all cases were reported to have had recurrence. The true burden of
melioidosis in the country is not well deﬁned. A lack of awareness among clinicians, a dearth of
adequate laboratories, and the absence of a surveillance system for the disease are major challenges
in determining the magnitude of the problem.
Keywords: melioidosis; Philippines; Burkholderia pseudomallei
1. Introduction and History of Melioidosis in the Philippines
Melioidosis, or Whitmore’s disease, is a potentially lethal infection caused by the Gram-negative
bacterium Burkholderia pseudomallei. Its clinical presentation is so diverse that the diagnosis relies
heavily on laboratory culture.
During the past few decades, melioidosis has emerged as an important public health concern,
especially in the South East Asian (SEA) region and northern Australia [1]. The increase in global
interest in the disease was a consequence of the rising number of reported cases, both within endemic
areas and among travelers, the occurrence of cases in areas not previously known to be endemic;
and also, its potential use as an agent of bioterrorism.
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After the disease was ﬁrst described by Alfred Whitmore and C.S. Krishnaswami in 1912 [1–3],
initially the majority of cases reported were from the SEA region. Reviews of the global distribution of
the disease showed that cases have been found in the tropical and subtropical regions, mainly between
20◦ north and 20◦ south of the equator—which includes the Philippines [2,4]. A recent modelling study
suggested that there could be as many as 9000 cases and 4500 deaths, due to melioidosis occurring in
the Philippines each year [5]. Certainly, nowhere near that number are being diagnosed, so how likely
is this to be true?
The ﬁrst documented case of human melioidosis in the Philippines occurred in 1948 in
a 25-year-old American soldier who presented with weight loss and symptoms of pneumonia.
Diagnosis was established through guinea pig inoculation of sputum and lymph node pus [6]. This was
not long after the disease had ﬁrst been recognized in countries like Vietnam [7] and Indonesia [8],
and before the ﬁrst indigenous case was described in Thailand [9]. However, in contrast to other SEA
countries, there has been little development with regards to deﬁning the epidemiology of the disease
in the Philippines. A further case in an American soldier was reported in 1957, although his illness had
started many years earlier, while he was stationed in the Philippines [10]. Sporadic cases were reported
thereafter in people who had either transited or stayed in the country. Some of these individuals also
had a history of travel to other parts of SEA, hence the evidence that the infection was acquired in the
Philippines was inconclusive [2]. However, in others, such as the ﬁrst case diagnosed in Taiwan in
1985, there was strong circumstantial evidence that infection was acquired in the Philippines during
a near-drowning incident in a river near Manila [11].
Cases have not been limited to humans: For example, an isolate from a horse from the Philippines
was included in a taxonomic study published in 1956, although no further clinical details are available
about this case [12]. Then in 1992, a number of primates imported from the Philippines to the
United Kingdom were involved in an outbreak of melioidosis [13]. However, there have been no other
cases among animals from the Philippines reported in the literature thereafter.
Indigenous cases, meaning those with no apparent travel history to other endemic areas, and who
were diagnosed and treated in the Philippines, had never been reported in the literature until 2002,
when a 49-year-old farmer from Bulacan in the Philippines presented with pain and swelling of the left
shoulder and was found to have melioidosis after Burkholderia pseudomallei was isolated from blood [14].
The second indigenous case, and the ﬁrst case published in an international journal, was reported
as recently as 2016 [15]. The patient was a farmer from Isabela with no history of travel outside the
country, who was diagnosed and treated in a hospital in Metro Manila.
The preponderance of reports of melioidosis among travelers from the Philippines, and the
paucity of indigenous cases, leads us to suspect that the disease is being grossly under-reported in the
country. This article describes the evidence for, and distribution of, melioidosis in the Philippines by
reviewing reports published in international and local publications and unpublished case reports that
were obtained from tertiary hospitals and local subspecialty organizations. These cases were examined
to determine common patient proﬁles, disease presentations, modes of diagnosis, treatment received,
and outcomes.
2. Materials and Methods
2.1. Review of Publications
Published reports citing cases of culture-conﬁrmed melioidosis from the Philippines were
collected. The melioidosis website (www.melioidosis.info) served as the main starting point for
the search, as it already contains a database of published case reports by country. In addition, PubMed
and Google Scholar were searched, using various combinations of keywords (and MESH terms,
where applicable) such as Philippines, Filipino, Southeast Asia, melioidosis, Whitmore’s disease,
Burkholderia pseudomallei, and Pseudomonas pseudomallei. The bibliography of each reference was
searched for further cases. Finally, the personal EndNote database of one of us (DABD) was searched
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for references that had been missed. From each reference, relevant information about each case was
extracted, such as age, sex, co-morbidities, risk factors, type of infection, mode of diagnosis, treatment
received, outcome, country where diagnosed, and year of diagnosis.
2.2. Collection of Locally Published and Unpublished Cases from the Philippines
Local medical journals and university papers available in the National Library of the Philippines,
different universities, and hospitals were searched for any mention of local cases of melioidosis.
Inquiries regarding cases of melioidosis were made to the Philippine Society for Microbiology and
Infectious Diseases, the Research Institute for Tropical Medicine, and other medical centers. Consent to
use the data was obtained from the authors of unpublished case series and reports that were collected.
3. Results and Discussion
A total of 25 articles, either single case reports or case series, describing culture-conﬁrmed
melioidosis in the Philippines were collected (Tables 1 and 2). Of these 25 papers, only 11 were listed
in the melioidosis.org database—although those not included had either been published or presented
at international conferences recently (between 2015 and 2017). This also included four unpublished
local reports which were obtained from different tertiary hospitals in Metro Manila. Only one of these
reports related to a case of melioidosis in an animal [13].
A total of 41 human cases was included in these articles, with 18 cases involving travelers and
23 indigenous cases. Among the indigenous cases, 20 were from the four previously unpublished
reports. Of these four unpublished papers, two were case series derived from a 3- to 5-year chart review
of patients that were culture-positive for B. pseudomallei from their respective institution, and the other
two were single case reports. Diagnosis was established via culture-based technique and VITEK among
indigenous cases. No additional molecular conﬁrmatory tests were performed for these specimens.
The patients were between the ages of 21 and 82 years, with a mean of 50.2 years (Table 3).
The patients were predominantly (85.4%) male. This is consistent with the epidemiologic data from
some other endemic areas [16–18]. Data on risk factors were limited, but only six patients were known
to be working in the agricultural sector. Geographical data were available for 20 indigenous cases,
where 11 were from areas with moderate to high rice production in the Philippines (Isabela, Pampanga,
and Bulacan). Figure 1 shows the geographical distribution of the reported cases in the Philippines,
and annual rice production per province. Although the number of cases in Metro Manila is inconsistent
with the expected high incidence of melioidosis among rice farmers, the authors suspected that these
patients had previous exposure to agricultural areas. In addition, the proximity and access to diagnostic
facility could have caused the relatively higher proportion of cases in Manila. All the indigenous cases
were diagnosed in tertiary hospitals in Metro Manila, which generally have better-equipped laboratory
and diagnostic facilities than most provincial hospitals, and it is likely that many patients are going
undiagnosed outside the city.
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Table 3. Summary of clinical characteristics of culture-conﬁrmed cases of melioidosis in the Philippines.
Clinical Characteristics Number of Cases
Mean Age 50.2
Sex
Male 35 (85.4%)
Female 6 (14.6%)
Comorbidities
Diabetes mellitus 24 (58.5%)
Cardiovascular disease 11 (26.82%)
Cancer 4 (9.76%)
Pulmonary tuberculosis 2 (4.9%)
Chronic kidney disease 1 (2.4%)
Drowning 1 (2.4%)
Heavy alcohol consumption 1 (2.4%)
Hyperlipidemia 1 (2.4%)
Osteoarthritis 1 (2.4%)
Organs involved
Pulmonary 22 (53.7%)
Soft tissue 12 (29.3%)
Hepatic 5 (12.2%)
Neurologic 4 (9.76%)
Splenic 2 (4.9%)
Mycotic aneurysm 2 (4.9%)
Osteomyelitis 1 (2.4%)
Positive cultures
Blood 17 (41.5%)
Respiratory (sputum) 16 (39.0%)
Abscess pus 7 (17.1%)
Wound swab/Tissue 3 (7.3%)
Synovial ﬂuid 1 (2.4%)
Outcome
Improved 22 (53.7%)
Relapsed 2 (4.9%)
Died 6 (14.6%)
No Data 5 (12.2%)
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Figure 1. Distribution of indigenous cases of melioidosis in the Philippines (reported from 2002 to 2016)
and the amount of rice production per province. Original image imported from: https://commons.
wikimedia.org/wiki/File:Philippine_provinces_Annual_Rice_Production_2015.png.
The most common co-morbidity was diabetes mellitus, comprising 58.5% of cases, followed
by cardiovascular disease (which includes hypertension and coronary artery disease) at 26.82%.
Diabetes mellitus is the most common co-morbidity and risk factor found in the literature [16,38,39].
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With the steadily increasing prevalence of type 2 diabetes in the Philippines [40], it is likely that the
incidence of melioidosis will increase correspondingly.
Pneumonia and soft tissue infection were present in 53.7% and 29.3% of cases respectively,
which again is consistent with the melioidosis literature from elsewhere [17]. Pulmonary diseases,
particularly pneumonia, chronic lower respiratory tract diseases, and tuberculosis, are among the
top 10 causes of mortality in the Philippines [41]. Since melioidosis may be difﬁcult to differentiate
from other respiratory diseases, it is possible that many cases labelled simply as ‘pneumonia’ or
other respiratory infections may actually have melioidosis. A high index of suspicion, and good
laboratory support, are necessary to make a speciﬁc diagnosis of melioidosis. Furthermore,
co-infection with B. pseudomallei and Mycobacterium tuberculosis was seen in two patients in this review,
which presents a further diagnostic and therapeutic challenge to clinicians. Other than pulmonary
cases, four neurological cases were reported among indigenous cases. Although, conclusions could
not be drawn, due to limited number of cases, this should be subject for further investigation if this
type of melioidosis occur more frequently in the country.
All cases were diagnosed by culture studies. Bacteremia was found in 41.5% of cases.
The most common antibiotic used were ceftazidime and trimethoprim-sulfamethoxazole for the
intensive phase and eradication phase, respectively. Most of the cases received the recommended
antibiotic treatment for melioidosis [42] such as ceftazidime (43.59%), meropenem (12.82%),
trimethoprim-sulfamethoxazole (53.84%), and amoxicillin-clavulanic acid (5.13%). Those treated
with different antibiotics were cases diagnosed earlier than 1990s, and those indigenous cases which
followed the result of the antibiotic sensitivity test. The reported recurrence rate among all cases were
4.9%, while the mortality rate was 12.6%. This, however, could be an underestimate due to lack of data
and follow-up.
Failure to consider melioidosis, which requires speciﬁc treatment, may be contributing
to the continued high mortality from pulmonary diseases in the Philippines. Local clinical
guidelines do not include ceftazidime and meropenem as empiric treatment unless classiﬁed as
high-risk community-acquired pneumonia, healthcare-associated pneumonia, or those at risk for
multidrug-resistant organisms.
4. Challenges
The greatest challenges for the Philippines are to raise awareness of melioidosis amongst clinicians
and laboratory staff, and to improve the availability of facilities capable of making a laboratory
diagnosis of the disease. During our enquiries with colleagues and local institutions about case reports,
many of those who responded admitted to being unfamiliar with melioidosis. Also, melioidosis is
rarely included in the curriculum of medical schools within the Philippines. It is notable that the
majority of the earlier cases in this series were diagnosed in travelers to other countries, albeit only
21 cases occurring over 70 years, implying considerable under-diagnosis of indigenous cases. However,
there are some encouraging signs, particularly, the fact that four unpublished reports, comprising
20 indigenous cases seen over a relatively short span of seven years, were identiﬁed. This suggests an
increasing awareness of the disease among physicians, resulting in improved diagnosis and reporting.
However, these were all diagnosed in Metro Manila, which is unlikely to be the area of highest
incidence in a country where the environment is predicted to be widely suitable for B. pseudomallei [5],
and the incidence of melioidosis in more rural areas requires further investigation. Areas such as
those in Mindanao, which are a highly rural area, post additional challenge since access to health care
facilities is another existing issue. However, this will require the strengthening of medical laboratories
in these areas, and education of staff in how to detect and identify B. pseudomallei.
Although the most common presentation of B. pseudomallei infection is pneumonia,
the 2016 community-acquired pneumonia (CAP) guidelines in the Philippines do not even mention
melioidosis as a differential diagnosis. There is no national surveillance system for melioidosis, nor is
the disease included in the list of notiﬁable disease in the Philippines [43].
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5. Conclusions and Recommendations
This report highlights the fact that melioidosis is indeed endemic in the Philippines but is likely
to be grossly under-reported. The clinical and epidemiological characteristics of the disease in the
Philippines, albeit based on limited data, are consistent with those described in published literature
from other countries. Furthermore, the data show that this condition has been successfully diagnosed
and treated in the country with increasing frequency over the past few years.
Further studies should be done on the extent and impact of this disease within the country. It is
recommended that a program of education of clinicians and laboratory staff about melioidosis should
be initiated, ideally starting at medical schools, and especially targeted at rural areas that are likely
to have the highest incidence of melioidosis. Furthermore, consideration should be given to making
the disease statutorily notiﬁable. This would provide more accurate information about the clinical
characteristics and distribution of the disease within the Philippines. Soil sampling studies should
also be undertaken in order to establish the geographic distribution of this microorganism, as well as
enable analysis of the population structure. Genotyping of bacterial isolates are in progress in order
to determine if indigenous strains were different than those identiﬁed elsewhere in Southeast Asia
or Australia. Studies should also be undertaken to describe the current knowledge and attitudes of
Filipino clinicians regarding melioidosis.
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Abstract: Melioidosis is a notiﬁable infectious disease registered with the Ministry of Health (MOH)
and Agri-Food & Veterinary Authority (AVA), Singapore. From a clinical perspective, increased
awareness of the disease has led to early detection and treatment initiation, thus resulting in
decreasing mortality rates in recent years. However, the disease still poses a threat to local pet,
zoo and farm animals, where early diagnosis is a challenge. The lack of routine environmental
surveillance studies also makes prevention of the disease in animals difﬁcult. To date, there have
been no reports that provide a complete picture of how the disease impacts the local human and
animal populations in Singapore. Information on the distribution of Burkholderia pseudomallei in
the environment is also lacking. The aim of this review is to provide a comprehensive overview of
both published and unpublished clinical, veterinary and environmental studies on melioidosis in
Singapore to achieve better awareness and management of the disease.
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1. Introduction
Melioidosis is an infectious disease associated with high mortality and morbidity in endemic
regions of Southeast Asia and northern Australia [1]. The etiological agent, Burkholderia pseudomallei,
can be found in the soil and water in these endemic regions. Infection generally occurs through
inhalation, ingestion or contact of skin wounds with contaminated soil, dust particles or water [2].
Melioidosis, also known as the great mimicker, can result in highly diverse disease manifestations,
often complicating diagnosis and delaying treatment [3–6]. Other than humans, B. pseudomallei can also
infect a wide range of animals including goats, sheep, camels, birds, crocodiles, kangaroos, etc. [7,8].
The zoonotic potential of B. pseudomallei (Bp) has also been reported [7,9]. Due to the hardy nature
of the bacterium, it is able to survive in the most nutrient-limiting environments, such as distilled
water [10,11].
The ﬁrst case of melioidosis in Singapore was reported in 1920 [12]. Since the 1980s, rapid
urbanization has occurred within the country, and today it is mainly dominated by high-rise buildings
and well-developed infrastructure. However, despite its urbanized setting, melioidosis still exists in
Singapore, with an overall annual incidence of 0.6–2.4 per 100,000 of the population between the years
2000 and 2015, as reported by MOH [13]. Furthermore, animal cases of melioidosis were reported as
early as in the 1980s by AVA (formerly called Primary Production Department). In this review article,
we describe the clinical, veterinary and environmental aspects of melioidosis in Singapore.
2. Clinical Aspects
2.1. Disease Epidemiology
Prior to 1989, there were only two published reports on the epidemiology of the disease in the
country. Tan et al. (1990) [14] reported a sudden increase in the number of cases from 5 cases in 1987 to
36 and 24 cases in the years 1988 and 1989, respectively, and attributed the increase to the generation
of infective aerosols as a result of soil excavation activities conducted around the island. The disease
was also a concern among healthy military personnel due to involvement with soil-related training
programs during these early years. Between 1987 and 1994, 23 cases (including 4 fatal cases) were
reported [15].
Three separate studies addressing the epidemiology of melioidosis were conducted, from 1989 to
1996, 1998 to 2007, and 2003 to 2014 [16–18]. The mean annual number of melioidosis cases reported
during these three study periods were 46, 70, and 44, respectively. The higher mean annual number
observed during the period from 1998 to 2007 was related to a melioidosis outbreak in 2004, which was
associated with higher-than-average rainfall [17]. A molecular typing study conﬁrmed that this 2004
outbreak was caused by highly heterogeneous B. pseudomallei isolates, rather than a single virulent
strain [19]. In the last-mentioned epidemiological study, spanning 2003–2014, a progressive 10%
reduction in the incidence of melioidosis cases was noted. However, the last 2 years (2015–2016) have
seen a rise in the number of melioidosis cases diagnosed (Figure 1). The early case-fatality rate, as
exempliﬁed by the 98 cases that occurred during the 2004 surge, was 52.6% [17]. The mortality rate has
since fallen to 18.4%, possibly as a result of increased disease awareness and earlier recognition by
clinicians, and prompt institution of deﬁnitive antimicrobial treatment.
In Singapore, the recent overall annual melioidosis incidence rate was 1.1 per 100,000 population.
The incidence rate was higher in those of Malay and Indian ethnicity (2.4 and 2.1 per 100,000
respectively) [18]. Males were predominantly affected, which can possibly be attributed to their
involvement in outdoor occupational or recreational activities [16–18]. Systemic melioidosis primarily
affects older individuals with underlying medical conditions, with the highest disease incidence rate
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being reported in the population cohort ≥45 years of age. Diabetes mellitus is the key co-morbidity,
reported in 47.9% to 56.7% of the diagnosed cases [16–18]. Patients with renal impairment were also at
higher risk of infection.
 
Figure 1. Annual number of human melioidosis cases from 2003 to 2016 in Singapore.
2.2. Clinical Features of Melioidosis Patients
In Singapore, the major systemic presentations of melioidosis are bacteraemia (60.3%), deep organ
abscesses (40.7%) and pneumonia (33.1%) [18]. In contrast to B. pseudomallei bacteraemia cases, the
incidence of cases presenting as pneumonia is on the decline. Conventionally, antimicrobial regimens
containing B. pseudomallei-active agents (e.g., ceftazidime or a carbapenem) have been utilized for
treatment of severe community-acquired pneumonia in Singaporean intensive care units. For deep
abscesses, the primary organs involved are liver, prostate and spleen, and these are often seen in
patients with poorly-controlled diabetes. The incidence of deep organ abscesses appears to be on the
rise [18,20,21]. Localized soft tissue infections have been seen, and some of these cases may be linked
to local trauma or inoculation. These patients often do not have diabetes or compromised immunity,
in contrast to the patients with bacteraemia or deep abscesses.
Singapore has also seen its share of melioidosis cases with uncommon clinical presentations. For
example, in 2006, there was a case of melioidosis osteomyelitis reported in a 32-year-old diabetic man,
who also had infection in the spleen and liver [22]. In another case, a 37-year-old Italian man possibly
acquired melioidosis through inhalation of dust generated by helicopter rotor blades during business
travel to Singapore. He developed bacteraemia, pneumonia, splenic abscess and osteomyelitis of the
head of humerus [23].
Involvement of the cardiovascular system, a rare occurrence associated with high morbidity and
relapse rates, has also been observed in melioidosis cases in Singapore [24]. Rao et al. (2009) [25]
reported two cases presenting with abdominal aortic pseudo-aneurysms requiring both medical and
surgical intervention, with only one surviving. A relapsing case of meningitis caused by B. pseudomallei
following inadequate treatment of the primary episode of melioidosis mycotic aneurysm was also
reported by Chlebicki et al. (2008) [26]. Between 1997 and 2000, ﬁve cases presenting with brain abscess
were also reported [27]. Successful treatment was achieved with drainage coupled with antibiotics,
although two of the cases failed to achieve complete neurological recovery [28].
2.3. Diagnosis
In Singapore, the reference standard for the diagnosis of melioidosis is based on the culture of
B. pseudomallei from clinical specimens [3,29], along with relevant clinical presentations. Biochemical
tests including API 20NE (bioMerieux, Lyon, France) and Vitek 2 GN card (bioMerieux, Lyon, France)
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are also conducted to conﬁrm the biochemical properties of the isolated B. pseudomallei. Since the
occurrence of 4 deaths in 23 melioidosis cases among apparently young and healthy military personnel
between 1987 and 1994, melioidosis has been a priority consideration for Singapore’s clinicians [15,30].
Risk factors including activities entailing soil and water contact, as well as underlying co-morbidities
such as diabetes and renal disease, will also raise diagnostic concerns among the clinicians [31].
A disadvantage of culture-based diagnosis is the delay of some days. Molecular methods such
as Bp-speciﬁc polymerase chain reactions (PCR) targeting bacterial DNA fragments provide rapid
diagnosis for melioidosis, but are not routinely used in local clinical laboratories and the sensitivity of
PCR can be low, especially with blood specimens [32,33]. While a serological test alone cannot offer
a deﬁnitive diagnosis of melioidosis, especially in endemic areas [34], seropositivity is an indicator
of exposure to B. pseudomallei. The most commonly used serological test for a melioidosis diagnosis
is indirect hemagglutination assay (IHA), which has been well evaluated and accepted since it is
cost-effective and has a short turnaround time, although in other countries it has been reported to lack
both sensitivity and speciﬁcity [3].
In Singapore, the IHA with a cut-off ratio of ≥1:16 for seropositivity was ﬁrst established by Yap et
al. (1991) [35]. The DSO Clinical Diagnostic Services Laboratory (CDSL) has been ISO15189 accredited
for performing the IHA test to facilitate melioidosis diagnosis for local samples. The laboratory
has conducted IRB-approved studies (Singhealth Centralized Institutional Review Board, DSO IRB
committee) and performed IHA tests on serum samples collected from culture-conﬁrmed melioidosis
cases, clinically unconﬁrmed cases, and healthy volunteers from 2004 to 2016. Based on unpublished
data (Table 1), it has been observed that all of the culture-conﬁrmed melioidosis cases were also positive
by IHA, 54.8% with very high (≥1:512) and 38.7% with high (1:128 to 1:256) titers. In contrast, the
two large cohorts (992 and 1027 cases) with suspected melioidosis or clinically unconﬁrmed infection
were mostly negative in the IHA test (89.4% and 86.5%, respectively). Furthermore, of 109 healthy
volunteers, 23 (21.1%) had low positive results (1:16 to 1:64) and one subject (0.9%) was highly positive
with an IHA titer of 1:128, suggesting previous exposure to B. pseudomallei, possibly due to engagement
in prior outdoor activities. The IHA is thus considered more useful in Singapore than elsewhere, and
those with high or very high IHA titers are considered likely either to be melioidosis cases with active
Bp infection or individuals who have had prior exposure to B. pseudomallei.
Table 1. IHA results on serum samples collected from culture-conﬁrmed melioidosis patients, suspected
melioidosis cases presenting to local hospitals and healthy volunteers from 2004 to 2016 [36].
Study Groups Subject Information/Year of
Blood Collection
Number (%) of Subjects with Different Levels of IHA Titer
Very High
Positive
≥1:512
High Positive
1:128 to 1:256
Low Positive
1:16 to 1:64
Negative
≤1:8
Culture-conﬁrmed
melioidosis (n = 31)
Acute, relapsed and recovered
cases with a mean age of 52.5
years old/2004–2013
17 (54.8%) 12 (38.7%) 2 (6.5%) 0 (0%)
Clinically
unconﬁrmed
infection (n = 992)
Patients with an active
infection/2006 31 (3.1%) 21 (2.1%) 54 (5.4%)
886
(89.4%)
Clinically
unconﬁrmed
infection (n = 1027)
Patients with an active
infection/2016 18 (1.8%) 20 (1.9%) 101 (9.8%)
888
(86.5%)
Healthy volunteers
(n = 109)
Age range: 18–60 mean age:
33.1 years old/2004–2013 0 (0%) 1 (0.9%) 23 (21.1%) 85 (78.0%)
2.4. Treatment
Clinicians in Singapore, particularly physicians, intensivists and emergency department
specialists, have melioidosis in mind early when a suspicious clinical pattern presents. Empiric
antibiotics are generally started pending culture results. Hence, ceftazidime or a carbapenem are
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featured in local empiric antibiotic guidelines for severe community-acquired pneumonia for this
reason. The treatment for melioidosis in Singapore is conducted in accordance with international
guidelines, consisting of an initial intensive phase followed by an extended eradication phase [37].
As initial empiric therapy for suspected melioidosis or for intensive phase treatment for conﬁrmed
melioidosis, either ceftazidime or meropenem is administered intravenously. The duration of treatment
for the intensive phase is at least 2 weeks. Some clinicians may extend treatment duration to
4 weeks or beyond, in circumstances such as multiple large deep organ abscesses or extensive
multi-lobar pneumonia. In addition, while not in the standard guidelines, some physicians also
add oral trimethoprim-sulfamethoxazole during the intensive phase for the perceived beneﬁt of good
penetration into deep organs and lungs as well as the anecdotal emergence of ceftazidime resistance,
despite the fact that such a practice has not been proven to be more efﬁcacious [38]. The eradication
phase is long, lasting at least 3 months, and consists of oral trimethoprim-sulfamethoxazole as
the backbone of therapy. Locally, some physicians may opt to add in a second agent, either
amoxicillin-clavulanate or doxycycline, in addition to trimethoprim-sulfamethoxazole. Drug tolerance
is always a concern during the extended treatment periods, and so close follow-up is advised.
In addition, due to the high prevalence of glucose-6-phosphate dehydrogenase (G6PD)-deﬁciency in
this region, G6PD screening is advised before commencement of trimethoprim-sulfamethoxazole.
For patients who are intolerant or who have known sulfonamide allergy, the combination of
amoxicillin-clavulanate plus doxycycline is used, although this regimen is perceived to be less
efﬁcacious than one containing trimethoprim-sulfamethoxazole. Eradication therapy is considered
adequate and ceases when follow-up clinical, radiological and biochemical (e.g., inﬂammatory markers
such as C-reactive protein) assessments document complete resolution. Otherwise, the eradication
phase treatment may be extended beyond 3 months. In some circumstances (e.g., disease complexity
or drug allergy), treatment may deviate from the standard antibiotic regimens [31]. In Singapore,
antibiotic susceptibility testing is routinely performed on B. pseudomallei, with alternative antibiotics
used when resistance to the standard antibiotics is detected. In 2010, Kung et al. [39] reported a
patient with mediastinal lymphadenitis, who developed resistance to ceftazidime during the course
of treatment. One of us has managed another patient with melioidosis, whose isolate developed
ceftazidime resistance on treatment, in 2008 [40]. The patient relapsed with overwhelming bacteraemia
and rapidly demised, prompting some clinicians to favor initial antibiotic therapy with a combination
of two active antibiotics.
The management of deep organ abscesses is challenging. There is a need to ensure adequate drug
penetration into the abscess cavity for adequate treatment, often necessitating an extended duration
of treatment. To reduce the microbial burden, some local clinicians advocate radiologically-guided
drainage of abscesses, where possible, especially in the liver and prostate. The rationale for such
an invasive procedure is multi-fold: (i) for diagnostic microbiological conﬁrmation of the disease,
(ii) for B. pseudomallei susceptibility testing, (iii) to reduce the microbial burden, and (iv) to shorten
treatment duration.
For severe septic melioidosis cases, in addition to antibiotic therapy, treatment in an intensive care
unit (ICU) with strict glycemic control [41] is also employed to improve the outcome [31]. Careful use
of anti-diabetic therapy in diabetic patients with septic melioidosis is recommended, and a recent study
by Liu et al. (2014) [42] highlighted the occurrence of more severe complications in diabetic patients
receiving sulphonylurea due to the suppression of the host inﬂammatory response by the drug.
3. Veterinary Aspects
3.1. Prevalence and Surveillance of Animal Melioidosis
Singapore has a diverse population of animals. For livestock animals, there are a total of 5 poultry
layer farms, 4 dairy (3 cattle and 1 goat) farms, 220 ﬁsh farms (food and ornamental) and 11 horse
establishments (racing and equestrian) [43]. As of 2016, the pet population, comprising dogs, cats,
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birds, ﬁsh, and small mammals, is estimated to be 780,100 [44]. In addition, there is a zoological
collection of 16,134 animals, consisting of 949 different species of Pisces, Amphibia, Reptilia, Aves and
Mammalia in Wildlife Reserves Singapore (WRS).
In Singapore, animal melioidosis cases are notiﬁable to AVA. To date, AVA has documented 454
conﬁrmed melioidosis cases between 1983 and 2016, comprising isolates from wild animals (including
the zoo animals at WRS), pet animals from local veterinary clinics, farm animals, and the environment,
such as outdoor multipurpose ﬁelds and ponds. At WRS, 37 sporadic cases in 26 animal species were
documented between 1983 and 2017 (Table 2). Notably, gorillas appeared to be highly susceptible to
melioidosis. In 1984, a total of 4 imported gorillas (2 from Monaco and 2 from Bristol zoo, imported
between 1982 and 1983) succumbed to melioidosis. Additionally, of another 2 gorillas imported
from Dublin zoo in 1992, one succumbed to melioidosis six months after importation. The other was
subsequently returned to Dublin zoo in 1993. B. pseudomallei was cultured from various organs of these
ﬁve deceased gorillas (Table 2). It was postulated that various factors, including social dynamics, diet
and housing, had resulted in increased susceptibility of these gorillas to B. pseudomallei infection.
Clinical signs can differ within each animal species, depending on the site of infection [45]. Based
on past observations, the ﬁrst clinical signs in infected animals were non-speciﬁc and consisted of
inappetence, lethargy and diarrhea. In some cases, infected animals can even succumb to infection
within one or two days without showing visible signs of disease.As previously reported, one key
feature of animal melioidosis was the formation of abscesses in one or multiple organs [7,46]. At WRS,
the most common sites of lesions in infected animals were the liver (Figure 2) and lungs (Figure 3).
Lung lesions were more commonly seen in primates [47], whereas liver lesions were more common
among the avian cases (78%). It is also interesting to note that lung lesions have never been seen in the
avian cases.
With the increase in global trade of animals for food, zoological exhibitions and as pets,
importation and movement of subclinically-infected animals poses a signiﬁcant risk to local animal
populations due to the propensity of B. pseudomallei for long latency periods. These animals can shed
B. pseudomallei in their faeces or through ruptured abscesses during the stressful transport process and
change in environment, which might serve as a source of infection or environmental contamination
when they are in close contact with naïve animals [48,49].
There is no formal active surveillance program for melioidosis in local pet, zoo or farm animals.
In Singapore, farm animals are mainly reared for dairy products and eggs, and are not slaughtered for
meat. In addition, only pasteurized milk is allowed to be sold for consumption. To date, there has only
been a single instance in which B. pseudomallei was isolated from the spleen of a clinically healthy dairy
goat from a local farm in 2014. However, subsequent sampling of the goats in the farm did not yield
any positive cases. As part of Singapore’s food safety program, AVA conducts post-mortem inspection
on imported livestock, i.e., pigs and accompanying viscera (spleen, liver, kidneys) at the local pig
abattoir. The inspection involves visual checks, palpation and, where necessary, incision to check for
abnormalities, including abscesses. Carcasses and viscera with multiple abscesses/pyemia will not
enter the food chain, as they will be condemned and subsequently incinerated if the examination
ﬁndings are consistent between AVA inspectors and Supervising Inspectors (SI). In addition, AVA
conducts regular microbiological surveillance on the condemned carcasses and viscera (liver, lymph
node, lung, spleen and kidney), which includes B. pseudomallei culture, to monitor the health status of
imported livestock. From January 2008 to December 2016, a total of 1696 samples were collected, of
which 341 (20%) were positive for B. pseudomallei. Thus, the risk of transmission from infected animals
to humans through the consumption of meat and animal products would be deemed negligible.
Ongoing work is being done to analyze the strains isolated from animals. The local farms also
have good animal husbandry practices in place and are required to report any abnormal clinical signs
observed. Furthermore, the health status of farm animals is also inspected regularly by AVA. These
additional measures provide some forms of surveillance for any ﬁrst signs of disease in farm animals.
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Figure 2. Multifocal abscess (black arrows) in the liver of a Douc langur with melioidosis.
 
Figure 3. Large abscess in the left caudal lung lobe (black arrow) of a Douc langur with melioidosis.
3.2. Laboratory Diagnosis for Animal Melioidosis
The diagnosis of melioidosis in animals requires the isolation and identiﬁcation of B. pseudomallei,
usually from swabs or abscesses from affected organs. Diagnosis of the reported animal cases is
usually obtained through post-mortem examination, unless the presenting clinical sign is a lesion on
the skin, as observed in a Chinese goral (Naemorhedus griseus) in 2008. Upon detection of the disease,
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environmental sampling from the surrounding soil and water where the animals reside is conducted
as part of the investigation procedure for source attribution.
In all cases, the standard Ashdown media or modiﬁed Ashdown broth containing colistin and
crystal violet [51] are used for the isolation of B. pseudomallei. Further conﬁrmation is achieved through
phenotypic characterization using biochemical tests, including the API 20NE kit or Vitek GN card,
and genotypic characterization using B. pseudomallei-speciﬁc real-time PCR [52].
3.3. Treatment and Prevention of Melioidosis in Zoo Animals
In Singapore, animals suspected of having melioidosis are generally given supportive treatment,
which may include ﬂuid therapy, anti-inﬂammatories and antibiotics. In the four parks managed
by WRS, as a preventive measure against melioidosis, proper water hygiene and environmental
surveillance are conducted to identify for the presence of B. pseudomallei in the exhibit areas.
Quarterly environmental sampling is conducted before introducing susceptible species into the parks.
For instance, between February 2016–2017, a total of 450 soil samples and 54 water samples were
collected from four sites, namely the Butterﬂy Park, Kidzworld, Chimpanzee Exhibit and Polar
Bear Exhibit. All samples were negative for B. pseudomallei by both culture and real-time PCR.
The Chimpanzee Exhibit was positive for B. multivorans in May 2016, but subsequent soil and water
samples collected from the same site were negative for the bacterium.
4. Environmental Melioidosis
4.1. Prevalence and Environmental Surveillance of B. pseudomallei
For a country long known to be endemic for melioidosis, Singapore has surprisingly few
publications on the isolation, distribution, prevalence and spread of the pathogen in the local
environment. After the ﬁrst case of melioidosis in 1920 [12], the next report on environmental isolation
of B. pseudomallei was in 1971 [53]. In this study, 8 of the 136 surface water samples collected within
the city of Singapore were positive for B. pseudomallei (isolation rate of 5.9%) (Table 3). In 1995,
Yap et al. [54] documented the recovery of 3 isolates from water samples collected from a moat within
an animal enclosure in Singapore Zoological Gardens (now known as WRS), where the gorillas had
earlier succumbed to melioidosis. Additionally, two soil isolates were obtained from an island off
mainland Singapore where two fatal human cases of melioidosis had been reported, and one isolate
from a residential compound where a pet German shepherd dog had died (Table 3) [54]. To date, the
most extensive environmental surveillance of B. pseudomallei in Singapore involved the collection of
395 soil samples during the period 1992 to 1996 for epidemiological investigation of the disease [16].
Seven of the soil samples obtained from 3 different sites were positive for the pathogen (Table 3) [16].
Between 2000 and 2013, DSO National Laboratories executed a number of projects on
environmental surveillance of B. pseudomallei (unpublished) (Table 4). One of these environmental
surveillance studies was conducted in the island off mainland Singapore where Yap et al. (1995) [54]
had previously reported the isolation of B. pseudomallei. Among the 188 soil samples collected from
ﬁelds, plantations and reclaimed lands (n = 98, 62 and 28, respectively), and 16 water samples from
streams or puddles, 3 soil samples from plantations (4.8%) and 2 water samples (12.5%) were positive
for B. pseudomallei. In 2001, through collaborative efforts with WRS and Prof Paul Ananth Tambyah
from the National University Hospital (NUH), 43 soil samples and 3 water samples were collected
from 3 animal enclosures. No B. pseudomallei was isolated.
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Between 2003 and 2005, environmental surveillance of B. pseudomallei was carried out at 9 locations
on mainland Singapore and 731 soil samples were collected. Two of these locations (Park C and Park
D) tested positive for B. pseudomallei, with isolation rates of 1.0% and 3.3%, respectively (Table 4). Data
from a subsequent surveillance project carried out from January to April 2013 showed that the isolation
rate of B. pseudomallei from soil samples collected from a forested hill in a southern island off Singapore
was 1.8%. However, rainwater and water samples collected from run-off from the forested hill were
negative for B. pseudomallei (Table 4).
It is worth noting that environmental surveillance studies to identify the source of infection are
confounded by the small area of Singapore, and the movement of the general population all over the
island. In addition, technical and funding issues, and the difﬁculty in getting approval from regulatory
bodies and private institutions have also hindered these environmental surveillance studies.
4.2. Detection of B. pseudomallei in Environmental Samples
Optimizing protocols for sample collection and laboratory processing for the isolation and
identiﬁcation of B. pseudomallei is one of the many technical challenges faced in environmental
surveillance studies. Due to the diverse range of colony morphotypes of B. pseudomallei when
cultured on Ashdown agar, considerable expertise is required for visual identiﬁcation of the bacterial
colonies [57]. The hamster inoculation method used by Thin et al. (1971) [53] is a long and tedious
process, making it challenging to sample extensive areas and collect large numbers of samples.
Similarly, Yap et al. (1995) [54] adopted a ‘small and sampling-biased’ approach in their study,
thus limiting the extent of sampling area.
Following the dissemination of an internationally-recognized SOP for environmental sampling of
B. pseudomallei by the Detection of Environmental Burkholderia pseudomallei Working Party (DEBWorP)
in 2012, samples could be collected systematically and processed more efﬁciently [58]. Using this SOP,
DSO embarked on an extensive island-wide environmental surveillance project for comprehensive
understanding of the distribution, prevalence, spread, and characterization of environmental
B. pseudomallei in the Singapore environment (manuscript in preparation). Moreover, with the recent
success of the air sampling methodology reported by Currie et al. (2015) [59], we will be reassessing
our air sampling protocols to increase our chances of isolating the pathogen from the air in Singapore.
4.3. Correlation between Environmental Isolates and Animal/Clinical Isolates
There have so far been few successes in directly correlating clinical isolates with environmental
isolates in the Singapore context. Using restriction endonuclease (RE) analysis with pulsed-ﬁeld gel
electrophoresis (REA-PFGE), Henget al. (1989) [16] reported that the genotype of B. pseudomallei
isolated from 4 soil samples in a locality was similar to that isolated from an elbow abscess of an adult
who sustained an injury at the location. However, Yap et al. (1995) [54] reported that the genotypes
of clinical isolates from 2 patients who died of melioidosis whilst staying in an island off Singapore
did not match those recovered from the soil. Instead, the study had more successes with animal
isolates—restriction endonuclease proﬁles of B. pseudomallei isolates obtained from infected gorillas in
Singapore Zoological Gardens matched the isolates obtained from the surrounding moat of the animal
enclosure. In addition, a soil isolate obtained from a residential compound matched the genotype of an
isolate from a pet German shepherd dog that succumbed to the disease [54] (Table 3). It is likely that
the relatively smaller and well-deﬁned boundaries of the animal enclosure and residential compound
increased the chances of locating the environmental source.
Advanced technologies, such as microarrays and multi-locus sequence typing (MLST) have
allowed more detailed study of the clinical, animal and environmental B. pseudomallei isolates in
Singapore. Sim et al. (2008 [47] performed high-resolution comparative genomic analysis to determine
the relatedness of 94 B. pseudomallei isolates from Southeast Asian origins, and demonstrated a core
genome and an accessory genome comprising of 86% and 14% of the genes (respectively) in the
Bp K96243 genome. Of these isolates, 68 were isolated from clinical (n = 35), animal (n = 17) and
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environmental (n = 16) sources from Singapore. Bp 22, isolated from a fatal melioidosis case in a young
and healthy individual in the 1980s, was amongst the clinical isolates studied. Seven environmental
B. pseudomallei isolates, including Bp DB and Bp DC [54], Bp 12-40, Bp 15-10, Bp 15-40, Bp SW1 and
Bp SW 9 isolated by DSO National Laboratories (herein referred as DSO isolates for easy reference),
were obtained in the vicinity of the origin of Bp 22. Unsupervised clustering of the accessory genomes
showed that Bp 22 and the DSO isolates belonged to a broad ‘Environmental’ cluster [47]. Interestingly,
Bp DB and Bp DC did not cluster together with the ‘Environmental’ isolates, but belonged to a broad
‘Animal’ cluster, instead [47] (Table 5). The results achieved with MLST analysis of these isolates was
in alignment with the genome clustering data, with Bp 22 and the DSO isolates belonging to ST423,
and Bp DB and Bp DC belonging to ST51 (Table 5) [60].
Table 5. Correlation of clinical and environmental B. pseudomallei isolates from an island off
Singapore [61].
Isolate Source Isolated by Accessory GenomeClade [47]
Sequence
Type (MLST)
[60]
Genomic
Clade
(WGS) [60]
22 Human, clinical Yap et al. (1995) [54] Environmental clade ST423 N.D.
DB Soil, environmental Yap et al. (1995) [54] Animal clade ST51 A
DC Soil, environmental Yap et al. (1995) [54] Animal clade ST51 A
15-10 Soil, environmental DSO 2000/01 Environmental clade ST423 B
15-40 Soil, environmental DSO 2000/01 Environmental clade ST423 B
12-40 Soil, environmental DSO 2000/01 Environmental clade ST423 B
SW1 Water, environmental DSO 2000/01 Environmental clade ST423 B
SW9 Water, environmental DSO 2000/01 Environmental clade ST423 B
Furthermore, using whole genome sequencing (WGS), which provides a higher resolution of
isolate matching, the seven environmental isolates were resolved into 2 clades: Clade A, which
comprised Bp DB and Bp DC; and Clade B, which was made up of DSO isolates [60]. Unfortunately,
the clinical isolate, Bp 22, was not included in this study. To examine the relatedness of Bp 22 with
DSO isolates, the genome sequence of Bp 22 was obtained from a DSO in-house sequencing project
and compared with the genome sequences of the seven environmental isolates. Using Phylogenetic
Tree Building Service by PATRIC v3.5.7 (https://www.patricbrc.org/app/PhylogeneticTree), we
determined that Bp 22 was indeed closely related to the 5 DSO isolates and was distinctly different
from Bp DB and Bp DC (Figure 4).
Figure 4. Whole genome phylogeny tree of clinical and environmental isolates from same locale in
Singapore. Phylogenetic tree generated using Phylogenetic Tree Building Service by PATRIC v3.5.7
(https://www.patricbrc.org/app/PhylogeneticTree), depicting the relationships of the clinical isolate
Bp22 and environmental isolates obtained from an island off Singapore. Bp K96243 was included as a
reference isolate.
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4.4. Characterization of Environmental B. pseudomallei Isolates from Singapore
While much attention has been paid to characterization of clinical isolates, the environmental
isolates from Singapore have been largely neglected in most studies. The antibiograms of
clinical isolates from Singapore have been investigated in detail in various studies, reporting
consistent susceptibility to ceftazidime, imipenem, amoxicillin-clavulanate, chloramphenicol and
tetracycline [14,62,63]. Unfortunately, similar studies of environmental B. pseudomallei isolates has
not been conducted. Currently, there are only a few studies of the virulence and pathogenesis of
environmental isolates. Lee et al. (2010) [64] reported the successful infection of tomato plants by two
local soil isolates (Bp 77/96 and Bp 109/96). However, these B. pseudomallei isolates did not infect
rice plants.
In terms of genome characterization of environmental isolates, the most extensive study was
reported by Nandi et al. (2015) [60] involving WGS of more than 100 B. pseudomallei genomes, including
13 local environmental isolates. These 13 isolates were collected from various sites in Singapore and
belonged to only three sequence types (STs), namely ST51, ST300 and ST423 (n = 7, 1 and 5 respectively),
hence implying a much lower diversity than in Thailand, where nine STs could be identiﬁed from a
single sampling site [65].
5. Conclusions
In recent decades, in the clinical setting in Singapore, melioidosis has gained considerable
notoriety, with early disease consideration and improved management practices resulting in low
mortality rates from the disease. However, it still poses a high threat to animal populations, as early
detection and treatment in animals is hindered by variability in clinical course of the disease and the
lack of a vaccine for disease prevention. Moving forward, AVA and WRS will be using molecular
characterization and typing of the existing isolates to better understand the relationship between the
B. pseudomallei strains present in the environment and those infecting the different animal populations
in Singapore.
Environmental sampling remains a challenge, as isolation of B. pseudomallei can be affected by
many parameters. Continued efforts in improving protocols and greater support from regulatory
authorities for conducting environmental surveillance studies would help identify endemic areas,
following which control measures could be applied to reduce disease incidence, particularly in the
animal population.
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Abstract: Melioidosis is an emerging disease in the Americas. This paper reviews conﬁrmed cases,
the presence of Burkholderia pseudomallei and the organization of national surveillance policies for
melioidosis in South America. Conﬁrmed cases in humans have been reported from Ecuador,
Venezuela, Colombia, Brazil, and Peru. The bacterium has been isolated from the environment in
Brazil and Peru. The state of Ceará, northeastern region of Brazil, is the only place where speciﬁc
public strategies and policies for melioidosis have been developed. We also discuss the urgent need
for health authorities in South America to pay greater attention to this disease, which has the potential
to have a high impact on public health, and the importance of developing coordinated strategies
amongst countries in this region.
Keywords: melioidosis; Burkholderia pseudomallei; South America
1. Introduction
Melioidosis is an infectious disease caused by Burkholderia pseudomallei, an environmental
bacterium that is being detected with increasing frequency across the world but that has only attracted
attention in the Americas in the past few years. Limmathurotsakul et al., in a recent review, estimated
that some 165,000 cases of the disease occurred each year in tropical areas of the globe, accounting for
approximately 89,000 deaths [1]. In this study, a substantial part of South America, including northern,
north-eastern and mid-western regions of Brazil, northeastern Colombia and south-western Venezuela,
and parts of Peru, Guyana, Suriname, Paraguay, Bolivia and Argentina, was considered to represent a
suitable environment for the bacterium [1].
Melioidosis is known to occur in the American continent; however, the true distribution of the
disease is undetermined. In South America, northeastern Brazil is known to be a deﬁnite endemic
area [1] and, by 2015, it had accounted for 32 of the 48 (67%) published cases from the whole continent
(Table 1) [2]. This study broadens the perspective on melioidosis in South America by reviewing
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reported cases and exploring the organisation of public policies. Despite the relative paucity of
published cases, melioidosis undoubtedly deserves to be included in the lists of infectious diseases of
potential epidemiologic importance in the region.
Table 1. Published Cases of Melioidosis in South America.
Case Age Gender Year ofDiagnosis
Country of
Diagnosis
Country Where
Infection Was Most
Likely Acquired
Outcome References
1 30 M 1962 Ecuador Ecuador Died [3]
2 50 M 1995 Venezuela Venezuela Survived [4]
3 60 M 1998 Colombia Colombia Survived [5]
4 65 M 1998 Colombia Colombia Survived [5]
5 50 M 2000 Venezuela Venezuela Survived [4]
6 66 M 2003 Portugal Venezuela Survived [6]
7 10 F 2003 Colombia Colombia Died [5]
8 40 M 2003 Colombia Colombia Died [5]
9 15 M 2003 Brazil Brazil Died [7–10]
10 14 F 2003 Brazil Brazil Died [7–10]
11 10 M 2003 Brazil Brazil Died [7–10]
12 12 F 2003 Brazil Brazil Survived [7–10]
13 50 M 2003 Netherlands Brazil Died [11]
14 46 F 2004 Colombia Colombia Survived [5]
15 28 M 2005 Spain Colombia Survived [5]
16 52 M 2005 Colombia Colombia Survived [5]
17 17 F 2005 Brazil Brazil Survived [12]
18 30 M 2005 Brazil Brazil Died [2,13]
19 22 M 2008 Colombia Colombia Survived [14]
20 17 M 2008 Brazil Brazil Died [15]
21 69 M 2008 Brazil Brazil Died [16,17]
22 48 M 2009 Brazil Brazil Survived [17]
23 47 M 2010 Brazil Brazil Survived [17]
24 28 M 2010 Brazil Brazil Died [18]
25 29 M 2010 Brazil Brazil Died [2]
26 56 M 2010 Brazil Brazil Survived [2]
27 53 M 2011 Brazil Brazil Survived [2]
28 3 M 2011 Brazil Brazil Died [2]
29 56 M 2011 Brazil Brazil Died [2]
30 7 M 2011 Brazil Brazil Survived [2]
31 29 M 2011 Brazil Brazil Survived [2]
32 21 M 2012 Brazil Brazil Died [2]
33 82 F 2012 Brazil Brazil Died [2]
34 31 M 2012 Colombia Colombia Survived [5]
35 36 M 2013 Colombia Colombia Survived [19,20]
36 19 F 2016 Peru Peru Died [21]
37 68 M 2013 Brazil Brazil Died [2]
38 57 M 2014 Brazil Brazil Died [2]
39 42 M 2014 Brazil Brazil Survived [2]
40 57 M 2014 Brazil Brazil Survived [2]
41 50 M 2014 Brazil Brazil Died [2]
41 72 M 2014? Colombia Colombia Survived [22]
42 42 M 2015 Brazil Brazil Survived [2]
43 13 F 2015 Brazil Brazil Died [23]
44 64 M 2016 Brazil Brazil Survived [23]
45 58 M 2016 Brazil Brazil Died [23]
46 54 M 2016 Brazil Brazil Survived [23]
47 100 M 2017 Brazil Brazil Died [23]
48 4 F 2017 Brazil Brazil Survived [23]
2. Review of Published Melioidosis Cases and the Presence of B. pseudomallei
In 1962, in Ecuador, Biegeleisen reported the ﬁrst case of melioidosis in South America [3]. Fifteen
years later, French researchers reported the isolation of B. pseudomallei from Brazilian and Peruvian
soil [24,25]. Since these early descriptions, only sporadic human cases of melioidosis had been reported
in four countries by the 1990s: Venezuela, Colombia, Brazil and Peru (in order of ﬁrst reporting)
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(Figure 1) [2,13,21]. A genetic study, which included isolates from Ecuador, Venezuela and Brazil,
suggested that isolates of B. pseudomallei from Central and South America probably had an African
origin and were most likely imported between 1650 and 1850, as a result of colonization and the slave
trade [26].
 
Figure 1. Melioidosis in South America.
2.1. Venezuela, Colombia and Peru
Three cases of human melioidosis have been described in Venezuela from 1995 to 2003 [4,6].
In Colombia, after the ﬁrst report in 1998 [27], a total of 11 further cases have been described up to
2015 (Table 1) [1–6,13,14,19–22,24–29]. Initially, the reports were clustered in the region of Antioquia,
where there is a university referral hospital, although two cases were reported from other regions.
In Peru, despite the initial report of environmental isolation, it was not until 2016 that the ﬁrst human
case was reported [21].
2.2. Brazil
The ﬁrst documented cases of melioidosis in Brazil occurred in 2003 in the state of Ceará, located
in the Northeastern region. Four siblings acquired acute infection after recreational exposure at the
town dam and three of them died within a week [7–10]. By 2017, 30 cases had been diagnosed
in Ceará [2,11,15–18,23]. Characterisation of clinical and environmental B. pseudomallei from Ceará
showed that considerable genetic diversity is present [30]. Apart from this, there are only two other
states with conﬁrmed cases in Brazil: a case reported in 2007 in the state of Mato Grosso, located in the
Midwestern region [12] and the other in Alagoas, also located in Northeastern region (Figure 2) [2].
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Figure 2. Melioidosis in Brazil.
2.3. Environmental Isolation
Besides the environmental isolation of B. pseudomallei reported in Peru and Brazil in 1977 [25],
it has also been isolated in the Brazilian states of Ceará [31] and Amapá [32], located in the Northern
region. The ﬁrst attempts at environmental isolation in Brazil were made in 1973 in rice plantations in
rural São Paulo, but these were unsuccessful [33].
2.4. Animal Melioidosis
There have been no reports of melioidosis in animals anywhere in South America.
3. Surveillance and Public Policies in South America
Limmathurotsakul et al. estimated the respective annual incidence and mortality of melioidosis
in South American countries to be as follows: Brazil, 872 and 339; Colombia, 157 and 64; Venezuela,
103 and 40; Peru, 39 and 16; Argentina, 18 and 7; Paraguay, 13 and 5; and Bolivia, 13 and
7. [1]. These numbers are relatively small in comparison to the estimated number of cases in Asia.
Nonetheless, if accurate this means that more than 1200 cases and nearly 500 deaths could be occurring
annually in South America, the majority of which are going undetected and untreated. So whilst it is
clearly not the top priority for public health authorities in the region, melioidosis still warrants some
attention. What, then, is the position in South America as far as public health policies are concerned?
Fifteen years have passed since melioidosis was ﬁrst diagnosed and documented in Brazil.
There is not, however, any national recognition of it as a public health problem. Undoubtedly there
are many reasons why melioidosis has not been prioritized. Other well-known and high-impact
infectious diseases, such as chikungunya and Zika virus infection, have competed for attention and
resources. Ceará is the only state that has developed speciﬁc policies and undertaken research
into the disease. The ﬁrst plan was established in 2004 following the family cluster described
above, with the proposal of epidemiologic surveillance for the Secretaria de Saúde do Ceará (SESA),
a government organization [34]. This document led to the publication of decree 1786/2005 establishing
melioidosis as compulsorily notiﬁable in the state. Although there is an ofﬁcial national list of notiﬁable
diseases, each federal unit has the autonomy to make its own list according to local needs. Since then,
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measures to enhance surveillance and management of melioidosis in Ceará have been established
gradually, such as the development of a complete protocol in Brazilian Portuguese covering issues
such as: deﬁnition of a suspect case, notiﬁcation and environmental investigations; procedures for
diagnosis and treatment, workﬂows for the submission of laboratory samples, and recommendations
for prevention. Other activities were developed: professional training materials, dissemination
of information about melioidosis at local, regional and national scientiﬁc events, research and
development, the use of new media and educational technology (for example, the establishment
of a web site: https://www.melioidose.com.br), trials of developing prospective surveillance in health
services, and raising laboratory diagnostic capacity. However, it would be fair to say that the success
of these initiatives has been limited. Professional awareness remains restricted to small groups of
physicians in Fortaleza, the state capital of Ceará. In addition, the general population does not know
about the disease, with rare exceptions such as in the locations where cases have been conﬁrmed.
The scarcity and limited capabilities of microbiology laboratories in most regions of Brazil is
also important in this respect. Preliminary studies in Ceará have demonstrated that few laboratories
are able to identify B. pseudomallei. In this state, most cases have occurred in small communities and
the diagnosis was only made when patients were transferred to larger reference centres located in
Fortaleza or the northern and southern regions of the state.
As far as the rest of South America is concerned, there are no policies relating to melioidosis
and no formal surveillance for the disease. Even in Colombia, where the greatest number of cases
outside Brazil have been detected, there are currently no speciﬁc or general public policies relating
to melioidosis.Currently, in Colombia the National Institute of Health conducts indirect surveillance
through the surveillance of antimicrobial resistance, but melioidosis is not statutorily notiﬁable and
is thus likely to be under-recognised. However, a pilot study to identify cases of melioidosis in
Colombia has recently been initiated. This collaborative study involving the US CDC, Tephinet,
the National Institute of Health and some of the larger referral hospitals in Antioquia, will develop an
epidemiological surveillance protocol and attempt to identify new cases of melioidosis, which will
be conﬁrmed using techniques such as MALDI-TOF and molecular methods.Once the collaborative
project is completed, the newly identiﬁed cases and a more formal melioidosis surveillance program
for Colombia will be announced. Concern over the emergence of melioidosis recently led to the ﬁrst
meeting focused on ‘Melioidosis in the Americas’ in Bogota in April 2018, which was attended by
representatives from Brazil, Colombia, Dominican Republic, Ecuador, Haiti, Panama, Paraguay, Peru,
Puerto Rico, Trinidad and Tobago, and the USA. A pamphlet on melioidosis in Spanish was developed,
which could used by public health stakeholders to improve recognition of the disease in Latin America.
It is hoped that this meeting will be the basis for further collaborations and perhaps even a regional
network to share information to improve melioidosis surveillance.
4. Current Challenges and Perspective
The biggest challengesrelating to melioidosis in South America are:
1. To raise professional and government awareness that this disease is present.
2. To alert clinicians to the fact that its early detection is critical if lives are to be saved.
In Ceará, new approaches have been designed such as the inclusion of melioidosis in the
curriculum of professional physicians, and the development of capacity amongst laboratory staff.
The Brazilian health system is organized according to the Sistema Único de Saúde (SUS), geared
to address the priorities for the local population. A recent pilot study involved the provision
of information about melioidosis to community health agents in cities and towns in rural areas.
These agents are part of the Family Health Strategy, a pillar of the development of primary care.
Historically, these professionals have played a major role in reducing the mortality from infectious
diseases in infants, such as diarrhoea, pneumonia, and measles [35]. Considering the environmental,
social and geographic context of melioidosis, it is possible that using this network might help to
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raise the awareness of melioidosis in the wider community. Lessons learned in Brazil might then be
extended to the rest of the continent. In addition, efforts should be made to integrate melioidosis into
the infectious diseases agenda of pan-American meetings and organisations such as the Pan-American
Health Organisation, in order to raise the proﬁle of the disease and to initiate discussions with
national public health organisations, universities and academic communities across the continent.
Consideration should be given to making the disease notiﬁable in countries where it is predicted to
be present.
An additional problem for South America is the relative under-development of the diagnostic
microbiology sector. This is not something that warrants speciﬁc attention as far as melioidosis is
concerned, but as laboratory capacity across the continent improves, it will be important to ensure
that technicians are trained in the isolation and identiﬁcation of B. pseudomallei. It is hoped that
developments in Brazil and Colombia, and the recent meeting in Bogota, will help to catalyse the
development of an integrated laboratory network among South American countries.
Although melioidosis is a relatively new disease to South America and the numbers of conﬁrmed
cases are as yet small, it is likely that it is being substantially under-diagnosed. It is only by sharing
experiences about organizing and planning surveillance activities in different places, taking into
consideration the individuality of each set of circumstances, that we may begin to understand the size
and extent of the problem. Shared dialogue, discussion and co-ordinated actions in both Portuguese
and Spanish may be the ﬁrst step to reach the goal. We believe that it is essential that health authorities
(national, state and municipal) should pay attention to this emerging problem. Investment in strategies
already initiated must continue if the lack of knowledge about melioidosis in the continent is to
be addressed.
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Abstract: Until recently, Sri Lanka was not considered a country with endemic melioidosis. However,
an increasing number of cases is being reported. National surveillance for melioidosis was
instituted after 2008. A total of 250 culture-positive cases was recorded between 2006 and May 2017.
Males predominated (71.6%). The age range was wide (2–92 years) reﬂecting a ubiquity of exposure.
The majority (201/250, 80%) lived in rural areas. All provinces were affected. Case load increased
during the two monsoonal periods (67%). There was representation of every population group
including farmers (n = 44), housewives (n = 24), school children (n = 10), professionals (n = 5),
businesspersons (n = 6), white-collar workers (n = 10) and blue-collar workers (n = 8). Diabetes was
the predominant risk factor (n = 163, 65.2%). Clinical presentations included community-acquired
sepsis and pneumonia, superﬁcial and deep abscesses, and septic arthritis. Mortality was 20.4%
(51/250). A majority (n = 212) of isolates belonged to the YLF (Yersinia-like ﬁmbrial) clade but 38 were
BTFC (B. thailandensis-like ﬂagellum and chemotaxis). A total of 108 isolates was genotyped and
46 sequence types (STs) were identiﬁed, 40 being novel. It is clear that melioidosis is endemic in
Sri Lanka with a wide geographic and demographic distribution. There is an urgent need to extend
surveillance of melioidosis to under-resourced parts of the country and to populations at high risk.
Keywords: melioidosis; Sri Lanka; epidemiology; Burkholderia pseudomallei
1. Introduction and History of Melioidosis in the Country
Sri Lanka lies in the tropics, between 5–10◦ N of the equator, and within the melioidosis belt.
Rice and rice ﬂour comprise the staple diet. Paddy lands are scattered throughout the island where the
predominant form of agriculture is rice farming in smallholdings, using traditional farming methods.
Sri Lanka (then Ceylon) (1927), followed British Malaya (now Malaysia and Singapore) (1921)
and Cochin China (now Vietnam) (1925/6) as one of the ﬁrst countries to report melioidosis, after its
initial description in Rangoon, Burma (now Myanmar) in 1912 [1]. This report of fatal melioidosis in a
European tea broker resident in Sri Lanka was the ﬁrst from the Indian subcontinent [2] and led to
the country being identiﬁed as an endemic area [3]. However, this early account was not followed by
any further cases. A limited sero-epidemiological survey in hospital-associated populations in 1972
concluded that the disease was unlikely to be of major public health importance in Sri Lanka [4].
Reviews on the global epidemiology of melioidosis and maps depicting the known endemicity of
melioidosis included Ceylon/Sri Lanka as an endemic area, based on this single case. Redfearn et al. [5]
included Ceylon (Sri Lanka) in their classic map (later reproduced in a much-quoted review by
Howe et al. [6]) as an area from which bacteriologically diagnosed cases of melioidosis had been
reported. Leelarasamee [7] and Leelarasamee and Bovornkitti [8] listed Sri Lanka as an area where
active cases of melioidosis had been seen. Dance, in 1991 [9], comprehensively reviewed the situation
in Sri Lanka, identifying it as an area with sporadic isolates but, later, did not speciﬁcally refer to it in
an update in 2000, probably due to a lack of subsequent cases [10]. Cheng and Currie [11] classiﬁed
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Sri Lanka, in their review of 2005, as belonging to an ‘area with sporadic case reports’. However, a few
years later, in spite of the lack of further cases, Currie et al. [12] mapped Sri Lanka (along with the
whole Indian subcontinent) as an area endemic for melioidosis and this was echoed by Wiersinga et al.
in 2012 [13].
Seven decades after the ﬁrst case of melioidosis was reported from Sri Lanka, sporadic reports
began to surface of infection acquired in Sri Lanka. This included a report of brain and lung abscesses
in a Belgian tourist, who had visited the country shortly before his illness [14], infection of a leg wound
sustained in the 2004 Indian Ocean tsunami in an Australian man holidaying in Sri Lanka [15], and
fatal septicaemia in a Sri Lankan male reported in 2006 [16]. This raised the possibility that melioidosis
might be emerging in parts of Sri Lanka. As a result of a World Health Organization-supported
laboratory-twinning project, additional cases were conﬁrmed in the Central and Western Provinces in
2006 and 2008 [17,18] and surveillance for melioidosis was commenced. Recently, further cases from
Sri Lanka, diagnosed locally and overseas, have been published [19–35].
2. Review of Melioidosis Cases and Presence of B. pseudomallei in the Country
A national network of clinical microbiology laboratories in the state and private sector was
established. A case deﬁnition for surveillance and a laboratory work-up procedure for the routine
culture of specimens and preliminary identiﬁcation of suspected isolates was drawn up. Reference
laboratory facilities for conﬁrmation of isolates by polymerase chain reaction (PCR) for the
LPxO gene [36] and serological testing for antibodies by the indirect haemagglutination assay (IHA) [37]
were set up. A standard questionnaire for the collection of demographic, geographic and clinical data
was designed. Ethics approval for the study was obtained from the Ethics Review Committee, Faculty
of Medicine, University of Colombo.
Primary isolation relied on conventional culture techniques for blood and other sterile ﬂuids, pus,
and occasional soft-tissue specimens on routine culture media such as blood and MacConkey agar.
Selective agar was not used for specimens from sites with normal ﬂora so it is possible that some cases
may have been missed. Suspected B. pseudomallei isolates were referred to the reference laboratory for
conﬁrmation by PCR. Awareness was raised, chieﬂy among clinical microbiologists, through lectures,
presentations and publications, e-mails and personal communication.
Between 2006 and March 2017, 250 culture-positive cases of melioidosis were identiﬁed by the
surveillance programme. More than a hundred additional cases were diagnosed and treated as
melioidosis on the basis of high antibody titres in the IHA test. However, this article will describe only
the culture-conﬁrmed cases.
The number of culture-positive cases increased from year to year (Figure 1).
Melioidosis was prevalent throughout the island with all 9 provinces affected, the highest number
being from the Western (n = 88), North-Western (n = 54) and Eastern (n = 33) provinces (Figure 2a).
There were no cases at higher elevations (Figure 2b) and only a few cases in the Northern Province,
where microbiology services are limited.
The age range of patients was wide (2–92 years), reﬂecting the ubiquity of soil exposure in the
Sri Lankan population (Figure 3).
The majority of patients were men (71.6%), as seen in other settings, probably reﬂecting
occupational soil exposure in a predominantly agricultural society. Unsurprisingly, rural populations
were chieﬂy affected (201/250, 80%). However, only 44 patients were farmers and there was
representation of every population group including housewives (n = 24), school children (n = 10),
professionals (including physicians and school principals) (n = 5), businesspersons (n = 6), white-collar
workers including irrigation ofﬁcers, technicians and clerks (n = 10) and blue-collar workers (n = 8,
including labourers and construction workers). Nine patients (7%) belonged to the defence forces
(army, police or civil defence) and 15 (12%) were drivers. Many gave a history of involvement in
cultivation. Therefore, melioidosis in Sri Lanka seems not to be a disease limited to rice farmers but
an infection related to the outdoor, agricultural, barefoot lifestyle still practised by the majority of the
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population. The large number of drivers, especially three-wheeler drivers and motorcyclists, in this
series is intriguing and a possible explanation is exposure to dust containing B. pseudomallei.
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Figure 1. Annual incidence of cases and fatalities (2017 data only up to March).
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Figure 2. Geographical distribution of melioidosis cases in Sri Lanka. (a) By province. (b) By topography.
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Figure 3. Age distribution of patients with melioidosis in Sri Lanka.
While diabetes was the predominant risk factor, found in 163 cases (65.2%), other organ disease
and alcoholism were seen, and thalassemia was a signiﬁcant risk in children, seen in 3 of our 10 children.
Other, more unusual, predisposing causes included IgA nephropathy, dengue haemorrhagic fever,
systemic lupus erythematosus (SLE) on prednisolone therapy, and lepromatous leprosy. However,
melioidosis was also seen in healthy adults and children with no obvious risk factors (n = 30, 13.2%).
As expected, clinical presentations were varied, ranging from acute sepsis to chronic abscess
formation, reﬂecting the protean nature of this infection and manifesting in the full gamut of its clinical
features (Figure 4). As in other series, lung infections predominated followed by musculoskeletal
infections including septic arthritis, muscle abscesses and osteomyelitis and abdominal involvement,
chieﬂy abscesses of the liver, spleen or psoas muscle. Skin and soft-tissue abscesses followed. While
more than half the patients were blood culture-positive and septic, a few presented with septicaemia
only without any obvious focus. Central nervous system infection was seen in the form of meningitis,
subdural empyema, cerebral abscess, brain-stem encephalitis, transverse myelitis, Guillain Barré
syndrome and status epilepticus. Genitourinary involvement was seen presenting as urinary tract
infection or prostatitis. The lymph nodes and salivary glands were the site of infection in many
patients. The cardiovascular system was also affected, with one patient presenting with pericardial
effusion and one with endocarditis, an extremely rare presentation reported only twice previously in
the literature [38,39]. Most patients had involvement of more than one organ or system.
 
ZĞƐƉŝƌĂƚŽƌǇ
Ϯϴй
DƵƐĐƵůŽƐŬĞůĞƚĂů
ϮϬй
ďĚŽŵĞŶ
ϭϲй
^ŬŝŶĂŶĚ^ŽĨƚƚŝƐƐƵĞ
ϭϮй
^ĞƉƐŝƐ
ϳй
ĞŶƚƌĂůŶĞƌǀŽƵƐ
ƐǇƐƚĞŵ
ϱй
'ĞŶŝƚŽƌƵƌŝŶĂƌǇ
ϰй
>ǇŵƉŚŶŽĚĞ
ϰй
^ĂůŝǀĂƌǇŐůĂŶĚƐ
ϯй
ĂƌĚŝŽǀĂƐĐƵůĂƌ
ϭй
Figure 4. Systems affected by melioidosis in Sri Lankan patients.
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It is of note that many patients showed involvement of the lower limbs such as septic arthritis,
psoas muscle abscess and cellulitis. Septic arthritis was the primary presentation or complicated the
clinical course of many patients. This may reﬂect bacterial entry by inoculation into the lower limbs
consistent with a barefoot lifestyle.
The overall mortality was 20.4% (51/250). This compares favourably with the mortality of
melioidosis in northern Australia (14%), as opposed to the mortality in Thailand (49%). However,
it is far higher than the 9% mortality recorded in the latter stages of the 20-year study in Darwin [40].
Eight patients had recurrence during this period, including two who had recrudescent disease within
two months of discharge whilst on eradication therapy, and four who had recurrences 6 months to
3 years after recovery (the time to recurrence was unknown in two). It is likely that some recurrences
were due to non-compliance with the lengthy oral treatment required in the ‘eradication phase’.
Looking more closely at the geographical distribution of this infection, melioidosis was present in
the wet, intermediate, dry and even arid zones of Sri Lanka. When charting seasonal trends based
on rainfall, particularly the south-western and north-eastern monsoons, it was seen that cases occur
throughout the year with a trend of two peaks during the monsoons (67% of cases) (Figure 5). This is
consistent with studies in many other countries that have shown increased numbers of cases during
the rainy season [11]. Flooding has been associated with an increase in the incidence of melioidosis
and a sharp peak was seen after torrential rainfall and ﬂooding in May/June 2016.
While most of the cases were sporadic and unrelated to each other, there were some interesting
epidemiological clusters. One was melioidosis affecting two thalassaemic siblings from Maha Oya
in the Uva Province that occurred six months apart. They had probably been infected during the
construction of a new house. The other was a cluster of 10 cases (with 4 deaths) that occurred in
Batticaloa in the Eastern Province in October/November 2015 following heavy rains. The deaths
included three female patients with severe community-acquired bronchopneumonia, suggesting
acquisition via inhalation.
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Figure 5. Monthly incidence of melioidosis (combined data for 2006–March 2017).
When the geographic data were plotted on topography and land-use maps of Sri Lanka,
an infection-free area, comprising the highlands above 500 m, was noticed (Figure 2B). It seemed that
while the distribution of melioidosis predictably coincided with rice-growing areas it appeared to
be absent from rubber- and tea-growing regions. It is intriguing to speculate on the reason for this
distribution. Is it due to the low temperatures in the hill country or different soil conditions or do the
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agricultural practices used in tea and rubber cultivation result in a lower risk of exposure? Further
research, including soil sampling for B. pseudomallei in these areas, is needed to elucidate this question.
A sero-epidemiological study was conducted in 32 blood banks distributed throughout the country
on 675 blood donors using the indirect haemagglutination assay between 2011 and 2013. Antibodies to
B. pseudomallei were quantiﬁed and the cut-off for seropositivity was set at an antibody titre of ≥40.
The sero-prevalence of antibodies against B. pseudomallei in the study population was 7.4% (50/675).
To determine demographic, geographic and other risk factors associated with positivity, binary
univariate logistic regression analysis was used to generate odds ratios (OR) with 95% conﬁdence
intervals (CI). Signiﬁcance was determined using a p value of <0.05. When the association between
province and positivity was explored, donors from the North-Western Province were more likely to be
positive than donors from the rest of the country, but the association did not reach statistical signiﬁcance.
Positivity increased progressively with age but this did not reach statistical signiﬁcance. There was a
signiﬁcantly larger proportion of females who were antibody-positive, 17/139 (12.2%) versus 33/529
(6.2%) of males (p = 0.019). A signiﬁcant association was noted between agriculture/gardening and
positivity (p = 0.032) and rural location and positivity (p = 0.022).
The majority of isolates (n = 212) belonged to the YLF (Yersinia-like ﬁmbrial) gene cluster which
is characteristic of South-East Asian strains. However, 38 of the bacterial strains were of the BTFC
(B. thailandensis-like ﬂagellum and chemotaxis) gene cluster, which is typically found in northern
Australia [41]. Variation in the bimA gene was explored in the initial 32 isolates. While the majority
of strains (n = 27) were bimABp, the variant bimABm, which is rarely found outside Australia, was
present in 5 strains [42]. It is interesting to note that two of these patients presented with neurological
melioidosis (brain-stem encephalitis and transverse myelitis, respectively), which is known to be
associated with the bimABm gene [43].
Multilocus sequence typing (MLST) [44] of 108 B. pseudomallei strains revealed a high diversity,
with 46 different sequence types (STs) represented in the collection (Table 1). Of these, 40 were
novel sequence types. This molecular epidemiology is more compatible with a bacterium that has
been endemic in the country over a long period of time, even millennia, than of one that had been
recently introduced. Strains from Sri Lanka cluster separately from strains from South-East Asia and
Australia, suggesting separation far back in geological time [45]. Currently Sri Lanka has the largest
representation (number of strains submitted) on the public MLST database of all the countries in
South Asia (https://pubmlst.org/bpseudomallei/).
Table 1. Sequence types (ST) of B. pseudomallei strains from Sri Lanka.
ST No ST No ST No ST No ST No ST No
13 2 590 944 1139 3 1147 3 1435 2
132 594 5 1132 8 1140 5 1148 1436
194 598 1133 1141 1152 2 1437
202 615 1134 1142 2 1179 1438
293 655 1135 9 1143 2 1314 1439
308 733 1136 8 1144 1364 1442
338 867 1137 18 1145 1413
474 912 2 1138 1146 1434 6
In a study summarizing global evidence for the environmental presence of B. pseudomallei [46],
where ‘deﬁnite’ presence of the bacterium was deﬁned as the detection of B. pseudomallei from the
environment using culture or a speciﬁc PCR, Sri Lanka was classiﬁed as a country deﬁnitely harbouring
the bacterium, based on a report by Inglis et al. [17]. A preliminary study to determine the presence
of B. pseudomallei in the soil of selected regions in Sri Lanka was undertaken in 2016. Four sites
throughout the east–west axis of the island, in close proximity to locations of diagnosed cases of
melioidosis, namely Nikaweratiya in the Kurunegala District of the North-Western Province, Hasalaka
in the Kandy District of the Central Province and Maha Oya and Kaluwanchikudy in the Ampara
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and Batticaloa Districts of the Eastern Province, respectively, were studied. Soil samples were taken
from rice ﬁelds and domestic gardens and subjected to molecular screening, using a quantitative
real-time PCR approach with multiple B. pseudomallei-speciﬁc targets. B. pseudomallei was present in all
four sites and more than 70% of all samples were B. pseudomallei-positive [abstract presented at World
Melioidosis Congress (WMC), 2016].
Only one case of animal melioidosis has been reported from Sri Lanka, that of a splenic abscess in
a cow that later succumbed to the infection [47].
3. Current Recommendations and Availability of Measures Against Melioidosis
An island-wide, laboratory-based, case-ﬁnding system centered on clinical microbiologists is
the main surveillance system for melioidosis in Sri Lanka. Clinical microbiologists have expertise
in the identiﬁcation of B. pseudomallei in clinical specimens by routine culture. Selective media are
not used. Suspected clinical isolates are referred to the reference laboratory for conﬁrmation and a
standard datasheet is completed for each culture-conﬁrmed patient. However, it is likely that this
method will fail to detect cases in areas not served by clinical microbiologists, such as large areas of
the Northern Province, unless the patients are referred to other centres.
Elucidation of the true epidemiology of melioidosis in Sri Lanka requires that it be made a
notiﬁable disease. Steps have been taken to inform the public health authorities of the presence and
extent of the infection in the country with a view to adding melioidosis to the list of notiﬁable diseases
in Sri Lanka.
Culture-conﬁrmed cases are treated according to standard published guidelines [48]. Government
hospitals, which are well distributed throughout the country, provide treatment free of charge.
Intravenous antibiotics for the acute phase and oral antibiotics for the eradication phase are available
in all hospitals and there is no out-of-pocket expenditure by the patients. Intensive-care facilities are
available in the larger hospitals. The moderately high case fatality rate appears to be related to late
diagnosis, rather than to limitations in the availability of effective treatment.
4. Awareness of Melioidosis
Awareness of melioidosis among health care personnel is still inadequate and has probably
contributed to the high case fatality rate. Although articles on melioidosis have appeared in the
popular press, public awareness of the infection is very low, including among high-risk groups such as
rice farmers and other cultivators. Island-wide awareness programmes to alert clinicians and public
health authorities to the presence and presentation of melioidosis are needed.
5. Major Achievements
Although sporadic cases of melioidosis have been described previously in Sri Lanka, this study
establishes, conclusively, that melioidosis is endemic in Sri Lanka, with a wide geographic and
demographic distribution. The absence of melioidosis in the high hills (>500 m above sea level) is
noted. This may be due to the low temperatures seen in these areas or the different agricultural
practices used in these regions, where tea is the main crop, as opposed to rice as in most other areas of
the country. The seasonal nature of the incidence of melioidosis, with an increase during the monsoons,
is demonstrated.
The demographic proﬁle of melioidosis in Sri Lanka is described for the ﬁrst time and is broadly
similar to countries with similar climate and agriculture. However, the wide distribution of cases
in all strata of society and all grades of occupation is noted. The proposition that the rural, outdoor,
agricultural, barefoot lifestyle of the majority of the population poses a general risk of acquisition
of melioidosis is postulated. Individuals in the defence forces and construction workers have been
conﬁrmed to be at risk, as shown previously, and new risk groups such as housewives and drivers
have been identiﬁed.
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The high rates of co-morbidity in patients in Sri Lanka, compared to other endemic areas
such as Thailand and Vietnam, is likely to reﬂect lower exposure to B. pseudomallei, probably due
to lower bacterial loads in the environment, so that clinical disease develops mainly in highly
susceptible populations.
A higher rate of bacteraemic cases and a lower rate of localized cases were seen in this series and
may be an artefact of blood culture-positive patients being investigated more thoroughly. The case
proﬁle resembled that described previously in other case series. Neurological melioidosis, which has
previously been described mainly in northern Australia, was seen. Musculoskeletal melioidosis was
more common and may be the consequence of a barefoot lifestyle.
Genotyping of bacterial strains revealed a high diversity of sequence types, widely distributed
throughout the island, confirming that the bacterium is endemic to the country. Strains from Sri Lanka
clustered together and separately from the south-east Asian and Australian strains, showing
regional speciﬁcity.
6. Current and Future Challenges
Increased construction and building activities in Sri Lanka may place construction workers,
engineers and the general public at risk. Small-scale farming, gardening and horticulture have become
popular for income generation and may increase exposure to this soil bacterium. Climate change
has led to an increase in natural disasters, such as storms, landslides and ﬂooding, that expose even
healthy persons to high doses and unusual routes of transmission.
Exposure-mitigating practices, such as use of mechanical agriculture and protective clothing
when coming into contact with mud and water, may reduce infection with B. pseudomallei. However,
this may not be feasible due to their lack of acceptability and adverse socioeconomic impact. The use
of doxycycline in farmers for leptospirosis prophylaxis may also protect against the acquisition of
melioidosis. The evidence base for such strategies needs to be studied. Other ‘at risk’ occupations
such as manual labourers, irrigation, water supply, construction, mining and road repair workers
may also need to adopt similar preventive measures, when required. Preventive strategies should
include more effective community-based diabetes prevention, detection and control that will reduce
the risk of clinical disease. Recrudescent melioidosis should be included in the agenda of migrant
health issues, including that of the diaspora that left Sri Lanka following civil disturbances over the
past few decades.
Sero-surveillance at the community level may serve to obtain a true reﬂection of the extent of
exposure to B. pseudomallei in the community. Targeted sero-surveillance in high-risk groups such
as rice farmers, defence personnel and diabetics may help to quantify the risk of clinical disease in
these individuals. Studies of the development of antibodies to B. pseudomallei during childhood and
estimation of the intensity of exposure and incidence of melioidosis in children by IHA testing of a
large cohort of children, with each year equally represented, would also add to knowledge of the
extent and timing of bacterial exposure.
Soil sampling to detect and quantify the presence of B. pseudomallei in soil in Sri Lanka and
mapping of the distribution of environmental B. pseudomallei will enable identiﬁcation of high-risk
geographic regions where heightened case detection can be implemented. The intriguing lack of
infection in the high hills should be explored by soil sampling at different altitudes and from different
agricultural settings.
Genotyping of further strains of B. pseudomallei will be useful to conﬁrm the diversity of sequence
types in Sri Lanka and to explore any associations of genotype with geographical distribution,
clinical presentation or virulence and any genetic difference between environmental and clinical
strains. The presence of the BTFC and BimABm variants in signiﬁcant numbers in Sri Lanka will
have implications for the geographical origins and evolution of the bacterium in geological time.
Whole-genome sequencing will allow further discrimination of south-Asian strains from those
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in Oceania and south-east Asia and help deduce evolutionary relatedness between isolates from
these regions.
The One Health concept is founded on the premise that the health of the environment, of animals
and humans are inextricably linked. Melioidosis, caused by a soil saprophyte and infecting both
animals and humans through soil and water exposure is the ideal candidate infection for the One Health
approach to disease mitigation and health promotion. Integrating local, national and global workers in
multidisciplinary teams to research this infection with a view to reducing its impact on human and
animal populations is essential to this endeavour. Convening such a platform for the south-Asian
region, which probably bears the highest burden of melioidosis but where the disease is currently
grossly under-diagnosed, is an urgent imperative.
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Abstract: Despite the fact that South Asia is predicted to have the highest number of cases worldwide,
melioidosis is a little-known entity in South Asian countries. It has never been heard of by the majority
of doctors and has as yet failed to gain the attention of national Ministries of Health and country ofﬁces
of the World Health Organization (WHO). Although a few centers are diagnosing increasing numbers
of cases, and the mortality documented from these institutions is relatively high (nearly 20%), the true
burden of the disease remains unknown. In India, most cases have been reported from southwestern
coastal Karnataka and northeastern Tamil Nadu, although this probably simply reﬂects the presence
of centers of excellence and researchers with an interest in the disease. As elsewhere, the majority
of cases have type 2 diabetes mellitus and occupational exposure to the environment. Most present
with community-acquired pneumonia and/or bacteremia, especially during heavy rainfall. The high
seropositivity rate (29%) in Karnataka and isolation of B. pseudomallei from the environment in Tamil
Nadu and Kerala conﬁrm India as melioidosis-endemic, although the full extent of the distribution
of the organism across the country is unknown. There are limited molecular epidemiological data,
but, thus far, the majority of Indian isolates have appeared distinct from those from South East Asia
and Australia. Among other South Asian countries, Sri Lanka and Bangladesh are known to be
melioidosis-endemic, but there are no cases that have conclusively proved to have been acquired in
Nepal, Bhutan, Afghanistan or Pakistan. There are no surveillance systems in place for melioidosis in
South Asian countries. However, over the past two years, researchers at the Center for Emerging and
Tropical Diseases of Kasturba Medical College, University of Manipal, have established the Indian
Melioidosis Research Forum (IMRF), held the ﬁrst South Asian Melioidosis Congress, and have been
working to connect researchers, microbiologists and physicians in India and elsewhere in South Asia
to raise awareness through training initiatives, the media, workshops, and conferences, with the hope
that more patients with melioidosis will be diagnosed and treated appropriately. However, much
more work needs to be done before we will know the true burden and distribution of melioidosis
across South Asia.
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1. Introduction
Melioidosis is a potentially fatal illness which is caused by the soil saprophyte and biothreat
agent Burkholderia pseudomallei. It is known to be highly endemic in northeast Thailand and northern
Australia, where annual incidence rates ranging from 4 to 41.7 cases per 100,000 population [1] have
been reported. A recent modeling study predicted that as many as 165,000 people may be infected
each year worldwide, with South Asia having the highest burden of the disease (44% of all cases) [2].
India is the largest country in South Asia and, having a suitable environment and an enormous
diabetic population, might well be a ‘hotspot’ for the disease. However, the true melioidosis burden
in India is unknown due to limited awareness and laboratory constraints throughout the country.
Clinical diagnosis is exceptionally challenging due to the varied clinical presentations, especially as the
disease can mimic other infections such as tuberculosis [3], which is highly endemic in resource-poor
countries such as India.
The majority of the Indian population resides in rural settings and might readily acquire the
infection through direct contact with soil and water. However, they have limited access to hospitals
where there are well-equipped microbiology laboratories and well-trained professionals to diagnose
the disease. The present-day situation in India is similar to that in Thailand in the mid-1980s when
melioidosis started to be diagnosed increasingly as microbiology services improved. In countries
such as India, limited awareness among clinicians and microbiologists about the disease has led
to misdiagnosis and inappropriate treatment. Furthermore, the spectrum of disease manifestations
ranges from the acute septicemic form to a chronic granulomatous form, and hence it mimics other
endemic infections with which it may be confused. Although there has been a plethora of melioidosis
case reports and short series published from India, there are no voluntary or mandatory surveillance
systems to notify the cases, and so there has been limited evidence to encourage governments to
formulate melioidosis-speciﬁc public health policies.
The challenges to the laboratory in diagnosing melioidosis are manifold. Wrinkled B. pseudomallei
colonies are frequently thought to be aerobic spore bearing bacteria, which are relatively common
environmental contaminants, and discarded. Any oxidase-positive Gram-negative, non-lactose
fermenting bacillus is likely to be considered as a ‘pseudomonad’ or ‘Pseudomonas sp.’, which is
unlikely to be identiﬁed further to the species level. Even commercial identiﬁcation kits and modern
automated systems (e.g., API 20NE, VITEK 2, and MALDI-TOF) are not 100% reliable for identifying
B. pseudomallei, especially in inexperienced hands [4]. However, awareness of the disease has recently
been increasing in this subcontinent and it is being diagnosed more frequently, especially in India, Sri
Lanka and Bangladesh. The current review aims to bring into focus a much neglected ‘killer’ disease
from this region, focusing on India, Pakistan, Bhutan, Nepal, and Afghanistan, as Bangladesh and Sri
Lanka are covered in separate reviews in this Special Issue.
2. History
Following the initial recognition of melioidosis by the British pathologist Alfred Whitmore and his
Indian assistant, CS Krishnaswami, in Myanmar in 1911, the ﬁrst case in South Asia was conﬁrmed in
Ceylon, now Sri Lanka, in 1927. The ﬁrst case from India was not diagnosed until 1953, in a 40-year-old
Scottish mining engineer suffering from prolonged fever, multiple abscesses and septicemia, who
became infected while working in the central part of the country but was diagnosed post-mortem
following his repatriation to Scotland [5]. Another fatal exported case was diagnosed in Switzerland in
1988 in a 40-year-old woman who had traveled extensively in India and Nepal [6]. It thus appeared
likely that melioidosis was endemic within India.
The ﬁrst indigenous case from India was detected in Mumbai in 1991 [7], which was followed
by a long period of silence. Meanwhile, the epidemics thought to be the bubonic plague in Beed
(Maharashtra) and pneumonic plague in Surat (Gujarat), which occurred in the mid-1990s, led to
the suggestion that at least some of the cases may have been melioidosis [8], although this was
questioned [9] and was never conﬁrmed ofﬁcially. This was followed by a series of publications
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from the Christian Medical College in Vellore, near the south-eastern coast of India, which raised
the likelihood of melioidosis being endemic in the country and the probability of it being a silent
killer due to incorrect diagnosis and treatment [10–14]. A small serosurvey carried out around the
same time suggested that a proportion of the local rural population had evidence of exposure to
B. pseudomallei [15].
3. Review of Melioidosis Cases and Presence of B. pseudomallei (Animal/Human/Environment)
We performed a PubMed search using the keywords ‘melioidosis’, ‘pseudomallei’, and ‘India’, and
reviewed the available references published between January 1991 and March 2018. Initially, titles
and abstracts were screened and articles identiﬁed as possibly relevant were reviewed as full text.
The reference lists of included articles were assessed for further relevant publications. A similar
search strategy was applied for Nepal, Pakistan, Afghanistan, and Bhutan. In addition, cases reported
from India were also identiﬁed from the website http://www.melioidosis.info. Duplicate cases were
screened and removed manually. Additional cases were identiﬁed from the personal EndNote database
of one of the authors (DABD), as many reports published in non-indexed journals were not available
on PubMed. Further, more detailed information was obtained from our own laboratory database
regarding cases diagnosed in Manipal since 2002, and Vellore since 2008.
3.1. India
The literature search revealed 190 articles (File S1) comprising case reports or series relating
to 583 individual patients with melioidosis from different parts of India (Table 1 and Figure 1).
The greatest number of cases were reported from Karnataka (306), followed by Tamil Nadu (146).
Figure 1 shows clearly that these cases were predominantly diagnosed in coastal areas, probably
reﬂecting the fact that the majority of the best-resourced hospitals are located in these regions. The ages
ranged from 0 to 84 years, although many publications did not provide enough detail to calculate
overall medians and interquartile ranges. A substantial majority of the patients were male, which
may be attributable to men being more likely to be involved in occupations involving soil contact,
but also to inequality in access to the health care between men and women. Diabetes was the most
common predisposing factor reported (391/559, 70%). Ceftazidime was the most common antibiotic
used in the intensive phase and cotrimoxazole for eradication therapy. The overall reported mortality
was 95 (17%), although this may have been an underestimate as there were many cases in which the
outcome was not reported (Table 1).
Figure 1. Cases reported from different parts of India and centers equipped to diagnose cases
of melioidosis.
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3.2. Manipal
The tertiary care hospital of Kasturba Medical College in Manipal has more than 2000 beds
and receives referred cases from primary and secondary health care centers. The hospital caters to
the hilly regions and the plains of Udupi district, and other neighboring districts including Uttar
Kannada, Shimoga, Davangere, Chikmagalur, Hassan, and Mangalore with many inpatient admissions
(approximately 72,025/year) and outpatient visits (approximately 627,210/year). The greatest number
of cases of melioidosis in any single center in India has been reported from Manipal since the ﬁrst
cases were recognized there in 2002 [16]. The incidence of melioidosis in Udupi district over the past
three years was equivalent to 0.8/1000 hospital admissions and 1/100,000 population. The numbers
have increased signiﬁcantly since 2006 following the upgrading of laboratory facilities and the
implementation of a program to raise awareness among doctors (Figure 2). However, being a tertiary
referral center in the sparsely populated coastal Udupi district, most patients visiting this hospital are
from middle and high socioeconomic backgrounds and may not have had as extensive exposure to the
environment as daily laborers or tenant farmers, meaning that this experience may underestimate the
true incidence of the disease in this district.
Figure 2. Annual numbers of melioidosis cases and mortality from Manipal.
Of the 231 patients with melioidosis diagnosed during 2006–2016 (which includes 82 cases
included in the literature review described above), the majority (84, 36.3%) presented with pulmonary
infection. Most patients presented during months of heavy rainfall (Figure 3). Organ failure was
observed in 43 (19%). Diabetes mellitus was the most common co-morbidity (159, 69%). Overall, 48%
of patients were bacteremic, and bacteremia (22/27; 81.4%) along with renal dysfunction (13/27, 48%)
were signiﬁcantly associated with mortality (p = 0.004). Mortality appears to have declined over the
past decade (Figure 2) and at present the rate is surprisingly low (27, 12%) compared with that in
Thailand (35%) [17], and equivalent to that in northern Australia (14%) [18]. In fact, melioidosis causes
a relatively small proportion of all deaths attributable to infectious diseases in Manipal. There are no
obvious links between changes in clinical management and this low mortality, although it is likely
that there has been an increasing awareness over the years, which might have led to more accurate
diagnosis and prompt treatment. The socioeconomic status of the patients seeking care at the tertiary
center may also mean that they are in better general health than populations in some other settings.
However, many patients are discharged against medical advice (DAMA) (mean 300/year over the
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past four years), mostly due to an inability to afford expensive medical treatment, and their outcome
remains unknown. A point prevalence study conducted at Kasturba Hospital (unpublished data)
showed that 60% of patients admitted to the hospital with suspected infection received empirical
antibiotics that would have been expected to be effective against melioidosis, mainly carbapenems
or beta-lactam/beta-lactamase inhibitor combinations. This could also be a cause of these patients
remaining undiagnosed by culture as well as having low mortality. It is also likely that there are many
patients who seek treatment in primary or secondary health care, private clinics, nursing homes or
government hospitals, who remain undiagnosed or misdiagnosed and whose deaths would never be
attributed to melioidosis.
Month Season
October–February Post-monsoon
March–May Summer
June–September Monsoon
Figure 3. Average monthly rainfall and melioidosis cases in Manipal, 2006 to 2017.
3.3. Vellore
The Christian Medical College (CMC), Vellore, is a tertiary care teaching hospital with more than
2800 beds, which caters to a wide populace with substantial representation from most states in India, in
addition to the patients referred from nearby districts in Tamil Nadu and Andhra Pradesh. The initial
reports from CMC helped the recognition of the endemicity of melioidosis in India since 1996 [10].
The most recent retrospective analysis of 114 patients with culture-conﬁrmed melioidosis at CMC
between January 2008 and December 2014 reﬂects the current scenario [19]. Patients came from 15 states
in India, but the greatest numbers were residents of West Bengal (26.3%), Jharkhand (22.8%) and Tamil
Nadu (14.9%), predominantly from rural areas. As previous studies have shown, diabetes mellitus
was found to be the most common risk factor (82.3%). Of the total cases, 41 (36%) presented with acute
disease (<2 months duration) while 73 (64%) had chronic manifestations. Patients with acute septicemic
melioidosis more frequently had bacteremia (80% vs. 41%; p < 0.001) and respiratory involvement (39%
vs. 16.4%; p = 0.007). The mortality for acute septicemic melioidosis was 17% as opposed to 13.6%
among those with chronic disease, with an overall case fatality rate of 14.9%. Respiratory involvement,
bacteremia, septic arthritis and skin involvement more commonly occurred with acute melioidosis,
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while chronic melioidosis had splenic, genitourinary and bone involvement. Respiratory involvement
and bacteremia were found to be independent predictors of mortality. Drug susceptibility to
carbapenems and ceftazidime was 100%, while resistance to trimethoprim-sulfamethoxazole and
doxycycline was found in 5.9% and 2.6%, respectively. Intensive therapy with ceftazidime or
meropenem followed by eradication treatment with trimethoprim-sulfamethoxazole, with or without
doxycycline, was administered in these patients. Relapse occurred in four (3.5%) patients after periods
of 2–7 years. Since the patient population was representative of regions that are geographically distant,
this is indicative of the widespread endemicity of the disease within India. However, the numbers are
likely to be a substantial underestimate as the diagnosis was only made in patients who were managed
at the tertiary care center and many cases are likely to have gone undetected in these regions due to
inadequate diagnostic facilities and limited awareness.
3.4. Other Neighboring Countries
Only a single case of imported melioidosis has been reported to date from Nepal, in a 35-year-old
patient returning from Malaysia [20]. There is some confusion in the literature about cases of
melioidosis originating from Pakistan due to the previous designation of Bangladesh as ‘East
Pakistan’ [21]. A case of pneumonia was diagnosed in the UK in a 60-year-old male described
as being from Pakistan [22]. Inquiries of the author of this report by one of us (DABD) revealed some
uncertainty about his true origin, and we have been unable to identify a single case of melioidosis
that was unequivocally acquired in Pakistan. No cases were identiﬁed from Bhutan or Afghanistan.
However, at this stage, it is unclear whether this reﬂects absence of the disease or simply lack of
awareness and diagnostic capability in these countries, as Limmaturotsakul et al. predicted that it is
likely that melioidosis exists undiagnosed in Nepal, Pakistan and Bhutan [2].
3.5. Serosurveillance
The only serosurveillance study undertaken in India since the 1990s was conducted among 711
healthy residents of Udupi Taluk. The study revealed an overall seropositivity rate (deﬁned as a
titer of ≥1:20 in the indirect hemagglutination (IHA) test) of 29% [23]. This suggests that exposure to
B. pseudomallei is relatively common, although cross-reaction with closely-related organisms cannot be
excluded [24].
3.6. Animals
There have been very few reports of animal melioidosis from any of the South Asian countries.
A single case in a male rhesus monkey imported from India was reported from the USA in 1969 [25].
B. pseudomallei was also reported to have been associated with two cases of bovine abortion in India,
although the antibiogram of the organisms isolated make it very unlikely that these were really
B. pseudomallei [26].
3.7. Environmental Evidence
There have been very few studies attempting to isolate B. pseudomallei from the environment in
India. One study in rice paddy along the southeast coast of Tamil Nadu conﬁrmed four environmental
isolates of B. pseudomallei [27]. Another study conducted along the Malabar coastal region of Kerala
found that 22.7% of the Burkholderia spp. strains isolated were B. pseudomallei [28]. Both studies were
conducted at a single time point and used culture followed by 16S rDNA sequencing rather than
speciﬁc B. pseudomallei PCR. In addition, a study from the Lahore district in Pakistan reported the
detection of Burkholderia spp. genomes in two (1.4%) environmental samples, although the method
used could not distinguish between B. pseudomallei and B. mallei [29]. Until further studies are done in
South Asia, the true distribution of B. pseudomallei in the environment will remain uncertain.
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3.8. Molecular Epidemiology in South Asian Countries
The molecular epidemiology of South Asian isolates of B. pseudomallei has not been
studied intensively. The ﬁrst molecular typing of Indian strains revealed several novel sequence
types, some of which were single locus variants (SLVs) of isolates from Thailand, Kenya, and China,
suggesting the possibility of the spread of B. pseudomallei along historical trading routes [30]. A study
using multi-locus sequence typing (MLST) of 32 clinical isolates from India found that the majority
(93.7%) had novel allelic proﬁles, with ST 1368 as the most common sequence type [31]. The majority
of the isolates were outliers in a population snapshot suggesting that Indian isolates are genetically
distinct from Australian and Southeast Asian isolates. However, some of the Indian isolates were
found to be single-locus variants of Sri Lankan isolates in the BURST analysis (Figure 4). This is
perhaps not surprising, given that Sri Lanka is a neighboring country with which there has always
been an active trade of goods and livestock. However, one of the sequence types (STs) reported from
the northeastern region of India (ST1051) was similar to an Australian isolate, and homoplasy cannot
be ruled out as a cause of such similarities without further molecular analysis such as whole genome
sequencing [32].
 
Figure 4. BURST cluster for South Asian countries with red shades depicting single locus variants and
blue shades depict double locus variants linking the various STs. A group of Indian STs form a separate
cluster not linked to other STs reported from other South Asian countries.
4. Current Recommendations and Availability of Measures against Melioidosis
It is well-established that melioidosis is associated with activities involving exposure to soil
and water [33]. Although it is likely that the risk of disease can be reduced by simple measures
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such as the use of protective gear such as boots and consumption of boiled or bottled water [34],
there are no current guidelines implemented in India or other South Asian countries for prevention
of melioidosis. The need for enhanced surveillance is discussed below and it is hoped that, as the
number of cases detected increases, state and national health authorities will develop and disseminate
relevant guidance, particularly targeted at the areas and populations identiﬁed to be at greatest risk.
Surveillance Systems and Reporting
Melioidosis is not currently notiﬁable in any country in South Asia. In India, for example, diseases
like tuberculosis, malaria, and dengue are highly endemic and are covered by speciﬁc guidelines
and public health policies that have been promulgated by the government to both the public and
health workers. The Integrated Disease Surveillance Program (IDSP) run by the Indian National
Center for Disease Control (NCDC) encompasses the top 12 priority diseases for laboratory-based
surveillance, which include dengue, chikungunya, Japanese encephalitis, meningococcal meningitis,
typhoid fever, diphtheria, cholera, shigella dysentery, viral hepatitis (A and E), leptospirosis and
malaria (http://idsp.nic.in/index1.php?lang=1&level=1&sublinkid=5985&lid=3925). An additional
22 syndromes are identiﬁed for ‘presumptive’ (i.e., clinically-based) surveillance. There are plans
to integrate and decentralize surveillance activities at the grassroots level to combat these diseases,
along with the development of human resource through training, upgrading of information and
communication technology for collection, collation, compilation, analysis and dissemination of data,
and strengthening of public health laboratories. However, melioidosis does not come under the
surveillance program of NCDC. It has been predicted that the number of deaths from melioidosis
globally is higher than that of dengue and leptospirosis [2], both of which are covered by IDSP. If so, the
disease would warrant much greater attention. Nonetheless, it is unlikely that this will happen unless
surveillance improves and greater numbers of cases are detected, an unfortunate ‘Catch-22’ situation.
Currently, the only sources of hard data about melioidosis in South Asia are published case reports,
which undoubtedly are still only the tip of the iceberg. It is thus down to South Asian researchers to
provide evidence to local policymakers to raise melioidosis up their list of priorities with the ultimate
aim of gaining a better understanding of the true burden of the disease through appropriate diagnosis
and surveillance.
5. Diagnostic Facilities
The clinical features of melioidosis are not characteristic and may be confused with those of many
other tropical diseases, especially tuberculosis. Diagnosis of melioidosis thus requires the facilities
and expertise of the microbiology laboratory through isolation and identiﬁcation of B. pseudomallei,
which remains the ‘gold standard’ for diagnosis of the infection. Although the organism is classiﬁed as
a ‘Tier 1 Select Agent’ in the USA (https://www.selectagents.gov/ohp-app1.html) and is worked on
at biosafety level 3 in many countries, such facilities are generally not available in clinical laboratories
in South Asian countries, and specimens are usually processed at biosafety level 2. Standard culture
media are generally used, although it may take several days to grow the organism. Selective media such
as Ashdown’s agar and broth, which increase the yield of B. pseudomallei from non-sterile body sites,
are rarely available outside a few specialist centers. In Manipal, for example, enrichment with ‘CV-C50’
broth for samples from non-sterile sites has improved the yield of culture [35]. Blood culture is the
specimen most frequently received by laboratories for the investigation of melioidosis. Continuously
monitored automated blood culture systems have largely replaced conventional blood culture broth or
biphasic media in many settings, at least in most private tertiary care hospitals in India. In Manipal, the
mean time to positivity for blood culture from patients with bacteremic melioidosis was 30.6 ± 14.2 h
(unpublished data). Of 27 patients who died, the blood cultures became positive within 24 h in
21 (77.7%) and 6 (22.2%) within 48 h of the sample collection, results that probably reﬂect high levels
of bacteremia, as has been shown in studies elsewhere [36].
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Various methods are used to identify Gram-negative bacilli in South Asian laboratories. With
the advent of automated identiﬁcation systems, most laboratories use methods such as API 20NE
and VITEK 2 for identiﬁcation of the organisms. However, it is likely that many isolates are being
dismissed as contaminants without being identiﬁed, or labeled, as ‘Pseudomonas sp.’ or ‘Burkholderia sp.’
Burkholderia spp. account for 1–9% of isolates from patients in various multicenter studies of bacteremia
in India [37–39]. In Manipal, Burkholderia spp. were isolated from 1.6% (114/7100) of positive blood
cultures over the past six years, of which 68.4% (78/114) were conﬁrmed as B. pseudomallei by type III
secretion system 1 (TTSS1) PCR. It is unlikely that Manipal is unique, which implies that many cases of
melioidosis are probably being missed in places where such isolates are not being correctly identiﬁed
to species level. In practice, any laboratory in South Asia could make a presumptive identiﬁcation of an
oxidase-positive Gram-negative rod as B. pseudomallei using a simple three-antibiotic disc test that was
recently shown to be highly speciﬁc in Vietnam [40]. Such an approach might usefully be promoted.
New methods are needed to reduce the time to diagnosis and appropriate treatment. One such
test, the Active Melioidosis Detect Lateral Flow Immunoassay (AMD-LFA) (InBios Inc., Seattle, WA,
USA), has shown promising results as a ‘point-of-care’ (POC) test for early diagnosis of melioidosis [41].
The kit has been evaluated in Manipal on clinical samples from patients suspected of having melioidosis
and had a sensitivity of 85.7% and speciﬁcity of 93.6% compared with enrichment culture [42].
However, the test gave some weak false-positive results on urine specimens and thus needs further
development and evaluation before it can be recommended as a POC test in endemic regions like
South Asia.
6. Antibiotic Susceptibility and Treatment
Although there are no national guidelines for treating melioidosis in India or other South Asian
countries, physicians in centers where cases are regularly diagnosed generally follow international
guidelines, i.e., ceftazidime during the acute phase and co-trimoxazole, which is cheap and widely
available, for eradication therapy. Generally, the antimicrobial susceptibility of isolates of B. pseudomallei
in South Asia mirrors that from other regions [43], although rare instances of ceftazidime resistance
have been reported [44]. Clinical failure of treatment despite apparent in vitro susceptibility has also
been described [45].
7. Awareness of Melioidosis
There is an overall lack of awareness of melioidosis in South Asian countries, as is even the case in
countries where the disease is diagnosed more often, such as Thailand [46]. Although there have been
no formal surveys of knowledge and understanding about the disease, our day-to-day observations
reveal that most doctors outside a few specialist centers have never heard of it, the public is completely
unaware of it, and it is not on the radar of policymakers, either at a state or a national level.
8. Establishing a Melioidosis Network
The Indian Melioidosis Research Forum (IMRF; www.melioidosisindia.com—Figure 5) was
initiated in 2015 during the First South Asian Melioidosis Congress (1st SAMC) in Manipal as an
interactive web portal intended to enhance communication between those in South Asia with an
interest in melioidosis. Thus far, it has connected researchers from 12 states of India and encouraged
research on melioidosis. An earlier workshop about laboratory processing and environmental sampling
had been conducted in Manipal in collaboration with the University of Cambridge, UK, and Mahidol
University, Thailand. Seven centers have already started detecting cases of melioidosis in their own
states after becoming involved in the network and are in regular contact with IMRF regarding the
diagnosis of the disease and conﬁrmation of the isolates. IMRF is well connected with the International
Melioidosis Network (www.melioidosis.info) and is in a position to act as a regional leader to connect
enthusiastic researchers from South Asia with the international melioidosis community. The ‘Center
for Emerging and Tropical Diseases’ in Manipal was established in 2017 and now acts as an informal
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reference laboratory for melioidosis. To date, it has conﬁrmed 80 clinical isolates of B. pseudomallei from
laboratories in different states of India, including Orissa, Hyderabad, Kerala, Pondicherry, and Assam
(Table 2). The center is currently working with the Medical University of Graz, Austria (Indo-Austrian
collaboration) and the Central Soil Salinity Research Institute (CSSRI), Haryana, on the ecology of
B. pseudomallei, and the Defense Research and Development Organization (DRDO), Gwalior, on the
molecular epidemiology of the pathogen. It has been instrumental in mentoring researchers and
microbiologists around the country and encouraging them to share their expertise and collaborate in
future projects.
 
Figure 5. The Indian Melioidosis Research Forum (IMRF) has effectively brought researchers from all
over India for research in melioidosis for the last two years.
Table 2. Isolates received by the Manipal Center for Emerging and Tropical Diseases for conﬁrmation
from various centers in India.
Institute (State) Number of Isolates
Amritha Institute of Medical Sciences (Kerala) 34
Pondicherry Institute of Medical Sciences (Puducherry) 20
Nizams Institute of Medical Sciences (Hyderabad, Telangana) 12
Government Medical College (Tiruvanthapuram, Kerala) 7
Kalinga Institute of Medical Sciences (Orissa) 4
Government Medical College and Hospital (Mallapuram, Kerala) 2
Tripura Medical College (Assam) 1
9. Current and Future Challenges
Melioidosis is clearly an emerging disease in South Asia. The number of cases that have
been microbiologically conﬁrmed is still relatively small and it is too early to know whether the
huge numbers of cases predicted to occur each year (more than 50,000 cases and 30,000 deaths
in India alone) are anywhere near accurate. However, India faces an ‘outbreak’ of diabetes of
enormous proportion. The prevalence of diabetes in India, according to the IDF Diabetes Atlas 2015
(http://www.diabetesatlas.org/across-the-globe.html), is reported to be 8.7% and, given the strong
association between diabetes and melioidosis, it is likely that the latter will become more common
as the former increases. Sadly, diagnostic microbiology services and laboratory-based surveillance
across South Asia remain poorly developed, particularly those serving the rural poor, which is the
very group that is at greatest risk of melioidosis.
The key challenges facing those with an interest in melioidosis in South Asia at this stage are
as follows:
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1. Collecting and collating better data on the number of cases of melioidosis occurring will require
extensive communication with laboratories that are capable of identifying the organism.
2. Training more physicians and laboratory staff to recognize the clinical features of the disease and
the characteristics of its causative organism (for example, through the use of the three-antibiotic
disc test mentioned above) will require concerted efforts through universities and colleges and
professional associations but will be difﬁcult because of the fragmented nature of healthcare in
the region.
3. Raising the proﬁle of the disease with both policymakers and the general public at both local
and national levels will inevitably have to be started locally, but, as the network of those with
an interest grows, it should become easier to provide the necessary evidence that the morbidity
and mortality of the disease warrant greater attention. One key objective would be to have
melioidosis included in the list of diseases that are statutorily reportable by laboratories, which
in turn would improve knowledge of the disease distribution and burden.
10. Conclusions
The burden of melioidosis in South Asia is predicted to be considerable, but as yet the evidence to
support this is scant. However, given the huge population, the very high prevalence of underlying
conditions predisposing to melioidosis such as diabetes mellitus, the shortcoming of diagnostic
laboratory services, and the lack of awareness amongst health professionals, it remains possible that
the predictions could indeed prove to be correct. There is evidence that interest in the disease is
growing amongst healthcare workers and researchers, but the key challenge will be to coordinate
efforts across this vast and diverse region. It is hoped that initiatives such as the IMRF and the SAMC
(the second of which was held in Sri Lanka in 2017 and the next will take place in Bangladesh in 2020)
will help to achieve this.
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Abstract: In Taiwan, melioidosis is an emerging disease that suddenly increased in the Er-Ren River
Basin, beginning in 2005 and in the Zoynan region during 2008–2012, following a typhoon. Additionally,
the disease sporadically increased in a geography-dependent manner in 2016. Subcutaneous inoculation,
ingestion, and the inhalation of soil or water contaminated with Burkholderia pseudomallei are recognized
as the transmission modes of melioidosis. The appearance of environmental B. pseudomallei positivity
in northern, central and southern Taiwan is associated with disease prevalence (cases/population:
0.03/100,000 in the northern region, 0.29/100,000 in the central region and 1.98/100,000 in the southern
region). However, melioidosis-clustered areas are confined to 5 to 7.5 km2 hot spots containing high-
density populations, but B. pseudomallei-contaminated environments are located >5 km northwestern
of the periphery of these hot spots. The observation that the concentration of B. pseudomallei-specific
DNA in aerosols was positively correlated with the incidence of melioidosis and the appearance of a
northwesterly wind in a hot spot indicated that airborne transmission had occurred in Taiwan. Moreover,
the isolation rate in the superficial layers of a contaminated crop field in the northwest was correlated
with PCR positivity in aerosols collected from the southeast over a two-year period. The genotype ST58
was identified by multilocus sequence typing in human and aerosol isolates. The genotype ST1001
has increased in prevalence but has been sporadically distributed elsewhere since 2016. These data
indicate the transmission modes and environmental foci that support the dissemination of melioidosis
are changing in Taiwan.
Keywords: melioidosis; Burkholderia pseudomallei; transmission modes
1. Introduction
Melioidosis is an emerging and fatally infectious disease that is endemic to Southeast Asia and
northern Australia [1]. However, its incidence may be underestimated in many regions, such as India,
South America, and Africa, because the disease is difﬁcult to diagnose due to its very diverse clinical
manifestations and the use of inadequate bacterial isolation and identiﬁcation methods. Annual disease
rates could be increasing worldwide as a result of transmission by travelers that were exposed to
contaminants in melioidosis-endemic areas [2–4]. Overall, approximately 165,000 human melioidosis
cases occur annually worldwide, and approximately 89,000 people die annually from this disease [5].
To date, no systematic international estimation of the clinical or sub-clinical incidence of melioidosis
has been performed using a consistent, standardized, and quality-controlled method under the same
health- or medically-controlled conditions. This makes it difﬁcult to adequately compare the incidence
of the disease among countries or regions and to predict the disseminated scope of melioidosis.
The pathogen underlying melioidosis is an environmental saprophyte and Gram-negative
bacterium called Burkholderia pseudomallei that is usually found in the soil and surface water, and is
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sometimes seen in air particles [6,7]. People acquire melioidosis from directly contacting, ingesting or
inhaling soil, water or dust contaminated with B. pseudomallei [8–10]. Nevertheless, melioidosis cases
are usually clustered during the rainy season, particularly after the appearance of a heavy rainfall,
cyclone, or typhoon [11–13]. The transmission modes of melioidosis probably differ because people’s
customs and lifestyles, as well as the geographical position of melioidosis case clusters differ. In this
review, we focus on studies of the incidence of melioidosis in Taiwan that provide insight into the
mechanism of melioidosis transmission.
2. Underestimated Period of Melioidosis in Taiwan (1984–2004)
The ﬁrst reported case of melioidosis in Taiwan involved a patient who acquired melioidosis
with multilobar pneumonia by drowning in the Philippines in 1984 [14]. Between 1984 and 2000,
12 pulmonary and two subcutaneous melioidosis cases and one melioidosis case with a mycotic
aneurysm were reported [15]. Of those patients, 73.3% (11/15) had no overseas travel history. Because
the symptoms of melioidosis are protean, melioidosis can go undetected. Its prevalence may therefore
have been underestimated by physicians in Taiwan during the earlier years of its presence. Because
B. pseudomallei is an uncertain airborne disease that belongs to a group of ‘selected agents’ that could be
utilized to develop bacterial weapons for bioterrorism [16], melioidosis in Taiwan has been classiﬁed as
a notiﬁable disease since 2000. This means that all of the culture-conﬁrmed cases of melioidosis should
be reported to the Centers for Disease Control (CDC) at the Department of Health in Taiwan. No case
was reported from 2000 to 2002, ﬁve were reported in 2003, and 13 were reported in 2004. However,
B. pseudomallei has consistently been isolated from soil at a depth of 30–60 cm in paddies in Taiwan
and other countries [17,18]. In synthetic soil or water media, B. pseudomallei can survive for 150 days or
more, indicating that affected Taiwanese individuals may have acquired melioidosis from indigenous
bacteria, rather than by traveling to endemic areas [19]. To explore the potential for exposure to
B. pseudomallei in Taiwan, an indirect ELISA (enzyme-linked immunosorbent assay) that targeted the
truncated ﬂagellin of the bacterium was developed [20]. Seropositive rates of approximately 4%, 2.8%,
and 5% were detected in northern, central, and southern Taiwan, respectively [21]. Approximately 3%
of the positive cases were patients with diabetes mellitus, which is a risk factor for melioidosis [22].
3. An Outbreak of Melioidosis in Taiwan (2005)
In 2005, after a typhoon event, melioidosis cases were clustered in the Er-Ren River Basin of Taiwan
during a three-month period [23]. In 2005, while 0.3 cases/100,000 population were infected throughout
the entire population of Taiwan, the incidence of melioidosis reached 122 cases/100,000 population in the
area downstream of the Er-Ren River Basin. In the affected area, the incidence rates were higher than
the 7.98–21.3 cases/100,000 population and 5.4–24.2 cases/100,000 population in Thailand and northern
Australia, respectively [24–26]. Approximately 75% of these melioidosis patients had B. pseudomallei
bacteremia, 50% had concomitant pleuropulmonary infections, and 20% died during hospitalization [27].
Pulsed-field gel electrophoresis (PFGE) typing revealed that two distinct genotypic clones appeared
during this outbreak [27]. These two distinct types have been demonstrated to be ST58 and ST99 by the
multilocus sequencing typing (MLST) method [28].
When compared with the seropositive rates of anti-B. pseudomallei ﬂagellin antibodies of 2.8–5% in
Taiwanese individuals before 2005, the rates were increased to as high as 36.6%, 21.6%, and 10.9% in the
downstream, midstream, and upstream regions of the Er-Ren River, respectively. Those seropositive
rates were associated with the incidence of melioidosis as follows: 120 cases/100,000 population in
the downstream region, 68 cases/100,000 population in the midstream region and 36 cases/100,000
population in the upstream regions. However, B. pseudomallei was only isolated from the soil in
the upstream region and never from the mid- or downstream regions, although PCR positivity to
B. pseudomallei-speciﬁc amplicons was relatively higher in mid- and downstream regions than in
upstream regions. People seemed to have acquired melioidosis through exposure to contaminated
soil that had ﬂowed down from the upstream river due to the heavy rain that was associated with
219
Trop. Med. Infect. Dis. 2018, 3, 26
the typhoon [26]. However, 70% (28/40) of the melioidosis patients in this outbreak denied recent
contact with mud or dirty water before their illness [27]. Approximately 32.8–34.8% of the 105 adults
who lived in the mid- and downstream areas of the Er-Ren River acknowledged having been ﬂooded
during this typhoon event [26].
After this outbreak, melioidosis was widely recognized as an indigenously emerging and fatally
infectious disease in Taiwan. The CDC (Taiwan) reinforced the education and management of melioidosis
usingmedical resources and improved the regulation of notifiablemelioidosis in Taiwan. Thus, the numbers
of melioidosis cases reported in the CDC database since this issue arose are more reliable than they
previously were [29]. From 2005 to 2007, the average incidences of melioidosis were 0.03 cases/100,000
population in northern Taiwan, 0.29 cases/100,000 in central Taiwan and 1.98 cases/100,000 in southern
Taiwan. The disease incidence was associated with PCR positivity for B. pseudomallei-specific amplicons,
which was found in 1.3%, 10.1% and 19.4% of environmental samples in northern, central, and southern
Taiwan, respectively. Viable B. pseudomallei was cultivated only from the soil in southern Taiwan (south of
the Tropic of Cancer; isolation rate, 12.6%), and environmental isolates were never found in central and
northern Taiwan (north of the Tropic of Cancer) [30]. B. pseudomallei is usually isolated from moist soil
or water in tropical and subtropical countries, and is rarely found in temperate countries [1]. Although
the favorable physical (pH and water content) and chemical (nutrients, salinity, organic, and inorganic
compounds) conditions for the growth of B. pseudomallei are inconsistent in many soil studies [19,31–34],
B. pseudomallei can thrive in rice fields when nutrients (e.g., fertilizer) are depleted during agriculture
practices and rice field management [31]. After harvesting rice, the straw is frequently burned in the rice
field in Taiwan. The presence or absence of B. pseudomallei related to rice field management in Taiwan is
unknown. However, the soil, even if relatively dry, may act as a reservoir during the dry season, with an
increase in the proliferation and potential for mobilization from soil into water in the wet season [35].
4. A Plateau in the Incidence of Melioidosis in Taiwan (2008–2012)
In 2008–2012, the annual incidence of melioidosis among the entire Taiwanese population increased
to 0.19 cases/100,000 population as compared with 0.07 cases/100,000 population in 2007 [36]. Most of the
cases were geographically clustered in the Er-Ren River Basin (size, 108 km2; population, 79,790 people)
and Zoynan region (size, 60 km2; population, 127,438 people) in Taiwan [36,37]. The average incidences
of melioidosis in both regions reached 16.7 cases/100,000 population (Er-Ren River Basin) and 10.9 cases/
100,000 population, respectively, from 2008 to 2011 (Zoynan region). Approximately 62.5–67% of melioidosis
patients were unemployed and had no recent travel history because most patients were elderly or
had chronic diseases, such as diabetes, renal failure, or cancer [37,38]. Acute pulmonary melioidosis
predominated (>70%). Furthermore, 88% of melioidosis cases were found during the rainy season,
and 22% of the patients died [38]. Based on molecular tracing observations, ST99 (multilocus sequencing
typing) was prevalent in the Er-Ren River Basin in 2005, but ST58 was found in the Zoynan region in
2008–2009, indicating that the epidemic strains of melioidosis were altered because the environmental foci
contaminated with B. pseudomallei differed [28].
Two hot spots for melioidosis occurred 10.3 km apart, but the climatic conditions, including rainfall
and wind strength, were different because the topographical characteristics differed, as described below.
The Er-Ren River Basin is a plain, and the Zoynan Region is a hilly area. Rainfall that lasts for a period
of 4–7 days is a trigger factor associated with an increase in melioidosis cases in both areas. However,
rainfall lasting 6–8 days and wind with a speed >19 m/s (>17.2 m/s is defined as a typhoon) and a specific
angle of wind direction (150◦, 220◦, or 280◦) are associatedwith increases in the number ofmelioidosis cases
in the flat Er-Ren River Basin. In the hilly Zoynan region, these wind speeds, when combined with rainfall
lasing five days, was also associated the incidence of melioidosis [37]. In Taiwan, over 80% of melioidosis
cases occurred in the rainy season when the typhoon appeared [13,26,27]. It is not surprising that the
wind speed (>19 m/s) was associated with the occurrence of melioidosis in Taiwan. When considering
the epidemiological survey described above, in the Er-Ren River Basin, B. pseudomallei was isolated from
upstream areas, but melioidosis cases were increased in the mid- and downstream areas [26]. The direction
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of the sampled site contaminated with B. pseudomallei at the hot spot is from the southeast to northwest.
Thus, the wind, with a 150◦ angle, as a vector could assist the transmission of B. pseudomallei to the patients
if the airborne particles (aerosols) were generated from contaminated soil or water.
In contrast, in the Zoynan region, if a strong northwest wind originating from a counterclockwise
cyclone occurred during the season the typhoon appeared, the incidence of melioidosis should be higher
in the southeast districts, even though B. pseudomallei is isolated from environments in the northwestern
region. In particular, the hills located south of the Zoynan region become a natural barrier to obstruct
the transmission of aerosols contaminated with B. pseudomallei. Indeed, 96% (80/83) of melioidosis cases
occurred north of the hilly Zoynan region, but rare cases occurred south of the Zoynan region [37].
To test this hypothesis, we first demonstrated that the concentration of B. pseudomallei-specific amplicons
was increased in the rainy season when the typhoon appeared when compared with that in the dry
season when the appearance of a typhoon is rare [39]. By sampling randomly but with an even
distribution geographically as much as possible, several sites contaminated with B. pseudomallei in the
northwestern wetted, cropped, or non-cropped soil of the hot spots were identiﬁed. The concentration
of B. pseudomallei-speciﬁc amplicons in aerosols was positively correlated with the incidence of
melioidosis and the appearance of a northwesterly wind. Moreover, the isolation rate in the superﬁcial
layers of the contaminated cropped ﬁeld in the northwest was correlated with PCR positivity for
aerosols that were collected from the southeast from 2011–2013. The genotype ST58 of B. pseudomallei
was identiﬁed from soil, aerosol, and human isolates. The airborne transmission of melioidosis was
demonstrated to move from contaminated soil to aerosols and/or to humans in the Zoynan region [6].
5. A New Hot Spot of Melioidosis in Taiwan (At the Present Time)
From 2000 to 2017, 516 melioidosis cases were reported in Taiwan. As melioidosis is a tropical
disease, approximately 86% (444/516) of cases are geographically distributed south of the Tropic
of Cancer in Taiwan (Figure 1A). Over 50% (223/444) of the cases were successively clustered in
the Er-Ren River Basin in 2005 and in the Zoynan region in 2008–2012, and in Siaogang–Fengshan,
more sporadic cases with subcutaneously localized infection have occurred since 2003 (Figure 1B).
Usually, acute pulmonary melioidosis with bacteremia is clustered after extreme climate events,
for example, heavy rainfall and typhoons, but melioidosis with localized infection can occur in dry
seasons. For example, patients who were admitted with melioidosis 7–14 days after heavy monsoonal
rainfall (188 mm) were more ill or were more likely to die (rainfall >211 mm) in Australia [40].
Over 1000 mm of rainfall during the wet season and a wind speed of >19 m/s (Er-Ren River Basin)
were indicators for melioidosis occurrence in Taiwan [27,37,38]. The genotype ST1001 of B. pseudomallei
was found in melioidosis patients dwelling in Siaogang–Fengshan in 2016. ST58 was prevalent in
soil and human isolates during 2008–2012, while ST1001 has been sporadically found in humans
and the environment. Both representative strains, vgh07 (ST58) and vgh16 (ST1001), have been
sequenced. The vgh07 (ST58) strain contains 16 genomic islands, including a potential pathogenic
island that harbors an invasive hemolytic gene, but vgh16 (ST1001) did not harbor any genomic
island [41,42]. When the BALB/c mice were infected with the strains intravenously and the strains
were re-isolated from liver extracts and used to re-infect the mice intravenously, repeatedly, the
phenotypic levels of 3-hydroxytetradecanoic acid (an indicator of lipopolysaccharide of B. pseudomallei),
bioﬁlm formation and ﬂagellar expression in both types were signiﬁcantly increased when compared
with those in the original parent strains. Moreover, the survival rates of the mice infected with
both types that re-isolated from liver extracts were obviously decreased, indicating that the animals,
as reservoirs, could increase the virulence of B. pseudomallei [43]. An environmental strain isolated
from Pahang, Malaysia, was reported to show up-regulation of adhesins, virulence factors, and stress
response-related proteins when the strain was injected intra-peritoneally into a mouse and re-isolated
from the spleen [44]. If ST1001 persists in animals that serve as reservoirs for a long time, this strain
can develop an increased virulence.
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More research is needed to explore themolecular links among the environment, animals, and humans
in Siaogang-Fengshan. However, since 2015, political considerations have resulted in a CDC (Taiwan)
policy that involves tightly regulating the biosecurity and biosafety of B. pseudomallei. The ability to use a
large panel of B. pseudomallei strains for molecular typing, as was previously possible, is now restricted.
Only six strains, including ST1001, were identified in the soil (n = 3), animals (n = 1), and humans (n = 2)
in Siaogang-Fengshan from 2015 to 2017. Their virulence in animals has not yet been determined.
Figure 1. Geographical distribution of melioidosis in Taiwan. (A) In the entire island with the case
number shown in brackets. (B) In Kaohsiung district. Two hot spots (Er-Ren River Basin and Zoynan
Region) and Siagogan-Fengshan (location, case number, and year in which it occurred) are shown as
red color.
6. Unresolved Problems Related to Melioidosis Dissemination in Taiwan
Melioidosis in Taiwan has successively clustered in certain areas, such as the Er-Ren River Basin,
Zoynan regions, and Siaogang-Fengshan, consisting of small-sized regions with areas containing
approximately 5–7.5 km2, and has spread through different transmission modes or via exposure to
different environmental foci [36]. As our insight into the geographical distribution of melioidosis cases
and environmental foci improves, physicians will be able to increase alertness and awareness, leading
to better control of the disease.
However, the pH value, solar strength, moisture, organic or inorganic content, temperature changes,
and salinity of soil each affect the growth of B. pseudomallei in the environment [9,19,31–34]. To detect the
presence of B. pseudomallei in the environment, the PCR detection rates are usually higher than those of
microbiological cultures in our studies [6,26,30,36]. The presence of phages in B. pseudomallei strains has
been reported to decrease their successful isolation from environmental samples [45]. Both B. cenocepacia
and B. multivorans, which are antagonistic to B. pseudomallei, are widely distributed throughout the rice
fields of Taiwan [46]. The secondary metabolites of Bacillus amyloliquefaciens isolated from soil can kill
B. pseudomallei in vitro [47]. The amoeba Paravahlkampfia ustiana and some Acanthamoeba sp. are predators
that graze on B. pseudomallei, while Hartmannella spp. and Acanthamoeba astronyxis may be reservoirs of
B. pseudomallei in soil or water [48–50]. The physical or chemical parameters influencing the growth of
B. pseudomallei in the environment are not completely understood in Taiwan. Although the geographical
distribution of B. pseudomallei in the environment is very uneven, high isolation rates in soil or water are
usually associated with a high incidence of melioidosis in surveys using a large area [26,30,36].
However, melioidosis-clustered cases are distributed within 5–7.5 km2 of the hot spot regions
with high-density populations, but an environment contaminated with B. pseudomallei was located
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>5 km away from the periphery of the hot spot [6,36]. When most of the patients in a population are
elderly or have diabetes and cannot participate in outdoor activities, a characterization of the vectors
that carry contaminated B. pseudomallei should be performed [37,38]. The airborne transmission of
infectious agents from aerosols to humans has been epidemiologically demonstrated using molecular
linking and statistical methods. However, the ﬁnding that the isolation rates of B. pseudomallei in
aerosols are very low contradicts the notion that the contaminated sources are contained in aerosols [6].
Additionally, in a rice paddy ﬁeld in Ubon Ratchathani, northeast Thailand, B. pseudomallei was never
isolated from air and rainwater samples during a 13-month prospective study [7]. In the absence of
improved isolation techniques, it is uncertain whether environmental uncultivated B. pseudomallei can
be considered an infective source.
Alternatively, it remains unclear how people become easily exposed to contaminated water or soil.
In Taiwan, approximately 20% of water samples that were obtained in the Zoynan regions after 2012
appeared to contain B. pseudomallei-speciﬁc amplicons [36]. In contrast, the content of B. pseudomallei in
samples obtained from rice ﬁeld water is reportedly as high as 60% in Thailand [7]. The occupational
risk of melioidosis is correlated with a farmer’s exposure to contaminated soil through agricultural
activity; approximately 86% of those diagnosed with melioidosis also lived near a river in Liao [1,51].
Spatial analysis revealed that, in northern Australia, melioidosis is particularly endemic in Townsville,
north Queensland, where one set of melioidosis cases was clustered in the area of the old course
of a major waterway [52]. In the Northern Territory of Australia, all of the B. pseudomallei-positive
environmental sites (n = 104) were permanently waterlogged, or waterlogged during the wet season,
or were irrigated [53]. Water serving as a transmission vehicle for B. pseudomallei has been suggested
when melioidosis case clusters are associated with the water supply [54,55]. Ingestion of or contact
with water contaminated with B. pseudomallei is probably the transmission mode. However, more
importantly, Taiwanese individuals, especially the elderly or patients, drink boiled water or routinely
avoid being in close proximity to rivers or waterlogged areas.
The A. lenticulata PT-14 strain was isolated from a well after a ﬂood disaster caused by a typhoon
and could become a host of the endosymbiont Burkholderia spp., as the 16S RNA genes of the bacterium
were detected in the amoeba. A. lenticulata is widely distributed in aquatic and terrestrial environments
and frequently contains various bacterial endosymbionts, such as Mycobacterium sp., Legionella sp.,
and Burkholderia sp. [56–58]. In an in vitro study, A. lenticulata PT-14 displayed endosymbiosis
with B. pseudomallei vgh07 (ST58) and vgh16 (ST1001) (data not shown). The levels of A. lenticulata
distributed in river or drinking water reservoirs differ according to season; speciﬁcally, certain 18S
RNA genes of A. lenticulata are frequently detected during September to November [59,60], a period
in which typhoon invasion usually occurs. Typhoons are an important environmental phenomenon
that triggers the incidence of melioidosis case clusters and is associated with high detection rates
of B. pseudomallei-speciﬁc amplicons in water [13,35,36]. The intracellular survival of bacteria in
amoeba was not only evolutionally designed to protect the bacteria from the harsh conditions of
the environment, but also to enable the bacteria to develop a virulence that allows intracellular
growth in mammals [61]. Thus, endosymbiotic B. pseudomallei, if they exist, not only interfere with
microbiological cultures using ﬁltered water, likely from sampling in Taiwan, but also become an
alternative transmission mode of melioidosis from water to humans.
7. Conclusions
As an emerging and fatally infectious disease, melioidosis occurs because of exposure to soil or
water contaminated with B. pseudomallei. Over 50% (223/444) of melioidosis cases were successively
clustered in the Er-Ren River Basin in 2005 and in the Zoynan region in 2008–2012, and cases were also
sporadically distributed throughout the Siaogang-Fengshan region in Taiwan. Subcutaneous inoculation,
ingestion, and inhalation of contaminated soil or water are the main routes of melioidosis transmission.
In 2005, individuals in the Taiwanese population acquired melioidosis seemingly through exposure to
contaminated soil that flowed downstream from an upstream river area. While the upstream area had
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soil from which B. pseudomallei was isolated at high rates, the downstream region had a high incidence
of melioidosis and high sero-prevalence for anti-B. pseudomallei antibodies. In 2008–2012, in the Zoynan
region, melioidosis-clustered cases increased after typhoon events. In a prospective study, aerosols that
contained B. pseudomallei-specific DNA were well distributed in the densely populated districts, but were
rarely found in their surrounding areas. The concentration of specific DNA in aerosols was correlated
with the melioidosis incidence and northwesterly wind in this endemic area. The isolation rate in the
superficial layers of the contaminated crop field in the northwest was correlated with the PCR positivity of
aerosols collected from the southeastern district over a two-year period. Because a strong northwest wind
originating from a counterclockwise cyclone occurred during the wet season with a typhoon, the number
of melioidosis cases was increased in a southeast district when B. pseudomallei was isolated from the
northwestern region. Thus, melioidosis is airborne and was transmitted from contaminated soils to
aerosols and/or to humans in Zoynan regions from 2008 to 2012. B. pseudomallei vgh07 (a representative
strain of ST58) and its similar strain, which has a high virulence, have been prevalent in human and
environmental isolates; however, the vgh16 strain (a representative strain of ST1001) and similar strains,
with low virulence, were isolated from 2003 to 2016. If the ST1001 strain shows long-term persistence
in animals or the environment as reservoirs, it could develop an increased virulence and potentially
cause another outbreak in Taiwan. Although airborne transmission from aerosols to humans can occur
in Taiwan, B. pseudomallei has a very low isolation rate in aerosols. Ingesting or coming into contact
with water contaminated with B. pseudomallei is the likeliest mode of melioidosis transmission. However,
more importantly, drinking boiling water and routinely avoiding proximity to rivers or waterlogged areas
are common practices among the Taiwanese population. Most of the patients with melioidosis denied
having contact with contaminated soil or water. Alternatively, the aim of endosymbiont B. pseudomallei
to protect itself in harsh environments and develop a virulence to allow its intracellular growth in
mammalian cells is likely another mode of melioidosis dissemination in Taiwan.
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Abstract: A recent modelling study estimated that there are 2800 deaths due to melioidosis in
Thailand yearly. The Thailand Melioidosis Network (formed in 2012) has been working closely
with the Ministry of Public Health (MoPH) to investigate and reduce the burden of this disease.
Based on updated data, the incidence of melioidosis is still high in Northeast Thailand. More than
2000 culture-conﬁrmed cases of melioidosis are diagnosed in general hospitals with microbiology
laboratories in this region each year. The mortality rate is around 35%. Melioidosis is endemic
throughout Thailand, but it is still not uncommon that microbiological facilities misidentify
Burkholderia pseudomallei as a contaminant or another organism. Disease awareness is low, and
people in rural areas neither wear boots nor boil water before drinking to protect themselves from
acquiring B. pseudomallei. Previously, about 10 melioidosis deaths were formally reported to the
National Notiﬁable Disease Surveillance System (Report 506) each year, thus limiting priority setting
by the MoPH. In 2015, the formally reported number of melioidosis deaths rose to 112, solely
because Sunpasithiprasong Hospital, Ubon Ratchathani province, reported its own data (n = 107).
Melioidosis is truly an important cause of death in Thailand, and currently reported cases (Report 506)
and cases diagnosed at research centers reﬂect the tip of the iceberg. Laboratory training and
communication between clinicians and laboratory personnel are required to improve diagnosis
and treatment of melioidosis countrywide. Implementation of rapid diagnostic tests, such as a
lateral ﬂow antigen detection assay, with high accuracy even in melioidosis-endemic countries such
as Thailand, is critically needed. Reporting of all culture-conﬁrmed melioidosis cases from every
hospital with a microbiology laboratory, together with ﬁnal outcome data, is mandated under the
Communicable Diseases Act B.E.2558. By enforcing this legislation, the MoPH could raise the priority
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of this disease, and should consider implementing a campaign to raise awareness and melioidosis
prevention countrywide.
Keywords: Burkholderia pseudomallei; melioidosis; Thailand; mortality; diagnosis; surveillance;
awareness; treatment; prevention
1. Introduction
Indigenous melioidosis was ﬁrst reported in Thailand by Chittivej et al. in 1955 [1]. The patient
came from Saraburi Province, Central Thailand, presenting at Pramongkutklao Hospital, Bangkok, with
lymphadenopathy. Pus collected from the patient was culture positive for Burkholderia pseudomallei [1].
In 1976, melioidosis was selected as the main discussion topic at the ﬁrst meeting of the Infectious
Disease Group of Thailand (now known as the Infectious Disease Association of Thailand) [2]. A total of
15 culture-conﬁrmed melioidosis patients diagnosed in Bangkok up to 1976 was noted, and the clinical
epidemiology of six fatal cases and two cases with unknown outcomes was discussed, raising the
public health threat caused by melioidosis countrywide [2]. Subsequent workshops on melioidosis and
interhospital case conferences organized by the Infectious Disease Group of Thailand and university
hospitals increased the awareness of all physicians and laboratory staff of the need to look for
melioidosis and B. pseudomallei, respectively, countrywide [3]. By 1985, 743 culture-conﬁrmed cases
of melioidosis had been reported from many provinces in Thailand; including Khon Kaen (n = 386;
mortality 50%), Ubon Ratchathani (n = 169; mortality 61%), Bangkok (n = 91), Chiang Mai (n = 61),
Nakhon Ratchasima (n = 30), Nonthaburi (n = 11), and Songkla (n = 6) [4].
In Thailand, underrecognition and misdiagnosis of melioidosis have been major obstacles to
saving lives from this disease. Worldwide, untrained laboratory personnel commonly misidentify
B. pseudomallei as a contaminant or other organism [5]. Leelarasamee et al. reported a total of
1165 isolates of B. pseudomallei identiﬁed in 46 hospitals from four regions of Thailand in 1995
(Northeast (n = 19), Central (n = 11), North (n = 9) and South (n = 7)) [6]. Nonetheless, the isolation rates
were suspiciously low or absent in many hospitals when compared with adjacent hospitals that had
reported very high numbers of melioidosis cases [6]. Focused training revealed that the microbiological
laboratories in hospitals with unusually low numbers of melioidosis cases had misidentiﬁed the
organisms, and the incidence rates of melioidosis in their areas were, in reality, also high [3].
From 1995 to 2015, melioidosis was heavily reported from Northeast Thailand [7,8] and rarely
reported from the other regions. This led many clinicians and researchers to the misapprehension
that melioidosis was not endemic in all regions of Thailand [9,10]. In this report, we review the latest
information on melioidosis in Thailand and show that training in B. pseudomalleii identiﬁcation for
laboratory personnel is still needed countrywide.
The case fatality rate (CFR) of melioidosis in general hospitals in Thailand decreased markedly
from 60–70% to 35–40% after the landmark study comparing ceftazidime with ‘conventional’ treatment
was published in 1989 [11]. Unfortunately, in 2018—20 years later—the CFR of melioidosis in
public hospitals is still around 30–35% [7,8]. Although the reported CFR is lower in university
hospitals, at around 10–20% [9,12], most people in Thailand receive medical care in public hospitals,
and university hospitals focus on tertiary care, providing service to less than 5% of the general
population [13]. Generic ceftazidime is widely available, and the cost is covered by the universal
coverage scheme; therefore, lack of effective antibiotics is not the issue in Thailand. To further reduce
the CFR, it is likely that heavy investment in intensive care units, an increase in the ratio of nurses
and doctors to patients, and an improvement in laboratory diagnostic capacity is needed. This has
been done successfully in Australia, where the CFR of melioidosis is now approximately 10% [14–17].
For resource-limited countries such as Thailand, it might be better to invest in prevention campaigns
and stop people from contracting melioidosis. However, the necessary developments leading to
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national prevention campaigns are impeded by the lack of disease awareness among lay people, lack
of a national campaign by the MoPH to raise such awareness [18,19], and lack of ofﬁcial mortality data
to support MoPH activities.
It is still unknown how many patients die of melioidosis in Thailand yearly. A recent modeling
study estimated that there are 7572 human melioidosis cases per year in Thailand, of whom 2838
(37%) die [8]. This is strongly supported by publications showing high numbers of culture-conﬁrmed
melioidosis cases diagnosed annually at major public hospitals in Thailand. Approximately 400 cases
are diagnosed at Sunpasitthiprasong Hospital, Ubon Ratchathani, each year, of which about 150 result
in death [7,20]. At Nakhon Panom Hospital, about 100 cases are diagnosed each year with about
30 deaths [21,22]. Melioidosis is one of the 83 diseases notiﬁable by law under the National
Communicable Disease Surveillance system in Thailand. However, only 15, 10, 13, 4, and 12 deaths
caused by melioidosis were ofﬁcially reported to the Thailand disease surveillance system (Report 506)
in 2010, 2011, 2012, 2013, and 2014, respectively [23–27]. It has been advised by the Bureau of
Epidemiology, MoPH, that the total number of deaths based on Report 506 should not be used
to represent the burden of the disease. However, these numbers have been used periodically
by policymakers to represent the burden of melioidosis in Thailand to the public via the mass
media (including newspapers and television broadcasts) [28]. Stakeholders occasionally compare the
reported number of deaths due to melioidosis (for example, 12 deaths in 2014) with that of dengue
(49 deaths in 2014) and leptospirosis (24 deaths in 2014) [28], and regard melioidosis as less important.
Therefore, the lack of ofﬁcial melioidosis death reports via Report 506 hampers initiatives to improve
awareness, diagnosis, treatment, and prevention of melioidosis in Thailand.
The Thailand Melioidosis Network was formed in 2012, and has been working closely with the
MoPH to investigate the burden, solve the problems of underreporting by Report 506, and develop
initiatives on melioidosis. Here, we review the current guidelines for diagnosis, treatment and
prevention of melioidosis in Thailand, explore how to improve the ofﬁcial data and increase awareness
of melioidosis. We discuss the needs and future challenges to save lives from melioidosis in Thailand.
2. Melioidosis Cases and Presence of B. pseudomallei in Thailand
We reviewed evidence of melioidosis and presence of B. pseudomallei from 1910 to 2015 in Thailand
(Figure 1). We searched PubMed for indigenous cases of melioidosis reported using the MeSH terms
‘melioidosis’ or ‘pseudomallei’ and ‘Thailand’. We also searched bibliographies from selected studies for
secondary references. We included literature in English and Thai. Only culture-conﬁrmed cases and
cultures positive for B. pseudomallei from environmental samples were included. Clinically-suspected
and serologically diagnosed melioidosis cases were excluded because of poor sensitivity and speciﬁcity
of clinical manifestations and serological diagnostic tests for melioidosis [5]. We have described the
evidence in each of six regions in Thailand: Northeast, North, East, West, South, and Central Thailand.
This six-region division, developed by the National Geographic Committee in 1977, was used because
it was set up for geographical and scientiﬁc purposes [29].
2.1. Northeast Thailand
Melioidosis is regarded as highly endemic in Northeast Thailand (Figure 1). It is the largest region
of Thailand, and is divided into 20 provinces. This region is a plateau surrounded by mountain ranges,
and much of the arable land consists of tropical sandy soil. Most of the published case reports and
cohorts arise from four provinces: Khon Kaen, Nakhon Panom, Udon Thani, and Ubon Ratchathani.
Srinagarind University, the Melioidosis Research Centre (MRC), Thailand MoPH–US Centers for
Disease Control and Prevention Collaboration (TUC), and Mahidol Oxford Tropical Medicine Research
Unit (MORU) have been collaboratively doing research with provincial hospitals in these four provinces
for more than a decade. The published evidence demonstrates that melioidosis is highly endemic
throughout the region. A study reported that 19 provincial hospital laboratories in Northeast Thailand
diagnosed 1865 culture-conﬁrmed cases of melioidosis in 2007 [7]. An environmental sampling study
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conducted in 2015 also found that B. pseudomallei is commonly present in six of the seven provinces
evaluated, including Burirum, Chaiyaphum, Khon Kaen, Udon Thani, Nong Bua Lam Phu, and Loei,
the exception being Nakhon Ratchasima [30]. We believe that the failure to detect B. pseudomallei in
Nakhon Ratchasima is likely to be a false-negative result due to small sample size and poor sensitivity
of the environmental sampling method [30], because B. pseudomallei is commonly found in clinical
specimens in Nakhon Ratchasima Hospital [6]. The preliminary results of a large environmental
study conducted by the Asia Partnership on Emerging Infectious Disease Research also found that
B. pseudomallei was prevalent in ﬁelds on both sides of the main roads in Mukdahan province [31].
An increase in the total number of culture-conﬁrmed cases diagnosed in Northeast Thailand, from
964 cases in 1994 (assuming one isolate per case) [6] to 1865 in 2007 [7], could be due to an increase
in incidence rates of melioidosis, an increase in usage of bacterial culture as shown by the rise of
the number of blood culture bottles used per year [32], and/or improved access to healthcare [33].
A genuine increase in incidence rates of melioidosis could be due to the rise in the prevalence of
diabetes mellitus (an important risk factor for melioidosis) [34], the rising age of farmers in rural
areas [35], increased land use for irrigated agriculture and rice farming [8], and/or depletion of soil
nutrients caused by crop residue burning and poor farming practices [30]. The latter two points may
also have led to an increase in presence of B. pseudomallei in the environment [8,30].
A number of captive zoo animals [36] and domestic animals [10,37] have been reported to have
culture-conﬁrmed melioidosis, both in Northeast Thailand and in all other regions in Thailand. A study
by Kasantikul et al. on fatal culture-conﬁrmed melioidosis in captive zoo animals in Thailand from
1997 to 2013 reported the highest incidence from the Northeast (n = 12) and South (n = 12) regions,
followed by the East (n = 3), North (n = 1), and Central (n = 1) areas [36]. A descriptive study of
culture-conﬁrmed melioidosis in animals in Thailand from 2006–2015 by Kongkaew et al. also reported
a total of 81 goats, 28 pigs, 18 cattle, 17 sheep, and 27 other livestock/pets at seven Veterinary Research
and Development Center in six regions of Thailand [37].
2.2. North Thailand
North Thailand is composed of 9 provinces, some of which share a border with Myanmar and
Laos. Its geography is comprised of several mountain ranges and the basins of four major rivers,
which are tributaries of the Chao Phraya River in Central Thailand. Melioidosis has occasionally
been reported from Chiang Mai, the largest province in the region [4,38,39]. From 2001 to 2003,
26 culture-conﬁrmed cases were diagnosed at Maharaj Nakorn Chiang Mai Hospital, and 42% of them
died [38]. A survey by Trakulsomboon et al. in 1999 reported that B. pseudomallei could be found in
soil in North Thailand, but the details of locations were not reported, and an updated study has not
been conducted [40].
In September 2017, a workshop organized by the MoPH, MRC, and Thailand Melioidosis Network
was conducted at the Faculty of Associated Medical Sciences, Chiang Mai University, to provide
information on melioidosis, the potential pitfalls in the identiﬁcation of B. pseudomallei and diagnosis of
melioidosis to laboratory staff from 17 hospitals in North Thailand and other regions. The immediate
result was that Chiangkom Hospital, Phayao, North Thailand, diagnosed 20 culture-conﬁrmed cases
in 2017 [41]. During this workshop, we found that some provincial hospitals in North Thailand did not
have high quality biochemical tests to identify B. pseudomallei, and misidentiﬁcation as Pseudomonas
spp. or contaminants was common. A recent study from Chiangrai Prachanukroh Hospital, Chiang
Rai, also found that B. pseudomallei was commonly misidentiﬁed as Acinetobacter spp. [42]. Lack of
laboratory staff training and the absence of an algorithm for identifying Gram-negative bacilli were
likely to have been the main causes of the misidentiﬁcation. In addition, the clinicians and laboratory
staff were unaware that they were ofﬁcially obliged to report culture-conﬁrmed cases to the disease
surveillance system (Report 506).
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2.3. East Thailand
East Thailand is characterized by short mountain ranges alternating with alluvial plains.
This region was historically not considered an endemic area for melioidosis; however, population-based
surveillance activities by TUC in Sa Kaeo province, located on the Cambodian border about
200 kilometers from Bangkok, indicated otherwise [22]. Estimates from this project showed the average
incidence of bacteremic melioidosis in Sa Kaeo from 2006–2008 to be 4.9 cases per 100,000 population
(95% conﬁdence interval (CI) = 3.9–6.1), with a population mortality rate of 1.9 per 100,000
(95% CI = 1.3–2.8) [22]. The annual incidence in Sa Kaeo was approximately 1/3 less than that
determined for Nakhon Panom, an area considered highly endemic for B. pseudomallei, in this same
study [22]. The CFR, however, was slightly higher in Sa Kaeo province at 44%, compared to Nakhon
Panom province at 34% (P = 0.1) among patients with known outcomes from bacteremic melioidosis.
These ﬁgures are likely to underestimate the true burden of B. pseudomallei, as the surveillance was
focused on hospitalized cases. This study shows that the incidence of bacteremic melioidosis in Eastern
Thailand is much higher than the ﬁgures reported to Report 506 of MoPH, Thailand suggest.
A descriptive study of animal melioidosis between 2006–2010 also reported a high number of
culture-conﬁrmed human melioidosis in two Eastern provinces, Chachoengsao (151 human cases and
2 goats), and Chonburi (76 human cases and 1 goat), where goat cases were diagnosed [10]. A recent
environmental study also found B. pseudomallei to be highly prevalent in all six provinces (Sa Kaeo,
Chachoengsao, Chonburi, Chanthaburi, Prachinburi, and Rayong) in East Thailand [30].
2.4. West Thailand
The geography of West Thailand is characterized by high mountains and steep river valleys
along the border with Myanmar. Diagnosis of culture-conﬁrmed melioidosis was rare within West
Thailand until recently [10]. A descriptive study of melioidosis between 2006 and 2010 found a number
of culture-conﬁrmed human cases in two provinces, Ratchaburi (50 human cases and 16 goats) and
Phetchaburi (8 human cases and 1 goat) [10]. A descriptive study of animal melioidosis by Kongkaew
et al. also reported a high incidence of animal melioidosis in Ratchaburi, West Thailand, compared to
all other provinces in the country [37].
During the workshop conducted at Chiang Mai University, North Thailand, in September 2017,
laboratory staff from Somdejphrajaotaksin Maharaj Hospital, Tak, West Thailand, also participated.
After the workshop, 3 culture-conﬁrmed cases were diagnosed at the hospital that year [43].
TUC contacted Maesot General Hospital, Tak province, and noted that 15 bacteremic melioidosis
patients had been diagnosed from 2013 to 2017. Finkelstein et al. also reported ﬁnding B. pseudomallei
in soil samples collected from Prachuap Khiri Khan, West Thailand [44]. These results suggest that
human melioidosis might have been misdiagnosed and underreported in West Thailand, which is on
the border with Myanmar where melioidosis was ﬁrst discovered in 1912 [45]. Training to improve
diagnosis of melioidosis should include provincial hospitals in West Thailand.
2.5. South Thailand
South Thailand is famous for its beautiful beaches. The western part has steeper coastlines
and is on the Andaman Sea, while the east side is mainly river plains and on the Gulf of Thailand.
Melioidosis is increasingly recognized as endemic in South Thailand. One of the most striking
phenomena was a number of culture-conﬁrmed cases reported from tsunami survivors in 2004 in
Phangnga [46–48], on the west coast of South Thailand. A foreign tourist was also suspected to have
acquired melioidosis at Koh Samui, an island in Surat Thani on the east coast of South Thailand [49].
In 2012, an outbreak of 11 culture-conﬁrmed cases (3 foreign tourists and 8 Thais) was observed in Koh
Phangan, another island in Surat Thani on the east coast, and an environmental survey established that
B. pseudomallei was widely found in water supplies on Koh Phangan [50]. Churangsuk et al. recently
reported that, between 2002–2011, 134 culture-conﬁrmed patients were diagnosed at Songklanagarind
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Hospital, Hat Yai, South Thailand [9]. Overall, 50% had localized infection, 37% were blood culture
positive, and the CFR was 7% [9]. The low CFR is likely to be due to the high proportion of patients
with localized infection [9], compared to cohorts diagnosed in other regions. Finkelstein et al. also
reported the ﬁnding of B. pseudomallei in all 14 provinces in South Thailand [44]. Therefore, it is
possible that melioidosis is endemic in all provinces, and further studies are needed to reveal the
true burden of melioidosis in South Thailand. A training workshop was organized by MRC, Prince
Songkla University (PSU), and Thailand Melioidosis Network during 20–21 December 2017 at PSU.
A standard operating procedure (SOP) for laboratory diagnosis was provided, and laboratory staff
from 6 provinces participated. The preliminary unofﬁcial report from the ofﬁce of Disease Control in
Songkla showed a signiﬁcant number of melioidosis patients, with high mortality [51].
2.6. Central Thailand
Central Thailand is a large plain consisting of clay soil. It includes 21 provinces and the Greater
Bangkok area, and all published evidence of culture-conﬁrmed human cases come from university
hospitals in this area (Figure 1a). Most published cases report a history of travelling to Northeast
Thailand, leading to the general understanding that those cases acquired B. pseudomallei outside
the region, and that melioidosis is not endemic in Central Thailand. However, recent evidence in
2014 showed the presence of culture-conﬁrmed melioidosis in ten goats in Bangkok, suggesting
that B. pseudomallei might be covertly present in the environment in the central region and in
Bangkok (Figure 1b) [52]. In addition, an environmental study published in 2016 conducted in
seven provinces in central Thailand also conﬁrmed the presence of B. pseudomallei in Phitsanulok,
Phetchabun, and Nakonnayok (Figure 1c) [30]. It is likely that melioidosis cases are occurring in
those three provinces, but they are possibly misdiagnosed and not reported. A recent animal study
also found that both captive animals in a zoo and domestic animals had died of culture-conﬁrmed
melioidosis in Central Thailand [36,37]. During the workshop conducted at Chiang Mai University,
laboratory staff from Uthai Thani, Central Thailand, also participated. In 2017, after the workshop,
a total of 35 culture-conﬁrmed cases were diagnosed at Uthai Thani hospitals [53]. These ﬁndings
all strongly suggest that the common statement, ‘melioidosis is not endemic in Central Thailand’,
is incorrect.
Figure 1. Evidence and distribution of melioidosis in Thailand from 1910 to 2015. Red icons represent
geolocated records of culture-conﬁrmed human cases (1a), culture-conﬁrmed animal cases (1b) and
presence of B. pseudomallei (1c). Green, orange, pink, rose, blue, and yellow colors represent Northeast,
North, East, West, South, and Central Thailand, respectively. Interactive data are available online [54].
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Geographically, melioidosis is likely to be endemic throughout Thailand. Action is needed to
evaluate whether B. pseudomallei isolated from clinical samples in all regions can be accurately identiﬁed
by laboratory personnel in hospitals, whether melioidosis cases are diagnosed and treated correctly,
and whether all culture-conﬁrmed melioidosis cases observed in each hospital, including university
hospitals, are reported to Report 506 accurately.
3. Current Recommendations and Availability of Measures against Melioidosis
Currently there are no ofﬁcial, national guidelines for diagnosis, treatment and prevention of
melioidosis in Thailand. In general, the international consensus guidelines for diagnosis [5] and
treatment [55] are used.
Microbiological facilities are largely available in all provincial hospitals [32]. Following international
sepsis campaigns [56], it is usual practice that doctors collect blood specimens for bacterial culture from
every patient who presents at a provincial hospital and is prescribed parenteral antibiotics. In our
experience, most Thai doctors do know about melioidosis and can diagnose and treat culture-conﬁrmed
cases of melioidosis appropriately if their laboratories can identify and report B. pseudomallei accurately.
However, there are no standard operating procedures (SOPs) or national guidelines for
identiﬁcation of B. pseudomallei. Most training and workshops are done ad hoc and do not include all
microbiological laboratories in the country. The issue of misidentiﬁcation of B. pseudomallei by many
laboratories indicates that formal, national SOPs and training are critically needed to improve the
identiﬁcation of B. pseudomallei.
4. Surveillance Systems and Reporting of Melioidosis in Thailand
TheNational Communicable Disease Surveillance system (Report 506) was established in Thailand
in 1968. Melioidosis has been one of the diseases for notiﬁcation since 2002. However, until 2014, only
about 10 fatal melioidosis cases per year were voluntarily reported in Report 506 [23–27]. The Thailand
Melioidosis Network, together with the MoPH, has been investigating the issue of why provincial
hospitals with microbiological facilities and fatal culture-conﬁrmed melioidosis cases do not report
them to the system. We found that many hospitals do not realize that they should report melioidosis
cases, say that they are too busy to report them, or do not want to report a rapid increase of fatal
melioidosis cases (for example, from 0 to 50 in a single province). We have been working through these
issues since 2012, providing reassurance to hospitals that no negative consequences will result if the
correct data are reported, that the MoPH is already aware of the situation, and that essential national
action to reduce the deaths caused by melioidosis cannot be implemented if data are not reported.
An improvement in reporting occurred in 2015. The number of melioidosis deaths formally reported
rose to 112 in 2015 and 100 in 2016, solely because Sunpasithiprasong Hospital, Ubon Ratchathani
province, began reporting (n = 107 and 87, respectively) [57? ]. It is likely that if all hospitals with
microbiological laboratories in Thailand were to report the outcomes of culture-conﬁrmed cases,
the total number of deaths caused by melioidosis could be higher than 1000 cases per year [7].
Since June 2016, reporting of culture-conﬁrmed melioidosis cases from every hospital with a
microbiology laboratory, together with ﬁnal outcome, has been mandated under the Communicable
Diseases Act B.E.2558 (A.D. 2015) [59]. Melioidosis is now one of the 57 diseases with a legal
requirement for notiﬁcation [59]. It is, therefore, important to educate and remind laboratory
staff, clinicians, statisticians, and epidemiologists to comply with the requirements of the existing
surveillance system by including every single case of melioidosis with cultures positive for
B. pseudomallei in their Report 506. By enforcing this legislation, the MoPH could raise the priority of the
disease, and should also consider implementing a large campaign to raise awareness and implement
melioidosis-prevention measures countrywide.
We believe that the main cause for the discrepancy between the estimated number of fatal cases
(n = 1000) and the model-predicted fatal cases (n = 2838) [8] is due to misdiagnosis and bacterial
misidentiﬁcation, which are still common outside Northeast Thailand.
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In addition to the failure of reporting culture-conﬁrmed cases, another important problem is the
reporting of serologically diagnosed cases from community hospitals to the Report 506 system. Many of
these cases are likely to be false positives, as it is well known that the indirect hemagglutination assay
(IHA) should not be used to diagnose melioidosis in endemic countries due to the high background
seropositivity [5]. This has led to a high number of false-positive melioidosis cases reported to Report
506, with few deaths, and therefore, reported CFRs are very low. For example, the CFR of melioidosis
was ofﬁcially reported as 0.5% (15/2902), 0.3% (10/3920), 0.2% (13/3711), 0.1% (4/2836), and 0.2%
(12/2544) for Report 506 in 2010, 2011, 2012, 2013, and 2014, respectively [23–27]. These incorrect CFRs
(ranging from 0.1 to 0.5%) have led to a false sense of security. People and policymakers mistakenly
believe that melioidosis is not an important infectious disease in Thailand, as less than 1% of reported
melioidosis cases were reported to have died. This is highly inaccurate, as the observed CFR of
culture-conﬁrmed cases in correctly designed studies in Thailand is between 30–35% [7,8].
The Thailand Melioidosis Network has proposed revising the reporting system to cover only
culture-conﬁrmed cases so that the true burden and true mortality (and CFR) could be demonstrated
to the MoPH. Nonetheless, due to the problem of maintaining diagnostic capacity for melioidosis at
community hospitals, the proposal was not accepted. The community hospitals require affordable
rapid diagnostic tests (RDT) with high accuracy (particularly with high positive predictive value in
melioidosis-endemic countries) to justify replacement of the IHA. Therefore, such an RDT is critically
needed for Thailand.
Currently, the MoPH is working to rectify the underreporting of deaths caused by melioidosis in
Report 506 by using (1) the hospital database known as ‘43 ﬁles reports’ and (2) existing microbiological
databases. The 43 ﬁle reports include International Statistical Classiﬁcation of Diseases 10 (ICD-10).
According to ICD-10, melioidosis is coded as A24. The MoPH is evaluating how many patients with the
ICD-10 code of A24 were reported to Report 506, and how many of those died countrywide. Other work
has used laboratory microbiological databases, and will evaluate how many patients with cultures
positive for B. pseudomallei were reported to Report 506, and how many of those died countrywide.
These activities will support the MoPH to improve understanding of the burden of melioidosis and the
discrepancies between cases diagnosed by attending physicians, microbiologically-conﬁrmed cases,
and those reported to Report 506.
5. Awareness of Melioidosis in Thailand
Awareness of melioidosis in the general Thai population is very low. A recent study showed
that 74% of lay adults had never heard of melioidosis, and 19% had heard of the disease, but had
no further knowledge [18]. Information about melioidosis is rarely given to the public by the mass
media, including television, newspapers, and radio stations. Basic information about the disease and
its prevention is also not taught in schools in Thailand [18]. In contrast, public awareness of other
common infections, such as HIV/AIDS, tuberculosis, malaria, leptospirosis, dengue, and inﬂuenza,
are high, as these topics are taught in schools and are frequently mentioned by the national media [18].
A contributing factor to poor awareness of the disease is that many melioidosis patients die
quickly before the microbiological results have been reported to the doctors caring for the patient.
Even for culture-conﬁrmed cases of melioidosis, doctors and healthcare workers are often too busy to
explain to patients and their families what melioidosis is. This is because the relatives have usually
never heard of this disease, and the explanation would take time. Most relatives in such scenarios are
informed that the cause of death was sepsis, septic shock, or bacteremia, without explaining about
melioidosis. They are also not informed about how to prevent other people in the family, or in the
community, from acquiring the same disease. Although those who survive melioidosis are educated
about the disease and receive oral eradicative treatment for up to 20 weeks, knowledge about the
importance of the disease is not effectively shared with their relatives, friends, or communities. This is
shown by the fact that most have never heard of the disease.
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6. Major Changes and/or Achievements
The Thailand Melioidosis Network was formed during a meeting in March 2012 [60]. The meeting
included scientists conducting melioidosis research and policymakers from across Thailand. The main
purpose was to (1) provide updated information to participants, (2) form collaborations among research
institutes and government authorities, and (3) discuss the important issues related to melioidosis in
Thailand, including epidemiology, diagnosis, treatment, prevention, public awareness, and public
engagement. The second meeting was held in September 2012 [61]. After the ﬁrst two meetings, group
email was used to communicate among the members.
The ﬁrst international congress devoted to melioidosis held in Thailand, entitled ‘International
Congress on Melioidosis’ with the theme ‘State of the art discoveries and trends towards the
21st century’, took place at the Siam City Hotel in Bangkok in 1998. The congress was organized
by the Chulabhorn Research Institute and the chairperson was Prof. StitayaSirisinha. There were
150 delegates from Thailand and several other countries. The meeting was later referred to as ‘The
2nd World Melioidosis Congress’, which has since been held every three years and rotated through
melioidosis-endemic countries. The international melioidosis meeting held in Kuala Lumpur, Malaysia
in 1994 and chaired by Prof. Savithiri Puthucheary was regarded as the ﬁrst World Melioidosis
Congress (WMC). The 3rd and 4th WMC were held in 2001 in Perth, Australia, and 2004 in Singapore,
respectively. In 2007, the 5th World Melioidosis Congress was again held in Thailand at Khon Kaen
province and hosted by MRC, with Prof. Surasak Wongratanacheewin as chairperson [62], followed
by the 6th WMC in Townsville, Australia. In 2013, over 300 delegates from 24 countries attended the
7th WMC in Bangkok [63]. It was hosted by MORU and the Faculty of Tropical Medicine, Mahidol
University, with Dr. Wirongrong Chierakul as chairperson. The 8th WMC was hosted by University of
Florida in Cebu, Philippines in 2016, with Asst. Prof. Apichai Tuanyok and Prof. Herbert Schweizer
as chairpersons.
Hosting these meetings in Thailand has helped to raise the proﬁle of melioidosis in the
Thai medical, scientiﬁc, and political communities, as well as attracting media attention for the
general public.
7. Current and Future Challenges
During the meetings of the Thailand Melioidosis Network in 2012, four priority areas were
identiﬁed [61]. These included (1) to enhance the surveillance system, (2) to increase public awareness,
(3) to improve diagnosis of melioidosis, and (4) to improve prevention of melioidosis.
First, the problem of underreporting by Report 506 must be solved. Although the rise in the
reported number of deaths in 2015 occurred, more needs to be done. Only one provincial hospital
(Sunpasitthiprasong Hospital) reported its melioidosis cases and their mortalities to Report 506.
This was partially supported by the research unit in Sunpasitthiprasong Hospital. In future,
the personnel who are responsible for the system might change jobs, and the system is not automated.
Although a lot of discussion with many hospitals has taken place, the data from these hospitals
have not yet been submitted to the national reporting system. An immediate need is educating and
supporting all hospitals with microbiological facilities to report their culture-conﬁrmed melioidosis
cases and their mortalities to Report 506. A long-term solution is to automate the reporting system,
similar to the systems in the Netherlands and China [64]. Another option is to have all admission and
laboratory data from all hospitals in Thailand collected into one central data system. Then, formal
analysis could be performed to identify the total number of cases for the Annual Epidemiological
Surveillance Report of the MoPH [65], rather than using data from Report 506 alone.
Secondly, in order to raise public awareness of melioidosis, a large national campaign led by the
MoPH is needed. Based on multiple studies in Thailand [18,19], lay people doubt that melioidosis is
responsible for more than 1000 deaths of Thai people each year. They often ask, if that were true, “Why
have I never heard or seen anything about this disease on television or in any campaign in hospitals?”
Credible sources are a crucial component to provide information about the disease [18,19]. Thai people
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rely on doctors, nurses, healthcare workers, and the government to provide regular information about
diseases and their prevention [18,19]. Therefore, information must come from the MoPH on a scale that
is appropriate to a disease that kills more than 1000 people each year and is preventable. If people do
not know about the disease and its true fatality rate, then prevention will be nearly impossible [18,19].
Third, the problem of misdiagnosis and bacterial misidentiﬁcation in hospital microbiological
laboratories outside Northeast Thailand has been described above. This is very likely due to the fact
that (1) most laboratory technicians erroneously believe that melioidosis is endemic only in Northeast
Thailand, (2) laboratory training around diagnostic testing is not adequate, (3) there is a lack of rapid
bacterial identiﬁcation tests, along with poor usage of B. pseudomallei selective culture media, and (4) a
lack of RDTs for melioidosis diagnosis direct from clinical specimens, obviating the need for bacterial
culture. Major university hospitals in Thailand could use instruments such as the Vitek 2 system
(BioMerieux, Lombard, IL, USA) or matrix-assisted laser desorption ionization-time of ﬂight mass
spectrometry (MALDI-TOFMS), if the appropriate databases for B. pseudomallei are available [66].
However, it is crucial that all microbiology laboratory personnel in Thailand should be sufﬁciently
familiar with B. pseudomallei to identify the organism within available resources, for example, using
standard biochemistry and drug susceptibility tests. All technicians should be trained to recognize
B. pseudomallei colonies, and not discard them as contaminants. All oxidase-positive Gram-negative
bacilli should be tested to see whether they are B. pseudomallei [5]. Reports of Pseudomonas spp. should
include a note that the organism was tested and conﬁrmed not to be B. pseudomallei. A simple three-disc
susceptibility testing method (demonstrating resistance to gentamicin and colistin but sensitivity to
amoxicillin/clavulanic acid [67,68]) should be used in areas where resources are limited and secondary
diagnostic tests (such as API 20NE and latex agglutination speciﬁc for B. pseudomallei) are not available.
All uncertain isolates should be sent for conﬁrmation to the Department of Medical Science, MoPH,
Thailand, university hospital laboratories, or any research organizations in the area willing to receive
bacterial isolates for conﬁrmation of identity.
A latex agglutination assay using a monoclonal antibody speciﬁc for B. pseudomallei has been
available in Thai research organizations for more than 17 years [69]. The test is useful for isolate
conﬁrmation, but cannot be used directly on clinical specimens. The Thailand Melioidosis Network
strongly advocates for the latex agglutination assay to be one of the standard tests available to all
microbiological laboratories in Thailand, together with the appropriate training. This should help to
solve the problem of misidentiﬁcation of B. pseudomallei countrywide [61].
A lateral ﬂow immunoassay (LFI) using a similar monoclonal antibody to the latex agglutination
assay has been developed by InBIOS (Seattle, WA, USA), and is currently being evaluated in several
countries [70,71]. LFI can be used for rapid colony identiﬁcation in a similar way to latex agglutination,
and has the potential for application directly on clinical specimens [70,71]. Other advantages are lower
cost when economy of scale is high, and longer shelf life. Currently, Prof. Wongratanacheewin at MRC
is funded by the National Science and Technology Development Agency of Thailand, to develop a LFI
for use in Thailand. The LFI could eventually replace latex agglutination as the production costs would
likely be lower, and it should easily be manufactured at adequate levels to supply the whole country.
Fourth, recommendations for melioidosis prevention should be promoted thoroughly and
intensively. Thailand is a hotspot for melioidosis, but only a small proportion of people in Thailand
follow recommended behaviors that can prevent melioidosis [18,19]. These include using protective
gear, such as rubber boots and gloves when in direct contact with soil and surface water, and consuming
bottled or boiled water. However, changing behavior is typically complex, and providing information
and boots alone is unlikely to be effective. This is shown by the fact that boots have been provided
to Thai farmers for leptospirosis prevention since 2000 [72], yet many people still work in rice ﬁelds
without using them [73]. Recent studies found that Thai people had no knowledge of melioidosis,
believed that there was no need to adopt the recommended preventive behaviors, and were not inclined
to use boots and gloves while working in muddy rice ﬁelds [18,19]. Practically, over-the-knee boots can
be used in ﬂooded rice ﬁelds without causing difﬁculty in walking, but they are still uncomfortable to
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wear in hot weather. Participants reported that input from numerous role models (physicians, diabetic
clinics, friends, and families), and from the government via mass media, would be required for them
to change their behavior. We strongly recommend that a multifaceted intervention at community
and government levels is required to bring about the desired changes. It is still unknown how many
melioidosis cases could be prevented by each recommended behavior. The size of the effect and
cost-effectiveness of those preventive measures is being evaluated in a large behavioral change trial
(NCT02089152). Nonetheless, the MoPH need not wait for the ﬁnal results of this study (expected at
the end of 2019) before launching a campaign, because the recommended preventive measures are
simple and align with those for many other infectious diseases. The recommendations are supported
by epidemiological studies [73,74], and are similar to prevention campaigns to raise awareness and
reduce the number of cases and deaths due to melioidosis that have been conducted for several years
in northern Australia [75].
In the long term, an effective vaccine against melioidosis, targeting at-risk groups, such as
people with diabetes and agriculture workers, would be the ideal strategy for reducing the burden
of disease and number of deaths from melioidosis in Thailand [76], and could be cost effective [77].
Ongoing research programs in Thailand [78] and internationally [79,80] to identify vaccine candidates
are making progress, but vaccine development needs a long timeframe, and the case for ongoing
funding of vaccine research relies on demonstrating the true extent of the disease burden in countries
like Thailand.
In conclusion, we strongly believe that a prevention campaign should be undertaken now by the
MoPH, together with enhancing disease surveillance systems, raising awareness of the disease and its
true mortality, and improving the diagnosis of melioidosis. We believe that formal campaigns from the
MoPH would enhance the usage of free boots that MoPH regularly provides to farmers. More lives
could be saved, not only from leptospirosis, but also from melioidosis.
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Abstract: Melioidosis is a severe tropical infectious disease caused by the soil-dwelling bacterium
Burkholderia pseudomallei, predominantly endemic to Southeast Asia and northern Australia. Between
the 1970s and the 1990s, the presence of B. pseudomallei causing melioidosis in humans and other
animals was demonstrated in four coastal provinces in southern China: Hainan, Guangdong, Guangxi,
and Fujian, although indigenous cases were rare and the disease failed to raise concern amongst local
and national health authorities. In recent years, there has been a rise in the number of melioidosis
cases witnessed in the region, particularly in Hainan. Meanwhile, although China has established
and maintained an effective communicable disease surveillance system, it has not yet been utilized
for melioidosis. Thus, the overall incidence, social burden and epidemiological features of the disease
in China remain unclear. In this context, we present a comprehensive overview of both historical and
current information on melioidosis in Southern China, highlighting the re-emergence of the disease
in Hainan. Surveillance and management strategies for melioidosis should be promoted in mainland
China, and more research should be conducted to provide further insights into the present situation.
Keywords: melioidosis; Burkholderia pseudomallei; epidemiology; China
1. Introduction
Melioidosis is a fatal infectious disease caused by Burkholderia pseudomallei, a saprophytic
environmental bacterium that is endemic in many tropical regions of the world and affects both humans
and animals [1,2]. In humans, although most organs of the body can be infected, acute pneumonia
and septicaemia often represent the most common clinical manifestations, and are associated with a
high mortality rate (10%–30%) for the disease [1,2]. Given the increase in the number of reported cases,
as well as the extension of endemic regions in past decades, melioidosis is deemed to be a re-emerging
infectious disease in many tropical countries [3], particularly in Southeast Asia and north Australia.
More strikingly, a recent modeling study predicted that the true global burden of melioidosis was
approximately 165,000 cases and 89,000 deaths a year [4], much higher than the total number of cases
that are documented or reported. Although the true disease burden remains difﬁcult to determine,
it appears likely that there has been a dramatic underestimation of its scale in part due to misdiagnosis
and underreporting in vast areas of the world appropriate for its endemicity. It is thus important to
raise the proﬁle of the disease across the tropical world.
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Similar challenges have been encountered in mainland China. The environmental presence
of B. pseudomallei was initially demonstrated in the 1970s and the ﬁrst human case of melioidosis
was identiﬁed in 1989 [5]; nonetheless, as only a few cases were identiﬁed at the time, attention
soon declined and the disease was neglected for many years. However, with the rapid economic
development and social transition over the past two decades, the situation has changed and there
has been a substantial increase in the number of cases diagnosed in Hainan, with the occurrence of
sporadic locally-acquired or imported cases in other areas throughout China. Clearly this shift requires
a reconsideration of the current status and epidemiology of the disease within China. However, thanks
to both preconceptions about the insigniﬁcance of the disease, and the fact that it has not been listed as
a nationally notiﬁable infectious disease, studies of the epidemiology of melioidosis in China are few
and far between and it is difﬁcult to obtain resources to study it further.
Here, we provide an overview of the historical and current aspects of melioidosis in China by
reviewing available data and information about human and animal melioidosis and B. pseudomallei
in mainland China, with an emphasis on its resurgence in Hainan, including some publications that
are only available in Chinese. We have excluded Hong Kong and Taiwan, which are both covered
elsewhere in this issue. We hope that this review will help to inform clinicians and policy makers
about the disease in southern China and lead to the formulation of plans to prevent and control it in
the future.
2. History
The ﬁrst event linking melioidosis to China occurred in France in the early 1970s when an
outbreak of melioidosis at the Jardin des Plantes zoo was attributed to a giant panda from China [6].
Nevertheless, as pandas uniquely inhabit the high-altitude mountainous areas of Southwest China,
where neither B. pseudomallei nor human or animal melioidosis has ever been reported, the panda
might actually have been a victim of this outbreak rather than the source.
In mainland China, the discovery of environmental B. pseudomallei preceded the identiﬁcation of
the ﬁrst human case of melioidosis by over 10 years. Since the early 1970s, horse farms and military
establishments in Hainan and Guangdong had reported an increase of mallein test positive horses
without any clinical features suggestive of glanders. A comprehensive environmental survey in the
vicinity of mallein-positive stables was undertaken to investigate whether B. pseudomallei might be
a potential cause of this phenomenon [7]. Between April and June 1975, Li and colleagues obtained
23 isolates of B. pseudomallei from 4.9% of pond waters sampled near these farms by inoculation
in golden hamsters. Subsequent experiments showed that horses infected with B. pseudomallei
gave positive mallein reactions [8]. From 1976 to 1979, the survey was extended to other southern
provinces and another nine environmental isolates were obtained from Guangdong and Guangxi,
two subtropical provinces close to Hainan, with no B. pseudomallei being cultured further north than
this [8]. Subsequently, B. pseudomallei was isolated in 1985 from a paddy ﬁeld in Putian, Fujian province,
a subtropical region adjacent to Taiwan [9]. The ﬁrst cases of culture-positive melioidosis were detected
in 1982, when Lu isolated B. pseudomallei from slaughtered pigs in Hainan [10]. In 1981, Li found
a prevalence of seropositivity (indirect hemagglutination (IHA) titer >1:40) ranging from 6.0% to
13.7% among people inhabiting the coastal areas of Hainan [8]. It thus appeared that exposure to
B. pseudomallei, and therefore human melioidosis, was also likely to be present in this region.
Efforts to ﬁnd cases of human melioidosis in Hainan continued throughout the 1980s, but most
attempts were in vain. Eventually, the ﬁrst human case of culture-positive melioidosis, presenting
with an ulcer on his left leg, was identiﬁed in Sanya City in 1989 [11]. Two patients with fatal
septicaemic melioidosis, both local farmers, were reported in 1990 from Zhanjiang City in Guangdong,
which is located at the southernmost peninsula of mainland China opposite Hainan island [11].
Subsequently, Song et al. conducted a prospective survey looking for human cases at the largest
provincial hospital on Hainan, Hainan People’s Hospital, in 1995 [12]. Within a one-year period, a total
of eight culture-conﬁrmed cases were identiﬁed, four of whom had acute septicaemia and the others
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chronic forms with abscesses in different organs. As elsewhere, seasonal and occupational associations
were seen, as all cases were farmers and most presented during the rainy season in Hainan (May to
October). Based on these ﬁndings, it was concluded that animal and human melioidosis were rare in
the region and few further studies were conducted on it during the 1990s.
3. Review of Melioidosis Cases and Resurgence of the Disease in Hainan
During the 21st century, particularly after the severe acute respiratory syndrome (SARS) outbreak
in 2003, China’s infectious disease surveillance, prevention and control systems expanded and
improved considerably. Since then, the overall incidence of notiﬁable infectious diseases has been
declining and some are even close to eradication [13]. By contrast, melioidosis has been one of the few
infectious diseases whose incidence has increased in recent years, especially in the Hainan province.
Clinical staff began to recognize increasing numbers of melioidosis cases in general hospitals in Hainan
and their awareness of the infection grew [14,15]. For example, compared with a total of eight cases
in 1996, approximately 20–30 cases were seen each year at Hainan People’s Hospital during the
2010s [15,16]. As culture facilities and diagnostic guidelines were already well established in this
institution, it is likely that this reﬂected a genuine increase in incidence.
This increased incidence drew the attention of local and national health authorities and so in 2011
the Institute for Communicable Disease Control and Prevention of China (ICDC) established a working
group with the aim of identifying and monitoring the incidence and epidemiology of melioidosis
throughout China. Following this, a preliminary sentinel network representing the major government
and teaching hospitals within Hainan was established, resulting in the identiﬁcation of a total of 396
culture-conﬁrmed cases (392 from Hainan, three from Guangxi and one from Guangdong) between
2002 and 2016 (Figure 1). The available medical records of 289 cases (all from Hainan) were reviewed
to establish information about the demographics, clinical features and outcomes. It was found that the
patients were distributed around the periphery of Hainan Island with no cases originating from the
two central mountainous prefectures (Wuzhishan and Qiong Zhong) as seen in Figure 2; three major
port cities (Sanya, Haikou, and Dongfang) contributed to nearly half the cases (123, 42.6%). Of 289
patients for whom data were available, 245 were male and 44 were female; apart from one neonate
(17 days), the other patients ranged from one year to 84 years old (median = 49.4 years), with the
highest proportion in the 51–60 year age group (Figure 3). Cases were seen in each month, but the peak
incidence occurred in August and September during the rainy season (from May to October) as seen in
Figure 4. Of the 238 patients whose occupations were known, local farmers formed a large proportion
(118, 49.6%). Among 277 cases with complete clinical information, septicaemia (153/277, 55.2%) and
pneumonia (149/277, 53.8%) represented the two major clinical manifestations; other less common
clinical features included musculo-skeletal or soft tissue abscesses (57/277, 20.6%), genitourinary
or prostatic infection (18/277, 6.5%), brain infection (9/277, 3.3%), liver or splenic abscesses (8/277,
2.9%), pyogenic arthritis (5/277, 1.8%), upper gastrointestinal hemorrhage (4/277, 1.4%), neck abscess
(4/277, 1.4%), suppurative parotitis (3/277, 1.1%), suppurative pharyngitis (3/277, 1.1%), and infected
aortic aneurysm (3/277, 1.1%) as seen in Table 1. Death occurred in 64 cases, resulting in an overall
mortality rate of 23.1% (64/277). The most common underlying co-morbidity was diabetes (131/277,
47.3%), followed by chronic liver disease (18/277, 6.5%), chronic lung disease (6/277, 2.2%), and chronic
renal disease (5/277, 1.8%). During the survey period of 2011-2016, a notable peak in cases (n = 106)
occurred in 2016, coinciding with record wet-season precipitation that year (Figure 2). This represented
an annual incidence rate of 1.16 per 100,000 for this region, where the resident population was
approximately 9,270,000 according to 2014 Census data. Even so, since this sentinel network did not
include all the hospitals in the region and depended on voluntary surveillance rather than mandatory
reporting, it is inevitable that a number of cases will have been missed and the true incidence would
be higher.
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Figure 1. Number of melioidosis cases by year identified during surveillance, Hainan, China, 2002–2016.
Figure 2. Location of Burkholderia pseudomallei and melioidosis cases in China. (a) The distribution of
endemic areas (n = 4, with green shading) and melioidosis cases in mainland China, with locations
of environmental isolation of B. pseudomallei and indigenous or imported human/animal cases of
melioidosis indicated (The number of human cases for each province was indicated in parentheses.
The patients outside the four endemic provinces all have a history of residence or travel to Hainan or
overseas endemic areas and thus are deemed as imported cases); (b) The distribution of melioidosis
cases according to different prefectures in Hainan (data only available for 289 of 401 cases) and in the
Leizhou Peninsula (46 cases) of Guangdong, China.
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Figure 3. Age distribution of 288 human melioidosis patients from Hainan, China, 2002–2014.
 
Figure 4. Monthly distribution of 289 melioidosis cases across 13 years (2002–2014) in Hainan, China.
Table 1. Summary of clinical presentation of 277 melioidosis cases from Hainan.
Presentation Number of Cases Percentage (%)
Septicaemia 153 55.2
Pneumonia 149 53.8
Musculoskeletal or soft tissue abscess 57 20.6
Genitourinary or prostatic infection 18 6.5
Brain infection 9 3.3
Internal organ (liver, kidney or splenic) abscess 8 2.9
Pyogenic arthritis 5 1.8
Upper gastrointestinal hemorrhage 4 1.4
Neck abscess 4 1.4
Suppurative parotitis 3 1.1
Infected aortic aneurysm 3 1.1
Orbital abscess 3 1.1
Suppurative pharyngitis 3 1.1
To search for additional records of melioidosis cases and B. pseudomallei isolates from mainland
China, especially those occurring before the start of the ICDC surveillance (2011), we also consulted
the international B. pseudomallei multi-locus sequence typing (MLST) database (https://pubmlst.org/
bpseudomallei/) [17]. Up to the end of 2017, among over 5300 B. pseudomallei isolates deposited in
this web accessible database, 205 were marked as originating from the Chinese mainland, comprising
195 human/animal isolates, ﬁve environmental isolates, and ﬁve isolates with unknown sources.
The isolation dates spanned from 1975 to 2015, but strains prior to 2011 accounted for only a small
proportion (66 isolates). As there were many duplicate cases between this dataset and our surveillance
database, we excluded these and have only included records prior to 2002 (11 isolates) in this review.
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4. Literature Review
Alongside this increase in the number of cases diagnosed, there has been a proliferation of
publications on melioidosis in China, many of which have been published in Chinese and are thus
not readily accessible to researchers in other countries. In order to undertake as comprehensive a
review of the available literature as possible, we conducted a search of two domestic science databases
(China Science Periodical Database, China Hospital Knowledge Database) and two international
scientiﬁc databases (PubMed of the National Library of Medicine and Web of Science) to identify
reports of documented human or animal cases of melioidosis from China. We used the key search
terms “melioidosis”, “Burkholderia pseudomallei” and “China”. We identiﬁed 196 articles to the end of
August 2018, which we reviewed for relevance based on whether they described melioidosis cases
or B. pseudomallei isolates from mainland China. A total of 86 articles (from 1981 to 2018) were ﬁnally
selected, of which only 31 were retrieved from international databases. Most of these documents
dealt with endemic provinces, but there were also case reports from non-endemic areas of central
and northern China, including Beijing [18], Shanghai [19], Jiangsu [20,21], Hunan [22], Qinghai [23],
Chongqing [24], Shaanxi [25], and Sichuan [26] as seen in Figure 2. Except for the Hunan case for
whom the residence/travel information was unavailable, each case occurring outside the known
endemic provinces of Hainan, Fujian, Guangdong, and Guangxi had a history of residence or traveled
to Hainan or overseas endemic regions before the onset of the disease, hence all of them should be
considered imported cases.
It is notable that several series of melioidosis cases have been described in China (Table 2) over the
past two decades. However, in most series, the individual case data have been omitted or summarized,
making it difﬁcult to identify duplications as well as to investigate clinical or epidemiological patterns
on a larger scale. In a retrospective study, Fang et al. described the clinical and epidemiological
features of 170 culture-conﬁrmed cases hospitalized in three general hospitals in Hainan, between
2002 and 2014 [35]. As noted above, a steady increase in the numbers of melioidosis cases was seen;
pneumonia (34.1%) was the most common manifestation, and people with diabetes and outdoor
laborers were at greatest risk of contracting the disease. In a prospective survey, Zheng et al.
characterized a cluster of 16 microbiologically conﬁrmed cases occurring after Typhoon Rammasun hit
northern Hainan on July 18th 2014 [36]. In a retrospective study undertaken by Chen et al., a total of
44 human cases were detected amongst 7786 febrile patients at the Afﬁliated Hospital of Guangdong
Medical College in Zhanjiang City between 1990 and 2005, 25 of whom died (56.8%) [28]. Since all
these cases came from surrounding counties/villages, it appears that the Leizhou Peninsula, which
has contributed to the majority of documented cases from Guangdong, should also be considered a
hotspot for melioidosis in southern China. Compared with Hainan and Guangdong, fewer melioidosis
cases have been recognized in the provinces of Guangxi and Fujian, despite the fact that B. pseudomallei
is known to be present in the environment [9,41]. However, a retrospective report was recently
published, which describes seven culture-proven cases of melioidosis hospitalized in a teaching
hospital in Nanning, the capital city of Guangxi, from October 2006 to March 2015 [40]. The clinical
characteristics, drug susceptibility results and epidemiological features of these cases were similar
to those in other known endemic regions. In parallel, although not documented in the published
literature, an indigenous female patient from Fujian with severe melioidosis was reported online in
November 2014 [42]. Interestingly, the patient was from Putian, where the environmental presence
of B. pseudomallei had previously been identiﬁed in 1985. It is thus likely that Guangxi, and possibly
Fujian, have been neglected as melioidosis-endemic, and improvements in awareness and diagnosis
of the disease are needed to improve the understanding of its true prevalence in these provinces.
In general, the range of clinical manifestations of melioidosis in China is similar to that seen elsewhere,
with relatively rare clinical manifestations reported in the literature, including suppurative parotitis
(one case) [43], osteomyelitis (three cases) [44] and pericarditis (one case) [45] from Hainan, as well
as prostatic abscesses (two cases) [46] and co-infection with Japanese encephalitis (one case) [47]
from Guangdong.
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Table 2. Human melioidosis cases reported from Hainan, Guangdong, and Guangxi.
Year of
Report
Location of
Infection
Duration of
Study
Number of
Cases 1 Outcome Reference
1992 Hainan &Guangdong 1975–1992 3 1 Survived/2 Died [8]
1998 Hainan 1995–1996 8 4 Survived/2 Died/2 Unknown [12]
2005 Hainan 2002–2005 12 4 Survived/8 Died [27]
2006 Guangdong 1990–2005 44 19 Survived/25 Died [28]
2006 Hainan 1996–2005 32 21 Survived/3 Died/9 treatment withdrawn [29]
2008 Hainan 2002–2006 19 12 Survived/7 Died [30]
2008 Hainan 2000–2007 25 9 Survived/6 Died/10 treatment withdrawn [31]
2009 Hainan 2000–2009 104 72 Survived/15 Died/17 treatment withdrawn [32]
2011 Hainan 2002–2008 122 81 Survived/19 Died/22 treatment withdrawn [14]
2013 Hainan 2007–2012 95 65 Survived/30 Died [15]
2014 Hainan 2009–2012 40 34 Survived/6 Died [33]
2014 Hainan 2010–2013 40 6 Survived /10 Died/24 Unknown [34]
2015 Hainan 2002–2014 170 124 Survived/46 Died [35]
2016 Hainan 2003–2014 60 32 Survived/26 Died/2 Unknown [16]
2016 Hainan Jul–Sep 2014 16 8 Survived/8 Died [36]
2017 Hainan 2002–2015 7 5 Survived (4 had nervous system sequelae)/1 Died/1 treatment withdrawn [37]
2017 Hainan 2000–2012 46 33 Survived/13 Died [38]
2018 Hainan 2012–2017 35 26 Survived/7 Died/2 treatment withdrawn [39]
2018 Guangxi 2006–2015 7 All Survived [40]
1 It was not possible to exclude duplicate reports and so there is overlap between these series.
In order to obtain a comprehensive dataset, we merged data from the three sources described
above (ICDC, MLST database, and the literature review) to give an inclusive picture of the melioidosis
distribution around mainland China (Supplementary Table S1), comprising 469 cases (401 from Hainan,
47 from Guangdong, 10 from Guangxi, one from Fujian and 10 cases imported into more northern
provinces) identiﬁed in the present study. The distribution of these cases is shown in Figure 2.
5. Environmental and Molecular Investigations of B. pseudomallei in Hainan
5.1. Environmental Distribution of B. pseudomallei
The incidence of melioidosis is closely associated with the environmental density of B. pseudomallei
in endemic areas. To estimate the abundance of the organism in soil and water and investigate
its relationship with the recent increase in melioidosis cases, several environmental surveys have
been conducted in Hainan over the past few years. In 2012, in a collaborative investigation by
ICDC and Sanya People’s Hospital, 70 soil and water samples were collected from 20 paddy ﬁelds
scattered across southern Hainan Island. There was no B. pseudomallei found, but four isolates of
Burkholderia thailandensis, a non-pathogenic species closely related to B. pseudomallei, were recovered
from four different locations [48]. In 2014 and 2017, two further investigations were conducted by
separate research groups [49,50], which were positive for B. pseudomallei by culture in 3 of 58 (5.2%)
and 2 of 70 (2.9%) environmental samples, respectively. Comparison of clinical and environmental
isolates using a combination of two discriminant genotyping techniques, multilocus sequence typing
and multiple locus variable number tandem repeat analysis (MLST and MLVA), suggested an
environmental origin for some of the cases. These studies were of limited scale, and could not determine
the geographic distribution of B. pseudomallei all over the island, but from August to December 2016,
Dong et al. conducted a more comprehensive environmental B. pseudomallei investigation, covering
all 18 counties of Hainan Island [51]. Among 360 sampling sites, 48 (13.3%) were positive for the
bacterium, and most of these were located in coastal counties (12/18), which corresponds with the
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distribution of clinical cases around the island. It is hoped that studies such as this will help to establish
a risk map, which may assist in the prevention of the disease in Hainan.
5.2. Genetic Diversity of B. pseudomallei Isolates from Hainan
Latterly, molecular epidemiological studies of the increasing numbers of available isolates of
B. pseudomallei have been a growing area of melioidosis research in Hainan. Using MLST, Fang et al.
divided 102 isolates from three hospitals into 41 sequence types (STs), among which 11 STs were
unique to Hainan and eight were novel [52]. In another recent study, 30 STs were found amongst
60 clinical isolates collected between 2003 and 2014, including six novel types [16]. It is clear from these
studies that B. pseudomallei in Hainan are highly genetically diverse, with some major STs being shared
with and linked to the subpopulations from other Southeast Asian endemic foci such as Thailand and
Malaysia. This makes it likely that the introduction of B. pseudomallei into Hainan is not recent and that
the island has probably been endemic for melioidosis for a long period. Interestingly, ST562 has been
found in both Hainan and northern Australia [53]. On the basis of SNP-based phylogenetic analysis,
Price et al. showed that Australian isolates of this clone belong to the Southeast Asian subpopulation,
which appears to have spread to, and become established in, the Darwin region in recent years [54].
ST562 is also represented amongst the two genomes (BPC006 and 350105) of B. pseudomallei from China
that have been sequenced and published [55,56]. Strain 350105 was obtained from Hainan in 1976 and
represents the earliest known ST562 isolate, but precisely how and when this long-range transmission
took place is unknown and would be worthy of further studies.
6. New Understanding of Melioidosis Epidemiology on Hainan
6.1. The Association between Typhoon and Case Clustering of Melioidosis
Climatic factors can exert a remarkable inﬂuence on the incidence of melioidosis, even causing
outbreaks. However, despite the known endemic areas of southern China (Hainan, Guangdong,
Guangxi, Fujian, and Hong Kong) being located in the typhoon-prone belt of the Western Paciﬁc, it was
only recently discovered that the potential impact of a typhoon strike on melioidosis incidence in the
region was demonstrated when Typhoon Rammasun (a Category ﬁve super typhoon) struck Hainan
in 2014 [36]. Within two months of the event, a cluster of 16 human cases of melioidosis concurred
around the point at which the typhoon struck land. Moreover, the patients manifested severe clinical
forms and a high mortality rate (50%), which had also been observed in typhoon-related melioidosis
clusters in Taiwan [57]. A correlation between typhoons and the occurrence of melioidosis was also
noted in a review of 15 conﬁrmed cases (2002–2007) from a municipal hospital in Zhanjiang City,
Guangdong [58]. Further studies are required to elucidate the mode and mechanism by which extreme
weather events inﬂuence the incidence of melioidosis in southern China and how this may be affected
by climate change.
6.2. Disease Burden and Risk Analysis
Deﬁning the burden and risk factors for melioidosis is important to raise awareness of the disease
in the public health community and develop preventive and control strategies for the disease [4].
However, although an increasing number of melioidosis cases have been witnessed in Hainan, our
knowledge of its full magnitude and epidemiology are still lacking. It appears that the main disease
burden is focused on the tropical coastal areas of southern China, especially those of Hainan Island,
the Leizhou Peninsula, and southern Guangxi. Compared with inland regions, these coastal regions
are characterized by higher population density, more abundant rainfall and more plentiful habitats
for B. pseudomallei (such as paddy ﬁelds and artiﬁcial ponds), which would favor the occurrence
of melioidosis. As with other endemic regions, diabetic and rural populations are at the highest
risk of contracting the disease, and the incidence is associated with rainfall and extreme weather
events. The rising incidence of melioidosis has been more evident in Hainan than in the other
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endemic provinces in recent years. The epidemiology of melioidosis represents the consequences of
a complicated interaction between multiple natural and social factors, such as the physicochemical
environment, climate, host population susceptibility and genetic variation of the pathogen [3], which is
as yet poorly understood. The impact of climate change (such as a rise in precipitation or higher
frequency of typhoon strikes) on the incidence of disease may be signiﬁcant in Hainan. In addition,
the booming real estate industry on the island, which is likely to cause considerable changes in land
use and the ecological environment, together with the rapid growth of the diabetic population in
Hainan [59] may also be implicated in the recently observed increased incidence. Thus, multiple
factors have probably contributed to a genuine increase in the incidence of melioidosis in Hainan,
and unless these factors are addressed, it is likely that the background incidence will continue to rise
in Hainan and, under appropriate conditions, further clusters and outbreaks may occur.
7. Surveillance and Reporting of Melioidosis Cases in Mainland China
7.1. Human
Although a highly efﬁcient nationwide reporting and monitoring network for infectious diseases
has been established in China since 2004 [60], melioidosis is still not included, largely due to the lack
of awareness and the fact that it is not listed as a statutorily notiﬁable infectious disease in the country.
Given the evidence of increasing incidence, ICDC has prioritized surveillance work in Hainan through
the establishment of the sentinel network described above. Between 2011 and 2017, this network has
involved seven tertiary and 12 county-level hospitals. In addition, in order to improve the ability of
medical and laboratory staff to recognize the disease, ICDC delivered training and workshops on
melioidosis diagnosis and B. pseudomallei identiﬁcation during 2016 and 2017 in Hainan. However,
no such surveillance or training has yet been undertaken in the Leizhou Peninsula and southern
Guangxi, despite the evidence that these are also melioidosis-endemic. It is therefore likely that
underreporting cases remains a major issue in these regions. Even though melioidosis has not yet been
incorporated into the national system for reportable infectious diseases, the disease should be added
into the local infectious disease reporting systems of these regions in the future.
Molecular epidemiological surveillance, which is widely accepted as a powerful tool for the
prevention and control of communicable diseases, has increasingly been implemented in China.
With the recognition of melioidosis as an emerging threat to both endemic and non-endemic areas,
since 2017 B. pseudomallei has been included in PulseNet China, a national monitoring platform for
major bacterial pathogens led by ICDC. This should enhance nationwide surveillance and enable
studies of the molecular epidemiology of the disease across China.
7.2. Animals
Melioidosis can affect a wide range of animal species, but its true incidence in wild and
domestic animals is far from clear in almost all parts of China. Following the initial identiﬁcation
of B. pseudomallei from environmental samples in Hainan, Lu et al. carried out surveys on farm
animals and succeeded in recovering B. pseudomallei from the viscera of pigs and goats collected in
the slaughterhouses of Haikou and Nanning in 1982 [10]. In 1993, a rhesus monkey was conﬁrmed as
having died of melioidosis in a health research centre in Fuzhou, Fujian province [61]. In 2005,
Chen isolated B. pseudomallei from dead dolphins at a marine park in Sanya City, Hainan [62].
Additionally, a melioidosis outbreak was reported at a livestock farm in Guangxi in October 2009,
resulting in the death of 12 Boer goats [63]. Based on these accounts, we believe that animal melioidosis
probably affects a variety of animal species in southern China, although the true range and economic
loss it causes are yet unknown.
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7.3. Guidelines
No standards or ofﬁcial guidelines for the diagnosis or management of melioidosis are available
in mainland China. Although serological tests such as IHA and ELISA were established and used to
diagnose melioidosis in some hospitals in Hainan and Guangdong in the 1990s [8], in our experience,
culture and the identiﬁcation of B. pseudomallei have now been accepted as the consensus standard and
is what has now been adopted for the diagnosis and reporting of the disease at hospitals and institutes
in endemic regions of China.
8. Diagnosis and Treatment
Accurate and efﬁcient diagnosis of melioidosis cases is crucial, both for saving lives and for
understanding the epidemiology of the disease. Unfortunately, owing to the lack of a consensus
guideline and the scarcity of studies, the true situation as far as melioidosis diagnosis is concerned is
largely unknown in mainland China. However, what is known from the literature does not give cause
for optimism [32,33,39]. Due to a lack of laboratory capacity and a lack of familiarity with the clinical
characteristics of the disease amongst clinicians, melioidosis patients are likely to be misdiagnosed
in most ordinary hospitals [32,33]; even in good tertiary hospitals, the rate of initial misdiagnosis
is high (80%–90%) [39]. Given the difﬁculty of clinical diagnosis of this protean disease, culture
and identiﬁcation of B. pseudomallei is accepted as the gold standard for the diagnosis of melioidosis
countrywide [14,32,33,35,39]. However, as yet this capacity is restricted to a few general or teaching
hospitals within endemic regions of China, where automated blood culture and commercial bacterial
identiﬁcation systems are deployed and microbiological investigations are routinely conducted.
In addition to the use of commercial identiﬁcation systems (e.g., VITEK, BD Phoenix, etc.), identiﬁcation
of B. pseudomallei commonly depends on laboratory staff recognizing the basic morphological and
cultural characteristics of B. pseudomallei [15,38]. However, waiting for the results of cultures may lead
to delays in initiating effective treatment. In a retrospective survey of 40 melioidosis cases in Hainan,
the time from admission to diagnosis was 4–19 days (average 8.2 days) [33]. To improve efﬁciency and
accuracy, molecular technologies (e.g., speciﬁc PCR, 16s rRNA sequencing, etc.) have been applied
for the conﬁrmation of the diagnosis by specialist centers in recent years; however, no proven rapid
screening approaches for B. pseudomallei (such as the latex agglutination assay [64] or even the ‘three
disc test’ for the characteristic antimicrobial susceptibility pattern [65]) are available in most hospitals
in endemic areas of China. However, computed tomography (CT) scans, magnetic resonance imaging
(MRI), and ultrasound have increasingly been used to identify internal abscesses in the liver, spleen,
prostate and brain [37,39]. Clearly, the capability for melioidosis diagnostics need to be increased,
and efﬁcient rapid screening methods for detecting B. pseudomallei need to be introduced to Hainan
and other endemic regions of mainland China.
As in other melioidosis-endemic regions of the world, lung or liver abscesses caused by
B. pseudomallei are often mistaken for tumors or tuberculosis in Hainan, as the clinical and imaging
features are difﬁcult to distinguish [66]. In addition, although extremely rare, a case of human glanders
was documented in China in 2004 [67]. A fatal human case of human B. thailandensis infection was also
reported in 2017 [68], although the validity of this has been questioned [69].
With the rise of the incidence of melioidosis, the major general hospitals in Hainan have gradually
gained experience and capability in providing effective diagnosis and treatment of melioidosis.
Once the diagnosis has been made, the treatment regimens used are consistent with international
consensus guidelines and consist of an initial intensive phase with intravenous antibiotics and
a subsequent eradication phase with oral antibiotics [40]. Compared with that of over 20 years
ago, the overall mortality rate of acute melioidosis cases has lowered from 50%–66% [27,28]
to 15%–25% [34,38,39]. Recurrence has been observed, but only in a tiny proportion of cases that
have received standardized treatment [32,39]. Improvements in patient outcomes are probably due
to a combination of factors: advances in diagnostic techniques, availability of appropriate drugs
(meropenem, imipenem and ceftazidime) and the regular performance of antibiotic susceptibility
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tests during therapy [40]. Nevertheless, the differences between hospitals and areas in their ability to
diagnose and treat patients with melioidosis, remains a major concern. Based on our observations, most
remote county-level hospitals in Hainan lack both the diagnostic capacity and access to appropriate
antimicrobial drugs. Furthermore, it is worth noting that the economic burden of treatment on
poor rural patients and their families is signiﬁcant, and some even choose to withdraw from
treatment [14,31,32].
Additionally, although the susceptibility of B. pseudomallei to carbapenems is almost universal,
the emergence of ceftazidime resistance has been reported as a problem in some hospitals in Hainan in
more recent years. Ceftazidime resistance was said to have risen from 0% to 20–30% of B. pseudomallei
clinical isolates between 2002 and 2014 in one institution in Hainan [70]. This requires conﬁrmation,
and warrants our continued surveillance and concern.
9. Current and Future Challenges
Over 40 years has passed since the ﬁrst identiﬁcation of B. pseudomallei in southern China;
nonetheless, our knowledge on this disease is still lacking and there are numerous challenges to
revealing its true epidemiology. In particular, some crucial questions remain unanswered, including
the ecology and distribution of B. pseudomallei in the environment within China, the true burden of the
disease in local residents, and its incidence among domestic and wild animals. Therefore, institutions,
hospitals and laboratories in this region and countrywide need to collaborate closely with each other
and undertake more comprehensive epidemiological and ecological studies to enhance our knowledge
and understanding of the disease within China.
Moreover, the main endemic area is the coastal zone (Hainan, Guangdong, Guangxi and Fujian),
which has experienced rapid development and has become one of the major economic centers of
China. In view of its proximity to Southeast Asia, the world’s largest known melioidosis focus,
and the booming economic and trade activities between them, close attention needs to be paid
to the current and future trends of the disease in this area. In the meantime, under the national
strategy of the Belt and Road Initiatives, Hainan has set the developmental goal of developing as
a major international tourism island and seaborne trade centre in the next decade, with important
progress towards these goals having already been made. In consequence, remarkable changes in the
environment and population size can be anticipated for this region, which may increase the population
at risk of infection with B. pseudomallei and pose greater challenges for the prevention and control
of this disease in China and even regionally. Therefore, we recommend that melioidosis should be
included in the national reportable diseases list, and that the sentinel surveillance network should
be strengthened, which should lay a good foundation for risk assessment and the formulation of
preventive strategies against this disease. Additionally, standard guidelines for the diagnosis and
management of melioidosis need to be developed and distributed to all physicians and laboratory staff
in both endemic and non-endemic areas of the country.
Although the national agency of disease control and prevention (ICDC) has set out to understand
the current status through case and pathogen surveillance, the lack of awareness and attention of
melioidosis amongst both government authorities and the general public is still a major challenge for
the management and control of the disease in China. In a nationwide context, the public and the media
hardly ever discuss this disease and threat it poses. Hence, we believe that a countrywide information
campaign about melioidosis should be initiated in order to draw attention to this important disease.
10. Conclusions
In summary, this review presents a comprehensive account of the history, current status,
and epidemiology of melioidosis in China. Surveillance data and a literature review clearly show that
melioidosis has become more common in both endemic and non-endemic areas of mainland China,
especially Hainan, in recent years, as in other parts of the world [71,72]. Surveillance and control
254
Trop. Med. Infect. Dis. 2019, 4, 39
strategies should be promoted to address this change, and further research should be conducted to
provide new understanding and insights into the causes of this trend.
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